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Novel	   CF3-­‐labelled	   lanthanide(III)	   complexes	   have	   been	   synthesised	   for	   use	   as	  
probes	  for	  19F	  and	  1H	  magnetic	  resonance	  spectroscopy	  and	  imaging.	  	  
The	   syntheses	   and	   evaluation	   of	   two	   classes	   of	   fluorinated	   paramagnetic	  
complexes	  are	  defined.	  Notably,	   the	   19F	  magnetic	   resonance	   relaxation	  processes	  
for	   the	   complexes	   have	   been	   assessed,	   allowing	   for	   the	   analysis	   of	   the	   interplay	  
between	   applied	   field,	   Ln3+	   ion	   and	   rotational	   correlation	   time	   on	   relaxation	  
properties.	  	  
Strategies	  employed	  to	  enhance	  signal	  intensity	  are	  discussed,	  examining	  a	  number	  
of	   different	   of	   fluorinated	   mono-­‐	   and	   di-­‐amide	   cyclen	   ligands.	   Systems	  
incorporating	   phosphinate	   pendant	   arms	   are	   of	   particular	   interest,	   resulting	   in	  
complexes	  with	  favourable	  isomer	  distributions,	  faster	  longitudinal	  relaxation	  rates	  
and	  narrower	  linewidths.	  	  
Finally,	   the	   synthesis	   of	   high	   molecular	   weight	   conjugates	   with	   paramagnetic	  
fluorinated	   complexes	   is	   described.	   Three	   different	   classes	   of	   medium	   to	   high	  
molecular	   adducts	   were	   considered,	   with	   the	   merits	   and	   limitations	   of	   each	  
assessed.	  The	  desirable	  formation	  of	  one	  species	  in	  solution,	  ease	  of	  solubility	  and	  
attractive	   19F	   and	   1H	   relaxometric	   properties	   render	   the	   chitosan	   conjugates	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  trifluoromethyl-­‐L-­‐phenylalanine	  	  
THF	  -­‐	  tetrahydrofurane	  
TPP	  -­‐	  tetraphenyl	  iron(III)porphyrins	  	  
tri-­‐BOC	  -­‐	  tert-­‐butoxycarbonyl	  
TSAP	  -­‐	  twisted	  square-­‐antiprismatic	  	  
UV	  -­‐	  ultraviolet	  
Vis	  -­‐	  visible	  





Chapter	  1:	  Introduction	  





1.1 Magnetic	  Resonance	  Imaging	  
	  	  
Magnetic	  Resonance	  Imaging	  (MRI)	   is	  a	  powerful	  and	  non-­‐invasive	  medical	   imaging	  
modality	  that	  exploits	  the	  intense	  water	  signal	  present	  in	  living	  systems	  to	  generate	  
high	  resolution,	  anatomical	  three	  dimensional	  images.1	  Proton	  MRI	  can	  establish	  the	  
distribution	  of	  water	  protons	  in	  the	  body	  through	  examination	  of	  the	  water	  proton	  
signal	   determined	   by	   the	   longitudinal	   relaxation	   time,	   T1,	   and	   the	   transverse	  
relaxation	  time,	  T2.	  The	  particularly	  strong	  signal,	  which	  is	  sensitive	  to	  tissue	  status,	  
provides	   indications	   of	   soft	   tissue	   anatomy.	   In	   clinical	   practice,	   it	   is	   possible	   to	  
distinguish	  between	  malignant	  and	  normal	  tissue	  owing	  to	  the	  significantly	  longer	  T1	  
value	  of	  malignant	  tissue	  (Table	  1.1).	  2	  	  
	  
Tissue	   Tumour	  T1(s)	   Normal	  T1(s)	  
Breast	   1.08	  ±	  0.08	   0.37	  ±	  0.08	  
Stomach	   1.24	  ±	  0.11	   0.76	  ±	  0.08	  
Skin	   1.05	  ±	  0.11	   0.62	  ±	  0.02	  
Muscle	   1.41	  ±	  0.08	   1.02	  ±	  0.03	  
	  
Table	  1.1:	  Longitudinal	  relaxation	  times	  (T1)	  for	  malignant	  and	  normal	  human	  tissue.
2	  
	  
In	  MRI,	  the	  signal	  intensity	  increases	  with	  increasing	  longitudinal	  relaxation	  rate,	  R1,	  
and	   decreases	   with	   increasing	   transverse	   relaxation	   rate,	   R2.	   The	   introduction	   of	  
paramagnetic	   gadolinium(III)	   contrast	   agents	   dramatically	   increase	   the	   relaxation	  
rates	  (R1	  and	  R2)	  of	  nearby	  water	  protons,	  with	  the	  percentage	  change	  of	  R1	  in	  tissue	  
being	   much	   greater	   than	   that	   of	   R2.	   Consequently,	   this	   class	   of	   agents	   are	   best	  
visualised	   using	   pulse	   sequences	   that	   emphasize	   changes	   in	   R1,	   which	   are	   more	  
commonly	   known	   as	   T1	   weighted	   images.1	   The	   resulting	   signal	   intensity	   increase	  
enhances	   distinction	   between	   normal	   and	   malignant	   tissue,	   thereby	   making	  
diagnosis	   easier.	   There	   are	   several	   paramagnetic	   gadolinium(III)-­‐based	   contrast	  
agents	   in	   clinical	   use,	   examples	   include	   [Gd(DO3A-­‐butrol)(H2O)]	   and	  
[Gd(DOTA)(H2O)]-­‐.	  









In	   addition	   to	   gadolinium(III)	   contrast	   agents,	   an	   alternative	   class	   of	   agents	   based	  
upon	  polysaccharide	  coated	  iron	  oxide	  particles	  are	  in	  clinical	  practice,	  however	  the	  
most	  commonly	  utilized	  are	  those	  containing	  gadolinium.3	  
	  
Whilst	   MRI	   has	   proved	   extremely	   successful	   and	   popular	   in	   the	   biomedical	   field,	  
studies	  of	  magnetic	   resonance	  spectroscopy	   (MRS)	  can	  be	  hindered	  by	   the	   intense	  
water	   signal,	   often	   requiring	   the	   need	   for	  water	   suppression.	   This	   is	   particularly	   a	  
problem	  in	  the	  detection	  of	  metabolites	  other	  than	  water,	  which	  is	  made	  extremely	  
difficult	  due	  to	  the	  relative	  signal	  intensity.	  In	  recent	  years,	  an	  alternative	  approach	  
using	  heteronuclear	  magnetic	  resonance	  has	  been	  explored.	  The	  key	  benefit	   is	  that	  
heteronuclei	   can	   provide	   physiological	   reporters	   and	   metabolic	   tracers	   while	  
avoiding	  the	  intense	  water	  and	  lipid	  signals.4,5	  Although	  13C,	  23Na	  and	  31P	  nuclei	  are	  
widely	   used	   in	   MRS,	   there	   is	   a	   significant	   loss	   of	   signal	   intensity	   owing	   to	   the	  
considerably	   lower	   gyromagnetic	   ratio	   of	   these	   nuclei	   with	   respect	   to	   1H.	  
Additionally,	   all	   of	   the	   aforementioned	   isotopes	   are	   naturally	   present	   in	   biological	  
tissues	  which	  can	  result	  in	  background	  signal	  issues.	  
	  
1.2	  	  19F	  Magnetic	  Resonance	  Imaging	  and	  Spectroscopy	  	  
	  
There	  are	  many	  merits	  of	  19F	  NMR	  spectroscopy	  that	  justify	  the	  high	  level	  of	  interest	  
and	  current	  research	  in	  this	  field.	  19F	  has	  a	  nuclear	  spin	  of	  ½,	  is	  100%	  abundant,	  has	  
high	  NMR	   sensitivity	   (0.83	   relative	   to	   1H	  NMR)	   and	  an	   impressively	   large	   chemical	  
shift	   range	   (>300	   ppm).	   This	   means	   there	   is	   the	   potential	   for	   multiple	   different	  
fluorinated	   agents	   to	   be	   detected	   simultaneously	   with	   very	   little	   danger	   of	   signal	  




overlap.	   The	   high	   gyromagnetic	   ratio,	   40.05	  MHz/T	   (approximately	   6%	   lower	   than	  
1H),	   allows	   for	   the	   use	   of	   existing	   proton	   NMR	   instrumentation	   with	   minimal	  
adjustment.	  Moreover,	  19F	  MRI	  can	  be	  used	  in	  conjunction	  with	  conventional	  1H	  MRI,	  
providing	  high	  spatial	  resolution	  anatomy.	  	  	  
	  
As	  with	  proton	  NMR	  spectroscopy,	   the	  various	  parameters	   such	  as	   signal	   intensity	  
(SI),	   chemical	   shift	   (δ),	   R1	   and	   R2,	   can	   be	   easily	   manipulated	   to	   extract	   potential	  
information	   on	   the	   desired	   compound.	   Furthermore,	   quantitative	   measurements	  
can	   be	   achieved	   through	   relative	   signal	   intensity	   measurements.	   Over	   the	   years,	  
each	  of	  these	  parameters	  has	  been	  utilised	  in	  the	  development	  of	  19F	  NMR	  reporter	  
molecules,	  for	  which	  a	  few	  examples	  are	  noted	  (Table	  1.2).	  
	  
Parameter	   Fluorinated	  Molecule	   NMR	  Parameter	  
pO2	   Perfluorocarbons	   R1	  (R2)	  
pH	   FPOL	   Δδ,	  J	  
[Mg]2+	   5F-­‐APTRA	   δ, ρατιο 
Gene	  Acitivity	   5FC	   Δδ,	  
Glycolysis	   FDG	   Signal	  Intensity	  
Drug	  Metabolism	   5FU	   Signal	  Intensity	  
	  
Table	  1.2:	  Fluorinated	  reporter	  molecules	  FPOL	  (fluoropyridocol),	  5F-­‐APTRA	  (5-­‐fluoro-­‐2-­‐aminophenol-­‐
N,N,O-­‐triacetate),	  5FU	  (5-­‐fluorocytosine),	  FDG	  (fluorodeoxyglycose)	  and	  5FU	  (5-­‐fluorouracil).6	  
	  
Another	  benefit	  in	  the	  use	  of	  19F	  NMR	  spectroscopy	  is	  that	  there	  is	  very	  little	  natural	  
fluorine	   in	   the	   body	   and	   so	   there	   is	   a	   near-­‐zero	   background	   signal.	   The	   small	  
concentration	  of	  natural	  fluorine	  present	  occurs	  mostly	  in	  the	  form	  of	  solid	  fluorides	  
in	  bones	  and	  teeth.7	  This,	  however,	  does	  not	   interfere	  with	  exogenously	  dispensed	  
fluorine	  compounds	  as	  endogenous	  fluorine	  has	  extremely	  short	  T2	  relaxation	  and	  is	  
therefore	   below	   the	   limits	   of	   NMR	   detection.7	   These	   factors	   combined	   render	   19F	  
MRI	   and	  Magnetic	   Resonance	   Spectroscopy	   (MRS)	   extremely	   promising	   for	   use	   in	  
biological	  studies.	  
	  




Increasingly	  fluorine	  is	  being	  used	  as	  18F	  for	  Positron	  Emission	  Tomography	  (PET).8,	  9	  
One	   of	   the	   key	   strengths	   of	   PET	   is	   the	   ability	   to	   use	   only	   nano-­‐	   to	   femto-­‐molar	  
concentrations,	   in	   comparison	   to	   the	  milli-­‐	   to	  micro-­‐molar	   concentrations	   required	  
for	  NMR	  spectroscopy.	  That	  being	  said,	  18F	  has	  a	  short	  half-­‐life	  (t1/2	  =	  110	  min)	  and	  all	  
18F-­‐	   containing	  probes	   simply	  detect	   radioactive	  decay,	   relaying	  no	   information	  on	  
multiple	  substrates.	   	  Conversely,	  19F-­‐containing	  molecules	  are	  generally	  very	  stable,	  
have	  an	  infinite	  shelf	  life	  and,	  owing	  to	  the	  expansive	  chemical	  shift	  range,	  19F	  NMR	  
spectroscopy	  can	  simultaneously	  provide	  information	  on	  a	  multitude	  of	  molecules.	  
	  
The	  possibility	  of	   19F	  MRI	  was	  first	   reported	  by	  Holland	  et	  al.10	  just	   four	  years	  after	  
the	   development	   of	   1H	   MRI	   by	   Lauterbur	   in	   1973.11	   Numerous	   common	   drugs	  
contain	  a	  fluorine	  atom	  and	  are	  therefore	  ideal	  for	  examination.	  One	  of	  the	  initial	  in	  
vivo	  studies	  investigated	  the	  metabolic	  pathway	  of	  the	  anticancer	  chemotherapeutic	  
agent	  5-­‐fluorouracil	  (Figure	  1.2).	  This	  was	  firstly	  performed	  in	  animals	  by	  Griffiths	  et	  
al.	  in	  198412,	  followed	  by	  the	  first	  human	  study	  by	  Wolf	  et	  al.	  in	  1987.13	  
	  
Figure	  1.2:	  Anticancer	  chemotherapeutic	  agent	  5-­‐fluorouracil.	  
	  
There	   have	  been	  many	   advances	   in	   19F	  NMR	   spectroscopy	   since	   the	   eighties,	  with	  
many	  new	  and	  diverse	  applications	  now	  in	  practice.	  With	  the	  relatively	  large	  number	  
of	   fluorine-­‐containing	   compounds	   being	   studied	   for	   19F	   MRI/MRS,	   it	   is	   useful	   to	  
categorise	   them	   based	   on	   their	   function.	   There	   are	   three	   major	   classes	   of	  
compounds:	   active	   agents,	   whereby	   the	   compound	   experiences	   a	   modification	  
following	   interaction	   with	   the	   local	   environment;	   passive	   agents,	   in	   which	   the	  
compound	  discloses	   information	   regarding	   tissue	  property;	   and	   fluorine-­‐containing	  
drugs	  whose	  metabolic	  fate	  and	  biodistribution	  can,	  in	  principle,	  be	  monitored	  by	  19F	  
NMR	  spectroscopy.	  	  	  	  
	  
	  




1.2.1	  Active	  Agents	  
	  
Active	   agents	   are	   intended	   to	   be	   transformed,	   reversibly	   or	   irreversibly,	   by	   a	  
selective	   parameter	   in	   vivo,	   such	   as	   pH	   or	   enzyme	   activity.	   This	   modification	   can	  
then	   be	   revealed	   by	   a	   detectable	   change	   in	   one	   or	  more	  NMR	  parameters,	  e.g.	   a	  
variation	  in	  chemical	  shift,	  scalar	  coupling	  or	  relaxation	  time.	  	  
	  
1.2.1.1	  pO2	  Reporters	  
	  
In	  cancer	  patients,	  it	   is	  essential	  to	  evaluate	  the	  levels	  of	  tumour	  oxygenation	  prior	  
to	  treatment	  as	  it	  has	  been	  shown	  that	  hypoxic	  tumour	  cells	  are	  much	  less	  receptive	  
to	   radiotherapy,	   and	   hypoxia	   appears	   to	   promote	   malignant	   progression	   and	  
metastasis	   of	   tumours.14	   Furthermore,	   some	   chemotherapeutic	   drugs,	   such	   as	  
streptonigrin	  and	  mitomycin,	  portray	  differing	  levels	  of	  efficiency	  depending	  on	  the	  
degree	  of	  hypoxia	  (Figure	  1.3).15	  	  
	  
Figure	  1.3:	  Streptonigrin	  (A)	  is	  10	  times	  more	  toxic	  to	  normally	  aerated	  cells	  than	  hypoxic	  cells,	  
whereas	  mitomycin	  (B)	  is	  more	  efficient	  in	  hypoxic	  cells.15	  
	  
The	  well-­‐established	  linear	  relationship	  between	  the	  partial	  pressure	  of	  oxygen,	  pO2,	  
and	  the	  19F	  NMR	  spin	  lattice	  relaxation	  rate,	  R1,	  allows	  for	  pO2	  measurement	  in	  vivo	  
(Equation	  1.1).16	  Quantitative	  evaluation	  of	  tissue	  oxygenation	  can	  be	  accomplished	  
by	  monitoring	  the	  reduction	  in	  19F	  NMR	  spin	  lattice	  relaxation	  rate,	  which	  is	  caused	  
by	  the	  paramagnetic	  effect	  of	  dissolved	  molecular	  oxygen.	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  +	  B	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  (1.1)	  
	  
where	  A	  is	  the	  anoxic	  relaxation	  rate	  and	  B	  represents	  the	  sensitivity	  of	  the	  reporter	  
molecule	  to	  the	  paramagnetic	  contribution	  of	  oxygen.	  
	  
Perfluorocarbons	   are	   biocompatible	   in	   an	   emulsified	   form	   and	  when	   administered	  
intravenously	  they	  are	  taken	  up	  in	  the	  well-­‐perfused	  tumour	  regions.17	  The	  level	  of	  
tumour	   oxygenation	   can	   then	   be	   determined	   in	   a	   non-­‐invasive	   manner	   by	  
monitoring	  the	  variation	  in	  relaxation	  rates	  (Figure	  1.4).	  
	  
	  
Figure	  1.4:	  Pseudo	  colour	  calculated	  pO2	   images	  coronal	   (A-­‐C)	  and	  sagital	   (D-­‐F)	  projections	   in	  a	  pig.	  
Three	   separate	   levels	   of	   inspired	   oxygen	   are	   shown:	   (A,	   D)	   ambient	   air	   breathing;	   (B,	   E)	   ~	   31min-­‐1	  
supplemental	  oxygen;	   (C,	   F)	  ~	  61	  min-­‐1	   supplemental	  oxygen.	  Areas	  of	  high	  pO2	  are	  highlighted	   red	  
with	  the	  lower	  pO2	  regions	  shown	  in	  blue.
16	  
	  
There	   are	   numerous	   perfluorocarbons	   available	   and	   the	   decision	   on	   which	   is	  
deemed	   most	   appropriate	   often	   comes	   down	   to	   cost	   and	   availability.	   There	   are	  
however	  some	  practical	  considerations	  that	  should	  be	  made.	  Perfluorocarbons	  such	  
as	   TheroxTM,	   which	   have	   multiple	   19F	   NMR	   spectroscopic	   resonances,	   can	   lead	   to	  
experimental	   complexity,	   unreliable	   relaxation	   measurements	   and	   poor	   signal	   to	  
noise	  ratio	  (Figure	  1.5).	  Conversely,	  through	  clever	  experimental	  design	  the	  multiple	  
resonances	  can	  be	  exploited	  to	  generate	  additional	  spectroscopic	  information.	  
	  





Figure	  1.5:	  Structures	  of	  A)	  Therox	  and	  B)	  Hexafluorobenzene.	  
	  
Hexafluorobenzene,	  which	  has	  only	  one	  19F	  NMR	  resonance	  has	  proved	  very	  popular	  
as	  it	  has	  the	  immediate	  advantage	  of	  experimental	  simplicity	  (Figure	  1.5).	  	  The	  many	  
benefits	  that	  have	  lead	  to	  its	  widespread	  use	  include:	  high	  symmetry;	  optimal	  signal	  
to	  noise	  ratio;	  high	  sensitivity	  to	  pO2	  changes;	   low	  cost;	  ease	  of	  availability;	   lack	  of	  
temperature	  dependence;	  and	  non-­‐toxicity.	  The	  drawback	  with	  hexafluorobenzene	  
is	  its	  high	  volatility	  (b.p.	  81oC)	  and	  low	  flash	  point	  (10oC)	  which	  renders	  it	  unsuitable	  
for	  human	  studies.18	  
	  
Much	   research	   has	   focused	   on	   the	   chemistry	   of	   fluoronitroimidazoles	   to	   detect	  
hypoxia.	   Fluoronitroimidazoles	   are	   capable	   of	   selective	   one-­‐electron	   reduction	   by	  
intracellular	  nitroreductases	  to	  yield	  reactive	  metabolites.	  In	  the	  presence	  of	  oxygen	  
the	  metabolites	  are	  readily	   re-­‐oxidised	  and	  cleared	   from	  the	  cells.	  However,	  under	  
hypoxic	  conditions	  they	  become	  covalently	  bound	  to	  cellular	  constituents,	  providing	  
a	   marker	   of	   tumour	   hypoxia.	   Many	   fluoronitroimidazoles	   have	   been	   explored,	  
examples	  include	  SR-­‐4554,	  CCl	  103F	  and	  Ro	  07-­‐0741,	  composed	  of	  3,	  6	  and	  1	  fluorine	  
atom(s)	  per	  molecule,	  respectively	  (Figure	  1.6).19	  
	  
	  
Figure	  1.6:	  Structures	  of	  Fluoronitroimidazoles	  A)	  SR-­‐4554,	  B)	  CCl	  103F	  and	  C)	  Ro	  07-­‐0741.	  
	  




Initial	  studies	  by	  Aboage	  et	  al.	  found	  that	  the	  retention	  of	  SR-­‐4554,	  quantified	  by	  19F	  
MRS,	   related	   well	   to	   the	   reported	   radiobiological	   hypoxic	   fraction	   of	   mouse	  
tumours.20	  Modulation	   of	   tumour	   oxygenation	   by	   the	   addition	   of	   hydralazine	   and	  
carbogen	  was	  also	  detected,	   successfully	  demonstrating	   the	  exquisite	   sensitivity	  of	  
19F	  MRS.	  Unfortunately,	   further	  studies	  within	   the	  same	  group	  could	   find	  no	   linear	  
correlation	  between	  the	  19F	  retention	  index	  and	  pO2	  parameters.21	  This	  suggests	  that	  
additional	   factors,	   such	   as	   blood	   flow/perfusion	   could	   be	   influencing	   the	   hypoxia	  
marker	   retention.	   	  A	  Phase	   I	   clinical	   study	  by	   Seddon	  et	  al.	   demonstrated	   that	   SR-­‐
4554	  was	  detectable	  in	  tumours	  of	  eight	  patients,	  with	  dosing	  concentrations	  of	  400-­‐
1600	  mg/m2,	  prior	  to	  being	  rapidly	  cleared.22	  It	  was	  reported	  that	  SR-­‐4554	  was	  well	  
tolerated	   however	   dosing	   at	   1600	   mg/m2	   induced	   nausea	   and	   vomiting	   in	   the	  
patient.	  This	  clearly	  demonstrates	  that	  there	  is	  fine	  balance	  to	  be	  struck	  between	  the	  
need	   to	   give	   a	   high	   dose	   to	   optimise	   19F	   signal	   to	   noise,	   and	   the	   need	   to	   avoid	  
unacceptable	  toxicity.	  
	  
In	   2009,	   Tanabe	   et	   al.	   reported	   the	   development	   of	   a	   19F-­‐labelled	   indolequinone	  
derivative,	   consisting	  of	  a	  hypoxia-­‐sensitive	   indolequinone	  parent	  unit	  and	  a	  nona-­‐
fluoro-­‐tert-­‐butyl	  reporter	  group.23	  Under	  hypoxic	  conditions,	  one-­‐electron	  reduction	  
of	  the	  fluorinated	  isoquinoline	  released	  the	  nona-­‐fluoro-­‐tert-­‐butyl	  alcohol	  consituent,	  
indicated	  by	  a	  19F	  NMR	  chemical	  shift	  change	  of	  ~5	  ppm	  (Scheme	  1.1).	  Conversely,	  
the	   addition	   of	   O2	   suppressed	   the	   release	   of	   the	   alcohol	   substituent.	   Further	  
optimization	   of	   the	   chemical	   structure	   is	   needed	   to	   increase	   solubility	   and	  













Scheme	  1.1:	  Bioreduction	  of	  19F-­‐labelled	  indoquinoline	  derivative	  under	  hypoxic	  conditions.	  
	  
	  




1.2.1.2	  Gene	  Therapy	  Reporters	  
	  
Gene	  therapy	  shows	  great	  potential	  for	  the	  treatment	  of	  various	  diseases.	  The	  main	  
difficulty	  of	  this	  work	  is	  the	  ability	  to	  gauge	  the	  success	  of	  transgene	  activity	  in	  situ,	  
in	  terms	  of	  gene	  expression,	  spatial	  extent	  and	  longevity	  of	  expression.	  However,	  by	  
introducing	  a	  non-­‐invasive	  reporter	  gene	   in	  conjunction	  with	  the	  therapeutic	  gene,	  
assessment	   of	   transfection	   can	   be	   quantitatively	   measured.	   Much	   research	   has	  
focused	  on	  reporter	  genes	  associated	  with	  optical	  imaging	  due	  to	  the	  low	  cost,	  ease	  
of	  availability	  and	  high	   sensitivities.24	  Other	   strategies	   include	   radionuclide	   imaging	  
and	  NMR	  spectroscopy.25	  
	  
LacZ,	  which	  encodes	  β-­‐galcosidase,	  has	  historically	  been	  the	  reporter	  gene	  of	  choice	  
for	  verifying	  effective	  transfection	   in	  biochemistry.	  Mason	  et	  al.	  devised	  a	  19F	  NMR	  
approach	  that	  assesses	  the	  β-­‐galactosidase	  activity	  in	  vivo.26	  The	  rapid	  cleavage	  of	  2-­‐
fluoro-­‐4-­‐nitrophenyl	  β-­‐D-­‐galactopyranoside	   (OFPNPG),	   in	   response	   to	   the	  action	  of	  
β-­‐galcosidase,	  to	  form	  the	  aglycone	  2-­‐fluoro-­‐4-­‐nitrophenol	  (OFPNP),	  results	  in	  a	  pH-­‐
dependent	   19F	   chemical	   shift	   of	   Δδ=	   -­‐4	   to	   –	   6	   ppm,	   relative	   to	   the	   substrate.	   The	  
signal	  of	  the	  aglycone	  is	  separated	  sufficiently	  from	  the	  substrate,	  thereby	  revealing	  
distribution	   of	   each	   entity	   separately	   and	   allowing	   for	   chemical	   shift	   selective	  
imaging	  at	  4.7	  T	  (Figure	  1.7).27	  The	  reduced	  intensity	  of	  the	  product	  signal	  is	  due	  to	  
the	  longer	  T1	  of	  the	  aglycone	  in	  comparison	  with	  the	  substrate.	  It	  may	  be	  possible	  to	  
selectively	  determine	  the	  pH	  at	  the	  site	  of	  enzyme	  activity	  as	  the	  aglycone	  product	  is	  
pH-­‐sensitive	  and,	  importantly,	  the	  pKa	  is	  in	  the	  physiological	  range.	  
	  
In	  an	  attempt	  to	  further	  enhance	  sensitivity	  and	  reduce	  toxicity,	  the	  introduction	  of	  a	  
trifluoromethyl	  group	  (CF3),	  in	  place	  of	  the	  single	  fluorine	  atom,	  was	  undertaken.	  As	  
expected,	  the	  signal	  to	  noise	  ratio	  was	  enhanced,	  however	  the	  chemical	  shift	  change	  
was	   reduced	   (Δδ	   <	   2	   ppm),	   most	   likely	   due	   to	   the	   transmission	   of	   the	   electron	  
density	  redistribution	  through	  an	  additional	  carbon-­‐carbon	  bond.	  	  
	  
	  





Figure	  1.7:	  Stacked	  NMR	  plot	  demonstrating	  the	  conversion	  of	  OFPNPG	  (2.9	  mg;	  9	  mmol)	  by	  PC3-­‐lacZ	  
prostate	   cancer	   cells	   (2	   x	   107	   in	   PBS,	   pH=7.4	   at	   37oC)	   to	   the	   aglycone	  OFPNP	  by	   stably	   transfected	  
PC3-­‐lacZ	  cells.	  	  OFPNP	  resonates	  approximately	  5	  ppm	  upfield	  of	  the	  substrate	  (OFPNPG,	  grey	  traces,	  
OFPNP	  black	  traces).	  Each	  spectrum	  was	  acquired	  in	  102	  s,	  and	  the	  conversion	  of	  OFPNPG	  to	  OFPNP	  
was	  assessed	  over	  a	  period	  of	  31	  min.	  The	  resulting	  concentration	  of	  OFPNP	  was	  not	  reported.	  27	  
	  
The	   success	   of	   many	   different	   types	   of	   anti-­‐cancer	   therapies	   is	   limited	   by	   their	  
toxicity	  to	  normal,	  healthy	  tissues.	  Gene	  directed	  enzyme	  prodrug	  therapy	  (GDEPT)	  
is	  a	  method	  developed	  to	  address	  this	  problem.	  Firstly,	  tumour	  cells	  are	  transfected	  
by	  a	  so-­‐called	  ‘suicide’	  gene.	  This	  gene	  can	  then	  selectively	  code	  an	  enzyme	  capable	  
of	   converting	   a	   nontoxic	   prodrug	   into	   a	   highly	   potent	   chemotherapeutic	   agent,	  
which	  in	  turn	  kills	  the	  cells	  expressing	  the	  gene.	  For	  the	  development	  of	  GDEPT,	  the	  
ability	   to	  monitor	   the	  degree	  of	   targeted	   gene	  delivery,	   in	   addition	   to	   subsequent	  
prodrug	   delivery	   and	   activation,	   would	   be	   of	   great	   value	   in	   both	   preclinical	   and	  
clinical	  development	  and	  evaluation.	  
	  
Cytosine	  deaminase	  (CD)	  is	  a	  microbial	  enzyme	  found	  in	  several	  bacteria	  and	  fungi,	  
but	  not	  in	  mammalian	  cells.	  CD	  is	  able	  to	  deaminate	  the	  minimally	  toxic	  pyrimidine	  
derivative	   5-­‐fluorocytosine	   (5-­‐FC)	   to	   the	   cytotoxic	   5-­‐fluorouracil	   (5-­‐FU).	   Ross	  et	   al.	  
demonstrated	   the	   feasibility	   of	   GDEPT,	   utilising	   subcutaneous	   human	   colorectal	  
carcinoma	  xenographs	  in	  nude	  mice	  transfected	  with	  yeast	  CD.28	  	  The	  conversion	  of	  
5-­‐FC	  to	  5-­‐FU	   in	  vivo	  resulted	  in	  a	  19F	  chemical	  shift	  change	  of	  ~1.5	  ppm,	  confirming	  
gene	   activity	   (5-­‐FC	   -­‐49.6	   ppm,	   5-­‐FU	   -­‐48.5	   ppm,	   at	   7T).	   Several	   reports	   of	   similar	  
systems	  in	  vivo	  have	  been	  reported	  in	  recent	  years.	  29,	  30	  
	  




More	   recently,	   Payne	   et	   al.	   reported	   a	   GDEPT	   strategy	   utilising	   another	   bacterial	  
gene,	  carboxypeptidase	  G2	  (CPG2).31	  This	  gene	  successfully	  activates	  the	  prodrug	  {4-­‐
[bis(2-­‐chloroethyl)amino]-­‐3,5-­‐difluorobenzoyl}-­‐L-­‐glutamic	   acid	   to	   its	   toxic	  
counterpart	  by	  cleavage	  of	  the	  glutamate	  group	  (Figure	  1.8).	  The	  resulting	  1	  ppm	  19F	  
chemical	  shift	  separation	  is	  adequate	  to	  allow	  for	  detection	  of	  prodrug	  activation	  in	  
vivo,	  however	  the	  compound	  is	  readily	  hydrolysed	  and	  protein	  binding	  broadens	  the	  
signal.	   To	   enhance	   the	   CPG2	   substrate,	   hydroxyethyl	   groups	   were	   introduced,	   in	  
place	  of	   the	  chloroethyl	  groups,	   resulting	   in	  a	  non-­‐toxic	  and	  stable	  pro-­‐drug.	  Upon	  
cleavage	  by	  CPG2	  there	  is	  a	  1.1	  ppm	  19F	  chemical	  shift	  separation	  and,	  importantly,	  
the	  activated	  drug	  has	  a	  narrow	  MRS	  resonance	  in	  the	  presence	  of	  bovine	  and	  foetal	  
bovine	  albumin.	  31	  	  	  
	  
Figure	  1.8:	  Activation	  of	  prodrug	  {4-­‐[bis(2-­‐chloroethyl)amino]-­‐3,5-­‐difluorobenzoyl}-­‐L-­‐glutamic	  acid.31	  
	  
1.2.1.3	  Enzyme	  Reporters	  
	  
The	  use	  of	   fluorinated	  compounds	   in	  studies	  of	  enzyme	  activity	   is	  of	  great	   interest	  
because	  of	   the	  possibility	  of	  carrying	  out	   the	  measurements	  non-­‐invasively	   in	  vivo.	  
Owing	   to	   steric	   and	   electrostatic	   considerations,	   a	   hydroxyl	   group	   can	   easily	   be	  
replaced	  by	  a	   fluorine	  atom	   in	  a	  variety	  of	   sugars	  with	  very	   little	  overall	   structural	  
disruption.	   As	   they	   still	   retain	   their	   enzyme	   substrate	   activity,	   they	   are	   ideal	  
molecules	   to	   probe	   enzymatic	   activity,	   and	   many	   of	   the	   early	   examples	   utilised	  
these	  .32	  	  	  
	  




Mendz	   et	   al.	   focused	   their	   work	   on	   fluorinated	   compounds	   containing	   carboxylic	  
ester	  groups	  to	  measure	  carboxylesterase	  activities	  in	  two	  different	  cellular	  systems:	  
erythrocytes	   and	   in	   the	   bacterium	   Helicobacter	   pylori.33	   Ethyl	   fluoroactetate	   and	  
diethyl	   fluoromalonate	   penetrated	   through	   the	   cell	   membrane	   where	   they	   were	  
subsequently	   converted	   to	   the	   corresponding	   acid	   via	   the	   carboxylesterases,	  
revealed	  by	  a	  shift	  in	  19F	  MR	  signal	  (Table	  1.3)	  
	  	  
Probe	   δF	  Free	  Acid	  (ppm)	   δF	  Ester	  (ppm)	  
Ethyl	  fluoroacetate	   -­‐58.8	   -­‐45.9	  
Diethyl	  fluoromalonate	   -­‐63.2	   -­‐72.8	  
	  
Table	  1.3:	  19F	  Chemical	  shifts	  to	  the	  free	  acid	  and	  ester	  forms	  of	  the	  different	  probes	  incubated	  with	  
rabbit	  liver	  esterase	  at	  310	  K	  in	  Hepes/Phosphate	  buffer,	  282	  MHz.	  Initial	  substrate	  concentration	  was	  
8	  mM.	  Chemical	  shifts	  are	  quoted	  relative	  to	  an	  external	  6-­‐Fluoro-­‐Tryptophan	  reference	  at	  0.0	  ppm.	  33	  
	  
Cubic	   octameric	   polyhedral	   oligomeric	   silsesquioxanes	   (POSS)	   are	   an	   excellent	  
scaffold	  for	  the	  accumulation	  of	  equivalent	  fluorine	  atoms.	   	  Chujo	  et	  al.	  reported	  a	  
highly	   fluorinated	   POSS	   (F-­‐POSS),	   employing	   trifluoroacetyl	   groups	   as	   the	   19F	   MR	  
signal	  moiety,	  covalently	  linked	  to	  silica	  nanoparticles	  (NPs)	  via	  a	  phosphordiamidate	  
linker.34	  The	  limited	  rotation	  of	  the	  linked	  F-­‐POSS	  results	   in	  significant	   loss	  of	  signal	  
intensity,	   owing	   to	   the	   extreme	   broadening	   of	   the	   19F	  MR	   signal.	   However,	   in	   the	  
presence	   of	   alkaline	   phosphatase	   (AP)	   the	   phosphordiamidate	   linker	   is	   cleaved	   by	  
enzymatic	   digestion,	   indicated	  by	   an	  enhancement	  of	   19F	  MR	   signal.	   Two	  different	  
sizes	  of	  NPs,	  280	  nm	  and	  150	  nm	  diameter,	  were	  investigated.	  The	  resulting	  rate	  of	  
signal	  intensity	  increase	  was	  shown	  to	  be	  essentially	  independent	  of	  size	  of	  NPs	  (t1/2	  
=	   6.2	   h	   and	   6.0	   h,	   respectively).	   While	   there	   remains	   room	   to	   improve	   on	   signal	  
sensitivity	   and	   solubility,	   there	   is	   also	   the	   exciting	   possibility	   of	   developing	   this	  
system	  further.	  For	  example,	  through	  modification	  of	  the	  linker	  the	  sensing	  of	  other	  
various	   enzymes	   and	   proteases	   could	   be	   possible.	   Moreover,	   it	   could	   have	   the	  
potential	  to	  probe	  pH	  via	  hydrolysis.	  
	  




Kikuchi	  et	  al.	  have	  examined	  the	  possibility	  of	   in	  vitro	   real	   time	   imaging	  of	  enzyme	  
activities,	   which	   could	   potentially	   offer	   a	   vast	   quantity	   of	   information	   on	   living	  
systems.35	   This	   is	   based	   on	   the	   ability	   of	   protease	   activities	   to	   modulate	   the	  
transverse	  relaxation	  time,	  T2.	  The	  probe	  consists	  of	  three	  sections;	  a	  Gd3+	  complex,	  
a	  19F-­‐containing	  group,	  and	  a	  short	  peptide	  linker,	  which	  acts	  as	  a	  substrate	  for	  the	  
enzyme	  caspase-­‐3	  (Figure	  1.9).	  Caspase-­‐3	  is	  used	  in	  the	  evaluation	  of	  cancer	  agents	  
as	   it	   is	   an	   effective	  marker	   enzyme	  of	   apoptosis.	  Upon	   cleavage	   of	   the	   C-­‐terminal	  
peptide	   bond	   by	   caspase-­‐3,	   the	   paramagnetic	   effect	   felt	   by	   the	   19F	   nucleus	   is	  
reduced	   and	   therefore	   the	   signal	   intensity	   increases	   as	   the	   19F	   linewidth	   narrows.	  
However,	  the	  high	  concentrations	  required	  for	  the	  detection	  of	  protease	  activity	  (1	  
mM,	  37	  0C,	  70	  min,	  7	  T),	  due	  to	  sensitivity	  limitations,	  suggest	  that	  this	  method	  will	  




































Figure	  1.9:	  The	  design	  principle	  of	  a	  19F	  MRI	  conjugate	  probe.	  
	  
1.2.1.4	  pH	  Reporters	  
	  
The	  pH	  of	  biological	  systems	  plays	  an	  important	  role	  in	  many	  physiological	  processes,	  
therefore	  a	  great	  deal	  of	  research	  has	  focused	  on	  optimising	  methods	  for	  measuring	  
intracellular	   pH.	   Owing	   to	   the	   high	   sensitivity	   of	   the	   19F	   NMR	   chemical	   shift	   in	  
relation	  to	  the	  microenvironment,	  many	  pH	  indicators	  incorporating	  a	  fluorine	  atom	  
(or	   fluorine-­‐containing	   group)	   have	   been	   investigated.	   In	   several	   cases	   the	  
fluorinated	  molecules	  exploit	  the	  chemical	  shift	  differences	  of	  their	  protonated	  and	  
deprotonated	   moieties.	   If	   they	   are	   in	   fast	   exchange	   generally	   only	   one	   signal	   is	  




observed,	  as	  the	  weighted	  mean	  shift	  of	  the	  acid	  and	  base	  forms.	  The	  pH	  can	  then	  
be	  measured	  using	  the	  Henderson-­‐Hasselbalch	  equation:	  
	  
pH	  =	  pKa	  +	  log10	  [(δobs	  –	  δacid)/	  (δbase	  –	  δobs)]	  	  	  	  	  	  	  	  	  	  	  	  	  	  (Equation	  1.2)	  
	  
where	  δacid	  and	  δbase	  	  is	  the	  limiting	  chemical	  shift	  in	  acid	  and	  base,	  respectively,	  and	  
δobs	  is	  the	  chemical	  shift	  observed	  at	  a	  given	  pH.	  Greatest	  sensitivity	  is	  found	  close	  to	  
the	  pKa	  due	  to	  the	  non	   linear	   form	  of	   the	  equation.	   If	   the	  exchange	   is	  slow	  on	  the	  
NMR	   time	   scale,	   both	   the	   protonated	   and	   deprotonated	   forms	   will	   appear	   as	  
separate	  signals.	  The	  pH	  can	   then	  be	  calculated	  by	  measuring	   the	   ratio	  of	   the	   two	  
observed	  peaks.	  
	  
The	   pioneering	   work	   by	   Deutsch	   et	   al.	   presented	   a	   series	   of	   mono-­‐,	   di-­‐,	   and	   tri-­‐
fluoro-­‐	  α-­‐methylalanines,	  capable	  of	  measuring	  intracellular	  pH	  in	  human	  peripheral	  
blood	   lymphocytes	   by	   19F	   NMR.36	   After	   crossing	   the	   cellular	   membrane	   into	   the	  
cytoplasm,	  they	  are	  subsequently	  hydrolysed	  to	  give	  the	  free	  amino	  acid,	  generating	  
the	   pH-­‐sensitive	   moiety.	   Tandem	   experiments	   with	   both	   the	   di-­‐	   and	  
trifluoromethylalanine	   methyl	   esters	   showed	   that	   intracellular	   pH	   measurements	  
from	   the	   two	   probes	   in	   the	   same	   cell	   suspension	   agreed	   to	   within	   0.05	   pH	   units	  
(Figure	  1.10).	  	  
	  
Figure	  1.10:	   In	  vitro	  19F	  NMR	  spectroscopic	  study	  of	  human	  lymphocytes	  with	  difluoromethylalanine	  
methyl	   ester	   (1	  mM,	   labelled	   CF2)	   and	   trifluoromethylalanine	  methyl	   ester	   (0.17	  mM,	   labelled	   CF3)	  
added	  at	  25oC,	  200	  MHz.	  Spectra	  were	  taken	  at	  6	  min	  intervals	  (1000	  scans,	  4.2	  μs	  pulse,	  acquisition	  
time	  0.35	   s).	   The	   resonances	  marked	  o	   arise	   from	  extracellular	   species,	  while	   those	  marked	   i	   arise	  
from	  intracellular	  species.36	  





A	   major	   drawback	   of	   this	   system	   is	   the	   associated	   error	   in	   determining	   accurate	  
chemical	  shift	  values,	  as	   illustrated	   in	  Figure	  1.10.	  The	  early	  work	  by	  Deutsch	  et	  al.	  
did	   however	   lead	   the	  way	   for	   the	  development	  of	   subsequent	   non-­‐toxic,	   19F	  NMR	  
indicators	  capable	  of	  measuring	  intracellular	  pH.	  	  
	  
An	   interesting	   example	   of	   a	   reporter	   capable	   of	   both	   intra-­‐	   and	   extracellular	   pH	  
measurement	   in	   blood	   cells	   is	   6-­‐fluoropyridoxamine	   (6-­‐FPAM).37	   The	   structure	   is	  
based	  on	  the	  pyridine	  vitamin	  B6	  core,	  with	  the	  introduction	  of	  a	  fluorine	  atom	  para	  
to	   the	   3	   phenolic	   group	   and	  modification	   of	   the	   4-­‐	   and	   5-­‐position	   hydroxymethyl	  
moieties	   (Figure	   1.11).	   6-­‐FPAM	   is	   readily	   transported	   across	   the	   cell	   membrane,	  
exhibits	   a	   pKa	   of	   7.05,	   provides	  well	   resolved	   resonances	   and	   has	   a	   chemical	   shift	  
independent	   of	   environment,	   obviously	   excluding	   pH.	   6-­‐FPAM	   shows	   a	   single	  
resonance	  in	  solution,	  indicative	  of	  fast	  exchange	  between	  acid	  and	  base	  forms,	  and	  
titration	   in	  plasma	  and	  blood	  cells	  showed	  no	  change	   in	  results.	  The	  chemical	  shift	  
range	   is	   10	   ppm,	   associated	   with	   the	   protonation	   and	   deprotonation	   of	   the	   3-­‐
phenolic	  OH	  group.	  Unfortunately,	  the	  anaesthetic	  gas	  isoflurane	  also	  appears	  in	  the	  
same	  spectral	  region,	  thereby	  causing	  complexity	  in	  the	  interpretation	  of	  data.	  This	  
could	  be	  prevented	  by	  using	  a	  different	  anaesthetic,	  or	  alternatively	  the	  introduction	  
of	  a	  CF3	  group	   in	  place	  of	  the	  fluorine	  atom	  would	  shift	   the	  reporter	  signal	  so	  that	  
there	  is	  no	  longer	  any	  interference.	  This	  could	  however	  alter	  the	  water	  solubility	  and	  




Figure	  1.11:	  Structure	  of	  6-­‐FPAM.	  
	  
In	  2009,	  Fahmy	  et	  al.	  reported	  a	  new	  class	  of	  fluorinated	  polyamidoamine	  (PAMAM)	  
dendrimers	   that	   exhibit	   a	   stimulus-­‐induced	   response	   to	   low	   external	   pH,	   which	  
triggers	   the	   dendrimers	   to	   irreversibly	   break	   down	   into	   their	   corresponding	  




dendrons.38	   19F	   MRI	   experiments	   were	   performed	   with	   chemical	   shift	   imaging	  
focused	   on	   the	   CF3	   resonance.	   The	   particulates	   were	   surface-­‐modified	   with	  
poly(ethylene	  glycol)	  (PEG),	  to	  enhance	  circulation	  and	  transportation	  in	  blood,	  prior	  
to	  intravenous	  injection	  into	  female	  B6	  mice.	  The	  disassembly	  of	  the	  dendrimers	   in	  
vivo	  was	   revealed	  by	   a	   reduction	   in	   signal	   intensity,	   caused	  by	   the	  decrease	   in	   19F	  
longitudinal	   relaxation	   rate	   at	   lower	   pH.	   Additionally,	   the	   19F	   signal	   linewidths	  
narrowed	   and	   became	   significantly	   sharper	   with	   altering	   the	   external	  
microenvironment	   from	  physiological	   pH	   to	   low	  pH	   (pH=7.5,	  ω1/2	   =	   300	  Hz,	   pH=2,	  
ω1/2	   =	   ~100	  Hz,	   4.0	  T).	   Scanning	  electron	  micrography	   (SEM)	   confirmed	   the	  break-­‐
down	  of	  the	  dendrimers.	  The	  amphiphilic	  nature	  and	  easily	  modifiable	  surface	  of	  the	  
PAMAM	   dendrimer	   opens	   up	  many	   possibilities	   for	   future	   development,	   targeted	  
drug	  delivery	  and	  responsive	  molecular	  imaging.	  	  
	  
Nanosized	   particles	   (<	   100	   nm)	   have	   been	   shown	   to	   accumulate	   in	   solid	   tumours	  
through	  enhanced	  permeability	  and	  retention	  (EPR)	  effects.39	  As	  such,	  Nagasaki	  et	  al.	  
have	   recently	   focused	   their	   research	   on	   the	   development	   of	   pH-­‐responsive	  
PEGylated	   19F	   nanoprobes.40	   The	   probe	   consists	   of	   two	   sections;	   a	   polyamine	   gel	  
core	  cross-­‐linked	  with	   trifluoromethyl	  containing	  groups,	  and	  an	  external	  matrix	  of	  
PEG	   chains	   that	   support	   acetal	   groups	   to	   enable	   linkage	   to	   tumour-­‐specific	  
molecules	  (Figure	  1.12).	  	  
	  
Figure	  1.12:	  Schematic	  illustration	  of	  tumour-­‐specific	  nanoprobe.40	  
	  
The	   fluorinated	  PEGylated	  nanogels	  have	  been	  designed	   to	  observe	   changes	   in	  pH	  
values	   between	   pH	   6.5	   and	   7.4,	   signified	   by	   a	   change	   in	   19F	   signal	   intensity.	   This	  




result	   is	   attributed	   to	   the	   unique	   ability	   of	   the	   gel	   core	   to	   swell	   at	   acidic	   pH	   and	  
shrink	  in	  basic	  media,	  thereby	  altering	  the	  molecular	  motion	  of	  the	  19F	  atoms	  and,	  in	  
turn,	  affecting	  the	  transverse	  relaxation	  time	  T2.	  At	  lower	  pH,	  the	  amino	  groups	  are	  
protonated,	   resulting	   in	   an	   8.7	   fold	   larger	   hydrodynamic	   volume	   in	   comparison	   to	  
that	  at	  the	  physiological	  pH,	   in	  addition	  to	  an	  increase	  in	  the	  ion	  osmotic	  pressure.	  
(Table	  1.4)	  
	  
pH	   Diameter	  (nm)	   T1	  (ms)	   T2	  (ms)	   S/N	  
7.4	   52	   <30	   <1	   0.0	  
6.5	   107	   280	   56.8	   7.6	  
5.5	   109	   304	   53.2	   5.8	  
	  
Table	  1.4:	  Changes	  in	  PEGylated	  nanogel	  parameters	  with	  varying	  pH.	  40	  
	  
As	   the	   extracellular	   pH	  of	   the	   tumour	   environment	   is	   typically	   0.4	   to	   1.0	   pH	  units	  
lower	   than	   physiological	   pH,41	   the	   probe	   should	   intensify	   signal	   inside	   the	   tumour	  
and	  essentially	  ‘turn-­‐off’	  the	  signal	  outside	  of	  the	  tumour.	  While	  phantom	  19F	  and	  1H	  
MR	  images	  yielded	  promising	  results,	   in	  vivo	  experiments	  need	  to	  be	  performed	  to	  
determine	   if	   the	   ‘on-­‐off’	   switch	   regulation	   successfully	   works	   in	   tumour	  
environments.	  
	  
1.2.1.5	  Metal	  Ion	  Reporters	  
	  
Metal	   ions,	  such	  as	  Ca2+	  and	  Mg2+,	  are	  present	  in	  many	  cells.	  Changes	  in	  their	   local	  
concentration	  occurs	  during	  many	  cellular	  processes,	  driving	   the	  desire	   for	   specific	  
reporter	   molecules.	   In	   the	   late	   1980s,	   fluorinated	   derivatives	   of	   the	   chelator	   o-­‐
aminophenol-­‐N,N,O-­‐triacetic	   acid	   (APTRA)	  were	  exploited	   for	   the	  determination	  of	  
cytosolic,	  ionized	  magnesium	  levels	  by	  19F	  NMR	  spectroscopy.42	  The	  magnesium	  ions	  
are	   in	  slow	  exchange	  with	  the	  5F-­‐APTRA	  and	  MF-­‐APTRA	  (Figure	  1.13),	  as	  shown	  by	  
the	   presence	   of	   both	   free	   and	   bound	   chelates.	   The	   relatively	   large	   chemical	   shift	  
change	  exhibited	  (Δδ≈10	  ppm)	  allows	  for	  the	  distribution	  of	  each	  entity	  separately.	  
Although	   complexation	   of	   the	   fluorinated	   APTRA	   derivatives	   with	   Ca2+	   ions	  




generated	   similar	   chemical	   shifts	   to	   that	   of	   complexed	   magnesium,	   previous	  
determinations	  in	  these	  cells	  proved	  that	  cytosolic	  free	  calcium	  is	  present	  at	  too	  low	  
a	   level	   to	   complex	   the	   indicator.	   Subsequent	   studies	  on	  APTRA	  derivatives	   include	  
the	  determination	  of	  changes	  in	  cystosolic	  free	  magnesium	  ion	  concentration	  during	  




Figure	  1.13:	  Structure	  of	  A)	  5F-­‐APTRA,	  B)	  MF-­‐APTRA	  and	  C)	  5FBAPTA.	  
	  
A	   reporter	   molecule	   capable	   of	   detecting	   many	   different	   divalent	   metal	   ions,	  
including	   	   Zn2+,	   Pb2+,	   Fe2+	   and	   Ca2+	   is	   5,5,-­‐difluoro-­‐1,2-­‐bis(o-­‐aminophenoxy)ethane-­‐
N,N,N’,N’-­‐tetraacetic	  acetic	  acid,	  more	  commonly	  known	  as	  5FBAPTA	  (Figure	  1.13).44	  
There	   is	   no	   need	   for	   an	   external	   reference	   with	   5FBAPTA,	   because	   the	   free	   and	  
bound	   moieties	   are	   in	   slow	   exchange	   on	   the	   NMR	   timescale,	   and	   appear	   as	   two	  
separate	  resonances.	  The	  metal	   ion	  concentration	  can	  then	  be	  calculated	  from	  the	  
signal	  integrals	  (Equation	  1.3).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  [M2+]	  =	  KD	  [M2+	  -­‐	  5FBAPTA]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (Equation	  1.3)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  [5FBAPTA]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
where	   KD	   is	   the	   dissociation	   constant	   and	   [M2+-­‐5FBAPTA]	   and	   [5FBAPTA]	   are	   the	  
peak	   integrals	   of	   the	   metal	   bound	   and	   free	   chelator	   signals,	   respectively.	   It	   is	  




important	  to	  note	  that	  KD	  depends	  on	   ionic	  strength,	  pH	  and	  concentration	  of	   free	  
Mg,	  all	  of	  which	  need	  to	  be	  evaluated	  independently	  for	  the	  above	  equation	  to	  hold	  
true.	  
	  
Schanne	  et	  al.	  cleverly	  used	  5FBAPTA	  to	  probe	  the	  effect	  of	  lead	  on	  intracellular	  free	  
Ca2+	  concentration	   in	  the	  rat	  osteoblastic	  bone	  cell	   line	  ROS	  17/	  2.8.45	  Ca-­‐5FBAPTA	  
and	  Pb-­‐FBAPTA	  resonances	  occur	  at	  δF	  5.8	  and	  4.9	  ppm,	  respectively,	  from	  the	  free	  
reporter	  molecule.	  Addition	  of	  5	  and	  25	  µM	  of	  Pb2+	   resulted	   in	  a	  50	  %	  and	  120	  %	  
increase	   in	   [Ca2+]	   over	   a	   time	   period	   of	   5	   h.	   This	   simple	   experiment	   successfully	  
demonstrated	  the	  unique	  ability	  of	  5FBAPTA	  to	  quantitatively	  measure	  multiple	  ion	  
concentrations	  in	  tandem.	  	  
	  
Plenio	   and	   Diodone	   synthesised	   a	   series	   of	   fluoro-­‐cryptands,	   capable	   of	   forming	  




Figure	  1.14:	  Structure	  of	  A)	  FN2O3	  and	  B)	  FN2O4.	  
	  
The	  change	  in	  19F	  NMR	  shift	  of	  FN2O4	  complexes	  correlates	  well	  with	  the	  ionic	  radii	  
of	  the	  metal	  ions,	  as	  does	  the	  1JCF	  coupling	  constants	  which	  range	  from	  253.0	  Hz	  for	  
FN2O4	   to	  238.5	  Hz	   for	   [Li.FN2O4]	   (Table	  1.5).	  These	  values	  give	  an	   indication	  of	   the	  
strength	   of	   metal-­‐fluorine	   interactions,	   suggesting	   that	   the	   smaller	   metals	   ions	  
migrate	   into	   the	   cavity	   and	   interact	  with	   the	   C-­‐F	   unit	  with	   less	   difficulty	   than	   the	  
larger	  ions.	  While	  this	  system	  benefits	  from	  multiple	  ions	  being	  able	  to	  be	  detected	  
simultaneously,	  it	  lacks	  capability	  for	  quantitative	  analysis.	  
	  
	  




	  	   δF/	  FN2O3	   δF/	  FN2O4	  
Ligand	   -­‐109.1	   -­‐114.4	  
Li+	   -­‐18.2	   -­‐12.8	  
Na+	   -­‐5.1	   -­‐11	  
K+	   N/A	   -­‐4.5	  
Rb+	   N/A	   -­‐1.7	  
Cs+	   Several	  Species	   -­‐4.6	  
Ca2+	   -­‐9.2	   -­‐11.9	  
Sr2+	   -­‐3.1	   -­‐9.5	  
Ba2+	   N/A	   -­‐5.1	  
	  
Table	  1.5:	  19F	  NMR	  shifts	  of	  Fluoro	  Cryptands,	  FN2O3	  and	  FN2O4,	  and	  their	  metal	  complexes	  
53	  
	  
1.2.2	  Passive	  Agents	  
	  
Passive	   agents	   do	   not	   interact	   with	   the	   local	   environment,	   they	   merely	   occupy	   a	  
space	   in	   tissue	  or	  organs.	   Such	  agents,	   as	  discussed	   in	  detail	  below,	  are	  extremely	  
useful	  in	  disclosing	  information	  on	  anatomical	  properties,	  such	  as	  vascular	  volume	  or	  
blood	  flow.	  	  
	  
1.2.2.1	  Marker	  for	  Alzheimers	  Disease	  
	  
Alzheimers	   disease	   is	   the	   principal	   cause	   of	   senile	   dementia,	   characterised	   by	  
amyloidosis	   and	   tauopathy.47	   Accumulation	   of	   plaques	   composed	   of	   amyloid	   β	  
peptide	  in	  human	  brains	  can	  be	  found	  many	  years	  before	  the	  launch	  of	  the	  disease,	  
thus	   detection	   of	   such	   plaques	   is	   vital	   in	   diagnosis	   of	   pre-­‐symptomatic	   patients.	  
Highuchi	   et	   al.	   intraveneously	   administered	   a	   19F-­‐containing	   amyloidophilic	  
compound	   (FSB,	   20	  mg	   kg-­‐1)	   to	   amyloid	   precursor	   protein	   transgenic	  mice	   (Figure	  
1.15).48	  	  The	  FSB,	  capable	  of	  crossing	  the	  blood-­‐brain	  barrier,	  specifically	  labelled	  the	  
amyloid	  β	  plaques	  and	  allowed	  them	  to	  be	  visualised	  in	  vivo	  by	  19F	  and	  1H	  MRI.	  The	  
drawback	  of	  the	  system	  was	  the	  low	  sensitivity	  of	  the	  19F	  MRI	  method.	  





Figure	  1.15:	  Structure	  of	  FSB	  
	  
The	   toxicity	   profile	   of	   FSB,	   examined	   as	   part	   of	   the	   study,	   indicated	   that	  
administrations	   >	   40	   mg	   kg-­‐1	   could	   be	   nephrotoxic.	   Thus,	   it	   was	   not	   possible	   to	  
increase	  the	  dosage	  in	  an	  attempt	  to	  enhance	  sensitivity.	  Flaherty	  et	  al.	  tackled	  this	  
problem	  by	  modifying	  the	  structure	  to	  include	  multiple	  equivalent	  fluorine	  atoms	  in	  
the	   form	  of	  a	   tetrafluorophenyl	  core	  or	  symmetrical	   trifluoromethyl	  groups	   (Figure	  
1.16).49	  Aside	  from	  the	  increase	  in	  signal,	  it	  was	  found	  that	  the	  more	  electropositive	  
tetrafluorophenyl	   core	  provided	  a	   stronger	   interaction	  with	   the	  amyloid	  β	  plaques	  
than	   FSB.	   This	   observation	  was	   tentatively	   attributed	   to	   the	   ability	   of	   the	   fluorine	  
atoms	  to	  form	  hydrogen	  bonds	  and	  interact	  with	  cations.	  The	  former	  is	  plausible,	  the	  
latter	  is	  very	  unlikely.	  
	  
	  
Figure	  1.16:	  Structures	  of	  A)	  tetraphenyl	  core	  derivative	  and	  B)	  trifluoromethyl	  derivative	  
	  
1.2.2.2	  Volume	  Reporters	  
	  
The	   significant	   gas	   solubility	   and	   strong	   ability	   for	   transportation	   of	   oxygen	   and	  
carbon	   dioxide	   renders	   perfluorocarbons	   ideal	   candidates	   as	   synthetic	   blood	  




substitutes.50	  Perfluorocarbons	  in	  their	  biocompatible	  emulsified	  form	  are	  utilised	  in	  
the	  measurement	  of	  lung	  filling	  by	  19F	  NMR	  spectroscopy.	  Relaxation	  measurements	  
are	   examined	   to	   gauge	   the	   regional	   pO2	   values	   in	   the	   lungs,	   which	   subsequently	  
leads	   to	   the	   determination	   of	   lung	   volume.	   The	   perfluorocarbons	   are	   often	  
administered	  to	  the	  lungs	  in	  the	  form	  of	  aerosols	  despite	  this	  being	  a	  rather	  stressful	  
approach	   for	   the	  test	  subjects.	  An	  alternative,	   less	  aggressive,	  method	   is	   to	  use	  an	  
inert	   gas	   and	   initial	   studies	   utilising	   CF4,	   C2F6	   and	   SF6	   have	   been	   explored.	   In	  
particular,	  SF6	  has	  shown	  potential	   for	  detection	  of	  diseases,	   including	  emphysema	  
and	  lung	  cancer	  (Figure	  1.17).51	  However,	  specialised	  instrumentation	  is	  required	  for	  
SF6	  detection,	  owing	  to	  its	  extremely	  short	  19F	  relaxation	  time	  (T1	  =	  5.9	  ±	  0.2	  ms).	  The	  
use	   of	   hyperpolarized	   gases,	   such	   as	   helium	   for	   this	   application,	   has	   increased	  
dramatically	  in	  recent	  years,	  reducing	  the	  demand	  for	  19F	  MRI	  of	  the	  lungs.52	  
	  
	  
Figure	  1.17:	  Three	  dimensional	  19F	  NMR	  spectra	  of	  SF6	  in	  the	  lungs	  of	  a	  large	  rat.	  Spectra	  obtained	  in	  
30	  min.	  Frames,	  from	  top	  left	  to	  bottom	  right	  are	  successive	  planes	  of	  the	  image	  from	  chest	  to	  back.	  
In	   the	   lungs	  25	  %	  of	   the	  volume	   is	  occupied	  by	  tissue.	  Therefore,	   the	   lungs	  are	  not	  as	  bright	  as	   the	  
large	  airways,	  where	  the	  spin	  density	  of	  pure	  gas	  is	  higher.	  51	  
	  
In	  cancer	  patients	  the	  growth	  of	  new	  blood	  cells,	  termed	  angiogenesis,	  is	  necessary	  
for	   cancerous	  cells	   to	  grow	  and	  spread.	  Therefore,	   it	   is	   vital	   to	  be	  able	   to	  monitor	  
tumour	   blood	   volume.	   Proton	   MRI	   contrast	   agents	   are	   capable	   of	   indicating	  
perfusion,	   an	   approach	   based	   on	   first	   pass	   kinetic	   analysis,	   however	   the	  
interpretation	  of	   results	   is	   very	   complex.53	  An	  alternative	  approach,	   in	   conjunction	  
with	   19F	   NMR	   spectroscopy,	   utilises	   intravenous	   biocompatible	   perfluorocarbon	  
emulsions,	  which	  are	  retained	  in	  the	  vasculature	  for	  a	  period	  of	  hours,	  to	  provide	  an	  




indication	  of	  vascular	  volume	  in	  a	  non-­‐invasive	  manner.54	  Fluorinated	  gases,	  such	  as	  
trifluoromethane,	   have	   been	   used	   for	   the	  measurement	   of	   cerebral	   blood	   flow,	   a	  
method	  based	  on	  inflow	  and	  outflow	  kinetics.55	  
	  
Inflammation	   is	   linked	  with	   a	   number	   of	   human	   diseases,	   including	   brain	   trauma,	  
transplant	   rejection	   and	   heart	   disease.	   Precise	   diagnosis	   is	   extremely	   difficult	   and	  
therapy	   is	   often	   limited	   to	   symptomatic	   treatment.	   In	   2008,	   Flogel	   et	   al.	  
demonstrated	   the	   feasibility	   of	   monitoring	   inflammation	   processes	   in	   vivo	   with	   a	  
‘positive	   contrast’	   at	  high	   local	   resolution	  using	   19F	  MRI.56	   Emulsified	  perfluoro-­‐15-­‐
crown-­‐5-­‐ether	   (PFCE),	   chosen	   because	   of	   the	   20	   equivalent	   fluorine	   nuclei,	   was	  
intravenously	   injected	   into	   two	   separate	   murine	   models	   of	   acute	   cardiac	   and	  
cerebral	  ischemia.	  The	  merging	  of	  1H	  and	  19F	  MR	  images,	  simultaneously	  collected	  at	  
9.4	   T,	   enabled	   an	   exact	   anatomic	   localisation	  of	   PFCE	   after	   injection	   (Figure	   1.18).	  
Repetitive	  imaging	  (5	  times	  within	  a	  7	  day	  period)	  revealed	  penetration	  of	  the	  PFCE	  
into	   the	   border	   zone	   of	   infracted	   areas	   in	   both	   models,	   showing	   a	   tremendous	  
degree	  of	  specificity.	  
	  
	  
Figure	  1.18:	  19F	  MRI	   in	  vivo	  demonstrating	  infiltration	  of	  PFCE	  after	  myocardial	  infarction.	  1H	  and	  19F	  
images	   from	   the	  mouse	   thorax	   recorded	  4	  days	   after	   ligation	  of	   the	   LAD	   show	  accumulation	  of	   19F	  
signal	  near	  the	   infarcted	  region	  (I)	  and	  at	   the	   location	  of	  surgery	  where	  the	  thorax	  was	  opened	  (T).	  
PFCE	  was	  injected	  at	  day	  0	  (2	  hours	  after	  infarction)	  via	  the	  tail	  vein.56	  
	  
1.2.2.3	  Cellular	  Therapeutics	  
	  
When	  cells	   are	   transferred	   to	  a	  patient	   to	   treat	  a	   specific	  disease	   this	   is	   known	  as	  
cellular	   therapeutics.	   A	   significant	   amount	   of	   research	   has	   focused	   on	   stem	   cell	  
transfers	  to	  help	  restore	  function	  to	  damaged	  tissues.	  For	  successful	  cellular	  therapy	  




it	   is	  critical	  that	  transferred	  cells	  are	  quantitatively	  monitored,	  post-­‐transplant,	   in	  a	  
non-­‐invasive	  manner.	   Traditionally,	   in	   vitro	   cultured	   stem	   cells	   are	   incubated	  with	  
contrast	   agents,	   such	   as	   Gadolinium	   diethylenetriamine	   penta-­‐acetic	   acid	  
[Gd.DTPA(H2O)],	   allowing	   the	   cells	   to	   serve	   as	   imaging	   agents	   and	   enabling	  
monitoring	  by	  1H	  MRI.57	  
	  
Alternatively,	   Chen	   et	   al.	   demonstrated	   that	   stem	   cells	   labelled	   with	   liquid	  
perfluorocarbon	  (PFC)	  nanoparticles	  produce	  sensitive	  cell	  markers,	  suitable	   for	   19F	  
MRI	  detection	  at	  11.7	  T	  (research)	  and	  1.5	  T	  (clinical)	  scanners.	  Two	  PFC	  cores	  were	  
examined,	   perfluorooctylbromide	   (PFOB)	   and	   perfluoropolyether	   (PFPE).	  
Mononuclear	  cells,	  harvested	  from	  human	  umbilical	  cord	  blood,	  internalized	  the	  PFC	  
nanoparticles	   readily	   whilst	   retaining	   their	   functionality.	   This	   enabled	   spatial	   cell	  
localization	  and	  detection	  of	  multiple	  fluorine	  signals.	  (Figure	  1.19).58	  	  
	  
	  
	  	  PFPE	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  PFOB	  
	  
Figure	  1.19:	  Localisation	  of	  labelled	  cells	  after	  in	  situ	  injection	  into	  the	  skeletal	  mouse	  thigh.	  At	  11.7	  T,	  
spectral	   discrimination	   permits	   imaging	   the	   fluorine	   signal	   attributable	   to	   106	   FBOB-­‐loaded	   (A)	   or	  
PFPE-­‐loaded	  (B)	   individually,	  which	  when	  overlaid	  onto	  a	   1H	  MRI	   image	  of	   the	  site	   (C)	   reveals	  FPOB	  
and	  PFPE	  labelled	  cells	  localized	  to	  the	  left	  and	  right	  leg,	  respectively.58	  
	  
Ruiz-­‐Cabello	  et	   al.	   reported	   the	   synthesis	   and	   evaluation	   of	   cationic	   PFCE	   labelled	  
neural	   stem	  cells	   (NSCs).	   Following	   injection	   into	   the	   stratium	  of	  mouse	  brain,	   the	  
labelled	   cells	  were	   identified	   in	   vivo,	   retaining	   a	   constant	   19F	   signal	   over	   a	   2	  week	  
period,	   consistent	  with	   low	   toxicity	   and	   high	   stability.59	   The	  MR	   sensitivity	   of	   140	  
pmol	  of	  PFCE	  per	  cell	  (at	  5	  mins	  of	  acquisition)	  is	  more	  than	  adequate	  to	  monitor	  cell	  




therapy	  of	  neurodegenerative	  diseases	  in	  the	  central	  nervous	  system,	  based	  on	  the	  
current	  injected	  cell	  doses	  in	  practice	  (of	  the	  order	  of	  1	  x	  105	  cells	  or	  more).	  
	  
Whilst	  it	  is	  vital	  to	  be	  able	  to	  track	  stem	  cells,	  as	  described	  above,	  it	  is	  of	  equal	  
importance	  to	  be	  able	  to	  quantify	  a	  specific	  cell	  population.	  Lymphoid	  cells,	  including	  
T	  cells,	  infiltrate	  the	  islets	  of	  Langerhans	  in	  the	  early	  stages	  of	  type	  1	  diabetes	  (T1D),	  
eventually	  destroying	  the	  insulin-­‐producing	  β	  cells	  of	  the	  islets.60	  In	  2007,	  Ahrens	  et	  
al.	  labelled	  T	  cells	  ex	  vivo	  with	  a	  PFPE	  nanoparticle	  tracer	  agent	  and	  administered	  
them	  into	  the	  nonobese	  diabetic	  mouse,	  a	  widely	  established	  model	  of	  human	  
T1D.61	  	  Quantitative	  cell	  migration	  was	  monitored	  using	  spin	  density-­‐weighted	  19F	  
MRI	  in	  conjunction	  with	  1H	  MRI	  to	  provide	  anatomical	  context,	  and	  a	  computational	  
algorithim	  provided	  cell	  counts.	  Approximately	  2	  %	  of	  the	  injected	  diabetogenic	  T	  	  
cells	  homes	  to	  the	  pancreas	  after	  48	  h. 	  
	  
In	  a	  subsequent	  report	  from	  the	  same	  group,	  a	  common	  fluorescent	  dye	  (BODIPy-­‐TR)	  
was	  conjugated	  to	  the	  PFPE	  nanoparticle	  tracer,	  allowing	  for	  studies	  of	  the	  cells	  post-­‐
imaging.62	  Naïve	  mouse	  T	  cells	  were	  labelled	  ex	  vivo	  and	  then	  injected	  to	  a	  simple	  
BALB/c	  mouse	  model	  (Figure	  1.20). 	  
	  
	  
Figure	  1.20:	   In	  vivo	  MRI	  of	   labelled	  T	  cells	   in	  a	  BALB/c	  mouse	  model.	  The	  19F	   image	  (pseudo-­‐colour)	  
shows	  a	   localized	   accumulation	  of	   T	   cells	   labeled	  with	  PFPE	  nanoemulsion	   in	   lymph	  nodes	   and	   the	  
grayscale	  underlay	   is	  an	  anatomical	   1H	   image.	   (A)	  and	  (B)	  display	  two	  consecutive	  2	  mm	  thick	  slices	  
through	  the	  torso,	  and	  for	  anatomical	  orientation	  the	  kidneys	  (K)	  and	  gut	  (G)	  are	  noted.62	  




The	   lymph	   nodes	   displaying	   the	   strongest	   19F	   MRI	   signal	   in	   vivo	   were	   surgically	  
extracted	  after	  imaging.	  Fluorescence	  activated	  cell	  sorting	  (FACS)	  was	  then	  used	  to	  
quantify	   the	  presence	  of	   the	   T	   cells	   and	   confirm	   the	   localisation	   information	   from	  
the	   1H	   and	   19F	   MRI	   results.	   This	   approach	   was	   subsequently	   applied	   to	   a	   murine	  
inflammation	   model	   using	   antigen-­‐specific	   T	   cells.	   The	   main	   difference	   with	   this	  
study	   is	   the	   clever	   exploitation	   of	   the	   fluorescent	   section	   of	   the	   labelled	   cells,	  
enabling	   the	   use	   of	   in	   vivo	   optical	   imaging	   to	   corroborate	   the	   19F	   MRI	   T-­‐cell	  
trafficking	  patterns	  and	  eliminating	  the	  need	  for	  post-­‐imaging	  biopsies.63	  
	  
1.2.2.4	  Highly	  Fluorinated	  19F	  MR	  agents	  
	  
Whilst	  PFCs	  have	  numerous	  advantages,	  such	  as	  low	  toxicity	  and	  high	  stability,	  they	  
also	   have	   limitations	   due	   to	   their	   low	   solubility,	   long	   T1	   relaxation	   times,	   split	   19F	  
signals	  and	  excessive	  retention	  in	  internal	  organs.	  As	  such,	  there	  is	  a	  growing	  interest	  
in	  the	  development	  of	  stable,	  hydrophilic	  molecules	  capable	  of	  emitting	  a	  single	  19F	  
signal	  from	  multiple	  fluorine	  atoms.	  	  
	  
Yu	  et	  al.	  reported	  the	  synthesis	  of	  a	  water	  soluble	  bispherical	  fluorocarbon	  molecule,	  
consisting	  of	  27	  equivalent	  fluorine	  atoms	  (Figure	  1.21).64	  In	  vivo	  studies	  on	  BALB/c	  
male	  mice	  (60	  mmol	  kg-­‐1	  19F)	  showed	  a	  single	  19F	  peak	  with	  no	  evidence	  of	  prolonged	  
organ	  retention	  (t1/2	  =	  12	  h)	  or	  degradation.	  The	  main	  advantage	  of	  spherical	  cones	  is	  
the	  ability	   to	  modify	   the	  structure	  at	   the	  cone	  without	  disrupting	   the	  symmetry	  of	  
the	   molecule.	   However,	   to	   increase	   19F	   MR	   sensitivity	   more	   equivalent	   fluorine	  
atoms	  would	  need	  to	  be	  added	  to	  the	  cone,	  and	  this	  approach	  can	  only	  go	  so	  far	  (~	  
100	  fluorine	  atoms).	  	  
	  
	  
Figure	  1.21:	  Structure	  of	  water	  soluble	  bispherical	  fluorocarbon	  




Wooley	  et	   al.	   developed	  a	   series	  of	   fluorinated	  polymeric	  micelles,	   self	   assembled	  
from	   co-­‐polymers	   with	   high	   fluorine	   content,	   as	   potential	   19F	   MR	   agents.65	   The	  
nanomaterials	   were	   designed	   to	   have	   a	   hydrophobic	   core,	   to	   enable	   therapeutic	  
loading,	  and	  a	  hydrophilic	  shell	  (owing	  to	  the	  incorporation	  of	  acrylic	  acid	  groups)	  to	  
ensure	  water	  solubility.	  All	  micelles	  gave	  a	  single	  resonance	  by	  19F	  NMR	  spectroscopy	  
(ω1/2	  =	  130	  Hz,	  T1	  =	  500	  ms,	  T2	  =	  50	  ms,	  11.7	  T)	  and	   the	   relaxation	   times	  were	  not	  
affected	  by	  size	  or	  composition	  of	  structure.	  While	  the	  19F	  phantom	  imaging	  studies	  
showed	   good	   SNR	   for	   all	   micelles,	   in	   the	   region	   of	   11-­‐32,	   this	   was	   only	   after	  
extremely	  long	  scan	  times	  (1024	  scans,	  13	  h).	  
	  
An	   alternative	   approach	   involves	   the	   use	   of	   diblock	   coploymers	   consisting	   of	  
hydrophilic	  blocks	  of	  poly-­‐acrylic	  acid	  and	  hydrophobic	  blocks	  of	  fluorinated	  acrylate	  
and	   methyacrylate.66	   In	   water/DMF	   mixtures	   they	   undergo	   spontaneous	   self-­‐
assembly	  to	  form	  stable	  micelles,	  ranging	  in	  size	  from	  20-­‐45	  nm,	  with	  a	  single	  peak	  
observed	   in	   the	   19F	   NMR	   spectra.	   Two	   distinct	   T2	   values	   were	   recorded	   for	   each	  
micelle;	   the	   shorter	   T2	   is	   caused	   by	   restricted	  movement	   of	   the	   fluorine	   nuclei	   in	  
chain	  segments	  (resulting	  in	  broader	  signals	  with	  poorer	  signal	   intensity),	  while	  the	  
longer	   T2	   is	   caused	   by	   large	   amplitude	   molecular	   motion.	   The	   acrylate	   system	  
revealed	  a	  sharper	  fluorine	  resonance,	  a	  shorter	  T1	  (ω1/2	  =	  231	  Hz,	  T1	  =	  511	  ms	  vs	  	  ω1/2	  
=	  280	  Hz,	  T1	  =	  676	  ms	  at	  7	  T	  for	  the	  methylacrylate)	  and	  superior	  MRI	  image	  intensity,	  
owing	  to	  the	  greater	  chain	  flexibility.	  	  
	  
It	  has	  long	  been	  known	  that	  fluorinated	  groups	  in	  polymeric	  structures	  are	  prone	  to	  
aggregate	  in	  water,	  which	  can	  lead	  to	  a	  reduction	  in	  molecular	  mobility.	  To	  combat	  
this	  problem,	  Whittaker	  et	  al.	  synthesised	  partially	  fluorinated	  polyelectrolytes.67	  By	  
exploiting	   the	   electrostatic	   repulsion	   between	   the	   different	   monomer	   units,	  
aggregation	   in	   water	   could	   be	   prevented,	   maintaining	   sufficient	   mobility	   and	  
obtaining	  images	  of	  high	  intensity	  (Figure	  1.22).	  	  
	  





Figure	  1.22:	  Structures	  of	  the	  different	  monomer	  units	  
	  
In	  2010,	  Whittaker	  et	  al.	  also	  reported	  a	  new	  class	  of	  hyper-­‐branched	  polymers	  that	  
are	   capable	   of	   controlled	   functionality,	   achieved	   through	   reversible	   addition-­‐
fragmentation	   chain	   transfer	   (RAFT)	   chemistry.68	   Four	   different	   hyper-­‐branched	  
polymers,	   incorporating	  acid	   (P1),	   alkyne	   (P2)	  and	  mannose	   (P4)	  end	  groups,	  were	  
investigated.	   Although	   P1	   exhibited	   significant	   toxicity	   in	   comparison	   to	   a	   control	  
polymer	   (PEG-­‐400)	   it	  was	   chosen	   for	   preliminary	   in	   vivo	   studies	   owing	   to	   its	   non-­‐
targeting	   properties	   (Figure	   1.23).	   Unfortunately	   results	   show	   minimal	   19F	   signal	  
immediately	  after	   injection	  into	  mouse	  tail	  vein	  (20	  mg/	  mL,	  100	  μL).	  This	  could	  be	  
due	   to	   the	   vast	   distribution	   of	   P1	   in	   the	   vasculature.	  While	   it	   is	   clear	   the	   system	  
requires	   many	   improvements,	   most	   notably	   in	   terms	   of	   reducing	   toxicity	   and	  
increasing	   signal	   intensity,	   there	   is	   huge	   potential	   for	   hyper-­‐branched	   polymers	   if	  




Figure	  1.23:	  Structure	  of	  Polymer	  P1	  
	  




1.2.3	  Fluorinated	  Drugs	  
	  
Fluorine	   atoms	   can	   be	   selectively	   incorporated	   into	   pharmaceuticals	   to	   alter	  
biological	  activity,	  lipophilicity,	  pKa	  and,	  or	  in	  vivo	  retention	  times.	  	  As	  such,	  there	  are	  
a	   vast	   number	   of	   fluorinated	   pharmaceuticals	   and	   industrial	   agents,	   ranging	   from	  
chemotherapeutics	   for	   cancer	   such	  as	   gefitinib,	   to	   antifungals	   such	   as	   fluconazole.	  
The	  diverse	  range	  of	  applications	   for	   fluorinated	  compounds	  render	   them	   ideal	   for	  
use	  in	  19F	  NMR	  spectroscopic	  analysis.	  
	  
Most	   studies	   to	   date	   have	   focused	   on	   the	   metabolic	   pathway	   of	   anticancer	  
chemotherapeutic	   agent	   5-­‐fluorouracil	   (5FU).	   The	   investigation	   into	   the	   uptake,	  
biodistribution	  and	  metabolism	  of	  5FU	  is	  required	  due	  to	  its	  restricted	  efficiency	  and	  
possible	   toxicity.69	   Ideally,	   all	   5FU	   should	   be	   converted	   to	   nucleosides	   and	  
nucleotides	   for	   cytostatic	   activity,	   requiring	   the	   activity	   of	   various	   kineases	   and	  
phosphorylases.	   However	   competing	   catabolic	   reactions	   convert	   5FU	   to	   5,6-­‐
dihydrofluorouracil	   (DHFU)	  and	  α-­‐	  fluoro	  β-­‐alanine	  (FBAL)	   in	  the	   liver,	  offering	  very	  
little	   toxicity.	  More	   troubling	   is	   the	   conversion	  of	   FBAL	   in	   the	   kidneys	   to	   generate	  
fluoride	   ions,	   which	   are	   cardio-­‐	   and	   neuro-­‐toxic.70	   19F	   NMR	   spectroscopy	   studies	  
analysing	   the	   chemical	   shift	   and	   relaxation	   properties	   of	   side	   products	   have	   been	  
used	  to	  monitor	  the	  metabolic	  pathway	  of	  5FU.71,	  72	  	  
	  
Owing	  to	  the	  restrictive	  toxicity	  profile	  of	  5-­‐FU	  a	  great	  deal	  of	  research	  has	  focused	  
on	   developing	   new	   anticancer	   drugs.	   Gemcitabine	   is	   one	   such	   drug,	   incorporating	  
both	   sugar	   and	   pyrimidine	   moieties	   (Figure	   1.24).	   Gemcitabine,	   once	   in	   cells,	  
requires	   conversion	   to	   a	   triphosphate	   derivative	   by	   phosphorylation.	   Once	   in	   its	  
active	  form,	  it	  is	  incorporated	  into	  DNA	  where	  it	  can	  inhibit	  DNA	  polymerases.	  It	  was	  
hypothesised	   that	   the	   rate	   limiting	  enzyme	   in	   this	   phosphorylation	  was	   the	   kinase	  
dCK.	  Blackstock	  et	  al.	  examined	  Gemcitabine	  uptake	  and	  clearance	  in	  two	  different	  
models	   of	   HT-­‐29	   human	   colon	   carcinoma	   xeonographs	   (160	   mg	   kg-­‐1);	   a	   control	  
model	  and	  a	  model	  infected	  with	  the	  dCK	  gene.73	  In	  vivo	  19F	  MRI	  results	  showed	  a	  2.5	  
fold	  greater	  accumulation	  of	  Gemicatabine	  in	  the	  dCK	  xenograph	  in	  comparison	  with	  
the	  control	  model.	  Unlike	  most	  compounds	  studied	  by	  19F	  MRI/S,	  which	  give	  rise	  to	  a	  




singlet,	  the	  two	  diastereotopic	  fluorine	  atoms	  on	  Gemcitabine	  give	  rise	  to	  a	  quartet	  
at	  -­‐42	  ppm.	  
	  
Figure	  1.24:	  Structure	  of	  Gemcitabine	  
	  
3-­‐Aminobenzamide	   (3-­‐ABA)	   is	   an	   inhibitor	   of	   poly(AD-­‐ribo)	   polymerase	   1,	   a	   key	  
enzyme	  for	  the	  early	  repair	  of	  spontaneous	  and	  stimulated	  DNA	  strand	  breaks.	  	  Brix	  
et	   al.	   evaluated	   the	   biodistribution	   and	   pharmacokinetics	   of	   a	   trifluoromethylated	  
derivative	   of	   3-­‐ABA,	   named	  3-­‐ABA-­‐TFE,	   in	   Copenhagen	   rats	  with	  Dunning	  prostate	  
adenocarcinoma	   (Figure	  1.25).74	  Full	   body	   in	   vivo	   19F	  MRS	   sampling	  of	   all	   nine	   rats	  
(400	  mg	  kg-­‐1)	  showed	  3-­‐ABA-­‐TFE	  signal	   intensities	   in	  tumours	  much	  weaker	  than	  in	  
the	  muscular	  and	  liver	  system,	  suggesting	  that	  intra-­‐tumoral	  uptake	  could	  be	  low	  in	  
comparison	   with	   normal	   tissue.	   There	   was	   no	   evidence	   of	   contamination,	  
degradation	  or	  formation	  of	  by-­‐products	  up	  to	  8	  days	  post-­‐injection.	  This	  provides	  a	  
good	  example	  of	  how	  MRS	  can	  be	  used	  to	  monitor	  the	  biodistribution	  of	  a	  drug	  in	  a	  




Figure	  1.25:	  Chemical	  Structure	  of	  A)	  3-­‐ABA,	  B)	  19F-­‐labelled	  derivative	  3-­‐ABA-­‐TFE	  and	  C)	  (±)-­‐fluoxetine.	  
	  
There	  have	  been	  many	   reports	  of	   fluorinated	  psychiatric	  agents	  being	   investigated	  
by	   19F	   MRS,	   including	   the	   antidepressant	   drug	   (±)-­‐fluoxetine	   (Prozac).	   In	   an	  
interesting	  report,	  Bolo	  et	  al.	  investigated	  the	  withdrawal	  kinetics	  in	  humans	  treated	  
with	  fluoxetine.75	  Six	  subjects,	  who	  had	  been	  receiving	  daily	  doses	  of	  100-­‐300	  mg	  for	  
a	   period	   of	   1-­‐12	   months,	   were	   studied.	   In	   vivo	   19F	   MRS	   of	   the	   brain	   and	   lower	  




extremities,	   in	  conjunction	  with	  blood	  plasma	  sampling,	  confirmed	  the	  presence	  of	  
the	  drug	  in	  both	  areas	  (δF	  =	  -­‐61.6	  ppm,	  ω1/2	  =	  54	  Hz,	  2.7	  T).	  Surprisingly,	  84	  days	  post	  
withdrawal	  from	  the	  drug,	  a	  19F	  MRS	  signal	  was	  still	  being	  detected	  after	  complete	  
disappearance	  from	  plasma	  and	  brain	  (Table	  1.6).	  The	  enduring	  signal	  is	  most	  likely	  
from	   the	   drug,	   or	   a	   metabolite	   of	   the	   drug,	   which	   is	   accumulated	   in	   the	   bone	  
marrow.	   This	   study	   is	   an	   excellent	   example	   of	   the	   unique	   capabilities	   of	   MRS,	   in	  
comparison	  with	  more	  traditional	  techniques.	  
	  
Last	  day	  signal	  was	  detected	  
SNR	  of	  last	  detected	  
signal	  
13	   1.4	  μM	  
40	   2.2	  
Still	  present	  at	  84	  days	   7	  
	  
Table	  1.6:	  Comparison	  of	  late	  post-­‐withdrawal	  19F	  MRS	  signal	  characteristics	  from	  different	  tissues.75	  
	  
1.3	  Paramagnetic	  NMR	  
	  
There	   are	  many	   applications	  which	   utilise	   lanthanide	   complexes	   as	  NMR	   shift	   and	  
relaxation	   reagents,	   ranging	   from	  molecular	   stereochemistry	   investigations	   to	   the	  
previously	  mentioned	  contrast	  agents	  for	  MRI.	  	  
	  
When	  in	  solution,	  the	  most	  stable	  oxidation	  state	  of	  the	  lanthanides	  is	  +3,	  giving	  an	  
electronic	  configuration	  of	   [Xe]	  4fn,	  with	  n	   varying	   from	  0	   (La3+)	   to	  14	   (Lu3+)	   (Table	  
1.7).	  Obvious	  exceptions	  to	  this	  are	  when	  the	  ion	  achieves	  an	  empty	  (f	  0),	  half	  filled	  (f	  
7)	  or	  full	  (f	  14)	  f	  orbital,	  examples	  include	  Eu2+	  and	  Ce4+.	  
	  
When	  a	  Ln3+	   ion	   interacts	  with	  a	  Lewis	  base,	  the	  presence	  of	  unpaired	  4f	  electrons	  
influences	  all	  NMR	  active	  nuclei	  within	  close	  proximity.	  This	  can	  lead	  to	  perturbation	  
of	   NMR	   parameters	   such	   as	   increased	   relaxation,	   resonance	   broadening,	   and	  
alterations	  in	  chemical	  shift	  values.	  The	  Gd3+	  ion	  is	  unique	  in	  that	  it	  has	  an	  isotropic	  
spatial	  distribution	  of	  unpaired	  f	  electrons.	  Each	  of	  the	  remaining	  Ln3+	  ions	  have	  an	  
anisotropic	   spatial	   distribution	   of	   unpaired	   f	   electrons,	   and	   are	   therefore	   able	   to	  




create	   a	   dipolar	   lanthanide-­‐induced	   shift	   in	   solution,	  more	   commonly	   known	   as	   a	  
pseudocontact	  shift.	  	  	  	  
	  
1.3.1 Chemical	  Shift	  
	  
The	  lanthanide	  induced	  shift	  for	  a	  nucleus	  of	  a	  ligand	  coordinated	  to	  a	  Ln3+	  ion	  can	  
be	  expressed	  as	  the	  sum	  of	  three	  terms:	  the	  diamagnetic	  (Δd),	  the	  contact	  (Δc),	  and	  
the	  pseudocontact	  shift	  (Δp)	  (Equation	  1.4).	  	  
	  
                                                      Δ = Δd + Δc + Δp	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.4)	  
	  
The	   diamagnetic	   shift,	   which	   stems	   from	   inductive	   and	   electrical	   field	   effects,	   in	  
addition	   to	   conformational	   changes,	   is	   generally	   insignificant.	   However,	   in	   cases	  
where	   the	   nuclei	   under	   investigation	   is	   directly	   coordinated	   to	   the	   Ln3+	   ion,	   the	  
diamagnetic	   shift	   plays	   a	   more	   important	   role.	   The	   contact	   shift	   originates	   from	  
through-­‐bond	  transmission	  of	  unpaired	  electron	  spin	  density	  to	  the	  nucleus	  from	  the	  
lanthanide	  4f	  orbital	  (Equation	  1.5).	  The	  Ln	  unpaired	  spin	  density	  can	  be	  transferred	  
to	   the	   nucleus	   of	   the	   ligand	   by	   direct	   spin	   delocalisation	   through	   weak	   covalent	  
bonding	  using	  the	  6s	  metal	  orbital	  or	  through	  spin	  polarisation	  from	  4f	  orbitals.	  As	  
the	  number	  of	  bonds	  between	   Ln3+	   and	   the	  nucleus	  under	   investigation	   increases,	  





-AΔc =<S > F =<S > 10
hγ B
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.5)	  
	  
Where,	  <Sz>	   is	   the	  calculated	  spin	  expectation	  value	   for	  a	  calculated	  paramagnetic	  
ion	  (Table	  1.7),	  	  γI is	  the	  gyromagnetic	  ratio	  of	  the	  nucleus,	  and	  A/h	  is	  the	  hyperfine	  
coupling	  constant	  of	  the	  nucleus	  under	  study.	  The	  large	  lanthanide	  induced	  shift	  of	  
the	  donor	  nucleus	  is	  associated	  with	  considerable	  line	  broadening.	  Consequently,	   if	  
the	  exchange	  between	  the	  bound	  and	  free	  state	  is	  slow	  on	  the	  NMR	  timescale,	  it	  is	  
unlikely	  there	  will	  be	  a	  detectable	  signal	  for	  the	  bound	  state.	  	  
	  




The	   pseudocontact	   shift	   originates	   from	   the	   local	   magnetic	   field	   induced	   by	   the	  
anisotropy	  of	  the	  magnetic	  moment	  of	  the	  lanthanide	  ion	  in	  the	  nucleus	  under	  study.	  
If	   the	   principal	   magnetic	   axes	   system	   is	   used,	   the	   pseudocontact	   shift	   can	   be	  
expressed	  by	  equation	  1.6:	  
	  
2 2 2 2 2
J B
2 2 3 3
C r A(3cos 1) r A 'sin cos2p
60k T r r
⎡ ⎤µ 〈 〉 θ− 〈 〉 θ φ
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⎣ ⎦
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.6)	  
	  
Where,	  CJ	   is	  the	  Bleaney’s	  constant	  characteristic	  of	  the	  Ln3+	  ion	  (Table	  1.7),	  <r2>A	  
and	  <r2>A’ are	  ligand	  field	  coefficients,	  µB	  is	  the	  Bohr	  magneton	  and	  r, θ and	  φ	  are	  
the	  spherical	  coordinates	  which	  describe	  the	  position	  of	  the	  nucleus	  under	  study.	  For	  
a	   given	   series	   of	   isostructural	   complexes,	   it	   is	   assumed	   that	   the	   ligand	   field	  










Ce	   [Xe]	  4f	  1	   2F5/2	   -­‐6.3	   -­‐0.98	   2.56	   -­‐-­‐-­‐-­‐	  
Pr	   [Xe]	  4f	  2	   3H4	   -­‐11	   -­‐2.97	   3.62	   0.27	  
Nd	   [Xe]	  4f	  3	   4I9/2	   -­‐4.2	   -­‐4.49	   3.68	   0.32	  
Pm	   [Xe]	  4f	  4	   5I4	   2	   4.01	   -­‐-­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	  
Sm	   [Xe]	  4f	  5	   6H5/2	   -­‐0.7	   0.06	   1.55-­‐	  1.65	   -­‐-­‐-­‐-­‐	  
Eu	   [Xe]	  4f	  6	   7F0	   4	   10.68	   3.40-­‐	  3.51	   -­‐-­‐-­‐-­‐	  
Gd	   [Xe]	  4f	  7	   8S7/2	   0	   31.5	   7.94	   3.01	  
Tb	   [Xe]	  4f	  8	   7F6	   -­‐86	   31.82	   9.7	   -­‐10.53	  
Dy	   [Xe]	  4f	  9	   6H15/2	   -­‐100	   28.55	   10.6	   -­‐6.95	  
Ho	   [Xe]	  4f	  10	   5I8	   -­‐39	   22.63	   10.6	   -­‐4.88	  
Er	   [Xe]	  4f	  11	   4I15/2	   33	   15.37	   9.6	   3.83	  
Tm	   [Xe]	  4f	  12	   3H6	   53	   8.21	   7.6	   9.29	  
Yb	   [Xe]	  4f	  13	   2F7/2	   22	   2.59	   4.5	   2.52	  
Table	  1.7:	  Various	  NMR	  parameters	  for	  paramagnetic	  lanthanide	  ions:	  a	  Normalised	  to	  100	  for	  
Dy77;	  bCalculated	  Values78;	  c,	  77;	  d	  Values	  in	  ppm78. 
	  
The	   interpretation	  of	   lanthanide	   induced	   shift	   values	   is	   relatively	   simple	  when	   the	  
exchange	  of	  nuclei	  of	   the	   ligand	  between	   the	  bound	  and	   free	   state	   is	   slow	  on	   the	  
NMR	   timescale.	   However,	   complications	   can	   arise	   due	   to	   the	   effect	   of	   the	   Curie	  
relaxation	  mechanism	  (refer	   to	  1.3.2)	  and	  extreme	   line	  broadening,	  especially	  with	  




complexes	  of	   the	   later	   lanthanides	   (eg.	  Tb,	  Dy,	  Ho).	   In	  an	  attempt	   to	  minimise	   the	  
Curie	  relaxation	  mechanism,	  measurements	  can	  be	  taken	  at	  high	  temperatures	  and	  
low	  magnetic	  field	  strengths.	  	  
	  
1.3.2	  Relaxation	  Theory	  
	  
As	  mentioned	   previously,	   the	   coordination	   of	   a	   paramagnetic	   lanthanide	   ion	   to	   a	  
ligand	   results	   in	   an	   increase	   in	   both	   the	   longitudinal,	   R1,	   and	   transverse,	   R2,	  
relaxation	  rates.	  The	  observed	  relaxation	  rate	  can	  be	  expressed	  as	   the	  sum	  of	   two	  
terms;	   the	   diamagnetic	   contribution, Rid,	   and	   the	   paramagnetic	   contribution,	  RiM	  
(Equation	  1.7).	  
	  
iobs id iMR R R= + 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.7)	  
	  
Rid	   corresponds	   to	   the	   relaxation	   rate	   of	   solvent	   nuclei	   in	   the	   absence	   of	   a	  
paramagnetic	  solute,	  and	  is	  often	  measured	  with	  diamagnetic	  (i.e.	  utilising	  Y3+,	  Lu3+,	  
or	  La3+)	  complexes.	  RiM	  originates	  from	  the	  electron-­‐nuclear	  interaction	  between	  the	  
nuclear	  spin	  of	  the	  nucleus	  under	  investigation,	  and	  the	  magnetic	  field	  generated	  by	  
the	  presence	  of	  unpaired	  4f	  electrons.	  Electron	  spin	  relaxation,	  molecular	  tumbling	  
and	  chemical	  exchange	  all	  modulate	  the	  electron-­‐nuclear	  interaction.	  The	  dominant	  
relaxation	  mechanisms	   for	  paramagnetic	   systems	  can	  be	  described	   in	   terms	  of	   the	  
contact	   contribution, Ricon,	   the	   dipole-­‐dipole	   contribution,	   Ridip,	   and	   the	   Curie	  
contribution,	  Riχ	  (Equation	  1.8).	  
	  	  
iM icon idip iR R R R χ= + + 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.8)	  
	  
The	   contact	   contribution,	  Ricon,	   is	   negligible	   for	   all	   Ln3+	   ions,	  with	   the	  exception	  of	  
gadolinium.	   For	   Ln3+	   ions	   (excluding	   gadolinium)	   with	   short	   electronic	   relaxation	  
times,	   (T1e),	   the	   dipolar	   contribution	   can	   be	   expressed	   by	   the	   simplified	   Solomon-­‐
Bloembergen	  equation:	  	  	  
	  









µ γ µ⎛ ⎞= = ⎜ ⎟π⎝ ⎠
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.9)	  
	  
where,	  µ0/4π	   is	  the	  magnetic	  permeability	  of	  a	  vacuum,	  r	   is	  the	  Ln-­‐nucleus	  distance	  
and	   µeff	   is	   the	   effective	   magnetic	   moment.	   The	   dipole-­‐dipole	   contributions	   to	  
longitudinal	  and	  transverse	  relaxation	  rates	  are	  approximately	  equal.	  Conversely,	  the	  
Curie	  spin	  contribution	   is	  more	  significant	   to	   the	  transverse	  relaxation	  rate,	  R2χ,	  as	  
opposed	  to	  the	  longitudinal	  relaxation	  rate,	  R1χ	  (Equations	  1.10	  and	  1.11).	  This	  effect	  
is	  most	  apparent	  with	  Ln3+	  ions	  with	  high	  µeff	  and	  long	  rotational	  correlation	  times.79	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  (1.10)	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  (1.11)	  
	  
where,	  ωI	  is	  the	  Larmor	  frequency	  of	  the	  nucleus	  and	  τR	  is	  the	  rotational	  correlation	  
time	  of	   the	   complex.	  Relaxation	  data	  generated	  at	  different	   field	   strengths	   can	  be	  
employed,	   using	   the	   above	   two	   equations,	   to	   allow	   an	   estimate	   of	   the	   Ln-­‐nucleus	  
distance.80,	  81	  
	  
1.3.3	  Relaxivity	  Theory	  
	  
The	   effectiveness	   of	   a	   paramagnetic	   substance	   to	   enhance	   the	   relaxation	   rates	   of	  
nearby	   nuclei	   is	   termed	   its	   relaxivity	   (r1),	   typically	   expressed	   in	  mM-­‐1s-­‐1.	   It	   is	  most	  
commonly	   utilised	   when	   assessing	   the	   ability	   of	   a	   contrast	   agent	   to	   increase	   the	  
relaxation	  rate	  of	  bulk	  water,	  defined	  as	  the	  increase	  in	  1/T1	  and	  1/T2,	  proportional	  
to	  the	  concentration	  of	  paramagnetic	  species,	  [Gd]:	  
	  
1/T1,obs = 1/ T1,d  + r1[Gd]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.12)	  
	  




The	  relaxation	  mechanism	  derived	  from	  the	  interaction	  between	  electron	  spins	  and	  
the	  water	  protons	   in	   the	   first	  coordination	  sphere	  of	   the	  gadolinium	   is	   termed	  the	  
inner	  sphere	  contribution.	  Additionally,	  the	  paramagnetic	  effect	  experienced	  by	  the	  
bulk	  solvent	  molecules	  diffusing	  around	  the	  paramagnetic	  complex	  can	  also	  increase	  
relaxivity,	  termed	  the	  outer-­‐sphere	  contribution.	  While	  the	  inner-­‐sphere	  and	  outer-­‐
sphere	  mechanisms	   are	   the	  most	   evident	   for	   increasing	   relaxivity,	   a	   third	   type	   of	  
water	   association	   should	   be	   taken	   in	   to	   consideration.	   When	   there	   is	   hydrogen	  
bonding,	   or	   alternative	   interactions,	   between	   the	   ligand	   and	   inner-­‐sphere	   water	  
molecules,	  a	   loose	   layer	  of	  water	  molecules	  between	   the	   inner-­‐	  and	  outer-­‐	   sphere	  
can	  arise.	   The	   contribution	   from	  such	  molecules	   is	   termed	   ‘second	   sphere’	   (Figure	  
1.26).	  The	  total	  paramagnetic	   relaxation	  rate	  enhancement	  due	  to	   the	  presence	  of	  
the	  paramagnetic	  species	  is	  therefore	  given	  by:	  
	  
ri = riIS + riOS + riSS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.13)	  
	  
where,	   the	   superscripts	   IS,	   OS	   and	   SS	   refer	   to	   inner-­‐sphere,	   outer-­‐sphere	   and	  
















Figure	  1.26:	  Illustration	  of	  	  inner	  –sphere,	  outer-­‐sphere	  and	  second-­‐sphere	  water	  molecules.	  




The	   longitudinal	   relaxation	   time	  of	   bound	  water	   protons,	   T1,	   in	   the	  magnetic	   field	  
range	  of	  0.2	  to	  2	  T,	  is	  controlled	  by	  the	  rotational	  correlation	  time	  of	  the	  complex,	  τR.	  
Therefore,	  by	  developing	  contrast	  agents	  which	  possess	  a	  high	  correlation	  time,	  τR,	  
relaxation	  times	  will	  be	  faster,	  leading	  to	  increased	  relaxivity.	  
	  
1.4	  Fluorinated	  Probes	  
	  
Fluorinated	  paramagnetic	  probes	  offer	  significant	  opportunities	  for	  use	  in	  biological	  
studies,	   as	   illustrated	   by	   the	   diverse	   range	   of	   applications	   discussed	   previously	  
(section	   1.2).	   While	   there	   have	   been	   many	   advances	   in	   utilising	   19F	   NMR	  
spectroscopy,	  there	  are	  still	  many	  issues	  currently	  unresolved.	  
	  
1.4.1 Key	  Difficulties	  with	  Fluorinated	  Probes	  
	  
The	  key	   issue	  with	   this	  work	   is	   the	   slow	   longitudinal	   relaxation	   rate,	  R1,	   of	   the	   19F	  
nucleus,	  which	  hinders	  the	  use	  of	  fluorinated	  probes	  in	  magnetic	  resonance.	  This	  is	  
particularly	  a	  problem	  with	  CF3	  groups,	  where	  R1	  values	  are	  typically	  of	  the	  order	  of	  
0.5	  to	  1	  s-­‐1.	  One	  approach	  to	  increase	  the	  signal	  intensity	  is	  to	  increase	  the	  number	  
of	  scans.	  Unfortunately,	  in	  MRS,	  this	  also	  results	  in	  an	  increase	  in	  spectral	  acquisition	  
time,	  as	  it	  is	  necessary	  to	  wait	  for	  a	  delay	  of	  3	  to	  5	  times	  T1	  to	  allow	  for	  full	  relaxation	  
of	  the	  nucleus	  prior	  to	  the	  next	  scan.	  This	  equates	  to	  an	  approximate	  repetition	  time	  
of	   3	   to	   6	   seconds.82	   The	   signal	   to	   noise	   ratio	   varies	   with	   the	   square	   root	   of	   the	  
number	  of	  scans	  acquired,	  therefore	  at	  least	  an	  order	  of	  magnitude	  increase	  in	  R1	  is	  
required.	  
	  
Currently,	  high	  concentrations	  of	  fluorinated	  compounds	  (~	  50	  mM)	  are	  required	  to	  
obtain	   reasonable	   signal	   intensities	   in	  high	   field	   19F	  MRI	   studies	   in	  biosystems.83,	  84	  
Consequently,	  the	  development	  of	  kinetically	  stable	  probes,	  with	  high	  sensitivity	  and	  








1.4.2	  Fluorinated	  Lanthanide	  Probes	  	  
	  
The	   introduction	  of	  a	  paramagnetic	   lanthanide	   ion	   in	  close	  proximity	  (within	  7.5	  Å)	  
to	  the	  19F	  nucleus,	  in	  a	  kinetically	  stable	  complex	  or	  conjugate,	  leads	  to	  much	  shorter	  
T1	   and	   T2	   relaxation	   times	   (as	   discussed	   in	   1.3.2).	   The	   enhancement	   in	   relaxation	  
rates	   of	   the	   19F	   nucleus	   has	   been	   shown	   to	   be	   approximately	   two	   orders	   of	  
magnitude,	   predominantly	   via	   dipolar	  mechanisms.82	  This	   results	   in	   a	  much	   faster	  
acquisition	  time	  and	  hence	  increased	  signal	  intensity	  per	  unit	  complex	  concentration.	  
	  	  
The	   pseudocontact	   shift,	   generated	   by	   the	   paramagnetic	   Ln3+	   ion	   (as	   discussed	   in	  
1.3.1),	   increases	   the	   sensitivity	   of	   the	   19F	   chemical	   shift	   to	   variations	   in	   the	  
microenvironment	  and	  structural	  changes.	  The	  introduction	  of	  Eu,	  which	  is	  a	  weakly	  
relaxing	   ion,	   results	   in	   a	   large	   dipolar	   shift	   but	   does	   not	   have	   much	   effect	   on	  
relaxation.	   Conversely,	   Dy	   is	   a	   strongly	   relaxing	   ion,	   and	   the	   dipolar	   and	   Curie	  
relaxation	  mechanisms	  follow	  an	  r-­‐6	  dependence.	  Therefore,	  the	  unique	  features	  of	  
each	   Ln3+	   ion	   can	   be	   exploited	   in	   the	   design	   and	   development	   of	   fluorinated	  
lanthanide	  probes.	  
	  
It	  must	  be	  appreciated,	  however,	  that	  the	  benefits	  of	  shorter	  relaxation	  times	  can	  be	  
outweighed	  by	  the	  reduced	  sensitivity	  associated	  with	  the	  broader	  signal	  linewidth.	  
Therefore,	  there	  is	  a	  fine	  balance	  to	  be	  struck	  in	  optimising	  the	  conditions.	  
	  
1.4.3	  Review	  of	  19F	  NMR	  in	  Lanthanide	  Systems	  	  
	  
While	  lanthanide	  shift	  reagents	  are	  often	  utilised	  for	  simplifying	  the	  interpretation	  of	  
spectra,	   there	  are	  very	   few	  examples	  on	   the	   relaxation	  and	  dipolar	   shift	  effects	  of	  
lanthanide	   ions	   on	   19F	   NMR	   spectroscopic	   parameters.	   A	   recent	   example	   of	   a	  
paramagnetic	  relaxation	  based	  fluorinated	  MRI	  probe	  to	  detect	  protease	  activity	  was	  
discussed	  in	  section	  1.2.1.3.	  
	  
One	  of	  the	  earliest	  examples	  reported	  is	  from	  Sherry	  et	  al.	  who	  examined	  a	  series	  of	  
Ln(F-­‐DOTPME)-­‐	   complexes	   and	   assigned	   several	   resolved	   19F	   NMR	   resonances	   to	  




specific	   diastereomers.	   This	   approach	   is	   based	   upon	   the	   comparison	   of	   resonance	  
integrals,	   assuming	   pendant	   arm	   interactions,	   and	   the	  magnitude	   and	   direction	   of	  
pseudocontact	   shifts.	   The	   addition	   of	   cationic	   detergents	   resulted	   in	   increased	  
selectivity	  for	  the	  Δ-­‐SSSS	  isomer,	  whereas	  introduction	  of	  neutral	  polyethylene	  glycol	  
showed	  variation	   in	   the	  chemical	   shift	  values	  but	  not	   the	  distribution	  of	   isomers.85	  
While	   the	   work	   is	   of	   much	   interest,	   it	   is	   limited	   not	   only	   by	   the	   similarity	   of	   the	  
chemical	   shift	   values	   of	   some	   of	   the	   isomers,	   but	   also	   by	   the	   fact	   that	   there	   are	  
several	  isomeric	  species	  present	  in	  solution	  (Figure	  1.27).	  
	  
	  
Figure	   1.27:	   19F	   NMR	   spectra	   of	   40	   mM	   Tm(F-­‐DOTPME)-­‐	   at	   25	   oC.	   The	   inset	   at	   the	   middle	   of	   the	  
spectrum	   is	   an	   expansion	   of	   the	   low	   frequency	   group	   of	   resonances.	   The	   labelled	   resonances	   are	  
assigned	  to	  the	  indicated	  isomer.85	  
	  
In	   2004,	   Aime	   et	   al.	   probed	   the	   relaxation	   enhancement	   obtained	   following	  
reversible	  binding	  of	  trifluorolactate	  to	  [GdDO3A(H2O)].86	  The	  two	  coordinated	  inner	  
sphere	   water	   molecules	   of	   the	   [GdDO3A(H2O)]	   can	   be	   replaced	   by	   the	  
trifluorolactate,	   forming	  a	   fairly	  weak	   ternary	   complex.	  Thus,	   the	   fluorine	  nuclei	   in	  
the	   anion	   are	   in	   close	   proximity	   to	   the	   paramagnetic	   Gd	   centre,	   leading	   to	   an	  
increase	   in	  relaxation	  (trifluorolactate	  T1	  =	  4500	  ms,	   [trifluorolactate-­‐GdDO3A]	  T1	  =	  
23	  ms	  at	  7T).	  This	  study	  was	  an	  excellent	  proof	  of	  principle	  to	  demonstrate	  that	  Gd-­‐
based	  probes	  could	  offer	  the	  opportunity	  to	  enhance	  relaxation	  of	  molecules	  other	  
than	  water.	  
	  
Atherosclerotic	   plaques,	   which	   exhibit	   micro-­‐deposits	   of	   fibrin,	   can	   accumulate	   in	  
the	  arterial	  system	  leading	  to	  a	  heart	  attack	  or	  stroke.	  It	  is	  therefore	  vital	  to	  be	  able	  
to	   screen	   such	   lesions.	   	   Wickline	   et	   al.	   developed	   fluorinated	   fibrin-­‐targeted	  


























the	   R1.87	   Results	   from	   in	   vitro	   19F	  MRI	   studies	   at	   4.7	   T,	   utilising	   a	   diseased	   human	  
carotid	   artery	   segment,	   reveal	   that	   the	   nanoparticles	   show	   a	   high	   degree	   of	  
specificity	   for	   the	   fibrin	   (Figure	  1.28).	  Moreover	  the	  nanoparticle-­‐fibrin	  binding	  can	  
be	   quantified	   by	   clever	   manipulation	   of	   integral	   measurements,	   which	   is	   then	  
corroborated	  with	  1H	  T1	  measurements	  (1.5	  T)	  and	  elemental	  (%	  gadolinium)	  analysis.	  
To	  properly	  assess	  the	  viability	  of	  this	  approach	  in	  vivo	  studies	  are	  needed.	  However,	  
the	  chelating	  agent,	  DTPA,	  can	  undergo	  metal	  dissociation	   in	  vivo	  so	  a	  more	  stable	  
analogue	  would	  be	  required	  for	  such	  experiments.	  	  
	  
Figure	  1.28:	  A)	  19F	  projection	  image	  acquired	  at	  4.7	  T	  through	  the	  entire	  carotid	  artery	  sample	  which	  
shows	   high	   signal	   along	   the	   lumen	   due	   to	   nanoparticles	   bound	   to	   fibrin.	   B)	   Concentration	  map	   of	  
bound	  nanoparticles	  in	  the	  carotid	  sample.87	  
	  
An	   example	   of	   a	   paramagnetic	   relaxation-­‐based	   fluorinated	   MRI	   probe	   to	   detect	  
protease	   activity	   was	   discussed	   in	   section	   1.2.1.3.	   In	   2009,	   this	   concept	   was	  
developed	  further	  through	   incorporation	  of	  a	  reporter	   fluorophore	  that	   is	  active	   in	  
both	  19F	  MRI	  and	  fluorescence	  measurements,	  allowing	  for	  dual	  studies.	  The	  probe,	  
when	   enzymatically	   cleaved	   by	   caspase-­‐3,	   releases	   the	   fluorophore	   from	   the	  
[GdDOTA(H2O)]	   complex	   instigating	   an	   increase	   in	   both	   19F	   MRI	   signal	   and	  
fluorescence.	  There	  are	  many	  drawbacks	  to	  this	  system,	  particularly	  the	  fact	  that	  the	  
[GdDOTA(H2O)]	   remains	   in	   solution	   with	   the	   fluorophore	   after	   cleavage	   causing	  
paramagnetic	  broadening	  and	  hampering	  of	  the	  19F	  signal.88	  
	  
When	   using	   MRI	   to	   detect	   changes	   in	   pH	   it	   is	   essential	   to	   be	   able	   to	   accurately	  
determine	   the	   local	   concentration	   of	   the	   probe	   otherwise	   any	   variations	   in	   the	  
reporter	  signal	  cannot	  be	  accurately	  ascribed	  to	  an	  alteration	  in	  pH.	  In	  an	  attempt	  to	  




solve	  this	  problem	  a	  ratiometric	  1H/	  19F	  MRI	  method	  for	  pH	  mapping	  was	  developed	  
in	   2009.89	   The	   Gd	   and	   19F	   moieties	   are	   hosted	   by	   a	   poly-­‐β-­‐cyclodextrin	   carrier,	  
thereby	  guaranteeing	  the	  fluorine	  and	  gadolinium	  nuclei	  are	  sufficiently	  separated	  to	  
prevent	  broadening	  of	  the	  19F	  signal	  (Figure	  1.29).	  The	  pH	  responsiveness	  arises	  from	  
the	  sulphonamide	  arm	  on	  the	  Gd(III)-­‐chelate	  which	  has	  a	  pKa	  of	  6.7.	  Upon	  formation	  
of	   the	   supramolecular	   adduct,	   under	   acidic	   conditions,	   the	   increase	   in	   molecular	  
reorientation	   time	   results	   in	   a	   significant	   increase	   in	   relaxivity.	   The	   19F	   signal	  
intensity	  measurement	  can	  then	  be	  used	  to	  normalise	  the	  relaxation	  enhancement	  
values.	   As	   discussed	   earlier,	   it	   would	   be	   possible	   for	   the	   two	   coordinated	   inner	  
sphere	  water	  molecules	  of	  the	  Gd	  chelate	  to	  be	  replaced	  by	  protein	  or	  a	  number	  of	  
anions	   which	   would	   definitely	   hinder	   the	   pH	   response.	   Furthermore,	   the	   affinity	  
constants	   have	   been	   used	   to	   gauge	   the	   ratio	   of	   the	   three	   components.	   A	   more	  
































Figure	   1.29:	   Schematic	   representation	   of	   the	   supramolecular	   adduct	   between	   poly-­‐β-­‐cyclodextrin,	  










1.5 Project	  Aims	  
	  
The	   main	   aim	   of	   this	   work	   is	   to	   develop	   multi-­‐disciplinary	   fluorinated	   lanthanide	  
probes,	   capable	   of	   use	   in	   both	   19F	   and	   1H	   magnetic	   resonance	   imaging	   and	  
spectroscopy.	  There	  are	  numerous	  cyclen-­‐based	  lanthanide	  complexes	  commercially	  
available	   for	   1H	  MRI	   studies,	   and	   previous	  work	   in	   Durham	  has	   demonstrated	   the	  
feasibility	   of	   introducing	   a	   CF3	   group	   into	   these	   structures.82	   The	   resulting	   stable	  
paramagnetic	   fluorinated	   complexes	   present	   faster	   relaxation	   rates	   and	   increased	  
signal	  intensity	  per	  unit	  complex	  concentration.	  	  
	  
The	  research	  detailed	   in	  this	  thesis	  builds	  on	  related	  recent	  work,	   focussing	  on	  the	  
synthesis	   and	   evaluation	   of	   novel	   fluorinated	   lanthanide(III)	   complexes.	   Many	  
parameters,	   such	   as	   the	  number	  of	   the	   fluorine	   atoms	   and	   the	   choice	  of	   Ln3+	   ion,	  
have	   been	   investigated,	   with	   the	   aim	   of	   optimising	   the	   1H	   and	   19F	   relaxation	  
parameters.	  Strategies	  are	  explored	  to	  promote	  the	  formation	  of	  one	  stable	  isomer	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2.0	  Spectroscopic	  and	  Relaxation	  Properties	  
2.1	  Introduction	  
	  
As	   discussed	   in	   Chapter	   one,	   fluorinated	   paramagnetic	   probes	   offer	   significant	  
opportunities	   for	  use	   in	  biological	  studies	  owing	  to	  the	  high	  sensitivity	  of	   19F	  NMR,	  
the	   large	   chemical	   shift	   range	   and	   the	   absence	   of	   a	   background	   signal.	   The	  
introduction	  of	  a	  paramagnetic	  centre	  within	  7	  Å	  to	  the	  19F	  nucleus	  can	  significantly	  
increase	  the	  longitudinal	  and	  transverse	  relaxation	  rates,	  allowing	  for	  a	  much	  faster	  
acquisition	   time	   and	   hence	   increased	   signal	   intensity	   per	   unit	   complex	  
concentration.1,2	   However,	   the	   benefits	   of	   shorter	   relaxation	   times	   can	   be	  
outweighed	  by	  the	  reduced	  sensitivity	  associated	  with	  the	  broader	  signal	  linewidth.	  
Therefore,	   there	   is	   a	   fine	   balance	   to	   be	   struck	   in	   optimising	   the	   signal	   aquisition	  
conditions.	  This	  balance	  is	  a	  function	  of	  the	  field	  chosen,	  the	  nature	  of	  the	  Ln3+	  ion,	  
and	  its	  average	  distance	  from	  the	  19F	  nucleus.	  
	  
The	   work	   contained	   in	   this	   chapter	   builds	   on	   the	   above	   theory	   through	   the	  
introduction	   of	   CF3	   groups	   in	   close	   proximity	   to	   lanthanide	   (Ln3+)	   ions	   in	   stable	  
macrocyclic	   complexes.	   Two	   different	   classes	   of	   Ln3+	   complexes	   (Figure	   2.1)	   have	  
been	   synthesised,	  with	   the	  aim	  of	   exploring	   their	   19F	   chemical	   shift	   and	   relaxation	  



























L1 (R= CF3), L




Figure	  2.1:	  Structures	  of	  [Ln.L1(H2O)]
3+,	  [Ln.L2(H2O)]
3+	  and	  [Ln.L3(H2O)]	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Ligand	  L2	  was	  prepared	  as	  an	  analogue	  of	  L1,	  replacing	  the	  trifluoromethyl	  group	  by	  a	  
methyl	   group	   to	   assess	   the	   impact	   on	   relative	   stability,	   and	   to	   compare	   the	  
behaviour	  of	  the	  Gd3+	  complexes.	  
	  
2.2	  Synthesis	  and	  Characterisation	  of	  Complexes	  
2.2.1	  L1	  and	  L2	  Synthesis	  
	  
The	   tetra-­‐amide	   ligands,	   L1	   and	   L2,	  were	   prepared	   via	   the	   same	  method.	   The	   first	  
step	   involved	   the	   acylation	   of	   the	   ortho-­‐substituted	   aniline	   with	   chloroacetyl	  
chloride,	  with	  subsequent	  purification	  by	  silica	  gel	  column	  chromatography	  to	  yield	  














R = CF3, 70 %
R = CH3, 72 %
R = CF3, 1
R = CH3, 2 	  
Scheme	  2.1	  
	  
The	  subsequent	  tetra-­‐alkylation	  of	  1,4,7,10-­‐tetraazacyclododecane	  (cyclen),	  	  proved	  
more	   difficult	   (Scheme	  2.2).	   Even	  when	  using	   a	   large	   excess	   of	   the	  α-­‐chloroamide	  
arm	   (6	   equivalents),	   the	   mono-­‐,	   di-­‐,	   tri-­‐	   and	   tetra-­‐amide	   ligands	   could	   all	   be	  
identified	   in	   the	   crude	   mixture	   by	   electrospray	   mass	   spectrometry	   (ESMS).	   The	  
isolation	   of	   the	   desired	   tetra-­‐amide	   ligand	   was	   achieved	   by	   silica	   gel	   column	  
chromatography.	  However,	  due	  to	  the	  similar	  Rf	  values	  of	  the	  products	  formed,	  the	  
overall	   yield	  was	  moderately	   low	   for	  both	  L1	   and	  L2.	   The	   slightly	   higher	   yield	  of	  L2	  
could	  be	  attributed	  to	  the	  smaller	  size	  of	  the	  methyl	  group,	  and	  hence	  a	  lesser	  steric	  
effect	  in	  the	  formation	  of	  the	  desired	  ligand.	  
























R = CF3, 47 %
R = CH3, 58 %
1 or 2
L1, R= CF3




The	  final	  step	  involved	  the	  complexation	  of	  the	  ligand	  with	  the	  appropriate	  Ln3+	  ion	  
(Scheme	   2.3).	   This	   was	   achieved	   via	   two	   different	   methods.	   The	   first	   approach	  
involved	  reaction	  of	  the	  ligand	  with	  LnCl3	   in	  a	  H2O/CH3OH	  mixture.	  The	  purification	  
was	   simple:	   the	   crude	  product,	   dissolved	   in	   CH3CN,	  was	   added	  dropwise	   into	   cold	  
Et2O,	  thereby	  removing	  any	  unreacted	  lanthanide	  salts.	  The	  benefit	  of	  this	  procedure	  




































[Ln.L2(H2O)]3+, R= CH3 	  
Scheme	  2.3	  
	  
The	  second	  approach	  involved	  the	  reaction	  of	  the	  ligand	  with	  Ln(OTf)3	  in	  CH3CN.	  The	  
complex	   was	   subsequently	   converted	   to	   the	   chloride	   salt	   using	   a	   chloride	   anion	  
exchange	  resin.	  In	  addition	  to	  the	  removal	  of	  the	  unwanted	  triflate	  signal	  in	  the	  19F	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2.2.2	  L3	  Synthesis	  
	  
The	   preparation	   of	   L3	   begins	   with	   the	   alkylation	   of	   cyclen	   with	   tert-­‐butyl	  
bromoacetate,	  under	  mildly	  basic	  conditions,	  following	  a	  literature	  method	  (Scheme	  
2.4).3	   The	   desired	   tri-­‐ester	   was	   purified	   by	   silica	   gel	   chromatography,	   thereby	  




	  Scheme	  2.4:	  Synthetic	  route	  to	  [Ln.L3]	  
	  
	  
The	   subsequent	  mono-­‐alkylation	   of	   the	   tri-­‐ester	   with	   1	   was	   achieved	   under	   basic	  
conditions,	  utilising	  KI	  as	  a	  catalyst.	  The	  removal	  of	  the	  tert-­‐butyl	  protecting	  groups	  
was	   accomplished	   by	   treatment	   with	   trifluoroacetic	   acid	   in	   CH2Cl2,	   yielding	   the	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desired	  ligand	  as	  a	  trifluoroacetate	  salt.	  Conversion	  to	  the	  chloride	  salt	  was	  achieved	  
using	  an	  anion	  exchange	  resin.	  	  
	  
The	   final	   step	   in	   the	   synthesis	   involved	   reaction	   of	   the	   L3	   with	   the	   appropriate	  
Ln(OAc)3	   salt	   in	   water,	   adjusting	   the	   pH	   to	   approximately	   6.	   The	   complex	   was	  
subsequently	   purified	   by	   alumina	   column	   chromatography,	   thereby	   ensuring	   the	  
removal	  of	  any	  unreacted	  lanthanide	  salts.	  
	  
2.3	  Characterisation	  of	  Complexes	  
	  
In	   ESMS,	   a	   characteristic	   isotope	  pattern	   is	   observed	   for	   each	   complex,	   associated	  
with	   isotope	   distribution	   of	   each	   Ln3+	   ion.	   This	   can	   be	   utilised	   to	   confirm	   the	  
presence	   of	   the	   desired	   complex	   (Figure	   2.2).	   In	   each	   case,	   the	   calculated	   and	  
experimental	  isotope	  patterns	  showed	  very	  good	  correspondence.	  
	  
Figure	  2.2:	  Electrospray	  Mass	  Spectrum	  of	  [Tb.L1(H2O)]
3+,	  showing	  measured	  and	  calculated	  values.	  
Accurate	  masses	  to	  seven	  significant	  figures	  were	  considered.	  
	  
For	  each	  class	  of	  complex,	   the	  1H	  and	  19F	  NMR	  properties	  were	  examined,	  and	  the	  
purity	  assessed	  by	  HPLC.	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2.3.1	  Estimation	  of	  Complex	  Hydration	  State	  
	  
Lanthanide	   ions	   in	   their	   emissive	   state	   are	   sensitive	   to	   quenching	   by	   vibrational	  
energy	  transfer.	  Many	  different	  quenching	  pathways	  contribute	  to	  the	  rate	  constant	  
for	  the	  depopulation	  of	  the	  lanthanide	  excited	  state	  in	  water	  (Equation	  2.1).	  	  
	  
kH2O	  =	  knr	  +	  ∑	  kXH	  +	  ∑	  kC=O	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.1)	  
	  
where,	  knr	   is	   the	   non-­‐radiative	   constant,	   ∑kXH	   	   is	   the	   energy	   transfer	   to	   nearby	   XH	  
oscillators,	  and	  ∑kC=O	  is	  the	  energy	  transfer	  to	  nearby	  C=O	  matched	  oscillators	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
In	  D2O,	   it	   is	   assumed	   that	  all	   exchangeable	  XH	  oscillators	  do	  not	   contribute	   to	   the	  
quenching.	   However,	   in	   aqueous	   media,	   quenching	   by	   OH	   groups	   is	   the	   most	  
prominent	  and	  therefore,	  the	  number	  of	  bound	  water	  molecules	  can	  be	  calculated	  
from	  the	  difference	  in	  the	  rate	  of	  quenching	  in	  H2O	  and	  D2O	  (Equation	  2.2).4,	  5	  
	  
q	  =	  A(kH2O	  –	  kD2O	  +	  corr	  Ln)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.2)	  
	  
where,	  A	  is	  a	  proportionality	  constant	  giving	  the	  sensitivity	  of	  the	  lanthanide	  ion	  to	  
vibronic	   quenching	   by	  OH	  oscillators,	   and	   the	   corr	   Ln	   term	   allows	   for	   the	   effect	   of	  
closely	  diffusing	  OH	  oscillators.	  The	  equation	  is	  modified	  slightly	  to	  make	  it	  specific	  
for	  terbium	  based	  complexes	  (Equation	  2.3).6	  
	  
q’Tb	  =	  5[(kH2O	  –	  kD2O	  –	  0.06)]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.3)	  
	  
The	   lifetime	  measurements	  of	   [Ln.L1(H2O)]3+,	   [Ln.L2(H2O)]3+	   and	   [Ln.L3(H2O)]	   in	  H2O	  
and	  D2O,	  indicate	  that	  there	  is	  one	  bound	  water	  molecule	  in	  each	  case	  (Table	  2.1).	  As	  
the	   geometry	   of	   the	   complex	   does	   not	   change	   significantly	   between	   the	   series	   of	  
lanthanides,	   it	  can	  be	  assumed	  that	  the	  Eu3+,	  Gd3+	  and	  Tb3+	  complexes	  of	  the	  same	  
ligand	  will	  also	  have	  the	  same	  hydration	  number.	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Complex	   kH2O	  (ms-­‐1)	   kD2O	  (ms-­‐1)	   q'	  
[Tb.L1(H2O)]3+	   0.56	   0.31	  	   0.97	  
[Tb.L2(H2O)]3+	   0.60	   0.36	   0.90	  
[Tb.L3(H2O)]	   0.57	   0.36	   0.75	  
	  
Table	  2.1:	  Lifetime	  measurements	  of	  [Ln.L1(H2O)]
3+,	  [Ln.L2(H2O)]
3+	  and	  [Ln.L3(H2O)]	  in	  H2O	  and	  D2O,	  
including	  calculation	  of	  hydration	  number	  (±	  20	  %)	  
	  
	  
2.4	  19F	  NMR	  Spectroscopic	  Properties	  
	  
The	  Tb,	  Ho,	  Er	  and	  Tm	  complexes	  of	  L1	  each	  formed	  one	  major	  species	  as	  revealed	  by	  
19F	   NMR	   spectroscopy	   (Figure	   2.3),	   	   with	   the	   percentage	   fraction	   falling	   in	   a	  
sequence	  that	  mirrors	  the	  change	  in	  ionic	  radius:	  Tm	  >	  Er	  >	  Ho	  >	  Tb.	  In	  each	  case,	  a	  
second	  species	  lacking	  C4	  symmetry	  is	  evident,	  existing	  either	  as	  four	  resonances	  in	  a	  
1:1:1:1	  ratio,	  or	  as	  two	  resonances	  in	  a	  1:1	  ratio	  where	  C2	  symmetry	  is	  retained.	  In	  
contrast,	   the	   diamagnetic	   complex,	   [Y.L1(H2O)]Cl3	   gave	   rise	   to	   only	   one	   resolved	  
resonance,	  although	  at	  656	  MHz,	  a	  minor	  species	  could	  be	  discerned	  as	  a	  shoulder	  to	  
the	   major	   resonance.	   Earlier	   crystallographic	   studies	   of	   structurally	   related	   tetra-­‐
amide	   complexes	   have	   verified	   the	   existence	   of	   9-­‐coordinate	   systems	   with	   one	  












Figure	  2.3:	  19F	  NMR	  spectra	  of	  [Tm.L1(H2O)]
3+	  (2	  mM,	  D2O:CD3OD	  (20	  %),	  295	  K,	  4.7	  T)	  showing	  the	  
presence	  of	  one	  major	  species	  
	  
	  
Immediately	  following	  dissolution	  of	  the	  Tb,	  Ho,	  Er	  and	  Tm	  complexes	  of	  L3	  in	  water,	  
comparable	   spectral	   features	  were	   noted.	  One	  major	   species	  was	   observed	   by	   19F	  
Dominant	  Species	   Minor	  Species	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NMR	   spectroscopy,	   in	   addition	   to	   minor	   species	   that	   varied	   in	   number	   and	  
proportion,	  according	  to	  the	  nature	  of	  the	  Ln3+	   ion	  (Table	  2.2).	   	  For	  the	  discussions	  
contained	   in	   this	   thesis,	   the	   chemical	   shift	   value	   quoted	   refers	   to	   the	   dominant	  
isomer.	   	   The	   sign	   of	   the	   19F	   pseudo-­‐contact	   shift	   follows	   the	   sign	   of	   the	   Bleaney	  
coefficients	   in	  each	  case;	  these	  are	  negative	  for	  Tb	  and	  Ho,	  and	  positive	  for	  Er	  and	  
Tm.9	  Therefore	  the	  fluorine	  resonances	  of	  Ho	  and	  Tb	  complexes	  are	  shifted	  to	  higher	  
frequency,	  whereas	  the	  Tm	  and	  Tm	  are	  shifted	  to	  lower	  frequency,	  with	  respect	  to	  
the	   diamagnetic	   Y	   complex.	   This	   is	   consistent	   with	   the	   adoption	   of	   a	   common	  
solution	   structure	   across	   the	   series,	  with	   each	   CF3	   group	   at	   a	   similar	   angle	   to	   the	  
main	  axis	  of	  the	  complex	  and	  a	  comparable	  distance	  from	  the	  metal	  ion.	  	  
	  
Complex	   δF	  /	  ppm	  
Bleaney's	  
coefficient,	  Cj	  	  
%	  Major	  	  
species	  
No.	  of	  minor	  
species	  
[Tb.L3(H2O)]	   -­‐51.9	   -­‐39	   68	   5	  
[Ho.L3(H2O)]	   -­‐56.9	   -­‐86	   85	   3	  
[Er.L3(H2O)]	   -­‐64.8	   +33	   82	   8	  
[Tm.L3(H2O)]	   -­‐77.4	   +53	   74	   6	  
[Y.L3(H2O)]	   -­‐62.0	   	  N/A	   92	   	  1	  
	  
Table	  2.2:	  19F	  NMR	  chemical	  shift	  data	  for	  [Ln.L3(H2O)]	  (2	  mM,	  D2O,	  295	  K,	  pD	  5.4,	  Ln	  =	  Tb,	  Ho,	  Er,	  Tm	  
and	  Y)	  	  
	  
The	   19F	   resonance	  observed	   in	   the	   corresponding	  Gd3+	   complexes	  of	  L1	   and	  L3	  was	  
extremely	  broad,	  with	  a	  chemical	  shift	  very	  close	  to	  the	  corresponding	  diamagnetic	  Y	  
complex	  ([Gd.L3(H2O)]	  δF	  =	  62.3	  ppm,	  ω1/2	  =	  1240	  MHz	  (2	  mM,	  D2O,	  pD	  5.4,	  295K,	  9.4	  
T)).	  
	  
2.5	  19F	  Relaxation	  Parameters	  
2.5.1	  19F	  NMR	  Relaxation	  Theory	  
	  
The	  introduction	  of	  a	  paramagnetic	  centre	  close	  to	  the	  19F	  nucleus	  can	  significantly	  
increase	   the	   longitudinal	   and	   transverse	   relaxation	   rates,	  R1	   and	  R2.	   There	  are	   five	  
main	  spin	  relaxation	  process	  for	  19F	  nuclei	  in	  non-­‐viscous	  solutions	  of	  paramagnetic	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molecules	   that,	   in	   principle,	   can	   contribute	   to	   this	   enhancement;	   chemical	   shift	  
anisotropy	   (CSA),	   inter-­‐nuclear	   dipole-­‐dipole	   (DD)	   interaction,	   electron-­‐nucleus	  
contact	   interaction,	   electron-­‐nucleus	   dipole-­‐dipole	   interaction	   and	   a	   special	   case	  
known	  as	  Curie	  relaxation.10-­‐13	  	  
	  
In	   the	   specific	   case	  of	   the	   fluorinated	  cyclen-­‐based	   systems	  under	   review,	   the	  CSA	  
and	   inter-­‐nuclear	   interactions	   can	   be	   discounted.	   This	   is	   because	   the	   CSA	  
contribution	  for	  a	  trifluoromethyl	  group	  is	  fairly	  small,14	  and	  the	  inter-­‐nuclear	  dipole-­‐
dipole	   (DD)	   interaction	   is	   insignificant	   in	   comparison	   to	   the	  much	   larger	   electron-­‐
nuclear	  interactions.	  The	  experimentally	  measured	  19F	  T1	  in	  diamagnetic	  Y3+	  and	  La3+	  
complexes	  is	  approximately	  1	  s,	  thus	  the	  combined	  CSA	  and	  inter-­‐nuclear	  DD	  cannot	  
account	   for	  more	   than	  1	  Hz	   in	   the	  measured	  paramagnetic	   relaxation	   rates;	   these	  
are	  normally	   of	   the	  order	   ~10-­‐1000	  Hz.	   Furthermore,	   the	   contact	  mechanism	  may	  
also	  be	  ignored,	  because	  DFT	  calculations	  for	  a	  19F	  nucleus	  positioned	  more	  than	  5	  Å	  
from	  the	  metal	  shows	  an	  expected	  zero	  value	  for	  this	  term.15	  
	  
The	   two	   remaining	   mechanisms,	   electron	   nucleus	   DD	   and	   Curie	   relaxation,	   do	  
contribute	  significantly.	  Their	  independent	  contributions	  to	  R1	  and	  R2	  are	  described,	  
respectively,	  in	  equations	  2.4	  to	  2.7:16,	  17	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in	  which 1e 2eT T= 	   is	  assumed,
1 1
R e R 1e( T )
− −
+τ = τ + ,τR	   is	  the	  rotational	  correlation	  time,	  
T1,2	  are	  the	  electronic	  relaxation	  rates,	  ωF is	  the	  fluorine	  Zeeman	  frequency,	  γF	  is	  the	  
magnetogyric	  ratio	  of	  the	  19F	  nuclei,	  µB	  is	  the	  Bohr	  magneton,	  k is	  the	  the	  Boltzmann	  
constant, ge	  is	  the	  electron	  g-­‐factor,	  µ0/4π is	  the	  magnetic	  permeability	  of	  a	  vacuum,	  
S(S+1)	  is	  the	  total	  electron	  angular	  momentum	  and	  r is	  the	  Ln-­‐19F	  distance.	  
	  
The	   resulting	   total	   relaxation	   rates,	   R1	   and	   R2,	   are	   given	   as	   a	   combination	   of	   the	  
electron-­‐nucleus	  DD	  and	  Curie	  relaxation	  mechanisms	  (Equations	  2.8	  and	  2.9).	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  (2.9)	  
	  
in	  which	   2 2 2 2eff e Bg Sµ = µ is	  the	  effective	  magnetic	  moment	  of	  the	  Ln
3+	  ion	  and ωe	   is	  
the	  electron	  Larmor	  frequency.	  
	  
2.5.2	  19F	  Relaxation	  Analysis	  
	  
As	  the	  relaxing	  lanthanide	  centre	  and	  the	  fluorine	  nuclei	  are	  in	  the	  same	  molecule,	  
the	  19F	  relaxation	  properties	  are	   independent	  of	  concentration.	  This	  was	  proven	  by	  
measuring	  the	  R1/	  R2	  values	  for	  [Ho.L1(H2O)]3+	  at	  1,	  2,	  4,	  6	  and	  8	  mM	  (D2O:CH3OH	  (20	  
%),	  295	  K,	  4.7	  T).	  No	  significant	  changes	  in	  the	  measured	  values	  were	  found.	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The	  Ln-­‐19F	  nucleus	  distance	  can	  be	  calculated	  by	  measuring	  the	  paramagnetic	  rate	  of	  
relaxation	  as	  a	  function	  of	  magnetic	  field	  (Equations	  2.8	  and	  2.9).	  The	  19F	  longitudinal	  
relaxation	  rates,	  R1,	  were	  measured	  using	  the	  inversion	  recovery	  technique,	  without	  
proton	  decoupling,	  at	  295	  K.	  The	  inversion-­‐recovery	  type	  function	  was	  fitted	  to	  the	  
resulting	   data	   using	   Levenberg-­‐Marquardt	   minimization	   of	   the	   non-­‐linear	   least	  
squares	  error	  functional.	  	  
	  
The	  variation	  of	  the	  observed	  linewidths	  (ω1/2)	  of	  the	  19F	  resonances,	  defined	  as	  the	  
peak	  width	  at	  half-­‐height,	  was	  used	  to	  calculate	  the	  19F	  transverse	  relaxation	  rates,	  
R2	  (Equation	  2.10).	  
R2	  =	  π	  x	  ω1/2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.10)	  
	  
To	   extract	   the	   Ln-­‐19F	   nucleus	   distance	   for	   complexes	   of	   L1,	   R1	   and	   R2	   values	  were	  
measured	  for	  a	  series	  of	  Ln3+	  ions	  at	  four	  different	  field	  strengths	  (Table	  2.3	  and	  2.4).	  	  
	  
	  	   R1/	  Hz	  
Complex	   4.7	  T	   9.4	  T	   11.7	  T	   16.5	  T	  
[Tb.L1(H2O)]3+	   115	   218	   250	   341	  
[Ho.L1(H2O)]3+	   84	   192	   224	   282	  
[Er.L1(H2O)]3+	   46	   109	   143	   200	  
[Tm.L1(H2O)]3+	   33	   60	   76	   102	  
	  
Table	  2.3:	  19F	  Longitudinal	  relaxation	  data	  for	  [Ln.L1(H2O)]
3+	  (2	  mM,	  D2O:CH3OD	  (20	  %),	  295	  K,	  Ln=	  Tb,	  
Ho,	  Er	  and	  Tm)	  	  
	  
	  	   R2/	  Hz	  
Complex	   4.7	  T	   9.4	  T	   11.7	  T	   16.5	  T	  
[Tb.L1(H2O)]3+	   261	   243	   287	   328	  
[Ho.L1(H2O)]3+	   97	   207	   259	   356	  
[Er.L1(H2O)]3+	   79	   124	   169	   197	  
[Tm.L1(H2O)]3+	   62	   94	   102	   158	  
	  
Table	  2.4:	  19F	  Transverse	  relaxation	  data	  for	  [Ln.L1(H2O)]
3+	  (2	  mM,	  D2O:CH3OD	  (20	  %),	  295	  K,	  Ln=	  Tb,	  
Ho,	  Er	  and	  Tm)	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While	   further	  simplifications	   to	  equations	  2.8	  and	  2.9	  can	  be	  made,	  sufficient	  data	  
has	  been	  collected	  to	  avoid	  further	  approximations	  and	  to	  perform	  a	  direct	  global	  fit	  
of	   experimental	   relaxation	   data	   to	   the	   equations.	   As	   the	   geometry	   does	   not	  
appreciably	   change	  between	   the	  different	   lanthanides,	   the	   Ln-­‐19F	  distance	  and	   the	  
rotational	  correlation	  time	  can	  be	  set	  to	  be	  global	  between	  the	  Ho,	  Tm	  and	  Er	  data	  
sets	  of	  L1	  complexes.	  While	  the	  Tb	  set	  is	  analysable,	  the	  rather	  large	  linewidth	  results	  
in	   huge	   point	   scatter,	   and	   therefore	  was	   excluded	   from	   the	   fitting.	   This	   approach	  
does	  not	  utilise	  the	  set	  values	  of	  µeff and	  τr+e	  published	   in	  the	   literature.	   Instead,	   it	  
allows	   the	  computer	   to	  calculate	   the	  values	  based	  on	  a	   least-­‐squares	   fitting	  of	   the	  
experimental	  data,	  with	  the	  values	  of	  µeff	  and	  τr+e	  kept	  local	  for	  every	  lanthanide	  data	  
set.	  
	  
When	  utilising	  a	  linear	  correlation,	  it	  is	  apparent	  that	  the	  point	  related	  to	  the	  highest	  
field	  is	  lower	  than	  expected	  (Figure	  2.4).	  However,	  when	  the	  full	  equation	  (Equation	  
2.8)	   is	   exploited,	   the	   fit	   is	   not	   linear	   and	   therefore	   the	   associated	   error	   is	   less	  
significant.	   The	   analysis	   was	   performed	   by	   Dr.	   Ilya	   Kuprov	   at	   the	   University	   of	  
Oxford,	  with	  a	  result	  of	  rLn-F	  =	  6.1	  ±	  0.2	  Å	  and	  τr	  =	  255	  ±	  20	  ps.	  These	  values	  are	  in	  
keeping	  with	  distances	  calculated	  for	  other	  complexes	  utilising	  similar	  amide	  arms.15	  
	  
Figure	   2.4:	   Longitudinal	   relaxation	   rates	   at	   different	   magnetic	   fields	   for	   [Ln.L1(H2O)]
3+	   (2	   mM,	  
D2O:CH3OD	   (20	   %),	   295	   K,	   Ln=	   Ho,	   Er	   and	   Tm).	   The	   steeper	   rise	   of	   the	   Ho	   curve	   as	   a	   function	   of	  
magnetic	  field	  is	  due	  to	  its	  shorter	  electron	  relaxation	  time	  in	  comparison	  with	  the	  other	  lanthanides.	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For	   the	   complexes	   of	   L3,	   the	   19F	   chemical	   shifts,	   R1	   and	   R2	   values	   have	   been	  
measured	  for	  a	  series	  of	  Ln3+	  ions	  at	  two	  different	  field	  strengths	  (Table	  2.5).	  
	  
	  	   R1	  /	  Hz	   R2	  /	  Hz	  
Complex	   4.7	  T	   9.4	  T	   4.7	  T	   9.4	  T	  
[Tb.L3(H2O)]	   72	   116	   61	   119	  
[Dy.L3(H2O)]	   75	   139	   116	   220	  
[Ho.L3(H2O)]	   48	   109	   69	   151	  
[Er.L3(H2O)]	   29	   65	   75	   157	  
[Tm.L3(H2O)]	   26	   51	   79	   91	  
	  
Table	  2.5:	  19F	  Longitudinal	  and	  transverse	  relaxation	  data	  for	  [Ln.L3(H2O)]	  (2mM,	  D2O,	  pD	  5.4,	  295K)	  	  
	  
For	  each	  of	  the	  Ln3+	   ions,	   it	  can	  be	  seen	  that	  as	  the	  magnetic	  field	   is	   increased	  the	  
relaxation	   rate	   decreases,	   allowing	   for	   faster	   acquisition	   time.	   However,	   the	   R2	  
values	  demonstrate	  that	  this	  faster	  relaxation	  is	  also	  accompanied	  by	  broadening	  of	  
the	   signal	   peak.	   Consequently,	   there	   needs	   to	   be	   a	   compromise	   between	   the	   two	  
factors	  to	  enable	  optimisation.	  	  
	  
For	   the	   complexes	   of	   L1	   and	   L3,	   the	   longitudinal	   and	   transverse	   relaxation	   rates	  
follow	  the	  order	  of	  Tb	  >	  Ho	  >	  Er	  >	  Tm,	  consistent	  with	  the	  presence	  of	  µ2eff	  and	  µ4eff	  	  
terms	  (Equations	  2.8	  and	  2.9).	  Assessing	  which	  Ln3+	   ion	   is	  most	  suitable	  for	   further	  
development	  is	  a	  difficult	  task,	  as	  each	  has	  advantages	  and	  shortcomings.	  With	  the	  
Tb3+	   complexes,	   there	   is	   a	   vast	   relaxation	   enhancement.	   However,	   this	   is	   coupled	  
with	  a	  linewidth	  so	  large	  it	  can	  inhibit	  accurate	  interpretation	  of	  results.	  Conversely,	  
the	   linewidth	  of	  Tm3+	   is	  more	  favourable	  but	  the	   lesser	   longitudinal	  relaxation	  rate	  
enhancement	   could	   mitigate	   against	   the	   use	   of	   this	   lanthanide,	   at	   lower	   fields	  
especially.	  Based	  on	  the	  above	  data,	  it	  could	  be	  tentatively	  suggested	  that	  Tb3+	  and	  
Ho3+	  complexes	  are	  best	  suited	  for	  further	  development	  at	  higher	  fields.	   	  However,	  
this	  preliminary	  assessment	  does	  not	  take	  into	  account	  the	  effect	  of	  minor	  species,	  
and	   how	   the	   Ln3+	   ions	   would	   perform	   in	   an	   imaging	   experiment	   (rather	   than	  
spectroscopy).	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Volumetric	   plots	   of	   the	   19F	   relaxation	   rates,	   resulting	   from	   equations	   2.8	   and	   2.9,	  
have	  been	  generated,	  calculating	  the	  19F	  longitudinal	  and	  transverse	  relaxation	  rates,	  
R1	  and	  R2,	  as	  a	  function	  of	  the	  applied	  magnetic	  field	  (B0),	  the	  rotational	  correlation	  
time	  (τR)	  and	  the	  distance	  between	  the	  19F	  nucleus	  and	  the	  paramagnetic	  centre	  (r).	  
These	  are	  based	  on	  an	  idealised	  Ln3+	  ion	  with	  a	  magnetic	  moment	   effµ of	  10.0	  Bohr	  
magnetons	   (viz.	   Tb:	   9.7;	   Dy	   and	   Ho	   10.6;	   Er	   9.6;	   Tm	   7.6	   BM)	   and	   an	   electronic	  
relaxation	  time	  of	  0.20	  ps	  (Figure	  2.5).	  Values	  for	  the	  electronic	  spin	  relaxation	  time,	  
τR, have	  been	  estimated	  to	  be	  in	  the	  range	  0.15	  to	  0.4	  ps	  for	  both	  the	  aqua	  ions	  (Tb,	  







Figure	   2.5:	   Volumetric	   plots	   showing	   the	   variation	   of	   R1	   (left)	   and	   R2	   (right)	   with	   applied	   field,	   Bo,	  
mean	  distance,	  r,	  between	  the	  paramagnetic	  centre	  and	  the	  effective	  rotational	  correlation	  time,	  τR;	  
the	  analysis	  is	  based	  on	  equations	  2.8	  and	  2.9,	  assuming	  µeff=10.0	  BM	  and	  τe	  =	  0.20	  ps.	  
The	   nuclear	   relaxation	   rates	   decrease	   relatively	   quickly,	   as	   the	   19F-­‐Ln3+	   distance	   is	  
increased	  due	  to	  the	  steep	  distance	  dependence	  of	  both	  dipolar	  and	  Curie	  terms.	  In	  
the	  19F-­‐Ln3+	  distance	  range	  predicted	  for	  L1-­‐L3	  complexes	  (5.5	  –	  6.5	  Å),	  and	  at	  a	  field	  
of	  3.0	  Tesla,	  R1	  and	  R2	  values	  of	  ~100	  Hz	  are	  expected.	  When	  moving	  to	  higher	  field	  
strengths,	  greater	  line	  broadening	  is	  predicted	  for	  complexes	  of	  Dy,	  Ho,	  Tb	  and	  to	  a	  
lesser	  extent,	  Er	  and	  Tm.	  	  
	  
2.6	  Proton	  Relaxation	  Parameters	  
	  
The	  main	  aim	  of	  this	  project	   is	  to	  design	  multidisciplinary	  probes,	  capable	  of	  use	  in	  
both	   19F	   and	   1H	  magnetic	   resonance	   imaging	   and	   spectroscopy.	   Consequently,	   the	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Gd3+	  analogue	  of	  each	   ligand	  has	  also	  been	  synthesised,	  and	   the	  corresponding	   1H	  
MR	  relaxometric	  properties	  assessed.	  
	  
2.6.1	  Proton	  Relaxation	  Theory	  	  
	  
Proton	   relaxivity	   directly	   refers	   to	   the	   efficiency	   of	   a	   paramagnetic	   substance	   to	  
enhance	   the	   relaxation	   rate	   of	   water	   protons.	   As	   discussed	   in	   section	   1.3.3,	   the	  
paramagnetic	  contribution	  to	  total	  relaxivity	  consists	  of	  inner-­‐sphere,	  second-­‐sphere	  
and	  outer-­‐sphere	  contributions	  (Equation	  2.11):	  
	  
ri = riIS + riOS + riSS                                                (2.11)	  
	  
The	  inner-­‐sphere	  contribution	  relates	  to	  the	  interaction	  between	  electron	  spins	  and	  








= ⎜ ⎟+ τ⎝ ⎠
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.12)	  
	  
in	  which	  C	   is	   the	  concentration	   in	  mM,	  q	   is	   the	  number	  of	  bound	  water	  molecules	  
per	   Gd3+	   (hydration	   number),	   T1m	   is	   the	   longitudinal	   relaxation	   time	   of	   the	  
coordinated	   water	   protons	   and	   τm	   is	   the	   water	   residence	   lifetime	   at	   the	   Gd3+	  
centre.20	  The	  longitudinal	  relaxation	  time	  of	  bound	  water	  protons	  is	  governed	  by	  the	  
dipole-­‐dipole	   (DD)	   and	   scalar	   (SC)	   mechanisms,	   where	   both	   are	   dependent	   on	  
magnetic	   field.	   	   The	   relaxation	   rate,	   1/T1m,	   is	   generally	   described	   by	   the	  modified	  
Solomon-­‐Bloembergen	  equation:	  
	  	  
2 2 2 2
0 c1 c2H B
6 2 2 2 2
1m GdH H c1 s c2
3 7g S(S 1)1 2
T 15 4 r 1 1
⎛ ⎞µ τ τγ µ +⎛ ⎞= +⎜ ⎟⎜ ⎟π +ω τ +ω τ⎝ ⎠ ⎝ ⎠
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.13)	  
	  
where	  γH	  is	  the	  nuclear	  gyromagnetic	  ratio	  for	  proton,	  g	  is	  the	  electron	  g-­‐factor, µB	  
is	  the	  Bohr	  magneton,	   rGdH	  is	  the	  electron	  spin	  –	  proton	  distance,	  ωH	  and	  ωS	  are	  the	  
nuclear	   and	   electron	   Larmor	   frequencies,	   respectively	   (ω = γB,	   where B	   is	   the	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magnetic	   field),	  and	  µci	   (i	  =	  1,	  2)	  are	   the	  correlation	  times	  relative	   to	   the	  electron-­‐
proton	   dipolar	   coupling.20	   The	   correlation	   times	   which	   are	   characteristic	   of	   the	  
relaxation	  processes	  are	  described	  by	  equation	  2.14:	  
	  
ci R ie m




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.14)	  
	  
in	  which	  τR	   is	   the	   rotational	   correlation	   time,	  Tie (i=	   1	   or	   2)	   are	   the	   electron	   spin	  
relaxation	  times	  of	  the	  metal	  ion	  and	  τm	  is	  the	  water	  residence	  lifetime	  at	  the	  Gd3+	  
centre	  (or	  ion).20	  
	  
The	  relaxation	  rates,	  1/T1e	  and	  1/T2e,	  also	  depend	  on	  magnetic	  field.	  It	  is	  common	  for	  
Gd3+	   complexes	   to	   be	   interpreted	   in	   terms	   of	   zero	   field	   splitting	   (ZFS)	   interaction,	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  (2.16)	  
	  
in	  which	  Δ2	  is	  the	  mean-­‐square	  ZFS	  energy	  and	  τv	  is	  the	  correlation	  time	  for	  the	  ZFS	  
modulation	   (resulting	   from	   the	   transient	   distortions	   of	   the	   complex).	   The	  
combination	  of	  equations	  2.13,	  2.15	  and	  2.16	  represent	  the	  Solomon-­‐Bloembergen-­‐
Morgan	  (SBM)	  theory.	  	  
	  
The	   second-­‐sphere	   term	   relates	   to	   a	   loose	   layer	   of	   water	  molecules	   between	   the	  
inner-­‐	   and	   outer-­‐sphere.	   They	   are	   not	   directly	   bound,	   but	   arise	   from	   other	  
interactions,	  such	  as	  hydrogen	  bonding,	  allowing	  them	  to	  remain	  in	  proximity	  to	  the	  
Gd3+	  ion	  for	  a	  relatively	  long	  time.	  Often	  this	  term	  is	  neglected	  or	  its	  effect	  is	  taken	  
into	  account	  in	  the	  outer-­‐sphere	  term.	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The	  outer-­‐sphere	  term	  is	  related	  to	  the	  paramagnetic	  effect	  experienced	  by	  the	  bulk	  
solvent	   molecules	   diffusing	   around	   the	   Gd3+	   complex.	   For	   low	   molecular	   weight	  
molecules,	  the	  outer	  sphere	  contribution	  can	  be	  given	  in	  a	  simplified	  form	  (Equation	  
2.17).	  
	  
( ) ( )os os1p S H
1R C 7J 3J
aD
⎛ ⎞= ω + ω⎡ ⎤⎜ ⎟ ⎣ ⎦⎝ ⎠
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.17)	  
	  
in	  which	  Cos	  is	  a	  constant	  (5.8	  x	  10-­‐13	  s-­‐2M-­‐1), a	  is	  the	  minimum	  distance	  between	  the	  
Gd3+	   and	   the	   water	   molecules, D	   is	   the	   diffusion	   coefficient,	   and	   J(ωi) is	   the	  
dependence	  on	  the	  electronic	  relaxation	  times.	  
	  
For	   the	   low	  molecular	  weight	   Gd3+	   complexes	   studied	  within	   this	   thesis,	   the	  most	  
significant	  contribution	  is	  usually	  from	  the	  inner	  sphere	  term.20	  
	  
2.6.2	  Proton	  Relaxation	  Properties	  of	  Gd3+	  Complexes	  
	  
For	  the	  measurement	  of	  relaxivity,	  the	  obvious	  solvent	  of	  choice	  is	  water.	  However,	  
due	  to	  the	  high	  number	  of	  fluorine	  atoms	  present	  in	  [Gd.L1(H2O)]3+,	  water	  solubility	  
was	   limited	   and	   therefore	   20	   %	   methanol	   was	   added	   for	   the	   experiments.	   As	   a	  
control,	  1H	  relaxivity	  measurements	  were	  made	  in	  a	  10,	  15,	  20	  and	  25	  %	  CD3OD/	  H2O	  
mixture.	  No	  significant	  changes	   in	   the	  measured	  values	  were	   found	   (2	  mM,	  295	  K,	  
1.4	  T).	  
	  
The	   solubility	   issues	   encountered	   with	   [Gd.L1(H2O)]3+	   prevented	   accurate	  
measurements	  of	  the	  temperature	  dependence	  of	  the	  transverse	  relaxation	  rate	  of	  
the	  17O	  water	  signal.	  Consequently,	  information	  on	  the	  water	  exchange	  rate,	  τm,	  was	  
obtained	  from	  the	  analysis	  of	  the	  temperature	  dependence	  of	  r1p in	  association	  with	  
standard	  analyses	  of	  the	  field	  dependence	  of	  relaxivity	  (0.01	  to	  70	  MHz)	  (Figure	  2.6).	  
This	   analysis	   is	   based	   upon	   the	   Solomon-­‐Bloembergen-­‐Morgan	   equations	   that	  
rationalise	   the	   time-­‐dependence	   of	   the	   water	   proton-­‐Gd3+	   dipolar	   coupling,	   in	  
addition	  to	  considering	  the	  contribution	  from	  the	  second	  sphere.21,	  22	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Figure	   2.6:	   Variation	   of	   relaxivity,	   r1p,	   with	   a)	   field	   and	   b)	   temperature,	   showing	   the	   estimated	  
contributions	  of	  inner	  and	  second	  sphere	  waters	  for	  [Gd.L1(H2O)]
3+	  (0.6	  mM,	  298	  K,	  pH	  6.5)	  
	  
For	  [Gd.L1(H2O)]3+,	  the	  relaxivity	  decreases	  as	  a	  function	  of	  temperature,	  	  consistent	  
with	  a	  relatively	  fast	  water	  exchange	  (τm	  =	  3.5	  µs)	  at	  the	  Gd3+	  centre	  (Figure	  2.6).	  The	  
proton	  relaxivity	  of	  [Gd.L1(H2O)]3+	  was	  calculated	  to	  be	  6.5	  mM-­‐1s-­‐1	  (20	  MHz,	  298	  K)	  
which	   is	   significantly	  higher	   than	  expected.	  Conversely,	   the	   tetra-­‐methyl	   analogue,	  
[Gd.L2(H2O)]3+,	  has	  a	  measured	  proton	  relaxivity	  value	  of	  3.8	  mM-­‐1s-­‐1	   (20	  MHz,	  298	  
K),	   which	   is	   comfortably	   in	   the	   region	   expected	   of	   tetra-­‐amides.23	   While	   the	  
relaxivity	  of	  [Gd.L2(H2O)]3+	  does	  decrease	  as	  a	  function	  of	  temperature,	  the	  profile	  is	  
significantly	  different	  from	  that	  of	  [Gd.L1(H2O)]3+	  (Figure	  2.7).	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Figure	   2.7:	   Variation	   of	   relaxivity,	   r1p,	   with	   a)	   field	   and	   b)	   temperature,	   showing	   the	   estimated	  
contributions	  of	  inner	  and	  second	  sphere	  waters	  for	  [Gd.L2(H2O)]
3+	  (0.4	  mM,	  298	  K,	  pH	  6.5)	  
	  
Analysis	   of	   the	   NMRD	   profile	   and	   the	   temperature	   dependence	   of	   the	   proton	  
relaxivity	   demonstrated	   a	  markedly	   slower	   rate	   of	  water	   exchange	   (τm	   =	   9	  µs)	   for	  
[Gd.L2(H2O)]3+.	   Further	   differences	   were	   apparent	   when	   examining	   the	   pH-­‐
dependence	   of	   the	   complexes.	   For	   [Gd.L1(H2O)]3+	   the	   relaxivity	   remained	   constant	  
over	   the	   pH	   range	   of	   4-­‐10,	   consistent	   with	   high	   kinetic	   stability.	   But	   with	  
[Gd.L2(H2O)]3+	   the	   relaxivity	   increased	   at	   high	   pH,	  most	   likely	   due	   to	   the	   onset	   of	  
base-­‐catalysed	  prototopic	  exchange.	  	  
	  
The	   presence	   of	   a	   larger	   contribution	   of	   the	   second	   sphere	   of	   hydration	   for	  
[Gd.L1(H2O)]3+,	  presumably	  associated	  with	  the	  presence	  of	  the	  CF3	  groups,	  helps	  to	  
rationalise	  the	  increased	  relaxivity	  in	  comparison	  with	  [Gd.L2(H2O)]3+.	  It	  is	  presumed	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there	  is	  well-­‐defined	  second	  sphere	  of	  hydration	  that	  assists	  the	  water	  exchange	  at	  
gadolinium,	  causing	  an	  increase	  in	  relaxivity.	  This	  is	  also	  evident	  from	  consideration	  




















r1p20 (mM-1 s-1) 3.8 6.5
Δ2 (s-2;×1019) 1.5 4.0
τV (ps) 8.5 13
ΔHv (kJ/mol) 5.0 2.0
τR (ps) 120 118
ΔHR (kJ/mol) 15 16
τM (µs) 9.0 3.5
ΔHM (kJ/mol) 51.0 30.1
q 1 1
r (Å) 3.0 3.0
a (Å) 4.0 4.0
D (cm2s-1;×10-
5) 2.24 2.24
ΔHd (kJ/mol) -28 -22
q’ 0 8
r’ (Å) / 4.4
	  
Figure	  2.7:	  Summary	  of	  selected	  relaxation	  parameters	   for	   [Gd.L1(H2O)]
3+	  and	   [Gd.L2(H2O)]
3+	  derived	  
from	  analysis	  of	  VT	   1H	  NMR	  relaxivity	  and	   fitting	  of	  NMRD	  profiles.	  Note:	  Parameters	  denoted	  with	  
prime	  refer	  to	  second	  sphere	  relaxivity	  
	  
As	  discussed,	  the	  high	  relaxivity	  value	  for	  [Gd.L1(H2O)]3+	  is	  somewhat	  unusual	  for	  this	  
type	   of	   tetra-­‐amide	   complex.	   To	   further	   our	   understanding	   of	   this	   result,	   a	   DFT	  
calculated	   structure	   of	   [Y.L1(H2O)]3+	   was	   generated,	   as	   a	   model	   for	   the	   related	  
lanthanide	   paramagnetic	   complexes,	   in	   collaboration	   with	   Dr	   Ilya	   Kuprov	   (Figure	  
2.9).	  
	  




Figure	  2.9:	  DFT	  calculated	  structure	  of	  [L1Ln]3+Cl3.	  Colour	  code:	  grey=	  carbon;	  white=	  hydrogen;	  dark	  
blue=	  nitrogen;	  red=	  oxygen;	  light	  blue=	  fluorine;	  turquoise=	  Ln.	  
	  
The	   DFT	   calculated	   structure	   identifies	   two	   possible	   hydrogen	   bonding	   sites	   for	  
water	  molecules;	  to	  the	  amide	  N-­‐H	  and	  to	  the	  relatively	  acidic	  C-­‐H	  proton.	  The	  latter	  
is	  encountered	  rather	  infrequently,	  and	  may	  be	  attributed	  to	  the	  positive	  charge	  on	  
the	  hydrogen	  of	  the	  CH2	  groups	  on	  the	  cyclen	  cage	  (owing	  to	  the	  close	  proximity	  of	  
the	  other	  electronegative	  groups).	  The	  most	  important	  hydrogen	  bond	  interaction	  is	  
between	   the	  amide	  NH	  and	  a	  water	  molecule.	   This	   interaction	   is	  enhanced	  by	   the	  
higher	   acidity	   of	   the	   amide	   proton,	   due	   to	   the	   proximity	   of	   the	   trifluoromethyl	  
group.	  Consequently,	  this	  results	   in	  these	  second	  sphere	  water	  molecules	  spending	  
longer	   time,	   on	   average,	   in	   the	   immediate	   vicinity	   of	   the	   paramagnetic	   ion.	  
Additionally,	  while	  the	  water	  molecules	  are	  bonded	  to	  the	  complex,	  they	  share	  the	  
same	   rotational	   correlation	   time	   with	   the	   complex.	   As	   discussed	   previously,	   the	  
relaxivity	  is	  proportional	  to	  both	  the	  time	  spent	  near	  the	  complex	  and	  the	  rotational	  
correlation	   time.	   Both	   parameters	   are	   increased	   in	   [Gd.L1(H2O)]3+	   and	   therefore	  
could	  contribute	  to	  the	   increased	  relaxivity	  value.	  The	  DFT	  structure	  calculated	  the	  
Ln-­‐19F	  nucleus	  distance	  to	  be	  6.2	  Å.	  This	  is	  in	  good	  agreement	  with	  the	  value	  of	  6.1	  Å	  
calculated	   from	   the	   relaxation	   rates	  measured	   at	   different	   field	   strengths	   (Section	  
2.5.2).	  	  
	  
The	  relaxivity	  of	  [Gd.L3(H2O)]	  was	  independent	  of	  pH	  (±	  7	  %)	  over	  the	  pH	  range	  2.5	  to	  
11.5,	   consistent	   with	   high	   kinetic	   stability	   with	   respect	   to	   acid-­‐catalysed	   or	   base-­‐
promoted	   dissociation	   pathways.	   The	   temperature	   dependence	   of	   the	   transverse	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relaxation	  rate	  of	  the	  17O	  water	  signal,	  in	  addition	  to	  the	  analysis	  of	  the	  temperature	  
and	  field	  dependence	  of	  r1p,	  allowed	  an	  estimate	  of	  the	  water	  exchange	  lifetime,	  τm,	  
based	  on	  standard	  ‘Swift-­‐Connick’	  methodology	  (Figure	  2.10).22	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Figure	   2.9:	   Variation	   of	   relaxivity,	   r1p,	   with	   a)	   field	   and	   b)	   temperature,	   showing	   the	   estimated	  
contributions	  of	  inner	  and	  second	  sphere	  waters.	  c)	  17O	  NMR	  -­‐	  	  variation	  of	  R2P	  with	  temperature	  for	  
[Gd.L3(H2O)]	  (0.6	  mM,	  298	  K,	  pH	  6.5).	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The	  proton	  relaxivity	  of	   [Gd.L3(H2O)]	  was	  found	  to	  be	  5.5	  mM-­‐1s-­‐1	   (20	  MHz,	  298	  K),	  
and	  the	  water	  exchange	  lifetime	  estimated	  to	  be	  0.9	  µs.	  Both	  values	  are	  typical	  of	  a	  
variety	  of	  related	  monoamide	  derivatives	  of	  [Gd.DO3A(H2O)].17	  
	  
2.7	  Sensitivity	  Enhancement	  in	  Spectroscopic	  and	  19F	  MR	  Imaging	  Studies	  
	  
A	  comparative	  study	  was	  undertaken	  to	  assess	  the	  gain	  in	  signal	  intensity	  for	  the	  Tb,	  
Ho,	   Er	   and	   Tm	   complexes	   of	   L1	   and	   L3	   over	   the	   diamagnetic	   yttrium	   analogue.	  
Equimolar	  (2	  mM)	  solutions	  were	  used	  and	  spectral	  signal	  intensity	  recorded	  at	  4.7	  
T,	  using	  an	  acquisition	  time	  of	  three	  times	  the	  measured	  T1	  value,	  acquiring	  spectral	  
data	  for	  20	  min	  in	  each	  case.	  In	  spectral	  processing,	  the	  line	  broadening	  was	  set	  to	  
50	   %	   of	   the	   observed	   linewidth	   and	   the	   relative	   signal	   intensity	   only	   took	   into	  
account	  the	  signal	  from	  the	  major	  species.	  The	  values	  obtained	  reveal	  the	  expected	  





intensity	   	   Complex	  
Relative	  signal	  
intensity	  
[Y.L1(H2O)]3+	   1.0	   	   [Y.L3(H2O)]	   1.0	  
[Tb.L1(H2O)]3+	   14.8	   	   [Tb.L3(H2O)]	   11.1	  
[Ho.L1(H2O)]3+	   9.2	   	   [Ho.L3(H2O)]	   5.5	  
[Er.L1(H2O)]3+	   8.6	   	   [Er.L3(H2O)]	   4.8	  
[Tm.L1(H2O)]3+	   5.7	   	   [Tm.L3(H2O)]	   4.8	  
	  
Table	  2.6:	  Assessment	  of	  19F	  NMR	  spectroscopic	  sensitivity	  for	  a)	  [Ln.L1(H2O)]
3+	  (2	  mM,	  D2O:CH3OH	  (20	  
%),	  295	  K,	  Ln=Y,	  Tb,	  Ho,	  Er	  and	  Tm)	  and	  b)	   [Ln.L3(H2O)]	   (2	  mM,	  D2O,	  295	  K,	  pD	  5.4).	  The	  acquisition	  
time	  was	  set	  as	  3	  x	  T1,	  with	  no	  delay	  time;	  total	  acquisition	  time	  was	  20	  min;	  in	  spectral	  processing	  the	  
line	  broadening	  was	  set	  as	  50	  %	  of	  the	  observed	  linewidth.	  	  
	  
From	  the	  results	   it	  can	  be	  seen	  that	  complexes	  of	  L1	  are	  superior	  to	  those	  of	  L3	   for	  
relative	   signal	   intensity	   gain,	   in	   comparison	   to	   the	   corresponding	   diamagnetic	   Y3+	  
complex.	   Complexes	   of	   L1	   incorporate	   12	   fluorines	   whereas	   complexes	   of	   L3	   have	  
only	   3.	   Moreover,	   complexes	   of	   L1	   have	   one	   major	   resonance	   by	   19F	   NMR	  
spectroscopy	   which	   is	   ≥	   70	   %	   of	   the	   overall	   observed	   signal	   intensity,	   whereas	  
complexes	   of	   L3	   have	   additional	   species	   present	   that	   limit	   the	   effective	   signal	  
intensity	  gain.	  	  




Preliminary	  imaging	  studies	  were	  carried	  out	  at	  7	  T	  by	  Prof.	  Andrew	  Blamire	  at	  the	  
Newcastle	  Magnetic	  Resonance	  Centre.	  R1	  values	  were	  estimated	  to	  be	  46.4	  s-­‐1	  and	  





,	   respectively,	   for	   a	   repetition	   rate,	   TR,	   of	   25	   ms.	   Equimolar	   solutions	   of	  
[Y.L3(H2O)]	   and	   [Er.L3(H2O)]	   were	   prepared,	   and	   fluorine	   MR	   images	   of	   were	  
collected	  over	  34	  min.	  The	  measured	  signal	  to	  noise	  ratio	   in	  [Er.L3(H2O)]	   	  was	  16.7,	  
compared	   to	   7.2	   in	   [Y.L3(H2O)],	   yielding	   a	   sensitivity	   enhancement	   of	   2.3	   (Figure	  
2.11).	   This	   is	   lower	   than	   the	   theoretical	   calculated	   sensitivity	   difference	   for	   Ernst	  
angle	   imaging,	  under	   these	  conditions,	  of	  4.4.	   	   Some	   loss	  of	   sensitivity	   is	  expected	  
due	  to	  R2	  decay	  during	  the	  echo	  time.	  Although	  the	  minimum	  repetition	  time	  could	  
be	  reduced	  further,	  the	  theoretical	  sensitivity	  increase	  in	  moving	  to	  an	  even	  shorter	  
TR	   is	   small.	   	   Scans	  were	   therefore	   collected	  with	   TR=25	  ms	   as	   a	   typical	   value	   that	  
could	  be	  used	  for	  multi-­‐slice	  measurements	  in	  vivo.	  
	  	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2.10:	  Gradient	  echo	  19F	   images	  of	  [Er.L3(H2O)]	  (left)	   	  and	  [Y.L
3(H2O)]	  (right)	  samples.	   	  Samples	  
contained	   5mM	   solution	   and	  were	   imaged	   using	   a	   Ernst	   angle	   excitation	   of	   a	   6	  mm	   thick	   slice,	   in-­‐




As	  with	  all	  compounds	  that	  are	  designed	  for	  in	  vivo	  applications,	  the	  cytotoxicity	  has	  
to	   be	   evaluated	   to	   determine	   whether	   or	   not	   the	   application	   will	   be	   viable.	   IC50	  
values	   were	   determined	   using	   the	   MTT	   assay,	   as	   described	   by	   Carmichael	   et	   al.,	  
which	   makes	   use	   of	   the	   conversion	   of	   MTT	   (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐	  
diphenyltetrazolium	   bromide)	   to	   a	   purple	   formazan	   product	   by	   the	  mitochondrial	  
succinate	   dehydrogenase	   of	   viable	   cells	   (Scheme	   2.5).24	   This	   insoluble	   formazan	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product	   was	   quantified	   spectrophotometrically	   upon	   dissolution	   in	   DMSO.	   IC50	  
values	   were	   determined	   as	   the	   drug	   concentration	   required	   to	   reduce	   the	  
absorbance	  to	  50%	  of	  that	  in	  the	  untreated,	  control	  wells,	  and	  represent	  the	  mean	  




Scheme	   2.5:	   Conversion	   of	   MTT	   (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐	   diphenyltetrazolium)	   to	   a	   purple	  
formazan	  product	  by	  the	  mitochondrial	  dehydrogenase	  of	  viable	  cells.	  
	  
The	  cytotoxicity	  of	  the	  complexes	  of	  L1-­‐	  L3	  was	  assessed	  using	  the	  NIH	  3T3	  cell	  line,	  
with	  an	  incubation	  time	  of	  24	  h	  (Table	  2.7).	  
	  
Complex	   IC50	  (µM)	  
[Gd.L1(H2O)]3+	   >	  200	  
[Tb.L2(H2O)]3+	   >500	  
[Gd.L2(H2O)]3+	   >500	  
[Gd.L3(H2O)]3+	   >500	  
	  
Table	  2.7:	  Cyctotoxicity	  results	  for	  complexes	  of	  L1	  –	  L3	  in	  NIH	  3T3	  cells,	  following	  24	  h	  incubation,	  
determined	  by	  the	  MTT	  assay.	  
	  
The	   limited	   solubility	   of	   [Gd.L1(H2O)]3+	   resulted	   in	   the	   complexes	   being	   tested	   at	  
lower	   concentrations	   which	   accounts	   for	   the	   lower	   IC50	   value	   in	   comparison	  
complexes	   of	   L2	   and	   L3.	   A	   control	   experiment,	   testing	   both	   the	   Gd3+	   and	   Tb3+	  
complexes	  of	  L2,	  demonstrated	  that	  the	  IC50	  value	  measured	  is	   independent	  of	  Ln3+	  
ion	   (within	  a	  given	   ligand	  set).	  All	   complexes	  of	  L1-­‐L3	  exhibit	   IC50	  values	  sufficiently	  
high	  to	  be	  considered	  non-­‐toxic.	  This	  is	  most	  likely	  to	  be	  due	  to	  their	  poor	  ability	  to	  
enter	  this	  cell	  type,	  under	  the	  experimental	  conditions.	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2.9	  Preliminary	  In	  vivo	  Studies	  
	  
The	   Ln3+	   complexes	   of	   monoamide	   derivatives	   of	   DO3A	   exhibit	   high	   kinetic	   and	  
thermodynamic	   stability	   with	   respect	   to	   metal	   dissociation	   and	   are	   very	   water	  
soluble.	   Hence,	   they	   are	   appropriate	   systems	   for	   consideration	   for	   use	   in	   vivo.	  
Preliminary	   in	   vivo	   studies	   were	   performed	   by	   Dr.	   Ian	   Wilson,	   at	   the	   Newcastle	  
Magnetic	  Resonance	  Centre,	  on	  SCID	  male	  mice	   (25	  g)	  with	  HT29	  tumours	   (human	  
colorectal	  carcinoma).	  Measurements	  were	  taken	  10-­‐14	  days	  after	  inoculation	  when	  
the	   tumours	   were	   ~10	   mm	   in	   diameter.	   Mice	   had	   their	   tail	   vein	   cannulated	   and	  
restrained	   within	   a	   39	   mm	   volume	   coil,	   and	   were	   anaesthetized	   with	   isofluorane	  
inhalation	   and	   kept	   warm	   using	   a	   warm	   air	   feedback	   system.	   Scout	   images	   were	  
acquired	   and	   slices	   selected	   for	   our	   region	   of	   interest	   (ROI),	   including	   tumour,	  
muscle	   and	   bladder.	   A	   dynamic	   gradient	   echo	   multi-­‐slice	   sequence	   was	   used	   for	  
imaging.	  The	  performance	  of	  [Gd.L3(H2O)]	  was	  compared	  to	  that	  of	  the	  commercial	  
contrast	  agent,	  Prohance	  (0.1	  mM	  kg-­‐1).	  Images	  were	  collected	  30	  seconds	  pre-­‐	  and	  
10	  minutes	  post-­‐injection	  for	  [Gd.L3(H2O)]	  and	  Prohance	  (Figure	  2.12).	  
Figure	  2.12:	  1H	  MRI	  images	  of	  SCID	  male	  mice	  collected	  at	  30	  secs	  pre	  and	  10	  mins	  post	  injection:	  
[Gd.L3(H2O)]	  (upper)	  and	  Prohance	  (lower)	  
Pre-injection: 
Post-injection (10 mins) L3Gd: 
Post-injection (10 mins) Prohance: 
Pre-injection: 
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The	   tumour	   area	   was	   analysed	   to	   measure	   the	  mean	   signal	   intensity	   profile	   as	   a	  
function	  of	  time.	  The	  increase	  of	  the	  mean	  signal	  intensity	  reached	  1.19	  (±	  0.02)	  for	  
[Gd.L3(H2O)]	  and	  1.22	  (±	  0.02)	  for	  Prohance.	  There	  was	  rapid	  uptake	  of	  [Gd.L3(H2O)]	  
observed	   in	   the	   tumour,	   which	   was	   subsequently	   released	   into	   the	   bladder,	  
indicative	   of	   renal	   excretion.	   These	   findings	   were	   very	   promising	   owing	   to	   the	  
similarity	   in	   results	   with	   the	   commercially	   available	   Prohance.	   As	   such,	   a	  
complimentary	   19F	   MRI	   study	   was	   performed	   using	   [Ho.L3(H2O)]	   (0.1	   mM	   kg-­‐1).	  
Disappointingly	  no	  fluorine	  image	  was	  recorded.	  This	  could	  be	  due	  to	  the	  presence	  
of	  multiple	  species	  in	  the	  19F	  NMR	  spectra,	  limiting	  the	  observed	  signal	  intensity,	  or	  it	  
could	   be	   that	   there	   are	   simply	   too	   few	   fluorines	   in	   complexes	   of	   L3,	   leading	   to	  
insufficient	  signal	  intensity	  in	  the	  observed	  region.	  
	  
2.10	  Stability	  of	  L3	  complexes	  
	  
As	   discussed	   in	   section	   2.4,	   the	   complexes	   of	   L3	   give	   rise	   to	   one	  major	   species	   in	  
solution,	   with	   many	   other	   minor	   species	   that	   vary	   in	   number	   and	   proportion	  
according	  to	  the	  nature	  of	  the	  Ln3+	  ion.	  However,	  if	  left	  in	  solution	  for	  more	  than	  48	  
h,	  the	  number	  and,	  more	  significantly,	  the	  proportion	  of	  major	  to	  minor	  species	  was	  
altered	  (Table	  2.8).	  	  
	  
Complex	  
%	  Major	  species	   No.	  of	  minor	  species	  
0	  h	   	  	  	  	  	  	  	  	  	  	  	  48	  h	   0	  h	   48	  h	  
[Tb.L3(H2O)]	   68	   	  	  	  	  	  	  	  	  	  	  	  43	   5	   8	  
[Ho.L3(H2O)]	   85	   	  	  	  	  	  	  	  	  	  	  	  62	   3	   7	  
[Er.L3(H2O)]	   82	  	   	  	  	  	  	  	  	  	  	  	  	  47	   8	   10	  
[Tm.L3(H2O)]	   74	   	  	  	  	  	  	  	  	  	  	  	  74	   6	   9	  
[Y.L3(H2O)]	   92	   	  	  	  	  	  	  	  	  	  	  	  	  92	   	  1	   1	  
	  
Table	  2.8:	  19F	  NMR	  spectroscopic	  data	  for	  [Ln.L3(H2O)]	  (2	  mM,	  D2O,	  295	  K,	  pD	  5.4,	  Ln	  =	  Tb,	  Ho,	  Er,	  Tm	  
and	  Y)	  at	  0	  and	  48	  h.	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This	  is	  most	  apparent	  for	  [Er.L3(H2O)]	  where	  the	  major	  species	  comprised	  >	  80	  %	  of	  
the	  observed	  signal	   immediately	   following	  dissolution,	  but	  reduced	  to	  ~	  47	  %	  after	  





Figure	  2.12:	  19F	  NMR	  spectra	  of	  [Er.L3(H2O)]	  at	  a)	  0	  h	  and	  b)	  48	  h	  (2mM,	  D2O,	  295K,	  pD	  5.4,	  4.7	  T)	  
	  
The	   isomeric	   species	   observed	   in	   these	   19F	  NMR	   spectra	   relate	   to	   the	  presence	  of	  
diastereoisomeric	   species.	   These	   may	   be	   ascribed	   to	   two	   differing	   elements	   of	  
chirality	   associated	   with	   the	   NCCN	   and	   NCCO	   metal	   chelate	   rings.	   There	   are	   a	  
number	   of	   different	   conformations	   that	   complexes	   of	   L3,	   or	   any	   cyclen-­‐based	  
system,	  can	  adopt	  (Figure	  2.14).	  	  
	  
Figure	  2.14:	  Conformations	  of	  the	  Ln3+	  complexes	  of	  DOTA	  showing	  the	  orientation	  of	  the	  cyclen	  ring	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Each	  NCCN	  chelate	  ring	   is	  characterised	  by	  a	  torsion	  angle	  of	  +60o	  or	  -­‐60o	  (δ	  or	  λ),	  
and	  in	  a	  similar	  fashion,	  the	  NCCO	  torsion	  angle	  of	  the	  acetate	  arms	  can	  be	  +30o	  or	  -­‐
30o	  (Δ	  or	  Δ).	  This	  gives	  rise	  to	  four	  stereoisomers,	  exisiting	  as	  a	  pair	  of	  enantiomers.	  
A	  common	  configuration	  is	  favoured	  –	  giving	  δδδδ/	  λλλλ	  pairs	  of	  isomers	  that	  are	  
observed	  crystallographically.	  There	  are	  other	  possible	  conformations,	  such	  as	  λδδδ,	  
but	   they	   are	   usually	   higher	   in	   energy	   and	   have	   not	   previously	   been	   observed	   in	  
crystallographic	  studies	  of	  Ln3+	  cyclen-­‐based	  complexes.26,27	  
	  
A	   third	   element	   of	   chirality	   relates	   to	   the	   dissymmetry	   presented	   by	   the	   ortho-­‐
substituted	  aryl	  substituent	  on	  the	  coordinated	  amide	  N.	  This	  can	  be	  thought	  of	   in	  
terms	  of	  placing	  the	  CF3	  group	  ‘cis’	  or	  ‘trans’	  with	  respect	  to	  the	  coordinated	  amide	  
oxygen.	  
	  
Evidently,	   the	   formation	  of	   new	   resonances	   in	   the	   19F	  NMR	   spectra	   over	   time	  will	  
reduce	  signal	  intensity.	  Thus,	  it	  is	  vital	  to	  be	  able	  to	  develop	  a	  fluorinated	  probe	  that	  




Two	   model	   fluorinated	   macrocyclic	   lanthanide	   (III)	   complexes	   have	   been	  
synthesised,	  and	  their	  spectroscopic	  and	  relaxation	  properties	  discussed.	  Analysis	  of	  
the	   interplay	   between	   applied	   field,	   Ln3+	   ion	   and	   rotational	   correlation	   time	   has	  
demonstrated	  that	  complexes	  of	  Tb	  and	  Ho	  are	  most	  favourable	  at	  lower	  field	  (3	  to	  7	  
T),	   yielding	   large	   increases	   in	  R1	  without	   experiencing	  excessive	   line	  broadening	  of	  
the	  resonances.	  Conversely,	  complexes	  of	  Er	  and	  Tm	  have	  been	  shown	  to	  be	  worthy	  
of	  consideration	  of	  use	  at	  fields	  greater	  than	  7	  T.	  	  
	  
The	   field	   dependence	   of	   the	   Curie	   contribution	   to	   the	   R1	   values	   has	   allowed	   the	  
distance	  between	  the	  Ln3+	  ion	  and	  the	  trifluoromethyl	  group	  to	  be	  estimated,	  which	  
has	  been	  confirmed	  by	  DFT	  calculations.	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Using	   complexes	  of	   Tb,	  Ho,	   Er	   and	  Tm,	   longitudinal	   relaxation	   rate	  enhancements,	  
versus	  diamagnetic	  analogues,	  can	  be	  achieved.	  This	  results	  in	  the	  faster	  acquisition	  
of	   data	   in	   a	   given	   time	   period,	   leading	   to	   signal	   intensity	   enhancements	   in	   both	  
spectroscopic	  and	  imaging	  studies.  
 
The	  possibility	  of	  1H	  /	  19F	  dual	  imaging	  studies	  has	  been	  explored,	  using	  complexes	  of	  
the	   Gd3+	   for	   the	   proton	   MRI	   work.	   Finally,	   the	   importance	   of	   achieving	   one	  
preferred,	  and	  stable,	   species	   in	  solution	  has	  been	  discussed.	  Strategies	   to	  achieve	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3.0	  Strategies	  to	  Enhance	  Signal	  Intensity	  
3.1	  Introduction	  
	  
The	   initial	  work	  discussed	   in	   chapter	   two	   focussed	  on	   the	  behaviour	  of	   lanthanide	  
complexes	   of	   a	   CF3-­‐labelled	   mono-­‐amide	   derivative	   of	   DO3A,	   [Ln.L3(H2O)]	   (Figure	  
3.1).	  Unfortunately	  there	  were	  limitations	  to	  this	  system,	  most	  notably	  the	  number	  
of	   isomeric	   species	   present	   in	   solution,	  which	   varied	   from	   one	   Ln	   to	   another	   and	  
gave	  rise	  to	  a	  changing	  distribution	  over	  time.	  Furthermore,	  the	  observed	  linewidths	  
were	   significantly	   broader	   than	   expected,	   owing	   to	   dynamic	   intramolecular	  
conformational	   processes.	   Previous	   studies	   have	   shown	   that	   by	   introducing	   a	  
substituent	  at	  the	  α-­‐	  position	  to	  the	  ring	  nitrogen,1,2	  or	  by	  replacing	  the	  carboxylate	  













































































Figure	  3.1:	  Structures	  of	  [Ln.L3(H2O)],	  [Ln.L
4(H2O)]
3-­‐,	  [Ln.L5]	  and	  	  [Ln.L6]	  	  
	  
Consequently,	   two	   main	   strategies	   were	   employed	   in	   an	   attempt	   to	   reduce	   the	  
number	  of	   isomeric	  species	  and	  minimise	  exchange	  broadening	  (Figure	  3.1).	  Firstly,	  
the	   development	   of	   chiral	   lanthanide	   complexes	   was	   investigated,	   through	   the	  




introduction	   of	   glutarate	   and	  phosphinate	   pendant	   arms	   ([Ln.L4(H2O)]3-­‐	   and	   [Ln.L5]	  
respectively).	  Secondly,	  a	  CF3	  quinoline	  was	  synthesised	  to	  prevent	  arm	  rotation	  and	  
to	  increase	  the	  local	  rigidity	  of	  the	  trifluoromethyl	  moiety	  ([Ln.L6]).	  	  	  	  
	  
The	  disappointing	  preliminary	  19F	  MRI	  in	  vivo	  studies	  with	  [Ho.L3(H2O)],	  as	  discussed	  
in	   chapter	   two,	   demonstrated	   that	   there	   was	   insufficient	   signal	   intensity	   in	   the	  
observed	  region.	  The	  simplest	  way	  to	  increase	  signal	  intensity	  is	  the	  incorporation	  of	  
more	   fluorine	   atoms	   in	   to	   the	   complex.	   Importantly	   the	   fluorine	   atoms	   must	   be	  
chemically	  and	  magnetically	  equivalent	  to	  ensure	  a	  single	  19F	  resonance.	  Therefore,	  
three	  further	  complexes	  were	  synthesised,	  each	  based	  on	  DO2A	  and	  possessing	  two	  
C2-­‐related	  CF3	  groups	   in	  each	  amide	  moiety	  (Figure	  3.2).	  The	  α-­‐substituent	   in	  L7b	   is	  
derived	   from	   (S)-­‐glutaric	   acid,	   leading	   to	   an	   enantiopure	   ligand,	   and	   L7a	   is	   the	  
















3.2	  Synthesis	  and	  Characterisation	  of	  Complexes	  
3.2.1	  Synthesis	  of	  [Ln.L4(H2O)]3-­‐	  	  
	  	  
The	  first	  step	  in	  the	  synthesis	  of	  L4	  involved	  the	  alkylation	  of	  tri-­‐BOC	  protected	  cyclen	  
with	   the	  α-­‐	   chloroamide	  arm,	  1	   (Scheme	  3.1).	  Surprisingly,	  even	  under	   fairly	  harsh	  
reaction	   conditions,	   utilising	   5	   equivalents	   of	   Cs2CO3	   and	   DMF	   as	   the	   solvent,	   the	  
yield	  was	  very	   low	  (11	  %).	  The	  BOC	  protecting	  groups	  were	  subsequently	   removed	  
by	  treatment	  with	  trifluoroacetic	  acid	  in	  CH2Cl2.	  This	  reaction	  was	  also	  low	  yielding	  at	  
23	  %,	  and	   therefore	   it	  was	  decided	   to	  explore	  an	  alternative	   synthetic	  pathway	   to	  






The	  second	  approach	  involved	  selective	  alkylation	  of	  cyclen	  with	  1,	  without	  the	  use	  
of	   any	   protecting	   groups	   (Scheme	   3.2).	   To	   ensure	   only	   mono-­‐alkylation	   occurred,	  
cyclen	  was	  used	  in	  a	  10	  fold	  excess	  and	  mild	  reaction	  conditions	  were	  employed.	  The	  
purification	  was	  very	  simple;	  the	  crude	  product	  was	  extracted	  into	  CH2Cl2	  and	  then	  





The	  bromination	  and	  subsequent	  esterification	  of	  (S)-­‐glutaric	  acid	  monomethyl	  ester	  
was	  achieved	  in	  situ	  (Scheme	  3.3).	  	  
	  








Firstly,	   the	   diazotization	   of	   the	   amino	   group	   was	   accomplished	   by	   reaction	   with	  
sodium	   nitrite,	   followed	   by	   treatment	   with	   hydrobromic	   acid	   in	   the	   presence	   of	  
sodium	  bromide	   at	   -­‐5	   oC.	   It	   is	   hypothesized	   that	   the	   diazonium	   salt	   undergoes	   an	  
intramolecular	   SN2	   reaction	   immediately	   after	   formation.	   This	   entails	   nucleophilic	  
attack	  of	  the	  oxygen	  of	  the	  carboxylic	  acid	  onto	  the	  electrophilic	  carbon,	  followed	  by	  




Scheme	  3.4:	  Proposed	  double	  inversion	  mechanism	  in	  the	  bromination	  of	  (S)-­‐glutaric	  acid	  
monomethyl	  ester	  
	  
Subsequent	  nucleophilic	  attack	  by	  bromide	  opens	  the	  ring	  resulting	  in	  the	  formation	  
of	  the	  α-­‐bromoacid,	  wherein	  the	  α-­‐carbon	  possesses	  the	  same	  configuration	  as	  the	  
starting	  material.	   The	   crude	   product	  was	   then	   stirred	   in	   anhydrous	   CH3OH,	   in	   the	  
presence	  of	  a	  catalytic	  amount	  of	  H2SO4,	  to	  yield	  the	  desired	  diester,	  7,	  in	  64	  %	  yield.	  	  
	  
The	  subsequent	  alkylation	  of	   the	  three	  remaining	  secondary	  nitrogen	  atoms	  of	   the	  
cyclen	   ring,	   6,	   with	   enantiomerically	   pure	   diester,	   7,	   was	   achieved	   under	   basic	  
conditions,	  utilising	  KI	   as	  a	   catalyst	   (Scheme	  3.5).	   The	   removal	  of	   the	  methyl	  ester	  
groups	  was	  accomplished	  by	  treatment	  with	  KOD,	  thereby	  allowing	  for	  the	  reaction	  
to	   be	  monitored	   by	   1H	   NMR.	   The	   crude	   product	   was	   purified	   by	   cation	   exchange	  
column	  chromatography	  (DOWEX	  50-­‐W,	  12	  %	  NH4OH	  dilution)	  to	  afford	  the	  desired	  
ligand	  as	  its	  ammonium	  salt,	  L4.	  










The	   corresponding	   complexes,	   [Ln.L4(H2O)]3-­‐,	   were	   prepared	   using	   an	   aqueous	  
solution	  of	  the	  appropriate	  metal	  acetate	  (pH	  6.5,	  85	  oC),	  and	  purified	  as	  potassium	  
salts	  by	  dialysis.	  
	  
3.2.2	  Synthesis	  of	  [Ln.L5]	  
	  
The	  preparation	  of	  L5	  began	  with	  the	  condensation	  of	  the	  mono-­‐alkylated	  macrocyle,	  
6,	   with	   paraformaldehyde	   to	   yield	   an	   imine	   which	   was	   trapped	   by	   reaction	   with	  
diethoxymethylphoshine	   (Scheme	   3.6).	   An	   Arbuzov	   rearrangement	   gave	   the	  
triethylphosphinate	  ester,	  9,	  as	  a	  mixture	  of	  stereoisomers	  differing	  in	  configuration	  
at	  each	  stereogenic	  P	  centre.	  Subsequent	  base	  hydrolysis	  afforded	  the	  chiral	  ligand,	  
L5.	  
	  






Scheme	  3.6:	  Synthetic	  Pathway	  to	  [Ln.L5]	  
	  
Metal	   complexation	   was	   achieved	   using	   an	   aqueous	   solution	   of	   the	   appropriate	  
metal	   acetate	   (pH	   6.5,	   85	   oC),	   and	   the	   resultant	   complex	   purified	   by	   short-­‐path	  
chromatography	  on	  neutral	  alumina.	  
	  
3.2.3	  Synthesis	  of	  [Ln.L6]	  
	  
The	   formation	   of	   the	   desired	   fluorinated	   quinoline,	   10,	   was	   achieved	   via	   a	   classic	  
Skraup	   synthesis	   of	   the	   meta-­‐substituted	   aniline	   with	   crotonaldehyde,	   with	   the	  
resulting	   product	   purified	   by	   silica	   gel	   column	   chromatography	   (Scheme	   3.7).	  
Subsequent	   bromination	   was	   accomplished	   by	   reaction	   of	   10	   with	   N-­‐
bromosuccinimide	   in	   carbon	   tetrachloride,	  utilising	  benzoyl	  peroxide	  as	   the	   radical	  
initiator.	   Unfortunately,	   both	   the	   mono-­‐	   and	   di-­‐brominated	   products,	   11	   and	   12,	  
were	   formed	   (2:1	   respectively).	   However,	   separation	   of	   the	   desired	   product	   was	  
readily	  achieved	  via	  silica	  gel	   column	  chromatography.	  Moreover,	  12	   can	  easily	  be	  
transformed	  back	  to	  the	  mono-­‐brominated	  compound,	  11,	  in	  a	  high	  yielding	  reaction	  
(89	  %).	  	  
	  









Selective	   mono-­‐alkylation	   of	   cyclen	   with	   the	   fluorinated	   quinoline,	   11,	   was	   first	  
attempted	  under	  basic	   conditions	   (K2CO3,	  CH3CN,	  55	   oC).	  Unfortunately	  di-­‐	  and	   tri-­‐
alkylation	  also	  occurred,	  even	  when	  using	  cyclen	  in	  a	  15	  fold	  excess	  and	  maintaining	  
the	   reaction	   temperature	   at	   20	   oC	   (Scheme	  3.8).	   Purification	  at	   this	   stage	  was	  not	  
possible.	   Thus,	   co-­‐condensation	   of	   the	   mixture	   of	   amines	   with	   paraformaldehyde	  




Scheme	  3.8:	  Synthetic	  Pathway	  to	  [Ln.L6]	  




Isolation	  of	  the	  desired	  triphosphinate	  ester	  13,	  as	  a	  mixture	  of	  stereoisomers,	  was	  
achieved	  by	  silica	  gel	  column	  chromatography	  in	  42	  %	  overall	  yield.	  Subsequent	  base	  
hydrolysis	  and	  complexation	  followed	  the	  same	  procedure	  as	  described	  for	  [Ln.L5].	  
	  
3.2.4	  Synthesis	  of	  [Ln.L7a(H2O)]-­‐	  
	  
The	   initial	   step	   in	   the	   preparation	   of	   L7a	   involved	   the	   preparation	   of	   the	   racemic	  
dimethyl	  α-­‐bromoglutarate,	  14,	   via	   a	   Hell-­‐Volhardt-­‐Zelinski	   reaction	   (Scheme	   3.9).	  	  
Molecular	  bromine	  was	  added	  dropwise	   to	  a	   solution	  of	   the	  acid	  chloride,	  derived	  
from	  the	  starting	  (±)	  glutaric	  acid	  mono-­‐methyl	  ester,	  and	  after	  3	  hours	  the	  reaction	  
was	  quenched	  by	  the	  addition	  of	  methanol	  at	  0oC.5	  The	  product	  was	  separated	  from	  
the	  undesired	  2,4-­‐dibromodimethylglutarate	  by	  distillation	  under	  reduced	  pressure,	  
using	  a	  long	  Vigreux	  column.	  
	  










Subsequent	   alkylation	   of	   cyclen	   with	   the	   racemic	   dimethyl-­‐α-­‐bromoglutarate,	   14,	  
under	   mildly	   basic	   conditions,	   gave	   a	   combination	   of	   the	   di-­‐	   and	   tri-­‐substituted	  
products	   (Scheme	   3.10).	   The	   di-­‐alkylated	   macrocyle,	   15,	   purified	   by	   silica	   gel	  
chromatography,	   was	   isolated	   as	   a	   mixture	   of	   diastereoisomers.6	   The	   low	   yield	  
achieved	   (29	  %)	   could	  possibly	  be	   increased	  by	   lowering	   the	   reaction	   temperature	  
and	  reducing	  the	  quantity	  and	  strength	  of	  base	  added,	  thereby	  reducing	  the	  amount	  
of	  tri-­‐alkylated	  species	  formed.	  
	  
The	  alkylation,	  base	  hydrolysis	  and	  complexation,	  was	  achieved	   in	  a	  similar	   fashion	  
to	  that	  described	  for	  L4.	  	  










3.2.5	  Synthesis	  of	  [Ln.L7b(H2O)]-­‐	  
	  
Owing	  to	  the	  low	  yield	  achieved	  in	  the	  synthesis	  of	  the	  bis-­‐alkylated	  cyclen	  15,	  in	  the	  
preparation	   of	   L7a,	   a	   different	   approach	   was	   taken	   in	   the	   synthesis	   of	   L8a.	   Direct	  
alkylation	  of	  cyclen	  with	  1,	  under	  anhydrous	  conditions,	  allowed	  the	  isolation	  of	  the	  
1,7-­‐disubstituted	   fluorinated	   diamine	   17,	   in	   37	   %	   yield	   (Scheme	   3.11).	   The	  
constitution	  of	   the	  C2	   symmetry	  was	  verified	  by	   13C	  NMR	  spectroscopic	  analysis	  as	  
only	  two	  cyclen	  ring	  CH2N	  resonances	  were	  observed	  (δc	  45.1	  and	  51.9	  ppm).	  








Alkylation	  of	  17	  with	  dimethyl	  (S)-­‐2-­‐bromoglutarate,	  7,	  under	  basic	  conditions	  gave	  
the	  corresponding	  diester,	  18	   (Scheme	  3.12).	   	  Removal	  of	   the	  methyl	  ester	  groups	  
yielded	  the	  ligand	  L7b,	  following	  treatment	  with	  cation	  exchange	  resin.	  1H,	  13C	  and	  19F	  
NMR	   spectroscopic	   analysis	   confirmed	   the	   presence	   of	   the	   (RR)-­‐enantiomeric	  
product	   (δF	  =	   -­‐	  62.0	  ppm,	  pD	  5.4,	  D2O).	  Conversely,	  analysis	  of	   the	   ligand	  L7a	  by	  19F	  
NMR	  spectroscopy	  gave	  spectral	  data	  consistent	  with	  a	  mixture	  of	  diastereoisomers	  













3.2.6	  Synthesis	  of	  [Ln.L8(H2O)]+	  
	  
Firstly,	   the	   trans-­‐protected	  cyclen,	  19,	  was	   formed	   following	   the	   literature	  method	  
via	   the	   reaction	  of	   benzylchloroformate	  with	   cyclen	   (Scheme	  3.13).7	   The	   following	  
alkylation	  reaction	  at	  each	  secondary	  nitrogen	  atom	  of	  the	  cyclen	  ring	  with	  tert-­‐butyl	  
bromoacetate	  proceeded	  in	  good	  yield.8	  
	  
The	   removal	   of	   the	   carbamate	   protecting	   groups	  was	   achieved	   via	   hydrogenation,	  
utilising	   Pd(OH)2/C	   as	   the	   catalyst.8	   The	   synthesis	   of	   the	   trans-­‐ester	   was	   not	  
attempted	   in	   one	   step	   because	   mono-­‐	   and	   tri-­‐ester	   derivatives	   would	   also	   be	  
formed,	   and	   the	   mixture	   of	   products	   would	   not	   be	   amenable	   to	   purification	   by	  
chromatography.	   Moreover,	   it	   would	   be	   extremely	   difficult	   to	   ensure	   that	   the	  




The	  dialkylation	  of	  the	  cyclen	  ring,	  21,	  followed	  the	  procedure	  noted	  for	  L4	  (Scheme	  
3.14).	   Subsequent	   treatment	   with	   trifluoroacetic	   acid	   in	   CH2Cl2	   afforded	   the	  
protonated	  ligand,	  L8,	  which	  was	  then	  mixed	  with	  a	  slight	  excess	  of	  the	  appropriate	  
Ln(OAc)3	  salt	  in	  water	  (pH	  6.5)	  to	  yield	  the	  crude	  complex.	  The	  desired	  monocationic	  
complexes,	   [Ln.L8(H2O)]+,	  were	   isolated	  as	   chloride	   salts,	   following	  anion	  exchange	  
chromatography	  (DOWEX,	  pre-­‐treated	  with	  1M	  HCl).	  	  	  







3.2.7	  Estimation	  of	  Complex	  Hydration	  State	  
	  
For	   each	   Tb	   complex	   of	   L4-­‐	   L8	   the	   hydration	   state,	   q,	   was	   measured	   by	   a	  
luminescence	   method,	   examining	   the	   radiative	   rate	   constants	   in	   H2O	   and	   D2O	  
associated	  with	   the	  decay	  of	   the	  ΔJ	   =	   -­‐1	   transition	  at	  545	  nm	   (theory	  explained	   in	  
section	  2.3.1).	  	  
	  
Complex	   kH2O	   kD2O	   q'	  
[Tb.L4(H2O)]3-­‐	   0.59	   0.35	   0.90	  
[Tb.L5]	   0.32	   0.28	   0	  
[Tb.L6]	   0.37	   0.28	   0.15	  
[Tb.L7a(H2O)]-­‐	   0.58	   0.34	   0.90	  
[Tb.L7b(H2O)]-­‐	   0.56	   0.31	   0.95	  
[Tb.L8(H2O)]+	   0.56	   0.32	   0.90	  
	  
Table	  3.1:	  Lifetime	  measurements	  of	  Tb	  complexes	  of	  L4-­‐L8	  in	  H2O	  and	  D2O,	  including	  calculation	  of	  
hydration	  number;	  k	  values	  have	  a	  10%	  error	  and	  values	  of	  q	  are	  ±	  20	  %.	  
	  




Results	   show	   that	   all	   complexes	   incorporating	   carboxylate	   or	   glutarate	   donor	  
pendant	   arms	   possess	   one	   coordinated	   water	   molecule	   (Table	   3.1).	   Conversely,	  
phosphinate	   complexes	   each	   have	   a	   q	   value	   of	   zero,	   owing	   to	   the	  more	   sterically	  
demanding	  nature	  of	  these	  pendant	  arms.	  
	  
3.3	  19F	  Spectroscopic	  Properties	  
	  
For	  each	  complex	  incorporating	  glutarate	  donor	  pendant	  arms	  (i.e	  complexes	  of	  L4,	  
L7a	   and	   L7b),	   19F	  NMR	   spectroscopy	   revealed	   the	   presence	   of	   a	  mixture	   of	   species,	  
whose	  relative	  abundance	  varied	  from	  one	  Ln	  to	  another	  (Table	  3.2).	  In	  contrast	  with	  
complexes	   of	   L3,	   the	   relative	   composition	   of	   isomeric	   species	   in	   solution	   changed	  
neither	  with	  time,	  nor	  with	  pH	  over	  the	  range	  4	  to	  8.	  	  
	  	  
Complex	   δF	  /	  ppm	   %	  Major	  species	   No.	  of	  minor	  species	  
[Tb.L4(H2O)]3-­‐	   -­‐59.1	   41	   7	  
[Er.L4(H2O)]3-­‐	   -­‐63.5	   59	   3	  
[Tm.L4(H2O)]3-­‐	   -­‐73.9	   60	   4	  
[Tb.L7a(H2O)]-­‐	   -­‐58.9	   58	   3	  
[Tm.L7a(H2O)]-­‐	   -­‐76.4	   52	   4	  
[Tb.L7b(H2O)]-­‐	   -­‐62.1	   88	   1	  
[Er.L7b(H2O)]-­‐	   -­‐64.3	   63	   4	  
[Tm.L7b(H2O)]-­‐	   -­‐78.4	   40	   5	  
	  
Table	  3.2:	  19F	  NMR	  chemical	  shift	  data	  for	  selected	  complexes	  of	  L4,	  L7a	  and	  L7b	  (2	  mM,	  D2O,	  295	  K,	  pD	  
=	  5.4,	  4.7	  T).	  
	  
With	  [Tm.L7b(H2O)]-­‐,	  six	  different	  resonances	  were	  observed,	  with	  the	  major	  species	  
comprising	  only	  42	  %	  of	   the	   total	   signal	   intensity,	  whereas	  with	   [Tb.L7b(H2O)]-­‐	  only	  
two	   resonances	   were	   observed,	   and	   the	   dominant	   species	   comprised	   88%	   of	   the	  
observed	   signal	   intensity.	   Interestingly,	   the	  major	   resonance	  observed	  by	   19F	  NMR	  
spectroscopy	   for	   [Tb.L7b(H2O)]-­‐	   was	   only	   minimally	   shifted	   with	   respect	   to	   the	  
hydrolysed	   ligand,	  L7b(<	  1	  ppm).	   Initially,	   this	  was	  assumed	  to	  be	  unreacted	   ligand.	  
However	   1H	   NMR	   spectroscopic	   studies	   showed	   the	   presence	   of	   paramagnetically	  




shifted	  macrocyclic	   ring	  protons.	   Furthermore,	  HPLC	  analysis	   revealed	   the	  absence	  
of	   any	   free	   ligand,	   and	   ESMS+	   data	   clearly	   demonstrated	   that	   the	   complex	   had	  
formed.	  	  From	  equation	  3.1,	  it	  is	  apparent	  that	  it	  is	  not	  only	  the	  Bleaney	  constant,	  CJ,	  
and	  the	  distance	  of	  the	  fluorine	  nuclei	  to	  the	  metal	  centre,	  r,	  which	  determines	  the	  
dipolar	   shift	   but	   also	   the	   angle	   of	   the	   fluorine	   nuclei	  with	   respect	   to	   the	   principal	  
axis,	  θ.	  If	  this	  angle	  is	  close	  to	  54o	  then	  the	  ((3cos2θ	  -­‐	  1)	  /	  r3)	  term	  tends	  to	  zero	  and	  
the	  resulting	  dipolar	  shift	  is	  noticeably	  reduced.	  This	  could	  suggest	  a	  reason	  for	  the	  
unexpectedly	   small	   shifted	   resonance	   observed	   by	   19F	   NMR	   spectroscopy	   for	  
[Tb.L7b(H2O)]-­‐	  with	  respect	  to	  L7b.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
As	   suggested	   earlier,	   replacing	   the	   carboxylate	   donor	   group	   in	   L3	   with	   a	   more	  
sterically	   demanding	   group,	   such	   as	   a	   phosphinate,	   could	   slow	   down	   the	   dynamic	  
processes	   that	   lead	   to	   exchange	   broadening	   in	   solution.	   Such	   complexes	   have	   an	  
additional	   element	   of	   chirality	   introduced	   upon	   complexation,	   giving	   rise	   to	   the	  
possibility	  of	  differing	  configurations	  at	  each	  phosphorus	  centre	  (Figure	  3.3).	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Figure	  3.3:	  Stereoisomers	  of	  [Ln.L5]	  and	  [LnL6]	  
	  
This	  results	  in	  the	  possible	  formation	  of	  32	  isomers,	  16	  of	  which	  will	  be	  enantiomeric	  
pairs.	   Previous	   studies	   have	   shown	   that	   a	   low-­‐energy	   common	   configuration	   is	  
favoured	   in	   solution,	  wherein	   the	   configuration	   at	   P	   is	   the	   same,	   i.e.	   the	   (RRR)	   or	  
(SSS)	   configuration.4,	   9	  With	   complexes	  of	  L5	   there	   is	   an	  added	  element	  of	   chirality	  
                               δdip = CJ     β2        (3cos2θ -1 )  B02                    (3.1)  
                     60(kT)2         r3 
 




introduced	  by	  the	  dissymmetry	  presented	  by	  the	  ortho-­‐substituted	  aryl	  substituent	  
on	  the	  coordinated	  amide	  N.	  This	  can	  be	  thought	  of	  as	  placing	  the	  CF3	  moiety	  ‘cis’	  or	  
‘trans’	  with	  respect	  to	  the	  coordinated	  amide	  oxygen	  (Figure	  3.4).	  Consequently	  this	  
results	   in	   the	   possible	   formation	  of	   two	   isomers,	   arising	   from	   the	   rotation	   around	  
the	  CN	  bond,	  and	  yields	  the	  feasibility	  of	  64	  isomers	  overall.	  	  	  
	  
	  
Figure	  3.4:	  Schematic	  representation	  of	  the	  two	  isomers	  of	  [Ln.L5]	  arising	  from	  the	  rotation	  of	  the	  
aromatic	  ring	  around	  the	  CN	  bond.	  
	  
Evidently,	   with	   complexes	   of	   L5	   one	   low-­‐energy	   conformation	   is	   preferred,	   as	  
demonstrated	  by	  19F	  NMR	  spectroscopy;	  no	  pH	  or	  time	  variation	  in	  the	  spectrum	  was	  
observed	  (Figure	  3.5).	  	  
	  
	  
Figure	  3.5:	  19F	  NMR	  spectra	  of	  [Ln.L5]	  (2	  mM,	  D2O,	  295	  K,	  pD	  =	  5.4,	  9.4	  T,	  where	  Ln	  =	  Tb,	  Dy,	  Ho,	  Er	  and	  












It	   is	   thought	   that	   line-­‐broadening	   associated	   with	   dynamic	   intramolecular	  
conformational	   exchange	   processes	   is	   minimised,	   owing	   to	   the	   bulkiness	   of	   the	  
phosphinate	   moiety,	   which	   inhibits	   cooperative	   arm	   rotation	   in	   this	   system.	   To	  
probe	   this	   aspect	   further,	   variable	   temperature	   19F	   NMR	   spectroscopic	   analyses	  
were	  undertaken,	  comparing	  the	  behaviour	  of	  the	  Tm	  and	  Ho	  complexes	  of	  L3	  and	  L5,	  
over	  the	  temperature	  range	  of	  278-­‐	  323	  K	  (2mM,	  D2O,	  pD	  5.4,	  11.7	  T).	  	  	  
	  





















ϕθθµ 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.2)	  
	  
As	  expected,	  from	  equation	  3.2,	  each	  complex	  displayed	  a	  linear	  variation	  of	  the	  19F	  
chemical	   shift	   with	   the	   inverse	   of	   the	   second	   power	   of	   the	   absolute	   temperature	  
(Figure	  3.6).	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  3.6:	  Linear	  variation	  of	  the	  observed	  19F	  shift	  of	  [Tm.L3(H2O)]	  and	  [Tm.L5]	  as	  a	  


















































The	  measured	  linewidth	  of	  [Ho.L5]	  was	  80	  Hz	  at	  288	  K,	  which	  increased	  to	  120	  Hz	  at	  
both	  310	  and	  323	  K.	  In	  contrast,	  the	  measured	  linewidth	  of	  [Ho.L3(H2O)]	  was	  260	  Hz,	  
which	   increased	   to	   700	   and	   then	   1000	   Hz	   at	   310	   and	   323	   K	   respectively.	   The	  
resonances	   of	   the	  minor	   species	   in	   [Ho.L3(H2O)]	   were	   also	   broadened	   and	   shifted	  
towards	   the	   major	   resonance,	   although	   they	   did	   not	   reach	   coalescence.	   This	  
behaviour	  suggests	  that	  the	  excessive	  broadening	  observed	  in	  complexes	  of	  L3	  may	  
be	   ascribed,	   at	   least	   in	   part,	   to	   dynamic	   exchange	   associated	   with	   stereoisomer	  
interconversion.	   Furthermore,	   the	   data	   indicates	   that	   the	   complexes	   of	   L5	   have	  
enhanced	   stereochemical	   rigidity	   on	   the	   NMR	   timescale,	   in	   comparison	   to	   their	  
carboxylate	  counterparts.	  	  	  
	  
The	  Tb	  and	  Tm	  complexes	  of	  L6	  gave	  rather	  different	  behaviour	  to	  each	  other.	  Both	  
complexes	  formed	  predominantly	  one	  species	  in	  solution,	  as	  confirmed	  by	  19F	  and	  1H	  
NMR	  analysis.	  Whilst	  the	  19F	  resonance	  of	  the	  Tb	  complex	  was	  considerably	  shifted	  
with	  respect	  to	  the	  hydrolysed	  ligand	  ([Tb.L6]	  δF	  =	  -­‐180.2	  ppm	  and	  L6	  δF	  =	  -­‐62.3	  ppm,	  
pD	  5.4,	  295	  K)	  the	  Tm	  complex	  was	  hardly	  shifted	  at	  all	  ([Tm.L6]	  δF	  =	  -­‐62.8	  ppm).	  	  This	  
suggests	  either	   that	   the	  N	  atom	  on	   the	   fluorinated	  quinoline	   is	   coordinated	   to	   the	  
Ln3+	   ion	   in	   the	  Tb	  complex	  but	   is	  not	  bound	   in	   the	  Tm	  analogue,	  or	   that	   there	   is	  a	  
different	   coordination	  environment	  present	   in	   the	  Tm	  complex	   that	  places	   the	  CF3	  
moiety	  at	  a	  very	  different	  angle	  with	  respect	  to	  the	  principal	  axis	  from	  that	  observed	  
with	  Tb	  analogue.	  This	  yields	  two	  separate	  structures,	  in	  which	  each	  is	  characterised	  
by	   the	   differing	   positions	   of	   the	   CF3	   moiety	   with	   respect	   to	   the	   principal	   axis,	  
presumably	  caused	  by	  the	  small	  differences	  in	  ionic	  radii	  of	  the	  two	  lanthanides.	  
	  
The	  Tb,	  Dy,	  Ho,	  Er	  and	  Tm	  complexes	  of	  L8	  each	  formed	  one	  predominant	  species	  (75	  
–	  85	  %)	  in	  aqueous	  solution,	  as	  indicated	  by	  19F	  NMR	  spectroscopic	  analysis.	  In	  each	  
case,	   pH	   and	   time-­‐dependent	   variation	   of	   the	   relative	   composition	   of	   isomeric	  
species	   was	   not	   observed.	   Again,	   the	   major	   species	   of	   [Tb.L8(H2O)]+	   was	   only	  
marginally	   shifted	   with	   respect	   to	   the	   hydrolysed	   ligand	   	   ([Tb.L8(H2O)]+	   δF	   =	   -­‐62.0	  
ppm	   and	   L8	   δF	   =	   -­‐61.3	   ppm,	   pD	   5.4,	   295	   K).	   To	   further	   our	   understanding	   of	   this	  




result,	   calculated	   DFT	   structures	   of	   [Tb.L8(H2O)]+	   were	   generated,	   in	   collaboration	  




Figure	  3.7:	  DFT	  calculated	  structures	  of	  [Tb.L8(H2O)]
+	  with	  three	  different	  phenyl	  ring	  arrangements.	  
Calculated	  distances	  between	  the	  metal	  and	  the	  CF3	  group	  A)	  rLn-­‐F	  =	  6.32	  Å,	  B)	  rLn-­‐F	  =	  7.07	  Å	  and	  C)	  rLn-­‐F	  








Three	  different	  phenyl	   ring	  arrangements	  were	   identified	   in	   low	  energy	  structures,	  
resulting	  in	  Tb	  to	  fluorine	  distances,	  rLn-­‐F,	  of	  6.32,	  7.07	  and	  7.14	  Å.	  	  Interestingly,	  each	  
arrangement	   had	   near	   identical	   energies.	   The	   calculated	   structures	   illustrate	   the	  
possibility	   of	   differing	   positions	   of	   the	   CF3	   group	  with	   respect	   to	   Tb3+	   ion,	   each	   of	  
which	  will	  have	  a	  profound	  effect	  on	  the	  observed	  19F	  chemical	  shift.	  	  
	  
Whilst	   there	   is	   an	  obvious	   improvement	   in	   spectral	   features	  when	   compared	  with	  
complexes	  of	  L3,	   the	  most	   suitable	   system	  for	   suppression	  of	  dynamic	  processes	   is	  
that	  based	  on	  L5,	  as	  illustrated	  in	  figure	  3.8.	  	  
	  
	  
Figure	  3.8:	  19F	  NMR	  spectra	  of	  [Tm.L5]	  (upper)	  and	  [Tm.L8(H2O]




3.4	  19F	  Relaxation	  Analysis	  
	  
In	  accordance	  with	  the	  19F	  relaxation	  theory	  discussed	  in	  chapter	  two,	  the	  relaxation	  
rates	  measured	  for	  the	  series	  of	  complexes	  of	  L4	  broadly	  follow	  the	  order	  of	  Tb>	  Er>	  






































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Complex	  
R1/	  Hz	   R2	  /	  Hz	  
4.7	  T	   9.4	  T	   4.7	  T	   9.4	  T	  
[Tb.L4(H2O)]3-­‐	   64	   98	   104	   283	  
[Er.L4(H2O)]3-­‐	   45	   80	   87	   109	  
[Tm.L4(H2O)]3-­‐	   28	   72	   72	   98	  
	  
Table	  3.3:	  19F	  Longitudinal	  and	  transverse	  relaxation	  data	  for	  [Ln.L4(H2O)]
3-­‐	  at	  4.7	  and	  9.4	  T	  (2	  mM,	  
D2O,	  pD	  5.4,	  295	  K).	  
	  
A	  similar	  account	  is	  true	  for	  complexes	  of	  L7a	  and	  L7b	  (Table	  3.4).	  The	  only	  exception	  
to	   this	   is	   the	   markedly	   lower	   R1	   and	   R2	   value	   measured	   for	   the	   most	   dominant	  
isomer	   of	   [Ln.L7b(H2O)]-­‐	   .	   	   In	   contrast,	   the	   minor	   isomer,	   which	   accounts	   for	  
approximately	   12%	  of	   the	   total	   signal	   intensity,	   has	   a	  much	  higher	   R1	   value	   (R1	   of	  
94/168	  Hz	   at	   4.7/	   9.4	   T	   respectively).	   This	   could	  possibly	   be	   attributed	   to	   the	   two	  
differing	  positions	  of	  the	  CF3	  moiety	  with	  respect	  to	  the	  principle	  axis,	  as	  discussed	  in	  
section	  3.3.	  	  
	  
	  
Table	  3.4:	  19F	  Longitudinal	  and	  transverse	  relaxation	  data	  for	  [Ln.L7a(H2O)]
-­‐	  	  and	  [Ln.L7b(H2O)]
-­‐	  	  at	  4.7	  
and	  9.4	  T	  (2	  mM,	  D2O,	  pD	  5.4,	  295	  K).	  
	  
The	   Tm	   and	   Tb	   complexes	   of	   L6	   give	   rather	   different	   behaviour	   to	   each	   other,	   as	  
expected	  by	  their	  differing	  structures	  (section	  3.3).	  The	  Tb	  complex	  reveals	  very	  fast	  
relaxation	   coupled	   with	   a	   relatively	   narrow	   line	   (Tables	   3.5).	   This	   suggests	   that	  
incorporation	  of	  the	  quinoline	  group	  has	  helped	  to	  prevent	  arm	  rotation,	  in	  addition	  
to	  the	  shortening	  of	  the	  mean	  distance,	  r,	  between	  the	  Tb3+	  ion	  and	  the	  CF3	  moiety	  
(with	   respect	   to	   [Tb.L3(H2O)]).	   Conversely,	   with	   [Tm.L6],	   where	   the	   fluorine	   nuclei	  
must	   be	   at	   a	   differing	   angle	   to	   the	   principal	   axis	   than	   with	   the	   Tb	   analogue,	  
Complex	  
R1/	  Hz	   R2	  /	  Hz	  
4.7	  T	   9.4	  T	   4.7	  T	   9.4	  T	  
[Tb.L7a(H2O)]-­‐	   70	   101	   75	   153	  
[Tm.L7a(H2O)]-­‐	   22	   67	   72	   98	  
[Tb.L7b(H2O)]-­‐	   9.4	   12.2	   19	   34	  
[Er.L7b(H2O)]-­‐	   38	   76	   92	   151	  
[Tm.L7b(H2O)]-­‐	   27	   65	   82	   96	  




relaxation	   rates	   similar	   to	   [Tm.L3(H2O)]	   are	   observed	   and	   so	   the	  mean	   distance,	   r,	  
must	  also	  be	  similar.	  
	  
Complex	  
[Tb.L6]	   [Tm.L6]	  
R1/	  Hz	   R2/	  Hz	   R1/	  Hz	   R2/	  Hz	  
4.7	  T	   112	   162	   23	   52	  
9.4	  T	   142	   186	   48	   74	  
11.7	  T	   181	   248	   59	   89	  
16.5	  T	   238	   309	   72	   107	  
	  
Table	  3.5:	  19F	  Longitudinal	  and	  transverse	  relaxation	  data	  for	  [Ln.L6]	  	  at	  4.7,	  9.4,	  11.7	  and	  16.5	  T	  (2	  
mM,	  D2O,	  pD	  5.4,	  295	  K).	  
	  
	  
When	   comparing	   the	   complexes	   of	   L8	   and	   L3,	   the	   R1	   and	   R2	   data	  measured	   were	  
generally	   very	   similar	   for	   a	   given	   Ln3+	   ion	   (Table	  3.6).	   	   This	   is	   indicative	  of	   a	  mean	  
similar	  distance,	  rLn-­‐F,	  between	  the	  Ln3+	  centre	  and	  the	  CF3	  group.	  The	  exception	  to	  
this	   is	  with	   [Tb.L8(H2O)]+,	  where	   the	   rLn-­‐F	  must	  be	  greater	   (section	  3.3)	   and	   thus	  R1	  
and	  R2	  values	  are	  significantly	  smaller.	  
	  
Complex	  
R1/	  Hz	   R2	  /	  Hz	  
4.7	  T	   9.4	  T	   4.7	  T	   9.4	  T	  
[Tb.L8(H2O)]+	   1.7	   2.8	   41	   132	  
[Dy.L8(H2O)]+	   92	   1158	   96	   213	  
[Ho.L8(H2O)]+	   47	   91	   72	   159	  
[Er.L8(H2O)]+	   33	   81	   78	   164	  
[Tm.L8(H2O)]+	   24	   56	   84	   102	  
[Y.L8(H2O)]+	   1.4	   1.4	   3.2	   3.1	  
	  
Table	  3.6:	  19F	  Longitudinal	  and	  transverse	  relaxation	  data	  for	  [Ln.L8(H2O)]
+	  	  at	  4.7	  and	  9.4	  T	  (2	  mM,	  
D2O,	  pD	  5.4,	  295	  K).	  
	  
Faster	  rates	  of	  longitudinal	  relaxation	  were	  measured	  for	  [Ln.L5]	  in	  comparison	  with	  
[Ln.L3(H2O)]	  which	  is	  consistent	  with	  a	  shorter	  rLn-­‐F.	  As	  discussed	  in	  section	  2.6.2,	  the	  
variation	  of	  R	  with	  r	  follows	  an	  r-­‐6	  relationship,	  and	  so	  this	  distance	  can	  be	  calculated	  
by	  measuring	  the	  paramagnetic	  rate	  of	  relaxation	  as	  a	  function	  of	  field	  (calculated	  to	  




be	  6.3	  Å	  for	  [Ln.L3(H2O)]).	  If	  it	  is	  assumed	  that	  the	  difference	  in	  R1	  values	  is	  solely	  due	  
to	   a	   variation	   in	   rLn-­‐F	   then	   the	  distance	   for	   [Ln.L5]	   	   	   can	   also	  be	  estimated.	  A	  mean	  
value	   for	   rLn-­‐F	   of	   6.0	   Å	   (±	   0.1)	  was	   calculated	   from	   the	   R1	   data	  measured	   for	   each	  
complex	   of	   L5	   (Table	   3.7).	   It	   is	   unsurprising	   that	   the	   8-­‐coordinate	   phosphinate	  
complexes	  are	  more	  compact	  than	  their	  9-­‐coodinate	  carboxylate	  counterparts,	  and	  
this	  is	  consistent	  with	  the	  reported	  X-­‐ray	  structural	  analyses	  of	  related	  systems.	  3,	  4,	  10	  
	  
Complex	  
R1/	  Hz	   R2	  /	  Hz	  
4.7	  T	   9.4	  T	   4.7	  T	   9.4	  T	  
[Tb.L5]	   84	   146	   102	   267	  
[Dy.L5]	   104	   185	   135	   251	  
[Ho.L5]	   58	   120	   74	   143	  
[Er.L5]	   71	   109	   67	   138	  
[Tm.L5]	   46	   63	   60	   84	  
[Y.L5]*	   1.2	   1.3	   10	   16	  
	  
Table	  3.7:	  19F	  Longitudinal	  and	  transverse	  relaxation	  data	  for	  [Ln.L5]	   	  at	  4.7	  and	  9.4	  T	  (2mM,	  D2O,	  pD	  
5.4,	   295	   K).	   *Note:	   For	   [Y.L5],	   the	   T2	   values	   	   quoted	   are	   T2*	   data,	   as	   there	   is	   evidence	   for	   dynamic	  
exchange	   broadening	   ,	   leading	   to	   an	   increased	   linewidth	   at	   higher	   T	   (323K)	   and	   the	   onset	   of	  
appearance	  of	  more	  than	  one	  species.	  
	  
3.5	  Proton	  Relaxation	  Properties	  of	  Gd3+	  Complexes	  
	  
Complexes	  of	  L5	  and	  L6	  have	  a	  q	  value	  of	  zero,	  as	  determined	  by	  analysis	  of	  the	  Tb	  
emission	   decay	   lifetimes	   in	   H2O	   and	   D2O	   (section	   3.2).	   From	   previous	   proton	  
relaxometric	   studies	   of	   structurally	   related	   Gd3+	   phosphinate	   systems,	   it	   can	   be	  
safely	  be	  assumed	  that	  the	  relaxivity	  of	  both	  L5	  and	  L6	  systems	  will	  be	  inherently	  low	  
(in	  the	  region	  of	  ~	  2	  mM-­‐1s-­‐1)	  owing	  to	  the	  lack	  of	  an	  inner-­‐sphere	  contribution.9	  For	  
this	  reason,	  the	  Gd3+	  complexes	  of	  L5	  and	  L6	  were	  not	  synthesised.	  	  
	  
The	  proton	  relaxivity	  of	  [Gd.L4(H2O)]3-­‐	  was	  found	  to	  be	  5.9	  mM-­‐1s-­‐1	  (60	  MHz,	  310	  K),	  
and	  independent	  of	  pH	  (±	  9	  %)	  over	  the	  pH	  range	  3.5	  to	  10.5.	  This	  is	  consistent	  with	  
high	   kinetic	   stability	   with	   respect	   to	   acid-­‐catalysed	   or	   base-­‐promoted	   dissociation	  
pathways.	  	  





For	   both	   [Gd.L7b(H2O)]-­‐	   and	   [Gd.L8(H2O)]+	   variable	   temperature	   R2/	   17O	  
measurements	  were	  undertaken,	  with	  Dr	  Mauro	  Botta,	  with	  10	  to	  20	  mM	  solutions	  
of	   each	   complex	   in	   17O-­‐enriched	   water,	   allowing	   for	   an	   estimate	   of	   the	   water	  
exchange	  lifetime,	  τm,	  based	  on	  standard	  ‘Swift-­‐Connick’	  methodology	  (Figure	  3.9).11	  	  














P ro ton 	  L a rmor	  F requenc y 	  /	  MHz
	  
	  
Figure	   3.9:	   a)	   Upper:	   NMRD	   profiles	   (298K),	   showing	   the	   estimated	   inner	   sphere	   contributions;	   b)	  
Lower:	  variation	  of	   the	   transverse	   17O	  relaxation	  rate	  R2p,	  with	   temperature	   for	   [Gd.L
8(H2O)]
+	   in	   red	  
(9.4	  T)	  and	  [Gd.L7b(H2O)]
-­‐	  in	  black	  (11.7	  T),	  scaled	  to	  20	  mM	  concentration.	  
	  
The	   significantly	   longer	   τm	   value	   found	   for	   [Gd.L8(H2O)]+	   (1.7	   μs	   versus	   	   0.1	   μs	   for	  
[Gd.L7b(H2O)]-­‐)	   is	   attributed	   to	   the	   differing	   overall	   charge	   of	   the	   two	   ionic	  
complexes,	   i.e.	  +1	   (long	  τm)	  and	  -­‐1	   (short	  τm).	  This	   is	  also	   indicated	   in	   the	  different	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values	   of	   the	   enthalpy	   (ΔHm#	   =	   42.0	   and	   50.3	   kJ	   mol-­‐1)	   and	   entropy	   of	   activation	  
associated	  with	  the	  water	  exchange	  process	  (ΔSm#	  	  =	  +6.3	  and	  +58.2	  J	  mol-­‐1	  K-­‐1).	  	  The	  
small	  value	  of	  ΔSm	  found	  for	  [Gd.L8(H2O)]+	  is	  consistent	  with	  an	  interchange	  exchange	  
mechanism,	   while	   the	   larger	   value	   calculated	   [Gd.L7b(H2O)]-­‐	   	   is	   a	   sign	   of	   a	  
dissociatively	  activated	  mechanism.12	  	  
	  
Further	  information	  on	  both	  complexes	  was	  extracted	  by	  analysing	  the	  temperature	  
dependence	  of	   r1p,	   in	   addition	   to	   the	   classical	   analyses	  of	   the	   field	  dependence	  of	  
relaxivity	  (0.01	  to	  70	  MHz	  (Figure	  3.9)).	  These	  analyses	  are	  based	  upon	  the	  Solomon-­‐
Bloembergen-­‐Morgan	   equations	   which	   rationalise	   the	   time-­‐dependence	   of	   the	  
water	  proton-­‐Gd3+	  dipolar	  coupling,	  in	  addition	  to	  considering	  the	  contribution	  from	  
the	  second	  sphere.13	  
	  
The	  measured	  proton	  relaxivity	  of	  [Gd.L7b(H2O)]-­‐	   	  and	  [Gd.L8(H2O)]+	  was	  8.1	  and	  6.3	  
mM-­‐1s-­‐1	   respectively	   (298	  K,	   20	  MHz).	   The	  higher	   relaxivity	   value	   for	   [Gd.L7b(H2O)]-­‐	  	  
correlates	  well	  with	  its	   longer	  rotational	  correlation	  time,	  its	  faster	  water	  exchange	  
rate	  and	  the	  presence	  of	  a	  significant	  second	  sphere	  term.	  It	  is	  hypothesised	  that	  the	  
presence	  of	  the	  proximate	  carboxylate	  groups	  may	  help	  to	  promote	  water	  exchange	  
between	  inner	  and	  second	  sphere	  water	  molecules.	  
	  
The	  variation	  of	  r1p	  with	  pH	  was	  also	  undertaken	  for	  both	  complexes	  (60	  MHz,	  310	  K	  









Figure	  3.10:	  pH	  dependence	  of	  the	  1H	  relaxivity,	  r1p,	  of	  [Gd.L
8(H2O)]
+	  and	  [Gd.L7b(H2O)]
-­‐	  showing	  the	  fit	  
to	  the	  measured	  data,	  with	  pKa	  =	  4.70	  (±	  0.05)	  and	  8.71	  (±	  0.05)	  (310K,	  60	  MHz,	  H2O)	  	  



















































R = CH2CH2CO2-   pKa= 4.70  
R= H  pKa= 8.71 




With	   [Gd.L8(H2O)]+	   the	  relaxivity	   increases	  by	  30	  %	  over	   the	  pH	  range	  8	   to	  10.	  This	  
can	   be	   ascribed	   to	   base	   catalysed	   prototopic	   exchange,	   associated	   with	   the	  
deprotonation	  of	  the	  amide	  proton	  (pKa	  =	  8.71	  (±	  0.05),	  as	  depicted	  in	  Figure	  3.11.14	  
It	  appears	  that	  the	  lanthanide	  ion	  acts	  as	  a	  charge	  sink,	  enhancing	  the	  acidity	  of	  the	  










With	   [Gd.L7b(H2O)]-­‐,	   a	   pH	  dependence	   of	   the	  measured	   r1p	  was	   observed	   over	   the	  
range	  of	  pH	  4	  to	  5.5,	  resulting	  in	  an	  18	  %	  change	  in	  relaxivity	  (pKa	  =	  4.70	  (±0.05),	  310	  
K).	  At	   low	  pH,	   the	  carboxylate	  arm	   is	  protonated	  and	   therefore	   the	  second	  sphere	  
contribution	   to	   relaxivity	   is	   high;	   the	   opposite	   is	   true	   at	   higher	   pH	   (Figure	   3.12).	  
Interestingly,	  such	  well-­‐defined	  pH-­‐modulation	  has	  not	  been	  reported	  previously	  for	  
















Figure	  3.12:	  Acid-­‐Base	  equilibrium	  between	  the	  protonated	  and	  non-­‐protonated	  form	  of	  
[Gd.L7b(H2O)]
-­‐	  	  	  
	  
Some	  general	  observations	  can	  be	  made	  for	  the	  series	  of	  Gd3+	  complexes	  of	  L1,	  L2,	  L3,	  


























Firstly,	  the	  water	  exchange	  lifetime,	  τm,	  increases	  with	  increasing	  charge.	  While	  this	  
is	  not	  unusual	  behaviour,	  the	  τm	  values	  are	  notably	  lower	  than	  those	  of	  structurally	  
related	  complexes	  that	  do	  not	   include	  CF3	  groups	  (i.e.	  τm=	  3.5	  μs	  for	   [Gd.L1(H2O)]3+	  
while	  τm=	  9	  μs	  for	  the	  methyl	  analogue	  [Gd.L1(H2O)]3+).	  Furthermore,	  the	  enthalpy	  of	  
activation	   decreases	   with	   increasing	   charge,	   and	   in	   the	   case	   of	   the	   carboxylate	  











r1p20 (mM-1 s-1) 6.5	   3.8	   5.5	   8.1	   6.3	  
τM  (µs) 3.5	   9	   0.9	   0.11	   1.7	  
τR   (ps) 118	   120	   88	   140	   106	  
τV   (ps) 13	   8.5	   14	   10	   14	  
Δ2  (s-2;×1019) 4	   1.5	   5.9	   2.8	   2.4	  
ΔHm# (kJ/mol) 30.1	   51	   48	   50.3	   42	  
ΔHs# (kJ/mol) /	   /	   32.4	   58.2	   6.3	  
Er  (kJ/mol) 16	   15	   18	   18	   15	  
Ev  (kJ/mol) 2	   5	   2	   1	   1	  
q 1	   1	   1	   1	   1	  
A/2πh (x106)rad s-1 -­‐22	   -­‐28	   -­‐2.9	   -­‐2.6	   -­‐2.6	  
q” 8	   0	   2	   4	   4	  
r' (Å) 4.4	   /	   4.4	   4.4	   4.3	  
	  
Table	  3.9:	  Summary	  of	  selected	  1H	  NMR	  relaxation	  parameters,	  derived	  from	  analyses	  of	  variable	  temperature	  1H	  relaxivity,	  17O	  NMR	  spectroscopy	  and	  fitting	  of	  the	  NMRD	  
profiles	   (298K).	  Note:	   The	  Gd-­‐H	  distances	   for	   the	   coordinated	  water	  molecule,	   r,	   and	   the	  outer-­‐sphere	  water	  molecules, a,	  were	   fixed	  at	   3.0	  and	  4.0Å	   respectively;	   the	  










The	   biodistribution	   of	   a	   complex	   can	   depend	   largely	   on	   its	   relative	   lipophilicity	  
and/or	  its	  hydrophilic	  properties.	  For	  this	  reason,	  it	  is	  sometimes	  useful	  to	  determine	  
the	  lipophilicity	  of	  a	  complex	  prior	  to	  any	  in	  vivo	  studies.	  	  
	  
To	  enable	  measurement	  of	  logP,	  it	  is	  necessary	  to	  have	  a	  method	  of	  calculating	  the	  
relative	   concentration	   of	   a	   complex	   in	   both	   octanol	   and	   water.	   For	   this	   study,	  
lanthanide	   luminescence	   was	   used.	   Water	   was	   saturated	   with	   1-­‐octanol,	   and	   1-­‐
octanol	   was	   saturated	   with	   water	   to	   ensure	   any	  miscibility	   effects	   were	   constant	  
throughout	  the	  experiment.	  Complexes	  were	  prepared	  as	  100	  μM	  solutions	  in	  water	  
and	  mixed	  with	   1-­‐octanol	   in	   1:2,	   1:1	   and	   2:1	   water:octanol	   ratios.	  Mixtures	   were	  
agitated	   for	   twelve	   hours,	   after	   which	   emission	   spectra	   of	   the	   water	   and	   octanol	  
layers	  were	  measured.	  For	  the	  Tb	  complexes	  of	  L1-­‐	  L8,	  the	  logP	  value	  was	  calculated	  






XP −= 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.5)	  
	  
Final	   logP	   values	  were	   calculated	   as	   the	   average	   of	   at	   least	   two	   replicates	   for	   the	  
three	  solvent	  mixtures	  (Table	  3.9).	  
	  
Complex	   Log	  Poct	   SD	   	  
[Tb.L1(H2O)]3+Cl3	   -­‐0.16	   0.04	   	  
[Tb.L2(H2O)]3+(OTf)3	   -­‐0.91	   0.11	   	  
[Tb.L2(H2O)]3+Cl3	   -­‐2.10	   0.23	   	  
[Tb.L3(H2O)]	   0.63	   0.09	   	  
[Tb.L4(H2O)]3-­‐	   -­‐2.03	   0.12	   	  
[Tb.L5]	   0.12	   0.06	   	  
[Tb.L6]	   -­‐0.04	   0.04	   	  
[Tb.L7b(H2O)]-­‐	   -­‐1.42	   0.10	   	  
[Tb.L8(H2O)]+	   -­‐1.23	   0.02	   	  
	  
Table	  3.9:	  LogP	  values	  for	  Tb	  complexes	  of	  L1-­‐L8	  
	  




Some	   general	   observations	   can	   be	   made.	   Firstly,	   in	   a	   control	   experiment	   with	  
[Tb.L2(H2O)]3+	   the	   counterion	   was	   varied,	   with	   results	   indicating	   that	   the	   triflate	  
complex	   is	   more	   lipophilic	   than	   the	   chloride	   salt.	   This	   is	   consistent	   with	   the	  
enhanced	   hydrophobicity	   of	   triflate	   salts.15	   The	   charged	   complexes	   have	   a	   more	  
negative	   value	   of	   logP	   than	   the	   neutral	   complexes,	   which	   is	   consistent	   with	   their	  
greater	  water	  solubility.	   It	   is	   interesting	  to	  note	  that	  the	  Tb	  complexes	  of	  L5	  and	  L6	  
are	  slightly	  more	  hydrophilic	  compared	  to	  [Tb.L3(H2O)].	  	  
	  
3.7	  Sensitivity	  Enhancement	  in	  19F	  Spectroscopic	  Studies	  
	  
Of	  all	  the	  complexes	  studies	  thus	  far,	  the	  most	  promising	  system	  for	  applications	  in	  
19F	  MRS	   and	  MRI	   is	   that	   based	   on	   the	   complexes	   of	   the	   triphosphinate	   ligand,	   L5.	  
They	   possess	   faster	   longitudinal	   relaxation	   rates	   and,	   in	   general,	   have	   narrower	  
linewidths	   owing	   to	   the	   suppression	   of	   dynamic	   exchange	   processes.	   Most	  
importantly,	  they	  exist	  in	  solution	  as	  one	  preferred	  species	  (>	  86	  %)	  and	  are	  stable	  as	  
a	   function	   of	   time.	   Thus,	   they	   are	   ideal	   complexes	   to	   assess	   19F	   signal	   intensity	  
enhancement.	  The	  diamagnetic	  analogue,	  [Y.L5]	  was	  used	  as	  a	  control,	  because	  it	  has	  
essentially	  zero	  effect	  on	  the	  relaxation	  of	  the	  CF3	  moiety.	  	  
	  
The	   experiment	   was	   set	   up	   in	   an	   analogous	   fashion	   to	   that	   undertaken	   for	   the	  
complexes	   of	   L1	   and	   L3,	   discussed	   in	   section	   2.8.	   Equimolar	   solutions	   were	   used	  
(2mM)	  and	  spectra	  was	  acquired	  at	  both	  4.7	  and	  9.4	  T.	  The	  acquisition	  time	  was	  set	  
to	   be	   three	   times	   the	  measured	   T1	   value	   and	   spectral	   data	  were	   aquired	   over	   15	  
minutes.	   In	  spectral	  processing,	  the	  line-­‐broadening	  function	  was	  set	  to	  be	  50	  %	  of	  
the	   observed	   linewidth,	   and	   the	   relative	   signal	   intensity	   was	   normalised	   to	   that	  
found	  for	  the	  diamagnetic	  yttrium	  complex	  analogue	  (Table	  3.10).	  
	  
The	   results	   follow	   the	   order	   expected	   (Tb>	   Dy>	   Ho>	   Er>	   Tm)	   on	   the	   basis	   of	   R1	  
enhancement,	   offset	   by	  R2	   ‘loss’	   of	   signal.	   The	   values	   obtained	   show	  an	   increased	  
signal	   intensity	  enhancement	  compared	  with	  the	  complexes	  of	  L3	   (30,	  20	  and	  14	  %	  
increase	  for	  Tb,	  Ho	  and	  Tm	  respectively	  at	  4.7	  T),	  which	  is	  consistent	  with	  the	  lower	  
R2	   values	   associated	   with	   the	  more	   rigid	   and	   stable	   structure	   of	   the	   phosphinate	  




complexes.	  Analysis	  of	  the	  above	  data	  strongly	  suggests	  that	  Dy	  and	  Tb	  complexes	  of	  
L5	  are	  the	  most	  promising	  for	  19F	  MRS	  studies,	  over	  the	  field	  range	  of	  3.0	  to	  9.4	  T.	  
	  
Complex	  
Relative	  Signal	  Intensity	  
4.7	  T	   9.4	  T	  
[Tb.L5]	   14.4	   15.2	  
[Dy.L5]	   12.5	   14.9	  
[Ho.L5]	   6.6	   9.3	  
[Er.L5]	   5.5	   8.9	  
[Tm.L5]	   4.8	   7.2	  
[Y.L5]	   1	   1	  
	  
Table	  3.10:	  Assessment	  of	  19F	  spectroscopic	  sensitivity	  for	  a)	  [Ln.L5]	  (2	  mM,	  D2O,	  pD	  5.4,	  295	  K,	  Ln=Tb,	  
Ho,	  Er,	  Tm	  and	  Y)	  at	  4.7	  and	  9.4	  T.	  The	  acquisition	  time	  was	  set	  as	  3	  x	  T1,	  with	  no	  delay	  time;	  total	  
acquisition	  time	  was	  15	  min;	   in	  spectral	  processing,	  the	  line	  broadening	  function	  was	  set	  as	  50	  %	  of	  
the	  observed	  linewidth.	  Values	  quoted	  are	  ±	  6	  %.	  
	  
3.8	  Sensitivity	  Enhancement	  in	  19F	  Imaging	  Studies	  
	  
A	  comparative	  imaging	  study	  was	  undertaken,	  in	  collaboration	  Prof.	  Andrew	  Blamire,	  
with	   the	   aim	   of	   addressing	   the	   gain	   in	   signal	   intensity	   for	   Tb,	   Dy,	   Ho,	   Er	   and	   Tm	  
complexes	   of	   L5,	   compared	   to	   the	   diamagnetic	   analogue	   [Y.L5].	   Images	   were	  
collected	   at	   7	   T,	   running	   data	   acquisition	   at	   the	   Ernst	   angle	   to	   optimise	   signal	   to	  
noise	   ratio	   (SNR),	   with	   a	   total	   acquisition	   time	   of	   6	   minutes	   per	   complex	   (Figure	  
3.14).	  	  
	  
Results	  show	  that	  [Dy.L5]	  produces	  the	  highest	  SNR,	  with	  [Ho.L5]	  and	  [Er.L5]	  providing	  
the	   next	   best	   sensitivity	   enhancement.	   This	   is	   consistent	   with	   the	   predicted	  
theoretical	   imaging	  enhancement	   values,	  which	   takes	   into	   account	  both	   the	   signal	  
enhancement	  by	  R1	  (from	  rapid	  pulsing	  and	  flip	  angle	  adjustment)	  and	  signal	  loss	  by	  
R2	  during	  the	  echo	  time.	  





Figure	  3.14:	  In	  vitro	  imaging	  data	  of	  [Ln.L5]	  (2mM,	  295	  K,	  7	  T).	  All	  images	  intensity	  scaled	  to	  the	  same	  
value.	  Experimental	  SNR:	  Tb-­‐	  135,	  Dy	  –	  211,	  Ho	  –	  175,	  Er	  –	  150,	  Tm-­‐	  132.	  Note:	  Inset	  Y	  image	  is	  scaled	  
by	  factor	  of	  10.	  
	  
3.9	  	  Conclusions	  
	  
Strategies	   employed	   to	   minimise	   dynamic	   chemical	   exchange	   processes,	   and	  
promote	   the	   formation	   of	   one	   stable,	   preferred	   species	   in	   solution	   have	   been	  
detailed	  and	  discussed.	  	  
	  
The	  lanthanide(III)	  complexes	  of	  the	  triphosphinate	  ligand,	  L5,	  have	  shown	  the	  most	  
promise	  for	  use	  as	  probes	  for	  19F	  MRS	  and	  MRI	  versus	  their	  carboxylate	  analogues,	  
[Ln.L3(H2O)].	   They	   exist	   in	   solution	   as	   one	   preferred	   species,	   and	   are	   stable	   over	  
time.	   In	   general,	   a	   faster	   longitudinal	   relaxation	   rate	   is	   observed	   and	   yet	   they	   still	  
possess	   narrower	   linewidths,	   owing	   to	   the	   suppression	   of	   dynamic	   chemical	  
exchange	  processes.	  These	  factors	  combined	  led	  to	  enhanced	  sensitivity	  of	  detection	  
in	  19F	  NMR,	  and	  phantom	  imaging,	  experiments	  versus	  a	  diamagnetic	  Y3+	  analogue.	  	  
	  
Comparison	  of	  selected	  1H	  relaxation	  parameters	  across	  the	  series	  of	  Gd3+	  complexes	  
highlighted	  that	  the	  water	  exchange	  lifetime	  increases	  with	  increasing	  charge,	  whilst	  
Tb Dy Ho
Er Tm Y




the	   enthalpy	   of	   activation	   decreases.	   Interestingly,	   in	   the	   case	   of	   the	   carboxylate	  
systems,	  the	  enthalpy	  of	  activation	  increases	  with	  increasing	  number	  of	  CF3	  groups.	  
	  
In	  Chapter	  4,	   the	   favourable	  characteristics	  displayed	  with	  the	  complexes	  of	  L5	  will	  
be	  optimised	  further	  in	  an	  attempt	  to	  fine	  tune	  the	  biodistribution	  properties	  of	  the	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Chapter	  4:	  High	  Molecular	  Weight	  
Fluorinated	  Conjugates	  




4.0	  High	  Molecular	  Weight	  Fluorinated	  Conjugates	  
4.1	  Introduction	  
	  
Low	   sensitivity	   is	   one	  of	   the	   key	   difficulties	  with	   19F	  MRI,	   as	   discussed	   in	   chapters	  
one,	  two	  and	  three.	  The	  signal	  to	  noise	  ratio	  can	  be	  improved	  by	  introducing	  more	  
fluorine	   atoms	   into	   the	   molecule,	   however	   there	   are	   limitations	   in	   applying	   this	  
strategy	  to	  the	  cyclen-­‐based	  systems	  under	  review.	  Another	  possible	  solution	  would	  
be	  to	  covalently	   link	  the	  complexes	  to	  a	  medium	  or	  high	  molecular	  weight	  adduct,	  
which	  would	   result	   in	   the	   number	   of	   fluorine	   atoms	   being	   significantly	   increased.	  




4.2	  Potential	  Platforms	  for	  Paramagnetic	  Probes	  
	  
There	   are	  many	   desirable	   characteristics	   that	   a	  medium	   to	   high	  molecular	  weight	  
molecule	  (1,000	  to	  6,500	  D)	  should	  possess	  to	  successfully	  act	  as	  a	  platform	  for	  the	  
development	  of	   fluorinated	  probes.	   Ideally,	   the	  molecule	  should	  have	  a	  number	  of	  
repeating	   functional	   groups	   capable	   of	   forming	   stable	   bonds	   with	   the	   desired	  
complexes.	  Also	  of	  great	   importance	  is	  water	  solubility	  and	  non-­‐toxicity	   in	  the	  final	  
conjugate.	  Bearing	  this	   in	  mind,	  three	  different	  classes	  of	  adducts	  were	  considered	  
for	   our	   studies;	   β-­‐cyclodextrin,	   silsesquioxane	   and	   chitosan.	   The	   merits	   and	  
limitations	  of	  each	  will	  be	  discussed	  in	  more	  detail	  below.	  
	  
4.2.1	  β-­‐	  Cyclodextrin	  
	  
Natural	  cyclodextrins	  are	  cyclic	  oligosaccharides	  composed	  of	  6,	  7	  or	  8	  α-­‐	  1,	  4-­‐	  linked	  
D-­‐(+)-­‐	   glucopyranose	   units,	   more	   commonly	   known	   as	  α-­‐,	   β-­‐,	   and	   θ-­‐	   cyclodextrin	  
respectively.	   	   They	   are	   best	   known	   for	   forming	   inclusion	   complexes	   in	   the	  
hydrophobic	   cavity	   of	   the	   cyclodextrin,	   and	   there	   are	   numerous	   practical	  
applications	   in	   engineering	   and	   pharmacy.1,2	   Owing	   to	   their	   good	   binding	   ability	  
towards	  aromatic	  units,	  coupled	  with	  the	  ease	  of	  availability,	  β-­‐cyclodextrin	  has	  the	  
most	   commercial	   potential.	   However,	   the	   downfall	   with	   β-­‐cyclodextrin	   is	   its	  
inherently	   low	   aqueous	   water	   solubility	   (18.5	   gL-­‐1).3	   Consequently,	   a	   chemically	  
modified	   β–cyclodextrin	   was	   used	   in	   our	   studies,	   whereby	   methoxy	   and	   amino	  




groups	  were	  incorporated	  into	  the	  structure	  to	  increase	  aqueous	  solubility	  and	  allow	  










































Another	  potential	  medium	  molecular	  weight	  adduct	   for	   the	  development	  of	  highly	  
fluorinated	  probes	  is	  the	  symmetric	  octa(3-­‐aminopropyl)silsesquioxane	  (Figure	  4.2).	  
Owing	   to	   its	   precisely	   defined	   architecture,	   the	   T8-­‐silsesquioxane	   core	   leads	   to	  
compact	   globular	   contrast	   agents,	   of	  which	   there	   are	   numerous	   examples.4	  When	  
considering	  the	  design	  of	  such	  conjugates	   it	   is	   important	  to	  note	  that	  hydrolysis	  of	  
the	  silsesquioxane	  core	  can	  occur	   in	  aqueous	  media.	   	  This	   is	  particularly	   important	  
with	  Gd3+	  -­‐based	  conjugates	  whereby	  hydrolysis	  can	  break	  the	  conjugate	  down	  into	  
smaller	  fragments,	  ultimately	  leading	  to	  a	  decrease	  in	  relaxivity.	  However,	  Mayer	  et	  
al.	   have	   studied	   the	  hydrolysis	   of	   structurally	   related	  T8-­‐silsesquioxane	   conjugates,	  
with	  very	  promising	  results.	  At	  pH	  7.4,	   in	  serum	  at	  37oC,	  a	  half	   life	  of	  15	  hours	  was	  
observed	  for	  the	  T8-­‐silsesquioxane	  core,	  with	  no	  change	  in	  relaxivity	  within	  the	  first	  3	  
hours.	   The	   first	   step	   of	   the	   hydrolysis	   pathway	   is	   rate	   limiting	   and	   so	   the	   major	  
species	   in	   vivo	   will	   be	   the	   starting	   silsesqiuoxane	   and	   the	   monomeric	   product,	  
thereby	  avoiding	  the	  build	  up	  of	  intermediate	  molecular	  weight	  species.5	  	  
	  






























Chitosan	  is	  a	  linear	  polysaccharide	  composed	  of	  randomly	  distributed	  β-­‐(1-­‐4)-­‐linked	  
D-­‐glucosamine	  and	  N-­‐acetyl-­‐D-­‐glucosamine	  (Figure	  4.3).	   Importantly,	   it	   is	  non-­‐toxic,	  
biodegradable	  and	  tolerated	  well	   in	  vivo.	   It	   is	  produced	  via	   the	  de-­‐N-­‐acetylation	  of	  
chitin	  and	  so	  it	  is	  a	  cost	  efficient	  and	  readily	  available	  high	  molecular	  weight	  platform	  
for	   our	   conjugation	  work.	  However,	   the	  main	   limitation	  of	   linear	   polymers	   is	   their	  
poorly	   defined	   architecture	   and	   random	   morphology,	   which	   can	   lead	   to	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Figure	  4.3	  
	  
To	  ensure	  adequate	  water	   solubility,	  a	   chitosan	  sample	  with	  an	  average	  molecular	  
weight	  of	  approximately	  6,500	  D	  was	  chosen	  for	  the	  development	  of	  our	  fluorinated	  
conjugated	  contrast	  agents.	  	  
	  
4.3	  Fluorinated	  Complexes	  for	  Linkage	  to	  Macromolecules	  
	  
As	  discussed	   in	  chapter	   three,	   the	  most	  promising	  system	  that	  we	  have	  developed	  
thus	  far	  is	  that	  based	  on	  the	  complexes	  of	  the	  triphosphinate	  ligand,	  L5	  (Figure	  4.4).	  
This	   is	   due	   to	   the	   faster	   longitudinal	   relaxation	   rates	   and	   narrower	   linewidths	  




observed,	  in	  comparison	  to	  the	  other	  cyclen-­‐based	  systems	  examined	  (i.e	  L1	  –	  L4	  and	  
L6-­‐L8).	   Consequently,	   complexes	   of	   L5	   were	   the	   obvious	   choice	   for	   linkage	   to	   the	  
macromolecules.	  Each	  of	  the	  carrier	  molecules	  include	  amino	  moieties,	  therefore	  by	  
slightly	  modifying	   the	   structure	  of	  L5	   to	   include	  a	   carboxyl	   group,	   linkage	  becomes	  




Figure	  4.4:	  Structures	  of	  [Ln.L5],	  [Ln.L9]	  and	  [Tb.L10(H2O)]
-­‐	  
	  
Solubility	   can	   be	   a	   problem	   with	   high	   molecular	   weight	   conjugates,	   as	   discussed	  
briefly	  above,	   therefore	  an	  additional	  complex	  was	  developed	   to	  specifically	   tackle	  
this	   issue	   (Figure	   4.4).	   Based	   on	  DO2A,	   the	   complex	   includes	   a	  methyl	   triethylene	  
glycol	  derivative,	  at	  the	  ortho	  position	  of	  the	  aromatic	  ring,	  to	  increase	  solubility.	  A	  










4.4	  Synthesis	  	  
4.4.1	  Synthesis	  of	  [Ln.L9]	  
	  
The	  first	  step	  in	  the	  synthesis	  of	  L9	  involved	  the	  esterification	  of	  the	  nitrile	  precursor,	  
by	  treatment	  with	  sulphuric	  acid	  in	  ethanol,	  to	  give	  23	  in	  a	  64	  %	  yield	  (Scheme	  4.1).	  
The	   alternative	  methyl	   ester	  was	   also	   attempted,	   however	   a	   low	   yield	   and	   lack	  of	  
stability	  deemed	  it	  unsuitable	  for	  further	  use.	  Subsequent	  acetlyation	  of	  23,	  utilising	  
chloroacetyl	   chloride	   in	   CH2Cl2	   with	   triethylamine,	   gave	   the	   corresponding	   α-­‐
haloamide,	  24.	  




Selective	   mono-­‐alkylation	   with	   cyclen	   was	   achieved	   under	   very	   mild	   reaction	  
conditions	   (no	  base,	  CH2Cl2,	  40oC,	   Scheme	  4.2).	  Co-­‐condensation	  of	   the	  amine,	  25,	  
with	   paraformaldehyde	   and	   diethoxymethylphosphine	   in	   THF	   afforded	   the	  
corresponding	   triethylphosphinate	   ester,	   26.	   Subsequent	   base	   hydrolysis	   and	  
complexation	   followed	   the	   same	   procedure	   as	   described	   previously	   for	   [Ln.L5]	   in	  
chapter	  three.	  	  





Scheme	  4.2:	  Synthesis	  of	  [Ln.L9]	  
	  
4.4.2	  Synthesis	  of	  [Tb.L10(H2O)]-­‐	  
	  
The	  mitsunobu	   reaction	   of	   triethylene	   glycol	  monomethyl	   ether	  with	   phthalimide,	  
DIAD	   and	   PPh3	   afforded	   the	   desired	   product,	   27,	   after	   purification	   by	   silica	   gel	  
chromatography.	   Subsequent	   hydrazinolysis	   of	   the	   phthalimide	   to	   give	   28	   was	  








Base	  hydrolysis	  of	  the	  ester,	  24,	  using	  potassium	  hydroxide	  gave	  the	  corresponding	  
acid,	   29,	   in	   86	   %	   yield	   (Scheme	   4.4).	   The	   active	   ester,	   30,	   was	   then	   prepared	   by	  
reaction	  of	  29	  with	  TBTU	  in	  DMF,	  utilising	  N-­‐methylmorphiline	  (NMM)	  as	  the	  base.	  
Subsequent	  reaction	  of	  the	  amino	  moiety	  on	  the	  methyl	  triethylene	  glycol	  derivative	  
28,	  with	  the	  active	  ester,	  30,	  afforded	  the	  desired	  product,	  31,	   in	  an	  excellent	  yield	  
(91	  %).	   Actylation	   of	  31	   was	   achieved	   by	   treatment	  with	   chloroacetylchloride	   and	  
























































The	  enantiopure	  2-­‐bromo	  amino	  acid	  diester,	  34,	  was	  prepared	   in	   two	   steps	   from	  
the	   commercially	   available	   L-­‐glutamic	   acid	   5-­‐benzyl	   ester	   (Scheme	   4.5).	   The	  
bromination	   step,	   to	   yield	   33,	   was	   achieved	   in	   an	   analogous	   fashion	   to	   that	  
described	   in	   the	   synthesis	   of	   (S)-­‐2-­‐bromoglutarate,	   7	   (section	   3.2.1).	   The	  
transesterification	  of	  33	  with	  tBuOAc,	  in	  the	  presence	  of	  a	  catalytic	  amount	  of	  HClO4	  

































Mono-­‐alkylation	  of	  DO2A,	  21,	  with	  the	  enantiopure	  diester,	  34,	  was	  achieved	  under	  
mildly	  basic	  conditions	  (NaHCO3).	  The	  desired	  product,	  35,	  was	  separated	  from	  the	  




Scheme	  4.6:	  Synthetic	  Pathway	  to	  [Ln.L10(H2O)]
-­‐	  
	  




Alkylation	   on	   the	   remaining	   secondary	   nitrogen	   atom	   of	   the	   cyclen	   ring,	   with	   32,	  
proceeded	   with	   a	   reasonable	   yield	   (65	   %).	   Removal	   of	   the	   benzyl	   and	   tert-­‐butyl	  
protecting	  groups	  was	  achieved	  in	  situ,	  by	  treatment	  with	  HBr	  in	  acetic	  acid	  at	  room	  
temperature.	  Purification	  by	  dialysis	  (MWCO	  500	  D)	  afforded	  the	  hydrolysed	  ligand,	  
which	  was	  then	  complexed	  with	  Tb(OAc)3	  as	  described	  for	  L7	  (section	  3.2.5).	  	  
	  
4.4.3	  Synthesis	  of	  β–Cyclodextrin	  Conjugates	  
	  
In	  comparison	  with	  the	  complexes	  of	  [Ln.L9],	  broader	  linewidths	  were	  expected	  in	  all	  
of	   the	   corresponding	   conjugates	   detailed	   in	   this	   chapter.	   This	   is	   owing	   to	   the	  
restricted	  mobility	  of	  the	  macromolecule	  carriers.	  As	  such,	  initial	  conjugation	  studies	  
were	  attempted	  with	  [Tm.L9]	  due	  to	  the	  narrower	   linewidth	  (ω1/2	  =	  21	  Hz,	  D2O,	  pD	  
5.5,	  4.7	  T)	  observed	  in	  the	  19F	  NMR	  spectroscopic	  analysis	  in	  comparison	  with	  [Tb.L9]	  
(ω1/2	  =	  27	  Hz,	  D2O,	  pD	  5.5,	  4.7	  T).	  
	  
Firstly,	   to	  enable	  conjugation,	   the	  carboxyl	  group	  of	   [Tm.L9]	  was	  converted	   into	  an	  
active	  ester	  form,	  by	  reaction	  with	  TBTU	  and	  NMM	  in	  anhydrous	  DMF	  (Scheme	  4.7).	  
The	   β–cyclodextrin	   derivative,	   dissolved	   in	   the	   minimum	   volume	   of	   water,	   was	  
immediately	  added	   to	   the	   reaction	  mixture	  once	   the	  active	  ester	  was	   formed.	  The	  
crude	   reaction	   mixture	   was	   purified	   by	   dialysis	   (MWCO	   1000	   D)	   over	   a	   48	   hour	  
period,	  thereby	  removing	  unreacted	  coupling	  reagents	  and	  excess	  complex.	  	  
	  
Analysis	  by	  MALDI+	  revealed	  that	  only	  one	  complex	  had	  conjugated,	  leaving	  six	  free	  
unreacted	   amino	   groups	   on	   the	   β-­‐cyclodextrin.	   In	   an	   attempt	   to	   achieve	   further	  
conjugation,	   the	   crude	   product	   was	   re-­‐reacted	   with	   [Tm.L9],	   this	   time	   utilising	  
harsher	   conditions	   (12	   eq.	   [Tm.L9],	   15	   eq.	   NMM)	   to	   try	   and	   drive	   the	   reaction	   to	  
completion.	  However,	   following	  purification,	   both	   the	   analysis	   by	  MALDI+,	   and	   the	  
determination	  of	   the	  percentage	  of	  Tm	  present	   in	   the	  sample,	   revealed	  no	   further	  
conjugation.	  





























































Scheme	  4.7:	  Synthetic	  scheme	  for	  the	  preparation	  of	  the	  β-­‐cyclodextrin	  complex	  conjugate	  
	  
As	  discussed	  in	  section	  4.2.1,	  these	  molecules	  are	  well	  known	  for	  forming	  inclusion	  
complexes	   in	   the	   hydrophobic	   cavity	   of	   the	   cyclodextrin	   core.	   This	   could	   greatly	  
hinder	   the	   extent	   of	   conjugation	   in	   our	   system.	   Consequently,	   the	   reaction	   was	  
repeated	   in	   the	   presence	   of	   cumene.	   It	   was	   hoped	   that	   the	   cumene	   would	  
preferentially	   become	   included,	   leaving	   the	   complex	   available	   to	   react	   with	   the	  
amino	  groups	  on	  the	  β-­‐cyclodextrin	  derivative.	  Unfortunately	  there	  was	  no	  change	  in	  
the	  level	  of	  conjugation.	  	  
	  
The	   possibility	   of	   steric	   effects	  was	   then	   considered.	   To	   probe	   this	   idea	   further,	   a	  
second	  β-­‐cyclodextrin	  derivative,	  with	  the	  incorporation	  of	  a	  linear	  linker	  chain,	  was	  
explored	   (Figure	   4.5).	   Furthermore,	   it	   was	   hoped	   that	   the	   added	   linker	   would	  
increase	   the	  mobility	   of	   the	   conjugate,	   resulting	   in	   narrower	   linewidths	   in	   the	   19F	  




spectrum.	  An	  analogous	  reaction	  to	  that	  described	  above	  was	  undertaken	  but,	  again,	  
analysis	   showed	   that	   only	   one	   complex	   had	   conjugated.	   Final	   purity	   of	   each	  












4.4.4	  Synthesis	  of	  Silsesquioxane	  Conjugates	  
	  
The	   poor	   solubility	   of	   the	   starting	   silsesquioxane	   material	   required	   the	   coupling	  
reaction	   with	   [Tm.L9]	   to	   be	   carried	   out	   in	   DMSO,	   utilising	   TBTU	   and	   N,N-­‐
diisopropylethylamine	   (DIPEA)	   (Scheme	   4.8).	   The	   reaction	   mixture	   was	   added	  
dropwise	   into	   cold	   diethyl	   ether	   and	   the	   precipitate	   collected.	   Purification	   of	   the	  






















































































Scheme	  4.8:	  Synthetic	  scheme	  for	  the	  preparation	  of	  the	  silsesquioxane	  complex	  conjugate	  




Mass	   spectra	   data	   was	   unable	   to	   be	   obtained,	   however	   HPLC	   analysis,	   29Si	   NMR	  
measurements	  and	  the	  determination	  of	  the	  percentage	  of	  Tm	  suggested	  complete	  




29Si	  Shift	  	  	  	  	  	  	  	  	  	  
(ppm)	  
%	  Tm	  
Silsesquioxane	   9.64	   -­‐64.1	   0	  
[(Tm.L9).Silsesquioxane]	   	  4.83	   -­‐65.8	   17.4	  	  
	  
Table	  4.1:	  HPLC	  (Method	  A	  in	  experimental	  section),	  29Si	  NMR	  and	  %	  Tm	  (Evans	  method7)	  results	  for	  
the	  starting	  silsesquioxane	  and	  [(Tm.L9).Silsesquioxane]	  	  
	  
The	  poor	  solubility	  of	  the	  silsesquioxane	  conjugate	  dictated	  that	  all	  experiments	  be	  
carried	  out	   in	  a	  H2O:CH3OH	  mix	   (50:50).	  Whilst	   these	  conditions	  are	  acceptable	  for	  
the	   running	   of	   NMR	   spectroscopy	   experiments,	   they	   are	   unacceptable	   for	   in	   vivo	  
studies.	  	  
	  
To	   overcome	   this	   solubility	   problem,	   [Ln.L10]	   was	   coupled	   with	   the	   silsesquioxane	  
starting	   material	   under	   the	   same	   conditions	   as	   described	   above.	   Interestingly,	   in	  
comparison	   with	   the	   [(Tm.L9).Silsesquioxane],	   HPLC	   and	   19F	   NMR	   spectroscopic	  
analysis	  revealed	  a	  mixture	  of	  products	  after	  purification.	  Analysis	  of	  the	  percentage	  
of	  Tm	  in	  the	  purified	  product	  corresponded	  to	  a	  degree	  conjugation	  of	  only	  27.4	  %.	  
This	   could	   be	   attributed	   to	   the	   differing	   carboxyl	  moieties	   in	   the	   two	  monomeric	  
complexes.	   The	   solubility	   of	   the	   final	   conjugate	   was	   increased;	   however	   a	  
H2O:CH3OH	  (80:20)	  mixture	  was	  still	  required	  for	  all	  experiments.	  	  
	  
4.4.5	  Synthesis	  of	  Chitosan	  Conjugates	  
	  
The	  coupling	  reaction	  of	   [Ln.L9]	   (where	  Ln=	  Gd	  and	  Tb)	  with	  chitosan	   (Scheme	  4.9)	  
was	   achieved	   in	   an	   analogous	   fashion	   to	   that	   described	   for	   the	   β-­‐cyclodextrin	  
conjugate	  (Section	  4.3.3).	  	  














































































Scheme	  4.9:	  Synthetic	  scheme	  for	  the	  preparation	  of	  the	  chitosan	  complex	  conjugates	  
	  
Following	   purification,	   the	   conjugates	   were	   analysed	   by	   gel	   permeation	  
chromatography	  (GPC).	  Results	  indicated	  an	  increase	  in	  the	  molecular	  weight	  of	  the	  
conjugates,	   with	   respect	   to	   the	   unreacted	   polymer	   (Table	   4.2).	   This	   data,	   in	  
conjunction	  with	  elemental	  analysis	  of	  the	  metal	  content,	  confirmed	  the	  formation	  
of	  covalently	  linked	  conjugates.	  
	  
Sample	   Mw	  a	   Mn	  b	   PDI	  c	  
Chitosan	   6,590	   2,250	   2.9	  
[(Gd.L9).Chitosan]	   16,500	   8,565	   1.9	  
[(Tb.L9).Chitosan]	   16,300	   8,615	   1.9	  
	  
Table	  4.2:	  Gel	  permeation	  chromatography	  (GPC)	  data	  for	  the	  starting	  glycol	  chitosan	  sample	  and	  the	  
corresponding	  Tb	  and	  Gd	  conjugates.	  Mean	  values	  obtained	  from	  two	  successive	  scans.	  a	  calculated	  
molecular	  weight	  averages	  expressed	  as	   the	  pullulan	  polysaccaride	  equivalent	  molecular	  weights;	   b	  
number	  average	  molecular	  weights;	  c	  polydispersity	  (Mw/Mn).	  




4.5	  pH	  Dependent	  Spectroscopic	  Behaviour	  
	  
The	  introduction	  of	  the	  carboxylate	  moiety	  in	  [Ln.L9]	  alters	  the	  acidity	  of	  the	  amide	  
NH.	  In	  general,	  the	  amide	  deprotonation	  equilibrium	  gives	  rise	  to	  a	  pKa	  value	  greater	  
than	  9.5.	  However,	   the	   introduction	  of	   an	   electron-­‐withdrawing	   group,	   capable	  of	  





Figure	  4.6:	  Acid-­‐Base	  equilibrium	  between	  the	  protonated	  and	  non-­‐protonated	  form	  of	  [Ln.L9]	  	  	  
	  
The	  amide	  deprotonation	   is	   indicated	  by	  a	   change	   in	   the	  chemical	   shift	  of	   the	  CF3	  
group.	  From	  pH	  5.4	  to	  pH	  10.1,	  a	  change	  in	  10.9	  ppm	  was	  detected	  for	  [Tm.L9]	  (-­‐88.9	  
ppm	  to	  -­‐99.8	  ppm)	  and	  a	  change	   in	  8.6	  ppm	  for	   [Tb.L9]	   (-­‐48.4	  ppm	  to	  –57.0	  ppm).	  
Only	   one	   19F	   NMR	   spectroscopic	   resonance	   is	   observed	   in	   each	   case	   because	   the	  
acid-­‐base	  equilibrium	  is	  fast	  on	  the	  NMR	  timescale,	  whereby	  the	  signal	  is	  indicative	  
of	  the	  mean	  acid	  and	  base	  form.	  
	  
A	  pH	  titration	  was	  performed	  for	  [Tm.L9]	  using	  a	  dilute	  solution	  of	  the	  complex	  in	  0.1	  
M	  NaCl	  (298	  K,	  188	  MHz).	  The	  NaCl	  was	  added	  to	  ensure	  a	  constant	   ionic	  strength	  
was	  maintained	  throughout	  the	  experiment,	  and	  a	  D2O	  coaxial	  was	  used	  to	  lock	  the	  
instrument.	  The	  resulting	  data	  shows	  a	  continuous	  change	  in	  19F	  chemical	  shift	  as	  a	  
function	  of	  pH.	  A	  pKa	  value	  of	  was	  8.62	  calculated	  for	  [Tm.L9].	  
	  
Examination	   of	   the	   19F	   NMR	   spectroscopic	   resonance	   linewidth	   variation	   with	   pH	  
reveals	  a	  maximum	  value	  at	  pH	  8.5.	  This	  corresponds	  well	  with	  the	  calculated	  pKa.	  It	  
is	  hypothesised	  that	  this	  exchange	  broadening	   is	  caused	  by	  the	  chemical	  exchange	  




between	  the	  protonated	  amide	  and	  its	  conjugate	  base.	  This	  is	  further	  supported	  by	  
the	  fact	  that	  the	  linewidth	  decreases	  in	  more	  basic	  and	  acidic	  media.	  
	  
4.6	  19F	  Spectroscopic	  and	  Relaxation	  Analysis	  
	  
The	   Tb	   and	   Tm	   complexes	   of	   L9	   each	   formed	   one	   predominant	   19F	   resonance	   in	  
solution	   (>85	  %)	  and	  were	  stable	  over	   time.	  Conversely,	   in	   the	   19F	  NMR	  spectra	  of	  
[Tb.L10],	   a	   mixture	   of	   species	   was	   observed	   (7	   resonances),	   with	   the	   dominant	  
species	  comprising	  only	  56	  %	  of	  the	  total	  observed	  signal	  intensity.	  Interestingly,	  the	  
[Ln.L9]	   and	   [Ln.L10]	   conjugates	   of	   cyclodextrin,	   silsesquioxane	   and	   chitosan	   all	  
exhibited	   improved	   spectral	   features	   in	   comparison	   with	   their	   corresponding	  
complexes	  (>90	  %	  one	  species).	  	  In	  each	  case,	  a	  single	  peak	  was	  observed	  in	  the	  19F	  
spectra,	  displaying	  the	  same	  chemical	  shift	  as	  the	  parent	  complex.	  	  
	  
The	   longitudinal	   and	   transverse	   relaxation	   rates,	   R1	   and	   R2,	   were	   measured	   as	   a	  





R1/	  Hz	   R2	  /	  Hz	  
4.7	  T	   9.4	  T	   4.7	  T	   9.4	  T	  
[Tb.L9]	   -­‐48.5	   86	   148	   147	   263	  
[Tm.L9]	   -­‐89.1	   48	   73	   83	   109	  
[Tb.L10(H2O)]-­‐	   -­‐45.1	   85	   133	   120	   198	  
[(Tm.L9).Cyclodextrin]	   -­‐48.5	   45	   79	   136	   190	  
[(Tm.L9).Silsesquioxane]a	   -­‐89.2	   44	   74	   103	   204	  
[(Tb.L10(H2O)).Silsesquioxane]b	   -­‐45.4	   80	   122	   196	   322	  
[(Tb.L9).Chitosan]	   -­‐48.5	   81	   131	   182	   407	  
	  
Table	   4.3:	   19F	   Longitudinal	   and	   transverse	   relaxation	   data	   for	   complexes	   of	   L9	   and	   L10	   ,	   and	   their	  
corresponding	  conjugates,	  at	  4.7	  and	  9.4	  T	  (2	  mM,	  D2O,	  pD	  5.4,	  295	  K);	  
a(2mM,	  CD3OD:D2O	  (50:	  50),	  
pD	  5.4,	  295	  K);	  b(2	  mM,	  CD3OD:D2O	  (20:	  80),	  pD	  5.4,	  295	  K).	  	  	  
	  
The	   R1	   value	   does	   not	   appear	   to	   significantly	   change	   between	   the	   complexes	   and	  
their	   corresponding	   conjugates.	   As	   expected,	   broader	   linewidths	   are	   displayed	   for	  
the	   conjugates,	   owing	   to	   the	   limited	   mobility	   experienced	   by	   the	   macromolecule	  
carrier.	  However	  there	  is	  still	  some	  local	  motion,	  as	  depicted	  in	  figure	  4.8,	  due	  to	  the	  















Figure	  4.7:	  Representation	  of	  the	  possible	  rotations	  around	  the	  bond	  of	  the	  amide	  linker.	  
	  
Owing	   to	   the	   limited	   conjugation	   achieved	   for	   [(Tm.L9).Cyclodextrin],	   and	   the	  
solubility	   issues	   encountered	   with	   both	   [(Tm.L9).Silsesquioxane]	   and	  
[(Tb.L10(H2O)).Silsesquioxane],	  these	  conjugates	  were	  not	  examined	  any	  further.	  The	  
highly	   fluorinated,	   water	   soluble	   [(Tb.L9).Chitosan]	   was	   therefore	   chosen	   to	   be	  
analysed	  further	  as	  a	  potential	  contrast	  agent	  for	  in	  vivo	  studies.	  	  
	  
4.7	  Proton	  Relaxation	  Properties	  of	  Gd3+	  Complexes	  
	  
The	   relaxivity	   profiles	   of	   [Gd.L9],	   as	   a	   function	   of	   temperature	   and	  magnetic	   field,	  
were	   analysed	   to	   allow	   for	   an	   estimate	   of	   the	   rotational	   correlation	   time,	   τr,	   and	  
other	  associated	  proton	  relaxation	  parameters	  (Figure	  4.8,	  Table	  4.4).	  	  	  














P ro ton 	  L a rmor	  F requenc y 	  /	  MHz
	  
Figure	  4.8:	  Variation	  of	  the	  observed	  relaxivity,	  r1obs,	  with	  field	  for	  [Gd.L
9]	  (0.4	  mM)	  at	  298	  K	  
(filled	  circles)	  and	  310	  K	  (open	  circles).	  
	  




Complexes	  of	  L9	  do	  not	  have	  a	  coordinated	  water,	  as	  determined	  by	  analysis	  of	  the	  
Tb	  emission	  decay	   lifetimes	   in	  H2O	  and	  D2O	   (τ(H2O)	  2.78	  ms,	   τ(D2O)	  3.84	  ms;	  q=	  0.2).	  
Thus,	  the	  measured	  relaxivity	  of	  the	  Gd	  analogue	  is	  low	  (3.3	  mM-­‐1s-­‐1,	  60	  MHz,	  298	  K),	  
owing	  to	  the	  lack	  of	  inner	  sphere	  contribution.	  	  
 
 
Parameter	   298	  K	   310	  K	  
r1p/mM-1 s-1 3.3	   2.5	  
τV/ps 22.9	   18.1	  
Δ2(s-2 ×  1019) 2.6	   2.6	  
EV/kJ mol-1 1	   1	  
q 0	   0	  
q” 3	   3	  
r’’/Å 4	   4	  
τR
’/ps 60	   40	  
 
Table	  4.4:	  Summary	  of	  selected	  relaxation	  parameters	  for	  [Gd.L9]	  fitting	  of	  NMRD	  profile.	  r1p	  is	  
the	   proton	   relaxivity;	   τV	   is	   the	   correlation	   time	   for	   the	   ZFS	   modulation;	   τR
	   is	   the	   rotational	  
correlation	   time;	  Δ2	   is	   the	  mean-­‐square	   zero	   field	   splitting	   energy;	   q	   is	   the	  number	  of	   inner	  
sphere	   water	   molecules;	   q”	   is	   the	   number	   of	   second	   sphere	   water	   molecules	   and	   r’’	   their	  
distance	  from	  Gd.	  
	  
The	  relaxivity	  of	  [(Gd.L9).Chitosan]	  was	  measured	  to	  be	  12.4	  mM-­‐1s-­‐1	  (60	  MHz,	  298	  K).	  
This	   significant	   increase	   in	   relaxivity,	   in	   comparison	  with	   the	  monomeric	   complex,	  
[L9Gd],	  is	  associated	  with	  a	  slower	  rotation	  of	  the	  Gd	  complex	  in	  the	  conjugate.	  This	  
results	   in	   a	   longer	   rotational	   correlation	   time	   and,	   hence	   a	   higher	   relaxivity	   value.	  
The	  variation	  of	   relaxivity	  with	  pH	  was	  also	  undertaken	   for	   [(Gd.L9).Chitosan],	  with	  
results	  showing	  an	  increase	  in	  relaxivity	  	  over	  the	  pH	  range	  7-­‐12	  (Figure	  4.9).	  This	  is	  
consistent	  with	  base-­‐catalysed	  prototopic	  exchange,	  related	  to	  the	  deprotonation	  of	  
the	  amide	  proton.	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Figure	  4.9:	  pH	  dependence	  of	  the	  1H	  relaxivity,	  r1p,	  of	  [(Gd.L
9).Chitosan]	  (0.6	  mM,	  60	  MHz,	  298	  K)	  
	  
The	   higher	   relaxivity	   value	   of	   [(Gd.L9).Chitosan]	   should	   allow	   for	   increased	   signal	  
intensity	   per	   unit	   concentration,	   versus	   low	   molecular	   weight	   Gd	   complexes.	  
Furthermore,	   high	   molecular	   weight	   molecules,	   such	   as	   [(Gd.L9).Chitosan],	   often	  
show	   enhanced	   permeability	   and	   retention	   (EPR)	   in	   tumour	   studies,	   resulting	   in	  
favourable	  slow	  release	  profiles.	  	  
	  
4.8	  Conclusions	  and	  Future	  Work	  
	  
Three	   different	   potential	   platforms,	   for	   conjugation	  with	   fluorinated	   paramagnetic	  
probes,	  have	  been	  synthesised	  and	  their	  spectral	  properties	  assessed.	  The	  	  desirable	  
formation	  of	  one	  species	  in	  solution,	  the	  ease	  of	  solubility	  and	  attractive	  19F	  and	  1H	  
relaxometric	  properties	  render	  the	  chitosan	  conjugates,	  [(Ln.L9).Chitosan],	  the	  most	  
promising	  candidates	  for	  use	  as	  imaging	  probes.	  	  
	  
More	  work	  is	  required	  to	  further	  examine	  and	  assess	  the	  full	  benefits	  of	  the	  chitosan	  
conjugates.	  Short	  term	  goals	  should	  include	  the	  in	  vivo	  testing	  of	  [(Gd.L9).Chitosan],	  
with	   the	   aim	   of	   assessing	   the	   distribution	   and	   tumour	   uptake	   of	   the	   conjugate.	  
Following	   this,	   the	  analogous	   19F	   	  MRI	   in	  vivo	  experiment	  should	  be	  undertaken	  to	  
determine	  if	  sufficient	  signal	  is	  being	  achieved	  from	  the	  Tb	  conjugate.	  
	  




Throughout	   this	   thesis,	   the	   effects	   of	   field,	   choice	   of	   lanthanide	   ion,	   design	   of	  
macrocyclic	   ligand	   and	   carrier	   system,	   have	   been	   documented	   and	   discussed.	  
Additionally,	   a	   number	   of	   strategies	   have	   been	   investigated	   with	   the	   aim	   of	  
increasing	  the	  signal	  intensity	  in	  19F	  imaging	  experiments,	  with	  much	  progress	  made.	  
While	  these	  systems	  still	  require	  optimisation,	  it	  is	  clear	  that	  structurally	  related	  1H	  /	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Chapter	  5:	  Experimental	  	  
Procedures	  




5.0	  Experimental	  Procedures	  	  	  
	  
5.1	  General	  Procedures	  
	  
Reaction	  Conditions	  
All	  solvents	  used	  were	  laboratory	  grade	  and	  were	  dried	  over	  the	  appropriate	  drying	  
agents	  when	   required.	  All	   reagents	  were	  used	   as	   supplied	  by	   commercial	   sources,	  
unless	   otherwise	   stated.	   Water	   refers	   to	   high	   purity	   water	   obtained	   from	   the	  
“PuriteSTILL	  Plus”	  purification	  system,	  with	  conductivity	  of	  0.04	  μS	  cm-­‐	   1.	  Reactions	  
requiring	  anhydrous	  conditions	  were	  carried	  out	  using	  Schlenk-­‐line	  techniques	  under	  
an	  atmosphere	  of	  dry	  argon.	  	  
	  
Purification	  Procedures	  
Thin	  layer	  chromatography	  was	  performed	  using	  silica	  plates	  (Merck	  Art	  5554)	  or	  
neutral	   aluminium	   oxide	   plates	   (Merck	   Art	   5550),	   each	   of	   which	   are	   fluorescent	  
under	  UV	  irradiation	  (254	  nm).	  Preparative	  column	  chromatography	  was	  performed	  
using	  silica	  (Merck	  Silica	  Gel	  60,	  230–400	  mesh)	  or	  neutral	  aluminium	  oxide	  (Merck	  
Aluminium	  Oxide	   90,	   activity	   II–III,	   70–230	  mesh),	   which	   had	   been	   pre-­‐washed	   in	  
ethyl	   acetate.	   Anion	   exchange	   chromatography	   was	   performed	   using	   anion	  
exchange	   resin	   DOWEX	   1X8	   200-­‐400	   MESH	   Cl	   (Sigma-­‐Aldrich),	   pre-­‐treated	   with	   a	  
solution	   of	   1M	   HCl	   or	   1M	   KOH	   in	   Purite	   water,	   or	   cation	   exchange	   resin	   DOWEX	  
50WX4-­‐100	   (Sigma-­‐Aldrich)	   pre-­‐treated	  with	   1M	  KOH	   in	   Purite	  water.	  Dialysis	  was	  
performed	   with	   Dialysis	   Tubing	   Cellulose	   Membrane	   MWCO	   500D	   and	   12,000D	  




Electrospray	   mass	   spectra	   were	   recorded	   on	   a	   Fisons	   VG	   Platform	   II,	   Waters	  
Micromass	   LCT	   or	   Thermo-­‐Finnigan	   LTQ	   FT	   instrument	   operating	   in	   positive	   or	  
negative	   ion	  mode	   as	   stated,	  with	  methanol	   as	   the	   carrier	   solvent.	   Accurate	  mass	  
spectra	  were	  recorded	  using	  the	  Thermo-­‐Finnigan	  LTQ	  FT	  mass	  spectrometer.	  GC-­‐MS	  
were	  acquired	  on	  a	  GSMS	  Thermo-­‐Finnigan	  instrument.	  	  
	  




NMR	  Spectroscopic	  Characterisation	  
1H,	   13C	   and	   19F	   NMR	   spectra	   were	   recorded	   in	   commercially-­‐available	   deuteriated	  
solvents	   on	   a	   Varian	  Mercury-­‐200	   (1H	   at	   199.975	  MHz,	   13C	   at	   50.289	  MHz,	   19F	   at	  
188.179	  MHz),	  Varian	  Mercury-­‐400	  (1H	  at	  399.960	  MHz,	  13C	  at	  100.572	  MHz,	  19F	  at	  
376.338	   MHz),	   Varian	   Inova-­‐500	   (1H	   at	   499.772	   MHz,	   13C	   at	   125.671	   MHz,	   19F	   at	  
470.253	  MHz)	  or	  Varian	  VNMRS-­‐700	  (1H	  at	  699.731	  MHz,	  13C	  at	  176.034	  MHz,	  19F	  at	  
658.407	   MHz)	   spectrometer.	   All	   chemical	   shifts	   are	   given	   in	   ppm	   and	   coupling	  
constants	  are	  reported	  in	  Hz.	  	  
	  
19F	  NMR	  Relaxation	  Analysis	  
19F	   NMR	   longitudinal	   relaxation	   times	   were	   measured	   in	   dilute	   D2O	   or	   CD3OD	  
solutions	   (typically	  2mM)	  at	  295	  K	  using	   the	   inversion-­‐recovery	   technique,	  without	  
proton	   decoupling,	   	   on	   Varian	   spectrometers	   operating	   at	   magnetic	   inductions	  
corresponding	  to	  fluorine	  frequencies	  of	  188,	  376,	  470	  and	  658	  MHz	  (Mercury-­‐200,	  
Mercury-­‐400,	   Inova-­‐500,	   VNMRS-­‐700).	   The	   resulting	   free	   induction	   decays	   were	  
subjected	  to	  backward	  linear	  prediction,	  optimal	  exponential	  weighting,	  zero	  filling,	  
Fourier	   transform,	  phasing	  and	  baseline	  correction	   (by	  polynomial	   fitting	   to	   signal-­‐
free	   spectrum	   areas).	   The	   signals	   were	   integrated	   by	   Lorentzian	   line	   fitting.	  
Inversion-­‐recovery	   type	   function	  was	   fitted	   to	   the	   resulting	   data	   using	   Levenberg-­‐
Marquardt	  minimization	  of	  the	  non-­‐linear	  least	  squares	  error	  functional.	  
	  
Proton	  Relaxometric	  Studies	  
The	  water	  proton	  1/T1	  longitudinal	  relaxation	  rates	  (20	  MHz,	  298	  K)	  were	  measured	  
on	   a	   Stela	   Spinmaster	   Spectrometer	   (University	   of	   Piemonte	   Orientale	   in	  
Alessandria,	   Italy)	   on	   0.5-­‐2	   mM	   aqueous	   solutions	   of	   the	   complexes.	   For	   the	   T1	  
determinations,	  the	  standard	  inversion-­‐recovery	  method	  was	  used	  with	  a	  typical	  90o	  
pulse	  width	  of	   3.5µs	  with	  16	  experiments	  of	   4	   scans.	   The	   reproducibility	  of	   the	  T1	  
data	  was	  estimated	  to	  be	  ±	  1%.	  The	  temperature	  was	  controlled	  with	  a	  Stelar	  VTC-­‐91	  
air-­‐flow	  heater	  equipped	  with	  a	  copper-­‐constantan	  thermocouple	  (uncertainty	  of	  0.1	  
±oC).	   The	   proton	   1/T1	   NMRD	   profiles	  were	  measured	   on	   a	   fast	   field-­‐cycling	   Stelar	  
Spinmaster	   FFC	   relaxometer	   over	   a	   continuum	   of	   magnetic	   field	   strengths	   from	  
0.00024	   to	   0.5	   T	   (corresponding	   to	   0.01-­‐20	  MHz	   proton	   Larmor	   frequencies).	   The	  




relaxometer	  operates	  under	  computer	  control	  with	  an	  absolute	  uncertainty	   in	  1/T1	  
of	  ±	  1%.	  Data	  points	  from	  0.47	  (20	  MHz)	  to	  1.7	  T	  (70	  MHz)	  were	  collected	  in	  a	  Stelar	  
Spinmaster	  spectrometer	  operating	  at	  variable	  fields.	  
	  
17O	  NMR	  Relaxation	  Studies	  
Variable	   temperature	   17O	   NMR	   spectroscopic	   measurements	   were	   recorded	   on	   a	  
JEOL	   ECP-­‐400	   (9.4T)	   spectrometer	   equipped	   with	   a	   5	   mm	   probe	   and	   a	   standard	  
temperature	   control	   unit.	   Aqueous	   solutions	   of	   the	   complexes	   (~	   20-­‐30	   mM)	  
containing	   2.8%	   of	   the	   17O	   isotope	   (Cambridge	   Isotope)	   were	   used.	   The	   observed	  
tranverse	   relaxation	   rates	   (R2)	  were	  calculated	   from	  the	  signal	  width	  at	  half-­‐height	  
( 1/2):	  R2	  =	  π 1/2.	  
	  
19F	  MRI	  Phantom	  Studies	  
19F	  phantom	  imaging	  data	  were	  collected	  at	  Newcastle	  Maagnetic	  Resonance	  Centre	  
using	  a	  7T	  Varian	  Unity	  Inova	  microimaging	  system	  (Varian	  Inc.,	  Palo	  Alto,	  California,	  
USA)	  equipped	  with	  broadband	  capability,	  actively	  shielded	  gradients	  and	  a	  purpose-­‐
built	  two	  turn	  circular	  19F	  surface	  coil	  (i.d.	  12	  mm,	  281	  MHz	  19F	  frequency)	  which	  was	  
used	  for	  both	  excitation	  and	  reception	  of	  the	  signal.	  Dilute	  aqueous	  samples	  (~	  2	  –	  5	  
mM)	   were	   placed	   in	   5	   mm	   NMR	   tubes	   and	   positioned	   on	   the	   axis	   of	   the	   coil.	  
Conventional	  proton	  MRI	  was	  used	   to	   localise	  and	   shim	   the	   samples	  based	  on	   the	  
proton	  water	  signal.	   	  Following	  19F	  pulse	  calibration,	  R1	  values	  were	  determined	  for	  
each	  sample	  using	  a	  saturation	  recovery	  sequence	  in	  order	  to	  calculate	  Ernst	  angle	  
pulses	  for	  optimal	  imaging	  sensitivity.	  	  Fluorine	  MR	  images	  were	  then	  collected	  using	  
a	  RF	  spoiled,	  gradient	  echo	  imaging	  sequence	  with	  repetition	  time	  (TR)	  10	  ms,	  echo	  
time	  (TE)	  0.88	  ms,	  a	  0.5	  ms	  sinc	  pulse	  for	  selection	  of	  a	  6	  mm	  thick	  slice,	  48	  x	  48	  mm	  
field	   of	   view,	   32	   x	   32	   matrix	   and	   50	   kHz	   receiver	   bandwidth.	   	   Relative	   imaging	  
sensitivity	   for	   the	  complexes	  was	  determined	  by	   ‘region	  of	   interest	  analysis’	  of	   the	  
signal	  to	  noise	  ratio	  in	  each	  image.	  
	  
19F	  MRI	  In	  Vivo	  Studies	  
MRI	   in	   vivo	   studies	  were	   performed	   in	   the	  Newcastle	  Magnetic	   Resonance	   Centre	  
using	   a	   Varian	   7	   T	   Unity	   Inova	   Pre-­‐Clinical	   system	   equipped	   with	   a	   1H	   39	   mm-­‐




diameter	  transmit/receive	  birdcage	  coil	  for	  proton	  images	  and	  a	  19F	  circular	  surface	  
coil	   for	   fluorine	   images	   (12	   mm	   diameter,	   281	   MHz	   19F	   frequency).	   Nude	   mice	  
bearing	  an	  HT29	  colorectal	  tumour	  xenograft	  were	  anaesthesised	  with	  oxygen/	  1-­‐2%	  
isoflurane	   and	   placed	   in	   the	   coil.	   A	   dynamic	   sequence	   was	   used	   in	   which	   5	  
background	   images	  were	  collected	   (30	  s)	  before	   the	  endovenous	  administration	  of	  
the	   contrast	   agent	   during	   the	   6th	   image.	   The	   remaining	   94	   images	   were	   dynamic	  
images	  for	  a	  total	  of	  100	  over	  a	  10	  min	  acquisition	  period.	  
	  
pH	  Measurements	  
All	  pH	  measurements	  were	  performed	  using	  a	  Jenway	  3320	  pH	  meter	  attached	  to	  an	  
Aldrich	  micro–pH	  combination	  electrode,	  calibrated	  using	  pH	  4.00	  ±0.02,	  7.00	  ±0.02	  
and	  10.00	  ±0.02	  buffer	  solutions	  by	  Aldrich.	  Diluted	  aqueous	  solutions	  of	  NaOH	  and	  
HCl	   (or	  where	  required	  NaOD	  and	  DCl	   in	  D2O)	  were	  used	  for	  pH	  adjustements.	  For	  
measurements	   in	   D2O	   the	   pD	  was	   calculated	   as	   pD	   =	   pH	   +	   0.41,	   where	   pH	   is	   the	  
meter	  reading.	  
	  
Melting	  Point	  Measurements	  
Melting	   points	   were	   recorded	   using	   a	   Gallenkamp	   apparatus	   (Sanyo)	   and	   are	  
uncorrected.	  
	  
Gel	  Permeation	  Chromatography	  
Gel	   permeation	   chromatography	   was	   undertaken	   at	   Smithers	   Rapra	   UK	   using	   a	  
Viscotek	   Model	   301	   TDA	   instrument	   with	   associated	   pump,	   autosampler	   and	  
refractive	  index	  detector	  (with	  differential	  pressure	  and	  light	  scattering).	  PLaquagel-­‐
OH	  guard	  plus	  2	  x	  PLaquagel-­‐OH	  Mixed-­‐H,	  30	  cm,	  8	  µm	  columns	  were	  used	  with	  an	  
eluent	   composed	   of	   0.5	  M	  NaNO3,	   0.01	  M	  NaH2PO4	   at	   pH	   2	   at	   a	   flow	   rate	   of	   1.0	  
ml/min	  at	  30˚C.	  The	  GPC	  system	  was	  calibrated	  using	  pullulan	  polysaccharides	  and	  
the	  data	  were	  analysed	  using	  Malvern/Viscotek	  ‘OmniSec’	  software.	  
	  
HPLC	  	  
Reverse	   phase	   HPLC	   traces	   were	   recorded	   at	   298	   K	   using	   a	   Perkin	   Elmer	   system	  
equipped	   with	   a	   Perkin	   Elmer	   Series	   200	   Pump,	   a	   Perkin	   Elmer	   Series	   200	  




Autosampler	  and	  a	  Perkin	  Elmer	  Series	  200	  Diode	  array	  detector	   (operated	  at	  254	  
nm).	  A	  4.6	  x	  150	  mm	  4µm	  Phenomenex	  Synergi	  Fusion	  RP	  80Å	  analytical	  column	  was	  
used.	   A	   gradient	   elution	  with	   a	   solvent	   system	   composed	   of	   H2O	   +	   0.1%	  HCOOH/	  
MeCN	  +	  0.1%	  HCOOH	  was	  performed	  for	  a	  total	  run	  time	  of	  20	  min	  (Table	  5.1).	  
	  
Time	  (min)	   Solvent	  A	  (%)	   Solvent	  B	  (%)	   Curvature	  
0	   95	   5	   0	  
5	   95	   5	   0	  
20	   0	   100	   1	  
25	   0	   100	   0	  
27	   95	   5	   -­‐3	  
30	   95	   5	   0	  
Table	  5.1:	  Flow	  rate	  =	  1ml/min;	  Solvent	  A	  =	  H2O	  +	  0.1%	  HCOOH;	  Solvent	  B	  =	  MeCN	  +	  0.1%	  HCOOH.	  
	  
Emission	  Spectra	  and	  Lifetime	  Measurements	  
Emission	  spectra	  and	  lifetimes	  were	  measured	  on	  a	  Fluorolog-­‐3	  and	  a	  Perkin	  Elmer	  
LS55	   luminescence	   spectrometer	   using	   FL	   Winlab	   software.	   All	   samples	   were	  
contained	  in	  quartz	  cuvettes	  with	  a	  path	  length	  of	  1	  cm	  and	  measurements	  obtained	  
relative	  to	  a	  reference	  of	  pure	  solvent	  contained	  in	  a	  matched	  cell.	  	  
	  
Lifetime	  measurements	  were	  measured	  by	  excitation	  of	  the	  sample	  by	  a	  short	  pulse	  
of	  light,	  followed	  by	  monitoring	  the	  integrated	  intensity	  of	  light	  (546	  nm	  for	  terbium)	  
emitted	   during	   a	   fixed	   gate	   time	   and	   set	   delay.	  Measurements	   were	  made	   for	   at	  
least	  20	  delay	  times	  over	  a	  period	  of	  three	  or	  more	  lifetimes.	  A	  gate	  time	  of	  0.1	  ms	  
was	   used,	   and	   the	   excitation	   and	   emission	   slits	   were	   set	   to	   10	   and	   2.5	   nm	  
respectively.	   The	  obtained	  decay	   curves	  were	  plotted	   in	  Microsoft	   Excel	   and	   fit	   to	  
the	  equation:	  
kteAAI −+= 10 	  
where	  I	  is	  the	  intensity	  at	  time	  t	  after	  the	  flash	  
A0	  is	  the	  intensity	  after	  decay	  is	  completed	  
A1	  	  is	  the	  pre-­‐exponential	  factor	  
and	  k	  is	  the	  rate	  constant	  for	  decay	  of	  the	  excited	  state.	  
The	  excited	  state	  lifetime,	  τ,	  is	  the	  inverse	  of	  the	  rate	  constan	  




Cell	  Culture	  and	  Cytotoxicity	  
NIH	   3T3	   (mouse	   skin	   fibroblast)	   cells	   were	   maintained	   in	   exponential	   growth	   as	  
monolayers	  in	  DMEM	  (Dulbecco’s	  Modified	  Eagle	  Medium)	  supplemented	  with	  10%	  
fetal	  bovine	  serum	  (FBS)	  and	  1%	  penicillin	  and	  streptomycin.	  Cells	  were	  incubated	  at	  
37	   °C,	  20%	  average	  humidity	  and	  5%	   (v/v)	  CO2.	   IC50	   values	  were	  determined	  using	  
the	  MTT	  assay,	  as	  described	  by	  Carmichael1,	  which	  makes	  use	  of	  the	  conversion	  of	  
MTT	   (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐	   diphenyltetrazolium	   bromide)	   to	   a	   purple	  
formazan	  product	  by	  the	  mitochondrial	  dehydrogenase	  of	  viable	  cells.	  This	  insoluble	  
formazan	   was	   quantified	   spectrophotometrically	   upon	   dissolution	   in	   DMSO.	  
Approximately	  1	  x	  104	  NIH-­‐3T3	  cells	  in	  100	  μL	  DMEM	  were	  seeded	  into	  each	  well	  of	  
flat-­‐bottomed	   96-­‐well	   plates	   and	   allowed	   to	   attach	   overnight.	   Complex	   solutions	  
were	  added	  to	  triplicate	  wells	  to	  give	  final	  concentrations	  over	  at	  least	  a	  2-­‐log	  range.	  
Following	   24	   h	   incubation,	  MTT	   (1.0	  mM)	  was	   added	   to	   each	  well,	   and	   the	   plates	  
incubated	  for	  a	  further	  4	  h.	  The	  culture	  medium	  was	  removed,	  and	  DMSO	  (150	  μL)	  
was	  added.	   The	  plates	  were	   shaken	   for	  20	   seconds	  and	   the	  absorbance	  measured	  
immediately	  at	  540	  nm	  in	  a	  microplate	  reader.	   IC50	  values	  were	  determined	  as	  the	  
drug	   concentration	   required	   to	   reduce	   the	   absorbance	   to	   50%	   of	   that	   in	   the	  




Lipophilicity	   was	   measured	   as	   the	   relative	   partitioning	   of	   the	   complex	   between	  
water	   and	   1-­‐octanol.	   Water	   was	   saturated	   with	   1-­‐octanol,	   and	   1-­‐octanol	   was	  
saturated	  with	  water.	  Complexes	  were	  prepared	  as	  100	  μM	  solutions	   in	  water	  and	  
mixed	  with	  1-­‐octanol	  in	  1:2,	  1:1	  and	  2:1	  water:octanol	  ratios.	  Mixtures	  were	  agitated	  
for	  twelve	  hours,	  after	  which	  emission	  spectra	  of	  the	  water	  and	  octanol	  layers	  were	  
collected.	   Emission	   spectra	   were	   measured	   on	   an	   Instruments	   SA	   Fluorolog	   3-­‐11	  
spectrometer	   and	   DataMax	   v2.1	   for	   Windows.	   The	   complex	   concentration	   was	  
calculated	   at	   the	   emission	   maximum	   with	   reference	   to	   calibration	   curves	  
constructed	  for	  at	  least	  five	  concentrations	  between	  0	  and	  100	  μM	  in	  water	  and	  1-­‐
octanol.	  For	  each	  mixture,	  the	  logP	  value	  was	  calculated	  according	  to	  the	  following	  
equation:	  









XP −= 	  
	  
Final	   logP	   values	   were	   calculated	   as	   the	   average	   of	   at	   least	   two	   replicates	   of	   the	  






































Chloroacetyl	   chloride	   (1.68	   g,	   14.9	  mmol)	  was	   added	   dropwise	   to	   a	   solution	   of	   2-­‐
aminobenzotrifluoride	   (2.00	   g,	   12.4	   mmol)	   and	   Et3N	   (1.51g	   ,	   14.9	   mmol)	   in	  
anhydrous	  CH2Cl2	   (15	  mL)	  at	   -­‐4oC	  (H2O	  /	   ice)	  under	  argon.	  The	  reaction	  was	  stirred	  
for	   7	   h,	   resulting	   in	   a	   pale	   yellow	   solution	   with	   an	   off-­‐white	   precipitate.	   After	  
filtration,	  the	  solution	  was	  washed	  first	  with	  dilute	  HCl	  (2	  x	  20	  mL),	  followed	  by	  H2O	  
(2	  x	  20	  mL).	  The	  organic	  phases	  were	  combined,	  dried	  over	  Na2SO4,	  and	  the	  solvent	  
removed	   under	   reduced	   pressure.	   The	   crude	   product	   was	   purified	   by	   silica	   gel	  
column	  chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  toluene	  to	  20%	  
CH2Cl2/	  toluene	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (2.05	  g,	  69	  %);	  m.p.	  99-­‐
101oC;	  	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  4.21	  (2H,	  s,	  CH2Cl),	  7.27	  (1H,	  t,	  J=	  8	  Hz,	  Hd),	  7.57	  
(1H,	  t,	  J=	  8	  Hz,	  He),	  7.64	  (1H,	  d,	  J=	  8	  Hz,	  Hc),	  8.20	  (1H,	  d,	  J=	  8	  Hz,	  Hf),	  8.73	  (1H,	  s,	  NH);	  	  
13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	   	  43.1	  (CH2Cl),	  120.8	  (q,	  2JCF=	  30	  Hz,	  Cb),	  124.1	  (q,	  1JCF=	  
271	  Hz,	   CF3),	   124.2	   (Cf),	   125.5	   (Cd),	   126.5	   (q,	   3JCF=	   5	  Hz,	   Cc),	   133.2	   (Ce),	   134.5	   (Ca),	  
164.5	  (CO);	  19F	  NMR	  (188	  MHz,	  CDCl3)	  δ	  	  -­‐61.16	  (CF3);	  	  ESI/MS-­‐	  m/z	  236.1	  [M–H]-­‐;	  MS	  
Calcd	  for	  C9H6NOF3Cl	  236.0096.	  Found	  236.0095;	  Anal	  Calcd	  for	  C9H6NOF3Cl	  C,	  45.49;	  




















2-­‐Chloro-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	  (2.00	  g,	  8.43	  mmol)	  was	  added	  to	  a	  
stirred	  solution	  of	  1,4,7,10	  –	  tetraazacyclododecane	  (0.29	  g,	  1.68	  mmol)	  and	  K2CO3	  	  
(0.23	  g,	  1.68	  mmol)	   in	  anhydrous	  CH3CN	  (10mL)	  at	  85oC	  under	  argon.	  The	  reaction	  
was	  left	  to	  boil	  under	  reflux	  for	  15	  h,	  to	  give	  a	  colourless	  solution	  with	  a	  pale	  yellow	  
precipitate.	   The	   precipitate	   was	   isolated	   by	   filtration	   and	   dried	   under	   reduced	  
pressure	   yielding	   a	   pale	   yellow	   solid.	   The	   crude	   product	  was	   purified	   by	   silica	   gel	  
column	  chromatography,	  eluting	  with	  a	  gradient	  starting	   from	  100%	  CH2Cl2	   to	  15%	  
CH3OH/	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (0.77	  g,	  47	  %);	  m.p.	  201-­‐	  
203oC;	   1H	  NMR	  (700	  MHz,	  CD3OD)	  δ	  2.06	  –	  3.59	   (24H,	  br.	  m,	  CH2	   ring	  and	  CH2CO),	  
7.14	  (4H,	  t,	  J=	  8	  Hz,	  Hd),	  7.46	  (4H,	  t,	  J=	  8	  Hz,	  He),	  7.52	  (4H,	  d,	  J=	  8	  Hz,	  Hc),	  8.20	  (4H,	  d,	  
J=	  8Hz,	  Hf),	  9.19	   (4H,	  br.	   s,	  NH);	   13C	  NMR	  (126	  MHZ,	  CD3OD)	  δ	  52.4	   (br.,	  CH2	   ring),	  
58.5	  (CH2CO),	  122.2	  (q,	  2JCF=	  30	  Hz,	  Cb),	  124.3	  (q,	  1JCF=	  272	  Hz,	  CF3),	  124.9	  (Cf),	  126.3	  
(Cd),	  126.8	  (q,	  3JCF=	  5	  Hz,	  Cc),	  133.6	  (Ce),	  135.9	  (Ca),	  171.1	  (CO);	  19F	  NMR	  (188	  MHz,	  
































methyl]-­‐1,4,7,10-­‐tetra-­‐cyclododec-­‐1-­‐yl]-­‐acetamide	   (11.4	  mg,	   11.6	  µmol)	  was	   added	  
to	  a	   stirred	  solution	  of	  TbIII(OTf)3	   (8.44	  mg,	  13.9	  µmol)	   in	  anhydrous	  CH3CN	   (2	  mL)	  
under	   argon	   at	   85oC.	   The	  mixture	   was	   left	   to	   boil	   under	   reflux	   for	   15	   h,	   and	   the	  
resulting	  solution	  was	  added	  dropwise	  into	  cold	  Et2O	  (3	  x	  20	  mL),	  generating	  an	  off-­‐
white	  precipitate.	  The	  precipitate	  was	  isolated	  following	  centrifugation	  and	  dried	  to	  
give	   the	   desired	   complex	   as	   a	   trifluoroacetate	   salt.	   The	   complex	   was	   dissolved	   in	  
H2O:	  CH3OH	  (75:	  25,	  5	  mL)	  and	  stirred	  for	  2	  hours	  with	  anion	  exchange	  resin	  (DOWEX	  
1X8	  200-­‐400	  MESH	  Cl,	  pre-­‐treated	  with	  1M	  HCl)	  to	  give	  the	  chloride	  salt.	  Following	  
filtration,	  the	  water	  was	  lyophilized	  to	  yield	  the	  hydrochloride	  salt	  as	  a	  white	  powder	  
(9.22	  mg,	   70	   %);	   1H	   NMR	   (500	  MHZ,	   CD3OD)	   Peaks	   range	   from	   -­‐81.45	   to	   185.90.	  
Selected	  peaks	  at	  :	  -­‐81.45,	  -­‐75.93,	  -­‐62.32,	  -­‐0.53,	  25.59,	  42.65,	  99.30,	  129.59,	  181.81,	  
185.90;	  19F	  NMR	  (470	  MHz,	  CD3OD)	  δ	   	   -­‐53.89	  (CF3,	  major	  species),	   -­‐42.34,	   -­‐51.89,	   -­‐
59.56,	  -­‐63.43	  (CF3,	  minor	  species);	  ESI/MS+	  m/z	  378.7	  [M]3+,	  567.3	  [M-­‐H]2+;	  MS	  Calcd	  




An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	  followed	  using	  N-­‐(2-­‐
trifluoromethyl-­‐phenyl)-­‐2-­‐{4,7,10-­‐tris-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐




1,4,7,10-­‐tetra-­‐cyclododec-­‐1-­‐yl]-­‐acetamide	  (13.1	  mg,	  13.4	  µmol)	  and	  HoIII(OTf)3	  (9.85	  
mg,	  16.1	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (10.4	  mg,	  68	  %);	  1H	  NMR	  
(500	  MHZ,	  CD3OD)	  Peaks	  range	  from	  -­‐177.84	  to	  118.45.	  Selected	  peaks	  at:	  -­‐177.84,	  	  -­‐
48.08,	  -­‐44.00,	  -­‐0.11,	  8.71,	  15.70,	  17.31,	  62.34,	  118.45;	  19F	  NMR	  (470	  MHz,	  CD3OD)	  δ	  -­‐
58.97	   (CF3,	   major	   species),	   -­‐47.77,	   -­‐50.92,	   -­‐55.66,	   -­‐61.66	   (CF3,	   minor	   species);	  
ESI/MS+	  m/z	  380.0	  [M]3+,	  570.9	  [M-­‐H]2+;	  MS	  Calcd	  for	  C44H44N8O4F12165Ηο	  380.7538.	  
Found	  380.7525;	  HPLC:	  tR	  =	  6.9	  min.	  
	  
6.	  [Gd.L1(H2O)]3+	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	   followed	  using	  N-­‐
(2-­‐trifluoromethyl-­‐phenyl)-­‐2-­‐{4,7,10-­‐tris-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐
methyl]-­‐1,4,7,10-­‐tetra-­‐cyclododec-­‐1-­‐yl]-­‐acetamide	   (42.3	   mg,	   43.3	   µmol)	   and	  
GdIII(OTf)3	  (31.4	  mg,	  51.9	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (34.8	  mg,	  
71	  %);	   19F	  NMR	   (188	  MHz,	  CD3OD)	  δ	   	   -­‐60.04	   (CF3);	   ESI/MS+	  m/z	  566.2	   [M-­‐H]2+;	  MS	  
Calcd	  for	  C44H43N8O4F12158Gd	  566.6228.	  Found	  566.6223;	  r1p	  =	  6.5	  mM-­‐1s-­‐1	  (20	  MHz,	  
298	  K);	  	  HPLC:	  tR	  =	  6.9	  min.	  
 
7.	  [Er.L1(H2O)]3+	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	  followed	  using	  N-­‐(2-­‐
trifluoromethyl-­‐phenyl)-­‐2-­‐{4,7,10-­‐tris-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐
1,4,7,10-­‐tetra-­‐cyclododec-­‐1-­‐yl]-­‐acetamide	   (19.4	  mg,	  19.9	  µmol)	  and	  ErIII(OTf)3	   (14.6	  
mg,	  	  23.8	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (18.6	  mg,	  82	  %);	  1H	  NMR	  
(500	  MHZ,	  CD3OD)	  Peaks	   range	   from	   -­‐55.76	   to	  100.31.	  Selected	  peaks	  at:	   -­‐55.76,	   -­‐
39.03,	   -­‐33.89,	   -­‐25.43,	   -­‐2.05	   7.54,	   9.32,	   10.30,	   81.43,	   94.56,	   100.31;	   19F	   NMR	   (470	  
MHz,	   CD3OD):	   δ	   -­‐63.44	   (CF3,	   major	   species),	   -­‐61.16,	   -­‐64.46,	   -­‐68.27	   (CF3,	   minor	  




An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	  followed	  using	  N-­‐(2-­‐
trifluoromethyl-­‐phenyl)-­‐2-­‐{4,7,10-­‐tris-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐
1,4,7,10-­‐tetra-­‐cyclododec-­‐1-­‐yl]-­‐acetamide	  (14.8	  mg,	  15.1	  µmol)	  and	  TmIII(OTf)3	  (11.2	  
mg,	  18.2	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (14.7	  mg,	  85	  %);	  1H	  NMR	  




(500	  MHz,	  CD3OD)	  Peaks	  range	  from	  -­‐153.56	  to	  100.41.	  Selected	  peaks	  at:	  -­‐153.56,	  -­‐
87.42,	  -­‐75.38,	  -­‐21.31,	  -­‐18.93,	  22.30,	  31.45,	  42.84,	  83.92,	  100.41;	  19F	  NMR	  (470	  MHz,	  
CD3OD)	   δ	   -­‐65.09	   (CF3,	   major	   species),	   -­‐64.08,	   -­‐69.07,	   -­‐75.93	   (CF3,	   minor	   species);	  




An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	  followed	  using	  N-­‐(2-­‐
trifluoromethyl-­‐phenyl)-­‐2-­‐{4,7,10-­‐tris-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐
1,4,7,10-­‐tetra-­‐cyclododec-­‐1-­‐yl]-­‐acetamide	   (10.2	   mg,	   10.4	   µmol)	   and	   YIII(OTf)3	   (6.7	  
mg,	  12.5	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (8.2	  mg,	  74	  %);	   	  19F	  NMR	  





Chloroacetyl	   chloride	   (2.53	   g,	   22.4	  mmol)	  was	   added	   dropwise	   to	   a	   solution	   of	   o-­‐
toluidine	   (2.0	  g,	  18.6	  mmol)	  and	  Et3N	   (2.26	  g,	  22.4	  mmol)	   in	  anhydrous	  CH2Cl2	   (15	  
mL)	  at	  -­‐4oC	  (water	  /	  ice)	  under	  argon.	  The	  reaction	  was	  stirred	  for	  7	  h,	  resulting	  in	  a	  
strong	  orange	  solution	  with	  an	  off-­‐white	  precipitate.	  The	  precipitate	  was	  filtered	  off	  
and	   the	  solution	  washed	   first	  with	  dilute	  HCl	   (2	  x	  20	  mL),	   followed	  by	  H2O	   (2	  x	  20	  
mL).	  The	  organic	  phases	  were	  combined,	  dried	  over	  Na2SO4	  and	  the	  solvent	  removed	  
under	  reduced	  pressure.	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  
over	   silica	   gel,	   eluting	  with	   a	   gradient	   starting	   from	   100%	   CH2Cl2	   to	   5%	   toluene	   /	  
CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (2.46	  g,	  72.3	  	  %);	  m.p.	  109-­‐111oC;	  
1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  2.29	  (1H,	  s,	  CH3),	  4.22	  (2H,	  s,	  CH2Cl),	  7.11	  (1H,	  t,	  J=	  8	  Hz,	  
Hd),	  7.20	  (1H,	  t,	  J	  =	  8	  Hz,	  He),	  7.21	  (1H,	  d,	  J=	  8	  Hz,	  Hf),	  7.87	  (1H,	  d,	  J=	  8	  Hz,	  Hc),	  8.21	  
(1H,	  s,	  NH);	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  17.7	  (CH3),	  43.4	  (CH2),	  122.6	  (Cf),	  125.9	  (Ce),	  
127.2	  (Cd),	  129.2	  (Cc),	  130.8	  (Cb),	  134.9	  (Ca),	  163.9	  (CO);	  EI/MS	  m/z	  183.0;	  Anal.	  Calcd	  
for	  C9H10NOCl	  C,	  58.86;	  H,	  5.49;	  N:	  7.63%.	  Found	  C,	  58.59;	  H,	  5.32;	  N,	  7.54%.	  








2-­‐Chloro-­‐N-­‐o-­‐tolyl-­‐acetamide	  (0.32	  g,	  1.76	  mmol)	  was	  added	  to	  a	  stirred	  solution	  of	  
1,4,7,10	  –	  tetraazacyclododecane	  (0.25	  g,	  1.4	  mmol)	  and	  K2CO3	  	  (0.20	  g,	  1.4	  mmol)	  in	  
anhydrous	  CH3CN	   (10mL)	  at	  85oC	  under	  argon.	  The	   reaction	  was	   left	   to	  boil	  under	  
reflux	   for	   15	   h,	   yielding	   a	   colourless	   solution	   with	   a	   pale	   yellow	   precipitate.	   The	  
precipitate	  was	  isolated	  by	  filtration,	  dried	  under	  reduced	  pressure	  to	  give	  the	  crude	  
product	   as	   a	   pale	   yellow	   solid.	   The	   crude	   product	   was	   purified	   by	   column	  
chromatography	  over	  silica	  gel,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  
10%	  CH3OH	  /	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (0.62	  g,	  58.3	  %):	  m.p.	  
206-­‐	  208oC;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  2.14,	  (12H,	  CH3),	  2.31-­‐3.80	  (24H,	  br.	  m,	  CH2	  
ring	  and	  CH2CO),	  6.90	  (4H,	  t,	  J=	  8	  Hz,	  Hd),	  7.12	  (4H,	  t,	  J=	  8	  Hz,	  He),	  7.20	  (4H,	  d,	  J	  =	  8	  
Hz,	  Hf),	  7.98	  (4H,	  d,	   J=	  8	  Hz,	  Hc),	  9.36	  (4H,	  s,	  NH);	  13C	  NMR	  (125MHz,	  CDCl3)	  δ	  18.6	  
(CH3),	  51.9	   (br.,	  CH2	   ring),	  57.2	   (CH2O),	  125.9	   (Cf),	  126.4	   (Ce),	  129.2	   (Cd),	  130.8	   (Cc),	  
132.5	  (Cb),	  136.5	  (Ca),	  170.7	  (CO);	  ESI/MS+	  m/z	  783.8	  [M	  +	  Na]+,	  761.2	  [M	  +	  H]+;	  MS	  




























An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	  followed	  using	  N-­‐o-­‐
tolyl-­‐2-­‐[4,7,10-­‐tris-­‐(o-­‐tolylcarbamoyl-­‐methyl)1,4,7,10tetraazacyclododec-­‐1-­‐yl]-­‐
acetamide	  (14.2	  mg,	  18.7	  µmol)	  and	  TbIII(OTf)3	  (13.6	  mg,	  22.4	  µmol)	  to	  yield	  the	  title	  
complex	   as	  a	  white	   solid	   (13.2	  mg,	  77	  %);	   1H	  NMR	   (200	  MHZ,	  CD3OD)	  Peaks	   range	  
from	  -­‐130.49	  to	  100.23.	  Selected	  peaks	  at	  :	  -­‐130.49,	  -­‐92.65,	  -­‐80.26,	  -­‐40.56,	  -­‐30.29,	  -­‐
18.59,	  -­‐3.20,	  20.36,	  39.65,	  65.42,	  92.36,	  100.23;	  ESI/MS+	  m/z	  306.2	  [M]3+,	  458.8	  [M-­‐
H]2+;	  MS	   Calcd	   for	   C44H56O4N8159Tb	   306.4553.	   Found	   306.4553;	   τ	   (H2O)	   1.65	  ms,	   τ	  
(D2O)	  2.74	  ms;	  q=	  0.90.	  	  
	  
13.	  [Gd.L2(H2O)]3+	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L1(H2O)]3+	  was	  followed	  using	  N-­‐o-­‐
Tolyl-­‐2-­‐[4,7,10-­‐tris-­‐(o-­‐tolylcarbamoyl-­‐methyl)1,4,7,10tetraazacyclododec-­‐1-­‐yl]-­‐
acetamide	  (28.9	  mg,	  38.0	  µmol)	  and	  GdIII(OTf)3	  (27.6	  mg,	  45.6	  µmol)	  to	  yield	  the	  title	  
complex	   as	   a	  white	   solid	   (25.6	  mg,	   74	  %);	   ESI/MS+	  m/z	   305.6	   [M]3+;	  MS	   Calcd	   for	  
C44H56N8O4155Gd	   306.1216.	   Found	   306.1216;	   r1p	   =	   	   3.8	   mM-­‐1s-­‐1	   (20	   MHz,	   298	   K);	  









acid	  tert-­‐butyl	  ester2	  
 
 
Tert-­‐butylbromoacetate	   (6.61	   g,	   33.9	   mmol)	   was	   added	   to	   a	   stirred	   solution	   of	  
1,4,7,10-­‐tetraazacyclododecane	   (1.95	   g,	   11.28	   mmol)	   and	   NaHCO3	   (2.83	   g,	   33.7	  
mmol)	   in	   anhydrous	   CH3CN	   (75	   mL)	   under	   argon.	   The	   reaction	   was	   left	   stirring	  
overnight	  at	  room	  temperature.	  The	  mixture	  was	  filtered	  and	  the	  solvent	  evaporated	  
to	  give	  a	  yellow	  oil	  which	  was	  purified	  by	  silica	  gel	  column	  chromatography,	  eluting	  
with	   a	   gradient	   starting	   from	   100%	   CH2Cl2	   to	   5%	   CH3OH/	   CH2Cl2	   to	   yield	   the	   title	  
compound	   as	   a	  white	   solid	   (2.86	   g,	   49.4	  %);	  m.p.	   181-­‐183oC;	   	   1H	  NMR	   (CDCl3,	   400	  
MHz)	  δ	  1.42	  (18H,	  s,	  tBu),	  1.43	  (9H,	  s,	  tBu),	  2.80-­‐2.96	  (12H,	  br.	  m,	  CH2	  ring),	  3.08	  (4H,	  
br.	  s,	  CH2	  ring),	  3.26	  (2H,	  s,	  CH2CO),	  3.35	  (4H,	  s,	  CH2CO),	  9.92	  (1H,	  s,	  NH);	  13C	  NMR	  
(CDCl3,	   125	   MHz)	   δ	   27.9,	   28.3	   (tBu),	   47.5,	   49.1,	   51.2	   (br.,	   cyclen	   CH2),	   55.9,	   57.9	  
(CH2O),	  81.5,	  82.1	   (CCH3),	  169.7,	  170.5	   (CO);	  ESI/MS+	  515.4	   [M	  +	  H]+;	  MS	  Calcd	   for	  














methyl]-­‐1,4,7,10	  tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	  tert-­‐butyl	  ester	  
	  
	  
2-­‐Chloro-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	  (167	  mg,	  0.91	  mmol)	  was	  added	  to	  
a	   stirred	   solution	   of	   1,4,7-­‐tris(tert-­‐butoxycarbonylmethyl)-­‐1,4,7,10-­‐tetraazacyclodo-­‐
decane	  (300	  mg,	  0.58	  mmol),	  KI	  (~10	  mg,	  as	  catalyst)	  and	  K2CO3	  (0.80	  g,	  0.58	  mmol)	  
in	  anhydrous	  CH3CN	  (20	  mL)	  at	  85oC	  under	  argon.	  The	  mixture	  was	  left	  to	  boil	  under	  
reflux	  for	  15	  hours,	  yielding	  an	  orange	  solution	  and	  white	  precipitate.	  The	  precipitate	  
was	   removed	   by	   filtration	   and	   the	   residue	   washed	   with	   CH2Cl2	   (2	   x	   30	   mL).	   The	  
solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  resulting	  oil	  purified	  by	  silica	  
gel	  column	  chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  5%	  
CH3OH	  /	  CH2Cl2	   to	  yield	  the	  title	  compound	  as	  a	  pale	  brown	  oil	   (254	  mg,	  61	  %);	   1H	  
NMR	  (400	  MHz,	  CDCl3)	  δ	  1.43	  (18H,	  tBu),	  1.45	  (9H,	  tBu),	  2.02-­‐	  3.66	  (24H,	  br.,	  CH2	  ring	  
and	  CH2CO),	  7.28	  (1H,	  t,	  J=	  8Hz,	  Hd),	  7.43	  (1H,	  t,	  J=	  8Hz,	  He),	  7.56	  (2H,	  m,	  Hc	  and	  Hf),	  
9.97	  (1H,	  s,	  NH);	  13C	  NMR	  (125MHz,	  CDCl3)	  δ	  28.1	  (CH3),	  49.0,	  53.7	  (br.,	  cyclen	  CH2),	  
55.9,	  56.7	  (CH2CO),	  82.1	  (CCH3),	  122.7	  (q,	  2JCF=	  30	  Hz,	  Cb),	  123.8	  (q,	  1JCF=	  274	  Hz,	  CF3),	  
126.1	  (Cf),	  126.4	  (q,	  3JCF=	  5	  Hz,	  Cc),	  129.4	  (Cd),	  132.4	  (Ce),	  135.6	  (Ca),	  172.3	  (CO),	  172.8	  
(CO),	  173.1	  (CO);	  19F	  NMR	  (188	  MHz,	  CDCl3)	  δ	  -­‐60.80	  (CF3);	  ESI/MS+	  m/z	  716.3	  [M	  +	  













Trifluoroacetic	   acid	   (3	   mL)	   was	   added	   to	   a	   solution	   of	   {4,7-­‐bis-­‐tert-­‐
butoxycarbonylmethyl-­‐10-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐1,4,7,10	  
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	  tert-­‐butyl	  ester	  (0.23	  g,	  0.32	  mmol)	  in	  CH2Cl2	  (5	  
mL).	   The	   solution	   was	   stirred	   at	   room	   temperature	   for	   2	   hours.	   The	   solvent	   was	  
removed	   under	   reduced	   pressure	   and	   the	   resulting	   solid	   repeatedly	   washed	   with	  
CH2Cl2	   (5	   x	   5	  mL),	   yielding	   the	   product	   as	   a	   trifluoroacetate	   salt.	   The	   residue	  was	  
dissolved	  in	  H2O	  (5	  mL)	  and	  left	  to	  stir	  for	  2	  hours	  with	  anion	  exchange	  resin	  (DOWEX	  
1X8	  200-­‐400	  MESH	  Cl,	  pre-­‐treated	  with	  1M	  HCl)	  in	  H2O	  to	  give	  the	  chloride	  salt.	  The	  
resin	  was	  filtered	  and	  the	  solvent	  removed	  under	  reduced	  pressure	  to	  yield	  the	  title	  
compound	  as	  a	  light	  yellow	  oil	  (0.13	  g,	  74	  %);	  1H	  NMR	  (400	  MHz,	  D2O)	  δ	  3.09-­‐	  3.60	  
(16H,	  br.,	  CH2	  ring),	  3.92	  (2H,	  br.,	  CH2CO),	  7.25-­‐	  7.94	  (4H,	  br.	  m,	  Ar);	   19F	  NMR	  (188	  
MHz,	  CDCl3)	  δ	  -­‐62.31	  (CF3);	  MS	  (ES+)	  m/z	  570.4	  [M	  +	  Na]+.	  
	  



















tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (45.8	  mg,	   83.6	   µmol)	  was	   dissolved	   in	  H2O	   (3	  




mL)	   and	   the	   pH	   adjusted	   to	   ~6.	   	   TbIIICl3	   (26.6	   mg,	   0.10	   mmol)	   was	   added	   to	   the	  
solution,	  which	  was	  subsequently	  left	  to	  boil	  under	  reflux	  for	  3	  h.	  Once	  cooled,	  the	  
solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  complex	  purified	  by	  alumina	  
chromatography,	   eluting	   with	   a	   gradient	   starting	   from	   5%	  MeOH/	   CH2Cl2	   to	   20%	  
MeOH/	  CH2Cl2	  (36.4	  mg,	  62	  %);	  1H	  NMR	  (200	  MHZ,	  D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐
405.23	   to	   	  263.19.	  Selected	  peaks	  at:	   -­‐405.23,	   -­‐401.36,	   -­‐371.42,	   -­‐356.98,	   -­‐151.46,	   -­‐
132.09,	   -­‐108.12,	   -­‐100.04,	   -­‐83.45,	   -­‐42.78,	   82.33,	   118.32,	   126.59,	   140.23,	   223.78,	  
230.24,	   254.00,	   263.19;	   19F	   NMR	   (188	   MHz,	   D2O,	   pD	   5.4):	   δ	   -­‐51.94	   (CF3,	   major	  
species),	   -­‐60.18,	   -­‐44.912,	   -­‐39.78,	   -­‐36.68	   (CF3,	  minor	   species);	   	   ESI/MS+/-­‐	   m/z	   742.1	  
[M+K]+,	  702.2	   [M-­‐H]-­‐;	  MS	  Calcd	   for	  C23H28O7N5F3159Tb	  702.1198.	  Found	  702.1189;	   τ	  
(H2O)	  1.76	  ms,	  τ	  (D2O)	  2.76	  ms;	  q=	  0.75;	  HPLC:	  tR	  =	  5.8	  min.	  
	  
18.	  [Ho.L3(H2O)]	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  	  was	  followed	  using	  {4,7-­‐
bis-­‐carboxymethyl-­‐10-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐
1,4,7,10tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (15.2	   mg,	   27.7	   µmol)	   and	   HoIII(OAc)3	  
(11.4	  mg,	  33.3	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (12.4	  mg,	  63	  %);	  1H	  
NMR	  (200MHz,	  D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐93.47	  to	  92.51.	  Selected	  peaks	  at:	  -­‐
93.47,	   -­‐79.34,	   -­‐69.09,	   -­‐58.23,	   -­‐47.42,	   -­‐36.03,	   -­‐32.12,	   14.86,	   18.69,	   23.04,	   28.93,	  
44.19,	   55.31,	   86.32,	   92.51;	   19F	   NMR	   (376	  MHz,	   D2O,	   pD	   5.4)	   δ	   -­‐64.24	   (CF3,	  major	  
species),	   -­‐62.72,	   -­‐62.13,	   -­‐60.45,	   -­‐57.90,	   -­‐56.21,	   -­‐54.20,	   -­‐50.84	   (CF3,	  minor	   species);	  	  
ESI/MS+/-­‐	   m/z	   732.1	   [M+Na]+,	   708.2	   [M-­‐H]-­‐;	   MS	   Calcd	   for	   C23H28O7N5F3165Ho	  
708.1250.	  Found	  708.1250.	  
 
19.	  [Gd.L3(H2O)]	  	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  {4,7-­‐
bis-­‐carboxymethyl-­‐10-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10-­‐
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	  (63.2	  mg,	  0.12	  mmol)	  and	  GdIII(OAc)3	  (46.3	  mg,	  
0.14	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (68.3	  mg,	  81	  %);	  19F	  NMR	  (376	  
MHz,	  D2O,	  pD	  5.4):	  δ	  -­‐62.82	  (CF3);	  ESI/MS+/-­‐	  m/z	  701.3	  [M-­‐H]-­‐,	  725.2	  [M+Na]+,	  741.2	  
[M+K]+;	  MS	  Calcd	  for	  C23H28O7N5F3155Gd	  698.1172.	  Found	  698.1162;	  r1p	  =	  5.5	  mM-­‐1s-­‐1	  
(20	  MHz,	  298	  K).	  




20.	  [Er.L3(H2O)]	  	  	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  {4,7-­‐
bis-­‐carboxymethyl-­‐10-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10-­‐
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	  (38.7	  mg,	  70.1	  µmol)	  and	  ErIIICl3	  (23.2	  mg,	  84.8	  
µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (35.4	  mg,	  71	  %);	  1H	  NMR	  (500	  MHz,	  
D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐101.68	  to	  164.03.	  Selected	  peaks	  at:	  	  -­‐101.68,	  -­‐89.93,	  
-­‐84.39,	   -­‐80.42,	   -­‐71.36,	   -­‐66.49,	   -­‐57.56,	   -­‐56.00,	   -­‐38.10,	   -­‐32.14,	   -­‐29.47,	   14.61,	   15.95,	  
18.69,	  21.86,	  33.45,	  128.93,	  136.42,	  153.89,	  164.03;	  19F	  NMR	  (188	  MHz,	  D2O,	  pD	  5.4)	  
δ	   -­‐64.65	   (CF3,	  major	   species),	   -­‐76.21,	   -­‐70.45,	   -­‐69.23,	   -­‐62.72,	   -­‐61.78,	   -­‐58.30,	   -­‐54.81	  
(CF3,	   minor	   species);	   ESI/MS+/-­‐	   m/z	   709.3	   [M-­‐H]-­‐,	   751.2	   [M+K]+;	   MS	   Calcd	   for	  
C23H28O7N5166ErF3	  709.1249.	  Found	  709.1240.	  
 
21.	  [Tm.L3(H2O)]	  	  	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  	  	  was	  followed	  using	  {4,7-­‐
bis-­‐carboxymethyl-­‐10-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10-­‐
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	  (26.0	  mg,	  47.5	  µmol)	  and	  TmIII(OAc)3	  (19.7	  mg,	  
56.9	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (19.3	  mg,	  57	  %);	  	  1H	  NMR	  (500	  
MHz,	  D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐246.31	  to	  380.04.	  Selected	  peaks	  at:	  -­‐246.31,	  -­‐
215.46,	   -­‐208.69,	   -­‐150.69,	   -­‐142.56,	   -­‐119.56,	   -­‐92.58,	   -­‐80.45,	   -­‐71.87,	   -­‐25.31,	   18.91,	  
24.58,	  35.89,	  40.01,	  45.69,	  79.35,	  320.56,	  340.23,	  380.04;	  19F	  NMR	  (188	  MHz,	  D2O,	  
pD	  5.4)	  δ	   -­‐75.91	   (CF3,	  major	  species),	   -­‐88.11,	   -­‐87.34,	   -­‐	  80.77,	   -­‐77.39,	   -­‐66.82,	   -­‐49.54	  
(CF3,	   minor	   species);	   ESI/MS+/-­‐	   m/z	   736.2	   [M+Na]+,	   712.2	   [M-­‐H]-­‐;	   MS	   Calcd	   for	  
C23H28O7N5F3169Tm	  712.1289.	  Found	  712.1278.	  
 
22.	  [Y.L3(H2O)]	  	  	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  {4,7-­‐
bis-­‐carboxymethyl-­‐10-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10-­‐
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (12.3	  mg,	   22.4	   µmol)	   and	   YIIICl3	   (5.3	  mg,	   26.9	  
µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (9.1	  mg,	  64	  %);	  19F	  NMR	  (188	  MHz,	  
D2O,	  pD	  5.4)	  δ	  	  -­‐61.98	  (CF3);	  ESI/MS+/-­‐	  m/z	  656.2	  [M+Na]+,	  632.2	  [M-­‐H]-­‐;	  MS	  Calcd	  for	  








23.	  1,5-­‐Dimethyl	  (2S)-­‐2-­‐brompentanedioate	  
	  
 
A	  solution	  of	  sodium	  nitrite	  (5.50	  g,	  80.1	  mmol)	  dissolved	  in	  H2O	  (50mL)	  was	  added	  
dropwise	  to	  a	  stirred	  solution	  of	  sodium	  bromide	  (16.0	  g,	  156	  mmol)	  and	  L-­‐glutaric	  
acid	  5	  methyl	  ester	  (6.41	  g,	  39.8	  mmol)	  in	  1M	  HBr	  (250mL),	  cooled	  at	  -­‐5oC.	  After	  18	  
h,	   conc.	   H2SO4	   (1mL)	   was	   added	   dropwise	   to	   the	   reaction	   mixture,	   which	   was	  
subsequently	   extracted	   with	   diethyl	   ether	   (2	   x	   250	   mL).	   The	   combined	   organic	  
extracts	  were	  washed	  with	  brine	   (2	  x	  200	  mL),	  dried	  over	  MgSO4,	   filtered,	  and	  the	  
solvent	   removed	   under	   reduced	   pressure.	   The	   crude	   material	   was	   dissolved	   in	  
anhydrous	  CH3OH	  to	  which	  conc.	  H2SO4	  (0.5	  mL)	  was	  added.	  The	  solution	  was	  left	  to	  
stir	   at	   50oC	   under	   argon	   for	   4	   h.	   Once	   cooled,	   the	   solvent	   was	   removed	   under	  
reduced	   pressure	   and	   the	   crude	   material	   purified	   by	   silica	   gel	   column	  
chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100	  %	  toluene	  to	  15	  %	  CH2Cl2	  
/	   toluene	   to	   yield	   the	   title	   compound	  as	   a	   colourless	   viscous	  oil	   (5.89	   g,	   62	  %);	   1H	  
NMR	  (400	  MHz,	  CDCl3)	  δ	  2.26	  (1H,	  m,	  CH2CHBr),	  2.36	  (1H,	  m,	  CH2CHBr),	  2.50	  (2H,	  m,	  
CH2CH2CHBr),	   3.67	   (3H,	   s,	   CH3),	   3.76	   (3H,	   s,	   CH3),	   4.36	   (1H,	   dd,	  =	   9,	   1	  Hz,	   CH);	   13C	  
NMR	  (126	  MHz,	  CDCl3)	  δ	  29.7	  (CH2CH2CHBr),	  31.2	  (CH2CHBr),	  44.5	  (CH),	  51.8	  (CH3),	  
53.0	   (CH3),	   169.8	   (C=O),	   172.4	   (C=O);	   	   ESI/MS+	   m/z	   239.0	   [M+H]+;	   MS	   Calcd	   for	  







2-­‐Chloro-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	  (0.20	  g,	  0.84	  mmol)	  was	  added	  to	  a	  
stirred	  solution	  of	  1,4,7,10	  –	  tetraazacyclododecane	  (1.45	  g,	  8.43	  mmol)	  and	  K2CO3	  	  
(0.12	  g,	  0.84	  mmol)	  in	  anhydrous	  CH3CN	  (10mL)	  at	  55oC	  under	  argon.	  After	  16	  h,	  the	  




solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  residue	  dissolved	  in	  CH2Cl2	  (20	  
mL).	  The	  solution	  was	  washed	  repeatedly	  with	  H2O	  (4	  x	  20	  mL),	  dried	  over	  MgSO4,	  
and	   the	   solvent	   removed	  under	   reduced	  pressure	   to	  yield	   the	   title	   compound	   as	  a	  
light	  yellow	  solid	  (0.12	  g,	  38	  %);	  m.p.	  123-­‐	  125oC;	  1H	  NMR	  (700	  MHz,	  CDCl3)	  	  δ	  2.62	  –	  
2.77	  (18	  H,	  br.	  m.,	  CH2	  ring	  and	  CH2O),	  7.22	  (1H,	  t,	  J=	  8	  Hz,	  Hd),	  7.51	  (1H,	  t,	  J=	  8	  Hz,	  
He),	  7.58	  (1H,	  d,	  J=	  8	  Hz,	  Hc),	  7.98	  (1H,	  d,	  J=	  8	  Hz,	  Hf),	  9.51	  (1H,	  s,	  NH);	  13C	  NMR	  (176	  
MHz,	   CDCl3)	   δ	   45.9,	   46.5,	   47.4	   (CH2	   ring),	   60.9	   (CH2CO),	   122.0	   (q,	   2JCF=	   30	  Hz,	   Cb),	  
124.2	  (q,	  1JCF=	  273	  Hz,	  CF3),	  125.3	  (Cf),	  126.4	  (Cd),	  126.5	  (q,	  3JCF=	  5	  Hz,	  Cc),	  132.9	  (Ce),	  
135.3	  (Ca),	  170.5	  (C=O);	  19F	  NMR	  (188	  MHz,	  CDCl3)	  δ	  -­‐60.72	  (CF3);	  ESI/MS+	  m/z	  374.3	  





























1,5-­‐Dimethyl	  (2S)-­‐2-­‐bromopentanedioate	  (0.26	  g,	  1.11	  mmol)	  was	  added	  to	  a	  stirred	  
solution	  of	  2-­‐(1,4,7,10-­‐tetraazacyclododecane-­‐1-­‐yl)-­‐N-­‐[2-­‐trifluoromethyl)phenyl]	  
acetamide	  (0.10	  g	  ,	  0.28	  mmol)	  and	  K2CO3	  (0.15	  g,	  1.11	  mmol)	  in	  anhydrous	  CH3CN	  
(30	  mL)	   at	   85oC	   under	   argon.	   The	  mixture	   was	   left	   to	   boil	   under	   reflux	   for	   15	   h,	  
yielding	  an	  orange	  solution	  and	  white	  precipitate.	  The	  precipitate	  was	   removed	  by	  
filtration	  and	  the	  residue	  washed	  with	  CH2Cl2	   (2	  x	  30ml).	  The	  solvent	  was	  removed	  
under	   reduced	   pressure	   and	   the	   resulting	   oil	   purified	   by	   silica	   gel	   column	  
chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  2	  %	  CH3OH	  /	  
CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  colourless	  viscous	  oil	  (0.19	  g,	  	  82	  %);	  1H	  NMR	  
(400	  MHz,	  CDCl3)	  δ	  1.78	  (6H,	  m,	  CHCH2),	  2.01	  (6H,	  m,	  CHCH2CH2),	  2.44	  (6H,	  m,	  CH2	  




ring),	  2.53	  –	  2.68	  (6H,	  br.	  m,	  CH2	  ring),	  2.75	  –	  2.98	  (4H,	  br.	  m,	  CH2	  ring),	  3.07	  (2H,	  m,	  
CH2CO),	  3.32	  (1H,	  s,	  CH),	  3.36	  (2H,	  s,	  CH),	  3.64	  (6H,	  s,	  CH3),	  3.66	  (12H,	  s,	  CH3),	  	  7.21	  
(1H,	  t,	  J	  =	  8	  Hz,	  Hd),	  7.54	  (1H,	  t,	  J	  =	  8	  Hz,	  He),	  7.60	  (1H,	  d,	  J=	  8	  Hz,	  Hc),	  8.14	  (1H,	  d,	  J=	  8	  
Hz,	  Hf),	  9.69	  (1H,	  s,	  NH);	  13C	  NMR	  (106	  MHz,	  CDCl3)	  δ	  24.8,	  25.0	  (CHCH2),	  30.6,	  30.8	  
(CHCH2CH2),	   50.0,	   50.2	   (CH3),	   51.0,	   51.5,	   51.8,	   52.8,	   	   (br.,	   CH2	   ring)	   61.3	   (CH2CO),	  
62.0,	  62.6	   (CH),	   121.3	   (q,	   2JCF	   =	  30	  Hz,	  Cb),	   124.2	   (q,	   1JCF	   =	  273	  Hz,	  CF3),	   124.5	   (Cf),	  
126.9	   (Cd),	   127.0	   (q,	   3JCF	   =	   5	   Hz,	   Cc),	   134.6	   (Ce),	   138.2	   (Ca),	   168.6	   (CONH),	   174.3	  
(COCH3);	   19F	  NMR	   (376	  MHz,	  CDCl3)	   δ	   -­‐60.87	   (CF3);	   ESI/MS+	  m/z	  848.8	   [M+H]+;	  MS	  




























Freshly	  made	  aqueous	  KOD	  solution	  (1.0	  mL,	  0.1	  M)	  was	  added	  to	  1,5-­‐dimethyl	  (2R)-­‐
2-­‐{4,7-­‐bis[(2R)-­‐1,5-­‐dioxopentan-­‐2-­‐yl]-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]carbomyl}	  
methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl}pentanedioate	  (0.15	  g,	  0.18	  mmol).	  The	  
reaction	  was	  kept	  under	  argon	  at	  40oC	  and	  monitored	  by	  1H	  NMR.	  After	  5	  h,	  no	  ester	  
methyl	  groups	  were	  observed	  in	  the	  1H	  NMR	  spectrum.	  The	  pH	  of	  the	  mixture	  was	  
increased	  to	  ~6	  and	  the	  solution	  loaded	  onto	  a	  DOWEX	  strong	  cation	  exchange	  resin.	  
The	  column	  was	  eluted	  with	  100%	  water	  to	  10%	  NH4OH	  and	  fractions	  were	  analysed	  
by	  ESMS+.	  The	  fractions	  were	  combined	  and	  lyphilised	  to	  yield	  the	  title	  compound	  as	  
a	  pale	  yellow	  oil	  (0.11	  g,	  77	  %);	  1H	  NMR	  (400	  MHz,	  D2O)	  δ	  1.83	  (6H,	  m,	  CHCH2),	  2.12	  
(6H,	  m,	   CHCH2CH2),	   2.40-­‐	   2.73	   (12H,	   br.	  m,	   CH2	   ring),	   2.80	   –	   3.04	   (4H,	   br.	  m,	   CH2	  
ring),	  3.12	  (2H,	  br.,	  CH2CO),	  3.38	  (3H,	  s,	  CH),	  7.18	  (1H,	  t,	  J	  =	  8	  Hz,	  Hd),	  7.49	  (1H,	  t,	  J	  =	  8	  




Hz,	  He),	  7.66	  (1H,	  d,	   J=	  8	  Hz,	  Hc),	  8.18	  (1H,	  d,	   J=	  8	  Hz,	  Hf),	  10.04	  (1H,	  br.	  s,	  NH);	   19F	  

























tetraazacyclododecan-­‐1-­‐yl}pentanedioic	  acid	   (23.1	  mg,	  28.7	  µmol)	  was	  dissolved	   in	  
H2O	  (3	  mL)	  and	  the	  pH	  adjusted	  to	  ~6.	  TbIII(OAc)3	  (11.6	  mg,	  34.4	  µmol)	  was	  added	  to	  
the	  solution,	  which	  was	  subsequently	  left	  to	  boil	  under	  reflux	  for	  3	  h.	  Once	  cooled,	  
the	  pH	  of	  the	  solution	  was	  increased	  to	  ~9.5	  resulting	  in	  a	  clear	  solution	  and	  white	  
precipitate.	  The	  precipitate	  was	  removed	  by	  centrifugation.	  The	  crude	  product	  was	  
purified	  using	  benzoylated	  dialysis	  tubing	  (9	  mm	  flat	  width,	  MWCO	  500)	  to	  yield	  the	  
title	  complex	  as	   its	  sodium	  salt	   (17.7	  mg,	  63	  %);	  1H	  NMR	  (200	  MHZ,	  D2O,	  pD	  =	  5.4)	  
Peaks	  range	  from	  -­‐90.63	  to	  	  120.15.	  Selected	  peaks	  at:	  -­‐90.63,	  -­‐56.93,	  -­‐48.91,	  -­‐35.62,	  
-­‐30.26,	  -­‐29.35,	  -­‐18.04,	  23.74,	  26.98,	  28.00,	  82.56,	  84.03,	  94.20,	  120.15;	  19F	  NMR	  (376	  
MHz,	  D2O,	  pD	  5.4)	  δ	  –59.1	  (CF3,	  major	  species),	  -­‐67.59,	  -­‐60.47,	  -­‐56.76,	  -­‐51.86,	  -­‐51.69,	  
-­‐45.36,	   -­‐42.09	   (CF3,	  minor	   species);	   ESI/MS+	  m/z	  958.1	   [M+Na]+;	   τ	   (H2O)	  1.69	  ms,	   τ	  
(D2O)	  2.86	  ms;	  q=	  0.90;	  HPLC:	  tR	  =7.1	  min.	  
	  
28.	  [Gd.L4(H2O)]3-­‐	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  (2R)-­‐
2-­‐{4-­‐[(2R)-­‐1-­‐carboxy-­‐5-­‐methoxy-­‐1,5-­‐dioxopentan-­‐2-­‐yl]-­‐10-­‐[(1R)-­‐1,3dicarboxypropyl]-­‐
7-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐
yl}pentanedioic	   acid	   (26.3	  mg,	   32.6	   µmol)	   and	   GdIII(OAc)3	   (13.1	  mg,	   39.2	   µmol)	   to	  




yield	  the	  title	  complex	  as	  a	  white	  solid	  (26.8	  mg,	  84	  %);	  19F	  NMR	  (376	  MHz,	  D2O,	  pD	  
5.4)	  δ	  –60.96	  (CF3);	  	  ESI/MS+	  m/z	  972.1	  [M+K]+;	  r1p	  =	  	  5.92	  mM-­‐1s-­‐1	  (60	  MHz,	  310	  K).	  
	  
29.	  [Er.L4(H2O)]3-­‐	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  (2R)-­‐
2-­‐{4-­‐[(2R)-­‐1-­‐carboxy-­‐5-­‐methoxy-­‐1,5-­‐dioxopentan-­‐2-­‐yl]-­‐10-­‐[(1R)-­‐1,3dicarboxypropyl]-­‐
7-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐
yl}pentanedioic	  acid	  (15.9	  mg,	  19.7	  µmol)	  and	  GdIII(OAc)3	  (8.2	  mg,	  23.7	  µmol)	  to	  yield	  
the	  title	  complex	  as	  a	  white	  solid	  (14.8	  mg,	  76	  %);	  1H	  NMR	  (200	  MHZ,	  D2O,	  pD	  =	  5.4)	  
Peaks	  range	  from	  -­‐62.03	  to	  	  83.71.	  Selected	  peaks	  at:	  -­‐62.03,	  -­‐48.36,	  -­‐47.03,	  -­‐52.10,	  -­‐
22.96,	  19.04,	  22.14,	  36.80,	  48.02,	  83.71;	  19F	  NMR	  (376	  MHz,	  D2O,	  pD	  5.4)	  δ	  –63.50	  
(CF3,	  major	  species),	  -­‐64.82,	  -­‐62.90,	  -­‐58.32;	  ESI/MS+	  m/z	  943.8	  [M+H]+.	  
	  
30.	  [Tm.L4(H2O)]3-­‐	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  (2R)-­‐
2-­‐{4-­‐[(2R)-­‐1-­‐carboxy-­‐5-­‐methoxy-­‐1,5-­‐dioxopentan-­‐2-­‐yl]-­‐10-­‐[(1R)-­‐1,3dicarboxypropyl]-­‐
7-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐
yl}pentanedioic	  acid	  (18.2	  mg,	  22.6	  µmol)	  and	  TmIII(OAc)3	  (9.4	  mg,	  27.1	  µmol)	  to	  yield	  
the	  title	  complex	  as	  a	  white	  solid	  (18.1	  mg,	  81	  %);	  1H	  NMR	  (200	  MHZ,	  D2O,	  pD	  =	  5.4)	  
Peaks	   range	   from	   -­‐128.09	   to	   	   150.85.	   Selected	   peaks	   at:	   -­‐128.09,	   -­‐99.30,	   -­‐68.20,	   -­‐
52.90,	   -­‐48.78,	   -­‐	   24.71,	   22.14,	   36.99,	   50.03,	   89.04,	   90.52,	   109.70,	   150.85;	   19F	   NMR	  
(376	  MHz,	  D2O,	  pD	  5.4)	  δ	  –73.9	  (CF3,	  major	  species),	  -­‐70.69,	  -­‐68.32,	  -­‐67.51;	  ESI/MS+	  





















2-­‐(1,4,7,10-­‐Tetraaza-­‐cyclododec-­‐1-­‐yl)-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	   (0.72	  
g,	   1.93	   mmol)	   was	   heated	   to	   80oC	   in	   anhydrous	   tetrahydrofuran	   under	   argon.	  
Paraformaldehyde	  (0.26	  g,	  8.67	  mmol)	   followed	  by	  diethoxymethylphosphine	   (1.18	  
g,	  8.67	  mmol)	  were	  added.	  The	  solution	  was	  boiled	  at	  reflux	  over	  molecular	  sieves.	  
After	  15	  h,	  the	  excess	  paraformaldehyde	  was	  removed	  by	  filtration	  and	  the	  solvent	  
removed	  under	  reduced	  pressure.	  The	  resulting	  orange	  oil	  was	  purified	  by	  alumina	  
gel	  column	  chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  1.7	  
%	  CH3OH	  /	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  pale	  yellow	  oil	  (0.96	  g,	  68	  %);	  1H	  
NMR	  (400	  MHz,	  CDCl3)	  	  δ	  1.15	  (9H,	  m,	  CH3),	  	  1.36	  (9H,	  m,	  CH3),	  2.41-­‐3.98	  (22H,	  br.	  m,	  
CH2	  ring	  and	  CH2P),	  3.16	  (2H,	  s,	  CH2CO),	  3.91	  (6H,	  m,	  CH2CH3),	  7.07	  (1H,	  t,	   J=	  7	  Hz,	  
Hd),	  7.41	  (1H,	  t,	  J=	  8	  Hz,	  He),	  7.46	  (1H,	  d,	  J	  =	  8	  Hz,	  Hc),	  8.11	  (1H,	  d,	  J=7	  Hz,	  Hf),	  9.61	  
(1H,	  s,	  NH);	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  13.4	  (d,	  1JCP=	  90	  Hz,	  PCH3),	  16.95	  (CH3),	  53.4	  
(d,	   3JCP	   =	   84	   Hz,	   CH2P),	   54.5,	   54.6,	   55.2	   	   (br.,	   CH2	   ring),	   60.5	   (CH2CO),	   62.1	   (br.,	  
CH2CH3)	  121.0	  (q,	  2JCF=	  30	  Hz,	  Cb),	  124.2	  (q,	  1JCF=	  273	  Hz,	  CF3),	  125.4	  (Cf),	  126.4	  (Cd),	  
127.6	   (q,	   3JCF	   =	   5	   Hz,	   Cc),	   	   133.2	   (Ce),	   135.8	   (Ca),	   169.3	   (C=O);	   31P	  NMR	   (162	  MHz,	  
CDCl3)	  	  δ	  52.33	  (1P,	  s,	  PCH3),	  52.47	  (2P,	  s,	  PCH3);	  19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	  -­‐60.98	  
(CF3),	   -­‐60.94	   (CF3);	   	   ESI/MS+	   m/z	   734.3	   [M	   +	   H]+,	   756.3	   [M+Na]+;	   MS	   Calcd	   for	  















Freshly	   prepared	   aqueous	   KOD	   solution	   (5	   mL,	   0.1	   M)	   was	   added	   to	   ethyl	   [(4,7-­‐
di{[ethoxy(methyl)phoshoryl]methyl}-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}	  
methyl)-­‐1,4,7,10-­‐tetraazacyclodecan-­‐1-­‐yl)methyl](methyl)phosphinate	   (61.0	   mg,	  
83.2	   µmol).	   The	   solution	   was	   left	   to	   stir	   at	   40oC	   under	   argon	   and	   the	   reaction	  
monitored	  by	  1H	  and	  31P	  NMR.	  After	  6	  h,	  the	  pH	  of	  the	  solution	  was	  lowered	  to	  ~6	  by	  
the	   addition	   of	   HCl.	   The	   solvent	   was	   removed	   under	   reduced	   pressure	   and	   the	  
residue	  washed	  repeatedly	  with	  CH2Cl2	  (3	  x	  5	  mL).	  The	  resulting	  oil	  was	  dissolved	  in	  
ethanol.	   The	  white	  precipitate	  was	   removed	  by	   filtration	  and	   the	   solvent	   removed	  
under	  reduced	  pressure	  to	  yield	  the	  title	  compound	  as	  a	  pale	  yellow	  oil	  (40.9	  mg,	  74	  
%);	   1H	  NMR	   (400	  MHz,	   D2O)	   δ	   1.12	   (9H,	   d,	   J=13	  Hz,	   PCH3),	   2.56-­‐3.83	   (22H,	   br.	  m,	  
cyclen	  CH2	  and	  CH2P),	  3.20	   (2H,	   s,	  CH2CO),	  7.14	   (1H,	  m,	  Ar),	  7.24	   (1H,	  m,	  Ar),	  7.48	  
(1H,	  m,	  Ar),	  7.60	  (1H,	  br.	  ,	  Ar),	  9.50	  (1H,	  s,	  NH);	  31P	  NMR	  (162	  MHz,	  D2O)	  δ	  40.62	  (3P,	  





















An	   analogous	   procedure	   to	   that	   described	   for	   [Tb.L3(H2O)]	   	   	   was	   followed	   using	  
[(4,7,-­‐di{[hydroxyl(methyl)phosphoryl]methyl}-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]	  
carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	  
acid	  (0.10	  g,	  0.15	  mmol)	  and	  TbIII(OAc)3	  (0.06	  	  g,	  0.18	  mmol)	  to	  yield	  the	  title	  complex	  
as	  a	  white	  solid	  (0.10	  g,	  85	  %);	  1H	  NMR	  (500	  MHZ,	  D2O,	  pD=	  	  5.4)	  Peaks	  range	  from	  -­‐
418.56	   to	   480.02.	   Selected	   peaks	   at	   :	   -­‐418.56,	   -­‐351.48,	   225.61,	   -­‐161.08,	   -­‐158.47,	   -­‐
136.41,	   184.07,	   -­‐174.08,	   81.32,	   115.96,	   110.41,	   138.07,	   156.71,	   283.67,	   383.43,	  
480.02;	  19F	  NMR	  (188	  MHz,	  D2O)	  δ	  –	  45.89	  (CF3);	  ESI/MS+/-­‐	  m/z	  828.2	  [M+Na]+,	  804.2	  
[M-­‐H]-­‐;	  MS	   Calcd	   for	   C23H37O7N5F3P3159Tb	   804.1111.	   Found	   804.1110;	   τ	   (H2O)	   3.13	  




An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  [(4,7,-­‐
di{[hydroxyl(methyl)phosphoryl]methyl}-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}	  
methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	   acid	   (0.10	   g,	  
0.15	  mmol)	  and	  DyIII(OAc)3	  (0.06	  g,	  0.18	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  
solid	  (0.10	  g,	  81	  %);	  1H	  NMR	  (500	  MHZ,	  D2O,	  pD	  =	  5.4)	  Peaks	  range	  from	  -­‐268.12	  to	  
183.70.	  Selected	  peaks	  at	  :	  -­‐268.12,	  -­‐212.04,	  -­‐187.35,	  -­‐147.96,	  -­‐83.45,	  -­‐49.03,	  -­‐35.01,	  
-­‐19.63,	   40.07,	   81.09,	   99.68,	   116.43,	   174.51,	   183.70;	   19F	   NMR	   (188	  MHz,	   D2O)	   δ	   –











An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  [(4,7,-­‐
di{[hydroxyl(methyl)phosphoryl]methyl}-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}	  
methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	   acid	   (0.10	   g,	  
0.15	  mmol)	  and	  HoIII(OAc)3	  (0.06	  	  g,	  0.18	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  
solid	  (0.09	  g,	  71	  %);	  1H	  NMR	  (500	  MHZ,	  D2O,	  pD	  =	  5.4)	  Peaks	  range	  from	  -­‐200.32	  to	  
204.60.	  Selected	  peaks	  at	  :	  -­‐200.32,	  -­‐162.54,	  -­‐136.20,	  -­‐117.74,	  -­‐90.83,	  -­‐52.19,	  50.13,	  
57.32,	  78.48,	  99.60,	  153.65,	  200.32;	  19F	  NMR	  (188	  MHz,	  D2O)	  δ	  -­‐61.20	  (CF3);	  ESI/MS+/-­‐	  




An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  [(4,7,-­‐
di{[hydroxyl(methyl)phosphoryl]methyl}-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}	  
methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	   acid	   (0.10	   g,	  
0.15	  mmol)	  and	  ErIII(OAc)3	  (0.06	  	  g,	  0.18	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  
solid	  (0.06	  g,	  49	  %);	  1H	  NMR	  (500	  MHZ,	  D2O,	  pD=	  5.4)	  Peaks	  range	  from	  -­‐168.09	  to	  
180.65.	  Selected	  peaks	  at	  :	  -­‐168.09,	  -­‐140.26,	  -­‐132.82,	  -­‐107.81,	  -­‐60.5,	  -­‐45.09,	  -­‐20.47,	  
32.17,	   45.78,	   58.92,	   74.18,	   107.45,	   112.95,	   140.85,	   172.65,	   180.65;	   19F	   NMR	   (188	  
MHz,	  D2O)	  δ	   -­‐72.78	   (CF3);	   ESI/MS+	  m/z	  815.1	   [M+H]+,	  837.1	   [M+Na]+;	  MS	  Calcd	   for	  
C23H39O7N5F3P3168Er	  815.1445.	  Found	  815.1395.	  
	  
37.	  [Tm.L5]	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  [(4,7,-­‐
di{[hydroxyl(methyl)phosphoryl]methyl}-­‐10-­‐({[2-­‐(trifluoromethyl)phenyl]carbamoyl}	  
methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	   acid	   (0.10	   g,	  
0.15	  mmol)	  and	  TmIII(OAc)3	  (0.06	  g,	  0.18	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  
solid	  (0.11	  g,	  89	  %);	  1H	  NMR	  (500	  MHZ,	  D2O,	  pD=	  5.4)	  Peaks	  range	  from	  -­‐361.35	  to	  
169.39.	   Selected	   peaks	   at	   :	   -­‐361.35,	   -­‐340.68,	   -­‐270.63,	   -­‐230.49,	   -­‐199.76,	   -­‐177.18,	   -­‐
161.41,	   -­‐93.79,	   -­‐64.16,	   -­‐40.56,	   20.64,	   30.09,	   40.49,	   44.42,	   59.16,	   93.32,	   128.51,	  
145.28,	  157.04,	  169.39;	   19F	  NMR	  (188	  MHz,	  D2O)	  δ	   -­‐90.59	  (CF3);	  ESI/MS+	  m/z	  816.1	  
[M+H]+;	  MS	  Calcd	  for	  C23H39O7N5F3P3169Tm	  816.1357.	  Found	  816.1348.	  
	  
	  








3-­‐(Trifluoromethyl)aniline	   (2.01	   	   g,	   12.4	   mmol)	   and	   crotonaldehyde	   (0.87	   g,	   12.4	  
mmol)	   were	   dissolved	   in	   concentrated	   HCl	   (6	  mL)	   and	   the	   solution	  was	   stirred	   at	  
90oC.	  After	  18	  h,	   the	  solution	  was	  neutralised	  carefully	  with	  1	  M	  KOH,	  keeping	  the	  
temperature	  of	  the	  solution	  at	  0oC.	  The	  crude	  was	  extracted	  into	  CH2Cl2	  (2	  x	  10	  mL)	  
and	   washed	   repeatedly	   with	   H2O	   (3	   x	   10	   mL).	   The	   organic	   layer	   was	   dried	   over	  
MgSO4	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	   crude	   product	  was	  
purified	  by	  silica	  gel	  column	  chromatography,	  eluting	  with	  a	  gradient	  starting	   from	  
100%	  CH2Cl2	   	   to	   5	  %	   CH3OH/	   CH2Cl2	   to	   yield	   the	   title	   compound	   as	   a	   viscous	   dark	  
orange	  oil	  (1.10	  g,	  42	  %);	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  2.66	  (3H,	  CH3),	  7.26	  (1H,	  d,	  J	  =	  9	  
Hz,	  Hb),	  7.53	  (1H,	  d,	  J	  =	  8	  Hz,	  Hf),	  7.73	  (1H,	  d,	  J	  =	  8	  Hz,	  He),	  7.94	  (1H,	  d,	  J=	  9	  Hz,	  Hc),	  
8.23	   (1H,	   s,	   Hh);	   13C	   NMR	   (176	  MHz,	   CDCl3)	   δ	   22.6	   (CH3),	   121.5	   (q,	   3JCF=	   4	   Hz,	   Cf),	  
124.1	  (Cd),	  124.2	  (q,	  1JCF=	  273	  Hz,	  CF3),	  126.8	  (q,	  3JCF=	  4	  Hz,	  Ch),	  128.2	  (Cb),	  128.8	  (Cc),	  
131.3	  (q,	  2JCF=	  33	  Hz,	  Cg),	  136.1	  (Ce),	  147.1	  (Ci),	  160.9	  (Ca);	  19F	  NMR	  (188	  MHz,	  CDCl3)	  







N-­‐bromosuccinimide	   (0.42	   g,	   2.3	  mmol)	   and	  benzoyl	   peroxide	   (10.2	   g,	   0.41	  mmol)	  
were	  added	  to	  a	  solution	  of	  2-­‐methyl-­‐7-­‐(trifluoromethyl)quinoline	  (0.45	  g,	  2.1	  mmol)	  
in	   CCl4	   (18	  mL)	   at	   80oC	   under	   argon.	   After	   15	   h,	   the	   solvent	   was	   removed	   under	  
reduced	   pressure	   and	   the	   crude	   material	   was	   purified	   by	   silica	   gel	   column	  
chromatography,	   eluting	   with	   a	   gradient	   starting	   from	   100%	   hexane	   to	   2%	   ethyl	  




acetate/	  hexane	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (0.16	  g,	  21%);	  m.p.	  138-­‐
139oC;	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  6.80	  (1H,	  CH),	  7.76	  (1H,	  d,	  J	  =	  9	  Hz,	  Hb),	  7.97	  (1H,	  
d,	  J	  =	  9	  Hz,	  Hf),	  8.09	  (1H,	  d,	  J	  =	  9	  Hz,	  He),	  8.33	  (1H,	  d,	  J=	  9	  Hz,	  Hc),	  8.36	  (1H,	  s,Hh);	  13C	  
NMR	  (126	  MHz,	  CDCl3)	  δ	  51.2	  (CH),	  121.8	  (Cd),	  123.7	  (q,	  3JCF=	  4	  Hz,	  Cf),	  124.0	  (q,	  1JCF=	  
273	  Hz,	   CF3),	   127.7	   (q,	   3JCF=	   4	  Hz,	   Ch),	   128.9	   (Cb),	   129.0	   (Cc),	   132.4	   (q,	   2JCF=	   33	  Hz,	  
CCF3),	   138.3	   (Ce),	   145.1	   (Ci),	   160.0	   (Ca);	   19F	   NMR	   (188	  MHz,	   CDCl3)	   δ	   -­‐63.20	   (CF3);	  






2-­‐(Dibromomethyl)-­‐7-­‐(trifluoromethyl)quinoline	  (0.16	  g,	  0.44	  mmol)	  was	  added	  to	  a	  
mixture	   of	   diethylphosphite	   (0.18	   g,	   1.3	   mmol)	   and	   diisopropylamine	   (0.15	   g,	   1.5	  
mmol)	   in	  anhydrous	  THF	   (5	  mL)	  at	  0oC	  under	  argon.	  After	  48	  h,	   the	  crude	  mixture	  
was	  slowly	  poured	  into	  ice	  water	  (20	  mL)	  and	  then	  extracted	  into	  CH2Cl2	  (2	  x	  20	  mL).	  
The	   combined	   organic	   extracts	   were	   dried	   over	   MgSO4	   and	   the	   solvent	   removed	  
under	   reduced	   pressure.	   The	   crude	   material	   was	   purified	   by	   silica	   gel	   column	  
chromatography,	   eluting	   with	   a	   gradient	   starting	   from	   100%	   hexane	   to	   2%	   ethyl	  
acetate/	  hexane	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (0.11	  g,	  89	  %).	  
Procedure	  B:	  
N-­‐bromosuccinimide	  (0.42	  g,	  2.3	  mmol)	  and	  benzoyl	  peroxide	  (10.0	  mg,	  0.41	  mmol)	  
were	  added	  to	  a	  solution	  of	  2-­‐methyl-­‐7-­‐(trifluoromethyl)quinoline	  (0.45	  g,	  2.1	  mmol)	  
in	   CCl4	   (18	  mL)	   at	   80oC	   under	   argon.	   After	   15	   h,	   the	   solvent	   was	   removed	   under	  
reduced	   pressure	   and	   the	   crude	   material	   was	   purified	   by	   silica	   gel	   column	  
chromatography,	   eluting	   with	   a	   gradient	   starting	   from	   100%	   hexane	   to	   2%	   ethyl	  
acetate/	  hexane	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (0.25	  g,	  40	  %);	  	  1H	  NMR	  
(700	  MHz,	  CDCl3)	  δ	  4.70	  (2H,	  CH2),	  7.67	  (1H,	  d,	  J	  =	  8	  Hz,	  Hb),	  7.71	  (1H,	  d,	  J	  =	  8	  Hz,	  Hf),	  
7.92	  (1H,	  d,	  J	  =	  8	  Hz,	  He),	  8.21	  (1H,	  d,	  J=	  8	  Hz,	  Hc),	  8.38	  (1H,	  s,	  Hh);	  13C	  NMR	  (126	  MHz,	  
CDCl3)	  δ	  34.0	  (CH2),	  122.9	  (q,	  3JCF=	  4	  Hz,	  Cf),	  123.3	  (Cd),	  124.0	  (q,	  1JCF=	  273	  Hz,	  CF3),	  




127.40	  (q,	  3JCF=	  4	  Hz,	  Ch),	  128.9	  (Cb),	  129.1	  (Cc),	  131.9	  (q,	  2JCF=	  33	  Hz,	  Cg),	  137.3	  (Ce),	  
146.8	  (Ci),	  158.7	  (Ca);	  19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	  -­‐63.26	  (CF3);	  	   	  ESI/MS+	  m/z	  290.0	  






2-­‐(Bromomethyl)-­‐7-­‐(trifluoromethyl)quinoline	   (0.14	   g,	   0.48	  mmol)	   was	   added	   to	   a	  
stirred	   solution	   of	   cyclen	   (0.83	   g,	   4.8	   mmol)	   in	   anhydrous	   CH3CN	   at	   55oC	   under	  
argon.	   After	   3	   h,	   the	   solvent	   was	   removed	   under	   reduced	   pressure.	   The	   crude	  
residue	  was	  dissolved	  in	  CH2Cl2	  (20	  mL)	  and	  washed	  repeatedly	  with	  H2O	  (5	  x	  30	  mL).	  
The	   organic	   layer	  was	   dried	   over	  MgSO4	   and	   the	   solvent	   removed	   under	   reduced	  
pressure	   to	   yield	   the	   crude	   product.	   This	   was	   used	   without	   further	   purification.	  








2-­‐(1,4,7,10-­‐Tetraazacyclododecan-­‐1-­‐ylmethyl)-­‐7-­‐(trifluoromethyl)quinoline	   (0.54	   g,	  
1.41	  mmol)	  was	  heated	  to	  80oC	  in	  anhydrous	  tetrahydrofuran	  (10	  mL)	  under	  argon.	  
Paraformaldehyde	  (0.19	  g,	  6.35	  mmol)	   followed	  by	  diethoxymethylphosphine	   (0.85	  




g,	  6.35	  mmol)	  were	  added.	  The	  solution	  was	  boiled	  at	  reflux	  over	  molecular	  sieves.	  
After	  15	  h,	  the	  excess	  paraformaldehyde	  was	  removed	  by	  filtration	  and	  the	  solvent	  
removed	  under	  reduced	  pressure.	  The	  resulting	  orange	  oil	  was	  purified	  by	  alumina	  
gel	  column	  chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  0.9	  
%	  CH3OH	  /	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  pale	  yellow	  oil	  (0.12	  g);	  1H	  NMR	  
(400	  MHz,	  CDCl3)	  	  δ	  1.27	  (9H,	  m,	  CH3),	  	  1.43	  (9H,	  m,	  CH3),	  2.62-­‐	  3.18	  (22H,	  br.	  m,	  CH2	  
ring	  and	  CH2P),	  4.04	   (6H,	  m,	  CH2CH3),	  4.21	   (2H,	  CH2),	  7.72	   (2H,	  m,	  Hb	  and	  Hf),	  7.90	  
(1H,	  d,	  J	  =	  8	  Hz,	  He),	  8.19	  (1H,	  d,	  J	  =	  8	  Hz,	  Hc),	  8.32	  (1H,	  s,	  Hh);	  13C	  NMR	  (176	  MHz,	  
CDCl3)	  δ	  14.2	  (d,	  1JCP=	  86	  Hz,	  PCH3),	  16.9	  (CH3),	  52.9	  (d,	  3JCP	  =	  95	  Hz,	  CH2P),	  53.2,	  54.6,	  
54.8	   (br.,	  CH2	   ring),	  60.7	   (CH2CO),	  61.9	   (br.,	  CH2CH3)	  121.0	   (q,	   3JCF=	  4	  Hz,	  Cf),	  122.4	  
(Cd),	  123.6	  (q,	  1JCF=	  273	  Hz,	  CF3),	  127.0	  (q,	  3JCF=	  4	  Hz,	  Ch),	  128.2	  (Cb),	  129.1	  (Cc),	  131.6	  
(q,	   2JCF=	   33	  Hz,	   Cg),	   136.7	   (Ce),	   146.6	   (Ci),	   174.3	   (Ca);	   31P	  NMR	   (162	  MHz,	  CDCl3)	   	   δ	  
53.48	   (2P,	  s,	  PCH3),	  53.71	   (1P,	  s,	  PCH3);	   19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	   -­‐63.08	   (CF3),	   -­‐








Freshly	   prepared	   aqueous	   KOD	   solution	   (5	   mL,	   0.1	   M)	   was	   added	   to	   ethyl	   [(4,7-­‐
di{[ethoxy(methyl)phosphoryl]methyl}-­‐10-­‐{[7-­‐(trifluoromethyl)quinolin-­‐2-­‐yl]methyl}-­‐
1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinate	  (0.12	  g,	  0.16mmol).	  
The	  solution	  was	   left	  to	  stir	  at	  40oC	  under	  argon	  and	  the	  reaction	  monitored	  by	  1H	  
and	  31P	  NMR.	  After	  24	  h,	  the	  pH	  of	  the	  solution	  was	  lowered	  to	  ~6	  by	  addition	  of	  HCl.	  
The	   solvent	   was	   removed	   under	   reduced	   pressure	   and	   the	   residue	   washed	  




repeatedly	  with	   CH2Cl2	   (3	   x	   5	  mL).	   The	   resulting	   oil	   was	   dissolved	   in	   ethanol.	   The	  
white	  precipitate	  was	  removed	  by	  filtration	  and	  the	  solvent	  removed	  under	  reduced	  
pressure	  to	  yield	  the	  title	  compound	  as	  a	  colourless	  oil	  (87.2	  mg,	  82	  %);	  1H	  NMR	  (400	  
MHz,	  D2O)	  	  δ	  1.52	  (9H,	  m,	  CH3),	  2.42-­‐	  3.21	  (22H,	  br.	  m,	  CH2	  ring	  and	  CH2P),	  4.18	  (2H,	  
CH2),	  7.80	  (1H,	  d,	  J	  =	  8	  Hz,	  Ar),	  8.04	  (2H,	  m,	  Ar),	  8.19	  (1H,	  d,	  J	  =	  8	  Hz,	  Ar),	  8.20	  (1H,	  s,	  
Ar);	  31P	  NMR	  (162	  MHz,	  D2O)	  	  δ	  40.64	  (3P,	  s,	  PCH3);	   	  19F	  NMR	  (376	  MHz,	  D2O,	  pD	  =	  





An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  [(4,7-­‐
di{[hydroxy(methyl)phosphoryl]methyl}-­‐10-­‐{[7-­‐(trifluoromethyl)quinolin-­‐2-­‐
yl]methyl}-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	   acid	   (42	  
mg,	  63.8	  µmol)	  and	  TbIII(OAc)3	   (25.7	  mg,	  76.6	  µmol)	   to	  yield	   the	   title	   complex	   as	  a	  
white	  solid	   (43.7	  mg,	  81	  %);	   1H	  NMR	  (200	  MHZ,	  D2O,	  pD=	   	  5.4)	  Peaks	  range	  from	  -­‐
318.12	   to	  256.01.	  Selected	  peaks	  at	   :	   -­‐318.12,	   -­‐263.12,	   -­‐220.78,	   -­‐201.36,	   -­‐160.47,	   -­‐
102.41,	  -­‐98.04,	  -­‐60.12,	  -­‐40.32,	  56.41,	  104.32,	  112.56,	  170.89,	  190.45,	  200.63,	  256.01;	  
19F	  NMR	  (188	  MHz,	  D2O)	  δ	  -­‐180.16	  (CF3);	  ESI/MS+/-­‐	  m/z	  836.2	  [M+Na]+,	  	  853.0	  [M+K]+;	  
MS	  Calcd	   for	  C25H38O6N5F3P3Na159Tb	  836.1138.	  Found	  836.1140;	   τ	   (H2O)	  2.70	  ms,	   τ	  
(D2O)	  3.57	  ms;	  q=	  0.15;	  HPLC:	  tR	  =	  10.6	  min.	  
	  
45.	  [Tm.L6]	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L3(H2O)]	  was	  followed	  using	  [(4,7-­‐
di{[hydroxy(methyl)phosphoryl]methyl}-­‐10-­‐{[7-­‐(trifluoromethyl)quinolin-­‐2-­‐
yl]methyl}-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl)methyl](methyl)phosphinic	   acid	   (30	  
mg,	  45.6	  µmol)	  and	  TmIII(OAc)3	   (18.9	  mg,	  54.7	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  
white	  solid	   (30.1	  mg,	  77	  %);	   1H	  NMR	  (200	  MHZ,	  D2O,	  pD=	   	  5.4)	  Peaks	  range	  from	  -­‐
392.04	   to	   420.56.	   Selected	   peaks	   at:	   -­‐392.04,	   -­‐295.47,	   -­‐241.18,	   -­‐190.78,	   -­‐163.74,	   -­‐




142.92,	  -­‐97.41,	  -­‐41.79,	  47.12,	  67.51,	  121.36,	  148.50,	  176.98,	  369.41,	  420.56;	  19F	  NMR	  
(188	   MHz,	   D2O)	   δ	   -­‐64.51	   (CF3);	   ESI/MS+/-­‐	   m/z	   824.2	   [M+H]+;	   MS	   Calcd	   for	  
C25H39O6N5F3P3169Tm	  824.1410.	  Found	  824.1411.	  
	  
46.	  (±)	  Dimethyl-­‐2-­‐bromoglutarate3	  
 
 
Glutaric	  acid	  monomethyl	  ester	   (12.0	  g,	  82.0	  mmol)	  was	  added	   to	   thionyl	   chloride	  
(25	  mL,	  0.34	  mol)	  and	  the	  mixture	  was	  heated	  at	  70oC	   for	  2	  h.	  Molecular	  bromine	  
(4.7	  mL,	  0.09	  mol)	  was	  added	  dropwise	   to	   the	   solution	  over	  a	  period	  of	  2	  h,	   after	  
which	   the	   reaction	  mixture	  was	  allowed	   to	   cool	   to	   rt.	  After	  14	  h,	   the	  mixture	  was	  
poured	  onto	  CH3OH	  (40	  mL)	  cooled	  on	  crushed	  ice	  and	  stirred	  for	  a	  further	  3	  h.	  H2O	  
(40	  mL)	  was	   added	   to	   the	   reaction	  mixture	   and	   the	   aqueous	   phase	  was	   extracted	  
with	  diethyl	  ether	  (3	  x	  40	  mL).	  The	  combined	  organic	  extracts	  were	  washed	  with	  H2O	  
(30	  mL)	  followed	  by	  5	  %	  NaHCO3	  solution	  (30	  mL).	  The	  organic	  phase	  was	  dried	  over	  
MgSO4,	   filtered	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	   crude	  
material	   was	   placed	   into	   a	   micro	   distillation	   apparatus	   equipped	   with	   a	   Vigreux	  
column	  (bath	  temperature	  130oC)	  and	  the	  title	  compound	  was	  distilled	  at	  70oC/	  0.1	  
mm	  Hg	  (10.9	  g,	  55	  %);	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  2.41	  (2H,	  m,	  CH2CH),	  2.45	  	  (2H,	  m,	  
CH2CO),	  3.60	  (3H,	  s,	  CH3),	  3.71	  (3H,	  s,	  CH3),	  4.37	  (1H,	  t,	  J=	  8	  Hz,	  CHBr);	  13C	  NMR	  (125	  
MHz,	  CDCl3)	  δ	  29.81	  (CH2CH),	  31.60	  (CH2CO),	  44.91	  (CHBr),	  52.13,	  55.19	  (CH3),	  169.9	  








Racemic	   dimethyl-­‐2-­‐Bromoglutarate	   (6.10	   g,	   25.5	   mmol)	   was	   added	   to	   a	   stirred	  
solution	  of	  1,4,7,10-­‐tetraazacyclododecane	  (2.02	  g,	  11.6	  mmol)	  and	  NaHCO3	  (2.14	  g,	  
25.5	   mmol)	   in	   anhydrous	   CH3CN	   (30	   mL)	   under	   argon	   at	   55oC.	   the	   reaction	   was	  
monitored	  by	  TLC	  (10%	  CH3OH/	  CH2Cl2).	  After	  5	  days	  the	  dimethyl-­‐2-­‐	  bromoglutarate	  
had	   been	   consumed.	   The	   solvent	   was	   removed	   under	   reduced	   pressure	   and	   the	  
resulting	   oil	   dissolved	   in	   CH2Cl2.	   The	   solution	   was	   washed	   with	   HCl,	   dried	   over	  
MgSO4,	   and	   the	   solvent	   removed	  under	   reduced	  pressure.	   The	   crude	  product	  was	  
purified	  by	   silica	   gel	   column	   chromatography	  eluting	  with	   a	   gradient	   starting	   from	  
100%	  CH2Cl2	  to	  12	  %	  CH3OH/	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  pale	  yellow	  oil	  
(1.05	  g,	  18	  %);	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.87	  (4H,	  m,	  CH2CH),	  2.30	  (4H,	  m,	  CH2CO),	  
2.33-­‐	  3.10	  (16H,	  br.,	  CH2	  ring),	  3.26	  (2H,	  m,	  CHBr),	  3.52	  (3H,	  s,	  CH3),	  3.68	  (3H,	  CH3),	  
7.72	  (2H,	  s,	  NH);	  13C	  NMR	  (125	  MHz,	  CDCl3)	  δ	  22.4	  (CH2CH),	  29.8	  (CH2CO),	  46.8,	  48.9	  
(CH2	  ring),	  51.7,	  51.9	  (CH3),	  64.2	  (CHBr),	  173.0	  (COCH),	  173.4	  (COCH2);	  ESI/MS+	  m/z	  







2-­‐Chloro-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	  (0.12	  g,	  0.50	  mmol)	  was	  added	  to	  a	  
stirred	  solution	  of	  1,7-­‐bis(α-­‐dimethylglutarate)-­‐1,4,7,10-­‐tetraazacyclododecane	  (0.12	  
g,	  0.25	  mmol),	  KI	   (~5	  mg)	  and	  K2CO3	   (71.2	  mg,	  0.5	  mmol)	   in	  anhydrous	  CH3CN	   (10	  
mL)	  at	  85oC	  under	  argon.	  The	  mixture	  was	  left	  to	  boil	  under	  reflux	  for	  18	  h,	  yielding	  a	  
dark	   orange	   solution	   and	   white	   precipitate.	   The	   precipitate	   was	   removed	   by	  
filtration	  and	  the	  residue	  washed	  with	  CH2Cl2	  (2	  x	  30mL).	  The	  solvent	  was	  removed	  
under	   reduced	   pressure	   and	   the	   resulting	   oil	   purified	   by	   silica	   gel	   column	  




chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  5	  %	  CH3OH	  /	  
CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  pale	  yellow	  oil	   (0.11	  g,	  55	  %);	  1H	  NMR	  (400	  
MHz,	  CDCl3)	  δ	  1.80-­‐	  3.41	  (30	  H,	  br.	  m,	  CH2	  ring,	  CHCH2,	  CH2CH,	  CH2CH2CH,	  CH2CO),	  
3.60	  (6H,	  s,	  CH3),	  3.63	  (6H,	  s,	  CH3),	  7.21	  (2H,	  t,	  J=	  8	  Hz,	  Hd),	  7.60	  (4H,	  m,	  He	  and	  Hc),	  
8.10	  (2H,	  d,	  J=	  8	  Hz,	  Hf),	  9.60	  (2H,	  s,	  NH);	  13C	  NMR	  (125	  MHz,	  CDCl3)	  δ	  22.9	  (CH2CH),	  
31.2	  (CH2CO),	  49.0,	  50.1-­‐50.3	  (br.,	  CH2	  ring),	  51.9,	  52.4	  (CH3),	  63.7	  (CHBr),	  120.5	  (q,	  
2JCF=	  30	  Hz,	  Cb),	  122.6	  (q,	  1JCF=	  272	  Hz,	  CF3),	  124.8	  (Cf),	  125.3	  (Cd),	  126.4	  (q,	  3JCF=	  5	  Hz,	  
Cc),	   133.0	   (Ce),	   136.9	   (Ca),	   170.1,	   172.5,	   174.3	   (CO);	   19F	   NMR	   (188	  MHz,	   CDCl3)	   δ	  
60.98	   (CF3),	   -­‐60.88	   (CF3);	   ESI/MS+	   m/z	   891.0	   [M	   +	   H]+;	   MS	   Calcd	   for	   C40H53O6N6F6	  






Freshly	   made	   aqueous	   KOD	   solution	   (2.5	   mL,	   0.1	   M)	   was	   added	   to	   2-­‐{7-­‐(1,3-­‐bis-­‐
methoxycarbonyl-­‐propyl)-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐
1,4,7,10-­‐tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐pentanedioic	   acid	   dimethyl	   ester	   (0.10	   g,	   0.11	  
mmol).	  The	  reaction	  was	  kept	  under	  argon	  and	  monitored	  by	  1H	  NMR.	  After	  5	  h,	  no	  
ester	  methyl	  groups	  were	  observed	  in	  the	  1H	  NMR	  spectrum.	  The	  pH	  of	  the	  mixture	  
was	   lowered	   to	  ~6	  and	   the	  solution	   loaded	  onto	  a	  DOWEX	  strong	  cation	  exchange	  
resin.	   The	   column	  was	   eluted	  with	   100%	  water	   to	   10%	  NH4OH	  and	   fractions	  were	  
analysed	   by	   ESMS+.	   The	   fractions	   were	   combined	   and	   lyphilised	   to	   yield	   the	   title	  
compound	  as	  a	  pale	  yellow	  oil	  (64	  mg,	  62	  %);	  1H	  NMR	  (400	  MHz,	  D2O)	  δ	  1.94-­‐	  3.40	  
(30	  H,	  br.	  m,	  cyclen	  CH2,	  CHCH2,	  CH2CH,	  CH2CH2CH,	  CH2CO),	  7.09	  (2H,	  t,	  	  J=	  8	  Hz,	  Ar),	  
7.66	  (4H,	  m,	  Ar),	  8.08	  (2H,	  m,	  Ar);	  19F	  NMR	  (376	  MHz,	  D2O)	  δ	  -­‐61.10	  (CF3),	  	  	  ESI/MS+	  
m/z	  836.4	  [M	  +	  H]+.	  


























An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  2-­‐{7-­‐
(1,3-­‐dicarboxy-­‐propyl)-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐
1,4,7,10-­‐tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐pentanedioic	   acid	   (20	   mg,	   23.9	   µmol)	   and	  
TbIII(OAc)3	  (10.0	  mg,	  29.8	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (17	  mg,	  72	  
%);	   1H	  NMR	   (200	  MHz,	   D2O,	   pD	   5.4)	   Peaks	   range	   from	   -­‐130.45	   to	   92.30.	   Selected	  
peaks	   at:	   -­‐130.45,	   -­‐110.24,	   -­‐90.86,	   -­‐87.42,	   -­‐65.32,	   -­‐61.23,	   -­‐60.40,	   -­‐38.07,	   31.78,	  
48.78,	   50.14,	   51.63,	   87.99,	   92.30;	   19F	   NMR	   (188	  MHz,	   D2O,	   pD	   5.4)	   δ	   -­‐58.91	   (CF3,	  
major	  species),	  -­‐	  57.43,	  63.49,	  72.10	  (CF3,	  minor	  species);	  ESI/MS+	  m/z	  1014.2	  [M	  +	  
Na]+;	  τ	  (H2O)	  1.78	  ms,	  τ	  (D2O)	  3.23	  ms;	  q	  =	  0.90;	  HPLC:	  tR	  =	  4.9	  min.	  	  
	  
51.	  [Gd.L7a(H2O)]-­‐	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  2-­‐{7-­‐
(1,3-­‐dicarboxy-­‐propyl)-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐
1,4,7,10-­‐tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐pentanedioic	   acid	   (40.0	   mg,	   47.9	   µmol)	   and	  
GdIII(OAc)3	  (19.2	  mg,	  57.3	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (32.2	  mg,	  




















2-­‐Chloro-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	  (1.42	  g,	  5.99	  mmol)	  was	  added	  to	  a	  
stirred	  solution	  of	  1,4,7,10-­‐Tetraazacyclododecane	  (0.34	  g,	  2.0	  mmol)	  and	  Et3N	  (0.61	  
g,	  6.0	  mmol)	   in	  anhydrous	  ethanol	  (20	  mL)	  at	  50oC	  under	  argon.	   	  After	  18	  h,	  crude	  
mixture	  was	  poured	  onto	  1M	  HCl	   (20	  mL)	   and	  washed	  with	  Et2O	   (2	   x	   30	  mL).	   The	  
aqueous	  layer	  was	  neutralised	  with	  1M	  NaOH	  and	  then	  extracted	  into	  CH2Cl2	  (3	  x	  30	  
mL).	   The	   organic	   extracts	   were	   combined,	   dried	   over	   MgSO4,	   and	   the	   solvent	  
removed	  to	  yield	  the	  title	  compound	  as	  a	  light	  yellow	  oil	  (0.43	  g,	  37	  %);	  1H	  NMR	  (400	  
MHz,	  CDCl3)	  δ	  2.79-­‐	  2.84	  (16H,	  br.	  m,	  CH2	  ring),	  2.34	  (4H,	  s,	  CH2CO),	  7.16	  (2H,	  t,	  J	  =	  7	  
Hz,	  Hd),	  7.41	  (2H,	  t,	   J	  =	  7	  Hz,	  He),	  7.51	  (2H,	  d,	  J=	  7	  Hz,	  Hc),	  7.77	  (2H,	  d,	  J=	  7	  Hz,	  Hf),	  
9.56	  (2H,	  br.,	  NH);	   13C	  NMR	  (500	  MHz,	  CDCl3)	  δ	  45.1,	  51.9	  (CH2	  ring),	  59.9	  (CH2CO),	  
121.0	  (q,	  2JCF=	  30	  Hz,	  Cb),	  124.1	  (q,	  1JCF=	  272	  Hz,	  CF3),	  	  124.3	  (Cf),	  125.5	  (Cd),	  126.4	  (q,	  
3JCF=	  5	  Hz,	  Cc),	  132.6	  (Ce),	  133.2	  (Ca),	  171.4	  (CO);	  19F	  NMR	  (376	  MHz,	  D2O)	  δ	  –60.84	  













































(S)-­‐2-­‐Bromo-­‐pentanedioic	   acid	   dimethyl	   ester	   (0.42	   g,	   1.76	  mmol)	  was	   added	   to	   a	  
stirred	   solution	   of	   N-­‐[2-­‐(trifluoromethyl)phenyl]-­‐2-­‐[7-­‐({[2-­‐trifluoromethyl)	  
phenyl]carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecane-­‐1-­‐yl]acetamide	   (0.46	   g	   ,	  
0.80	   mmol)	   and	   K2CO3	   (0.24	   g,	   1.76	   mmol)	   in	   anhydrous	   CH3CN	   (20	   mL)	   at	   85oC	  
under	  argon.	  The	  mixture	  was	  left	  to	  boil	  under	  reflux	  for	  18	  h,	  yielding	  a	  pale	  yellow	  
solution	   and	  white	   precipitate.	   The	   precipitate	   was	   removed	   by	   filtration	   and	   the	  
residue	   washed	   with	   CH2Cl2	   (2	   x	   30ml).	   The	   solvent	   was	   removed	   under	   reduced	  
pressure	  and	  the	  resulting	  oil	  purified	  by	  silica	  gel	  column	  chromatography,	  eluting	  
with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  to	  3.5	  %	  CH3OH	  /	  CH2Cl2	  to	  yield	  the	  title	  
compound	  as	  a	  colourless	  viscous	  oil	  (0.38	  g,	  	  54	  %);	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.84	  
(4H,	  m,	   CHCH2),	   2.08	   (4H,	  m,	   CHCH2CH2),	   2.39	   (6H,	  m,	   CH2	   ring),	   2.51	   (2H,	  m,	   CH2	  
ring),	  2.62	  (2H,	  m,	  CH2	  ring),	  2.73	  (2H,	  m,	  CH2	  ring),	  2.75	  –	  2.90	  (4H,	  br	  m,	  CH2	  ring),	  
2.98	  –	  3.21	  (4H,	  br	  m,	  CH2CO),	  3.32	  (2H,	  s,	  CH),	  3.58	  (6H,	  s,	  CH3),	  3.64	  (6H,	  s,	  CH3),	  
7.19	  (2H,	  t,	  J	  =	  8	  Hz,	  Hd),	  7.52	  (2H,	  t,	  J	  =	  8	  Hz,	  He),	  7.58	  (2H,	  d,	  J=	  8	  Hz,	  Hc),	  8.17	  (2H,	  d,	  
J=	   8	   Hz,	   Hf),	   9.58	   (2H,	   s,	   NH);	   13C	   NMR	   (700	   MHz,	   CDCl3)	   δ	   25.1	   (CHCH2),	   30.8	  
(CHCH2CH2),	   50.3,	   50.4	   (CH3),	   51.2,	   51.3,	   51.7,	   51.8,	   53.5	   (CH2	   ring),	   60.8	   (CH2CO),	  
62.2,	  62.8	   (CH),	   120.4	   (q,	   2JCF=	  30	  Hz,	  Cb),	   124.6	   (q,	   1JCF=	  272	  Hz,	  CF3),	   	   	   124.6	   (Cf),	  
126.3	   (Cd),	   127.7	   (q,	   3JCF=	   5	   Hz,	   Cc),	   	   133.1	   (Ce),	   136.0	   (Ca),	   170.3	   (CONH),	   172.9	  
(CONH),	   173.5	   (COCH3),	   173.6	   (COCH3);	   19F	   NMR	   (376	  MHz,	   CDCl3)	   δ	   –60.85	   (CF3);	  	  
































Freshly	   prepared	   aqueous	   KOD	   solution	   (5	  mL,	   0.1	  M)	  was	   added	   to	   1,5-­‐dimethyl	  
(2R)-­‐2-­‐[7-­‐[(2R)-­‐1,5-­‐dimethoxy-­‐1,5-­‐dioxopenta-­‐2-­‐yl]-­‐4,10-­‐bis({[2-­‐(trifluoromethyl)	  
phenyl]carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl}pentanedioate	   (0.21	  
g,	   0.23	  mmol).	   The	   solution	  was	   left	   to	   stir	   at	   40oC	   under	   argon	   and	   the	   reaction	  
monitored	  by	  1H	  NMR	  spectroscopy.	  After	  4	  h,	  the	  pH	  of	  the	  mixture	  was	  lowered	  to	  
~6	  and	  the	  solution	  loaded	  onto	  a	  DOWEX	  strong	  cation	  exchange	  resin.	  The	  column	  
was	   eluted	   with	   100	   %	   water	   to	   10	   %	   NH4OH	   to	   yield	   the	   title	   compound	   as	   a	  
colourless	  oil	   (0.15	  g,	  78	  %);	  NMR	  (200	  MHz,	  D2O)	  δ	  1.62-­‐	  2.08	   (8H,	  m,	  CHCH2	  and	  
CHCH2CH2),	  2.28-­‐3.05	  (20H,	  br	  m,	  CH2	  ring	  and	  CH2CO),	  3.53	  (2H,	  br	  s,	  CH),	  7.38	  (4H,	  
m,	  Ar),	  7.58	   (2H,	  m,	  Ar),	  7.67	   (2H,	  m,	  Ar);	   19F	  NMR	  (376	  MHz,	  D2O)	  δ	  –61.11	   (CF3);	  

























An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L7a(H2O)]-­‐	  was	  followed	  using	  (2R)-­‐
2-­‐{7-­‐[(1R)-­‐1,3-­‐dicarboxypropyl]-­‐4,10-­‐bis({[2-­‐(trifluoromethyl)phenyl]	  




carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl}pentanedioic	   acid	   (0.10	   g,	  
0.12	  mmol)	  and	  TbIII(OAc)3	  (0.05	  g,	  0.14	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  
solid	   (0.06	   g,	   46%);	   1H	  NMR	   (200	  MHz,	   D2O,	   pD	   5.4)	   Peaks	   range	   from	   -­‐120.47	   to	  
83.93.	  Selected	  peaks	  at:	  -­‐120.47,	  -­‐96.23,	  -­‐80.56,	  -­‐65.43,	  -­‐36.89,	  -­‐20.40,	  22.36,	  34.09,	  
50.41,	  60.84,	  83.93;19F	  NMR	  (188	  MHz,	  D2O,	  pD	  5.4)	  δ	  -­‐62.10	  (CF3,	  major	  species),	  -­‐




An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L7a(H2O)]-­‐	  was	  followed	  using	  (2R)-­‐
2-­‐{7-­‐[(1R)-­‐1,3-­‐dicarboxypropyl]-­‐4,10-­‐bis({[2-­‐(trifluoromethyl)phenyl]	  
carbamoyl}methyl)-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl}pentanedioic	   acid	   (0.05	   g,	  
0.05	  mmol)	  and	  GdIII(OAc)3	   (0.02	  g,	  0.07mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  
solid	  (0.08	  g,	  63	  %);	  19F	  NMR	  (188	  MHz,	  D2O,	  pD	  5.4)	  δ	  -­‐60.20	  (CF3);	  r1p	  =	  8.1	  mM-­‐1s-­‐1	  
(20	  MHz,	  298	  K);	  HPLC:	  tR	  =	  5.2	  min.	   	  
	  




1,4,7,10-­‐Tetraazacyclododecane	   (5.0	   g,	   29.0	   mmol)	   was	   dissolved	   in	   a	   solution	   of	  
distilled	  H2O:	   dioxane	   (50:20,	   70	  mL)	   ,	   followed	  by	   addition	   of	   disodium	  hydrogen	  
phosphate	  (14.0	  g,	  98.6	  mmol).	  The	  pH	  of	  the	  solution	  was	  adjusted	  to	  2.7	  by	  careful	  
addition	   of	   conc.	  HCl.	   Benzyl	   chloroformate	   (11.9	  mL,	   70.0	  mmol)	   in	   dioxane	   (~20	  
mL)	  was	  added	  dropwise	  over	  a	  period	  of	  2	  h	  and	  the	  solution	  left	  to	  stir	  for	  a	  further	  
18	   h	   at	   room	   temperature,	   yielding	   a	   colourless	   solution	  with	   a	  white	   precipitate.	  
The	   solvent	  was	   evaporated	   under	   reduced	   pressure	   and	   the	   residue	   dissolved	   in	  
H2O	  (100	  mL),	  followed	  by	  adjustment	  of	  the	  pH	  to	  7	  by	  addition	  of	  conc.	  KOH	  (aq).	  
The	  aqueous	  phase	  was	  extracted	  with	  Et2O	  (2	  x	  100	  mL),	  followed	  by	  CH2Cl2	  (2	  x	  100	  




mL).	  The	  organic	  phases	  were	  combined,	  dried	  over	  MgSO4,	  filtered,	  and	  the	  solvent	  
removed	  under	  reduced	  pressure	  to	  give	  a	  clear	  oil.	  The	  oil	  was	  repeatedly	  washed	  
with	  Et2O	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (8.40	  g,	  64	  %);	  m.p.	  115-­‐117oC;	  
1H	   NMR	   (500	  MHz,	   CDCl3)	   δ	   2.07	   (2H,	   br.	   s,	   NH),	   2.80–3.14	   (8H,	   br.	  m,	   CH2	   ring),	  
3.42–3.81	   (8H,	   br.	  m,	   CH2	   ring),	   5.16	   (4H,	   s,	   Cbz	   CH2),	   7.30–7.38	   (10H,	  m,	   Ar);	   13C	  
NMR	   (125	  MHz,	   CDCl3)	   δ	   48.0,	   50.8	   (CH2	   ring),	   67.4,	   68.1	   (Cbz	   CH2),	   128.3,	   128.7,	  
128.9,	  129.1,	  136.1	  (Ar(q)),	  156.3,	  156.4	  (CO);	  ESI/MS+	  m/z	  441.1	  [M	  +	  H]+;	  MS	  Calcd	  
for	  C24H33O4N4	  441.2496.	  Found	  441.2494.	  
	  
58.	  4,10-­‐Bis-­‐tert-­‐butoxycarbonylmethyl-­‐1,4,7,10-­‐tetraazacyclododecane-­‐1,7-­‐
dicarboxylic	  acid	  dibenzyl	  ester6	  
 
 
1,4,7,10-­‐Tetraazacyclododecane-­‐1,7-­‐dicarboxylic	   acid	   dibenzyl	   ester	   (2.0	   g,	   4.54	  
mmol)	  and	  tert-­‐butyl	  bromoacetate	  (1.83	  g,	  9.34	  mmol)	  were	  dissolved	  in	  anhydrous	  
CH3CN	  (25	  mL)	   followed	  by	  the	  addition	  of	  Cs2CO3	   (4.0	  g,	  12.2	  mmol).	  The	  mixture	  
was	   left	   to	  boil	   under	   reflux	   for	   18	  h.	   The	   caesium	   salts	  were	   filtered	  off,	   and	   the	  
solvent	  removed	  under	  reduced	  pressure.	  The	  resulting	  dark	  yellow	  oil	  was	  purified	  
by	   silica	   gel	   chromatography,	   eluting	  with	  a	   gradient	   starting	   from	  100%	  CH2Cl2	   to	  
2%	  CH3OH/	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  light	  yellow	  oil	  (2.18	  g,	  72	  %);	  1H	  
NMR	  (400	  MHz,	  CDCl3)	  δ	  1.39	  (18H,	  s,	  tBu),	  2.74-­‐	  2.83	  (8H,	  br.	  s,	  CH2	  ring),	  3.12-­‐	  3.42	  
(12H,	   CH2	   ring	   and	   CH2CO),	   5.08	   (4H,	   s,	   CH2Ar),	   7.18-­‐	   7.29	   (10H,	  m,	   Ar);	   13C	   NMR	  
(CDCl3,	   176	  MHz)	  δ	  28.0	   (CH3),	   46.7-­‐	  46.9	   (br.,	  CH2	   ring),	   54.2-­‐	  54.5	   (br.,	   CH2	   ring),	  
55.9	  (CH2CO),	  66.8	  (CH2Ar),	  80.7	  (CCH3),	  127.7,	  127.8,	  128.0,	  128.3,	  128.5	  (Ar),	  136.8	  
(Ar(q)),	   156.3,	   170.4	   (CO);	   ESI/MS+	   m/z	   669.4	   [M	   +	   H]+;	   MS	   Calcd	   for	   C36H53O8N4	  













acid	  dibenzyl	  ester	  (2.10	  g,	  3.15	  mmol)	  was	  dissolved	  in	  absolute	  ethanol	  (20	  mL)	  to	  
which	   Pd(OH)2/C	   (Pd	   content	   10%,	   30	   mg)	   was	   added.	   The	   mixture	   was	  
hydrogenated	  in	  a	  Parr	  hydrogenation	  apparatus	  (40	  psi)	  for	  3	  days.	  The	  catalyst	  was	  
removed	  by	  filtration	  and	  the	  ethanol	  removed	  under	  reduced	  pressure	  to	  yield	  the	  
title	  compound	  as	  a	  white	  solid	  (1.02	  g,	  81	  %	  yield);	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.45	  
(18H,	  s,	  tBu),	  2.71	  (8H,	  br.	  s,	  CH2	  ring),	  2.82	  (8H,	  br.	  s,	  CH2	  ring),	  3.31	  (4H,	  s,	  CH2CO);	  
13C	  NMR	  (125MHz,	  CDCl3)	  δ	  27.3	  (CH3),	  51.8,	  53.4	  (CH2	  ring),	  82.7	  (CCH3),	  171.9	  (CO);	  
ESI/MS+	  m/z	  401.1	  [M+H]+;	  MS	  Calcd	  for	  C20H41O4N4	  401.3122.	  Found	  401.3121.	  
 
60.	  {7-­‐tert-­‐Butoxycarbonylmethyl-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐
methyl]-­‐1,4,7,10tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	  tert-­‐butyl	  ester	  
 
 
2-­‐Chloro-­‐N-­‐(2-­‐trifluoromethyl-­‐phenyl)-­‐acetamide	  (0.12	  g,	  0.50	  mmol)	  was	  added	  to	  a	  
stirred	   solution	   of	   (7-­‐tert-­‐butoxycarbonylmethyl-­‐1,4,7,10-­‐tetraazacyclododec-­‐1-­‐yl)-­‐




acetic	   acid	   tert-­‐butyl	   ester	   (0.10	   g,	   0.25	  mmol),	   KI	   (~5	  mg)	   and	   K2CO3	   (72	  mg,	   0.5	  
mmol)	  in	  anhydrous	  CH3CN	  (10	  ml)	  at	  85oC	  under	  argon.	  The	  mixture	  was	  left	  to	  boil	  
under	   reflux	   for	   18	   h,	   yielding	   a	   pale	   yellow	   solution	   and	   white	   precipitate.	   The	  
precipitate	  was	  removed	  by	  filtration	  and	  the	  residue	  washed	  with	  CH2Cl2	  (2	  x	  30mL).	  
The	  solvent	  was	   removed	  under	   reduced	  pressure	  and	   the	   resulting	  oil	  purified	  by	  
silica	  gel	  column	  chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100%	  CH2Cl2	  
to	  2.5%	  CH3OH	  /	  CH2Cl2	  to	  yield	  the	  title	  compound	  as	  a	  colourless	  oil	  (0.14	  g,	  52	  %);	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.22	  (18H,	  s,	   tBu),	  2.14-­‐	  3.70	  (24H,	  br.	  m,	  CH2	  ring	  and	  
CH2CO),	  	  7.27	  (2H,	  t,	  J=	  8	  Hz,	  Hd),	  7.43	  (2H,	  t,	  J=	  8	  Hz,	  He),	  7.58	  (2H,	  d,	  J=	  8Hz,	  Hc),	  7.80	  
(2H,	  d,	   J=8	  Hz,	  Hf),	   8.07	   (2H,	   s,	  NH);	   13C	  NMR	   (176	  MHz,	  CDCl3)	  δ	  27.9	   (CH3),	   49.0,	  
52.5	  (br.	  CH2	  ring),	  55.8,	  57.4	  (CH2CO),	  82.1	  (CCH3),	  121.4	  (q,	  2JCF=	  30	  Hz,	  Cb),	  123.9	  
(q,	  1JCF=	  272	  Hz,	  CF3),	  125.8	  (Cf),	  126.4	  (q,	  3JCF=	  5	  Hz,	  Cc),	  127.3	  (Cd),	  132.6	  (Ce),	  134.9	  
(Ca),	  171.4,	  172.56	  (CO);	  19F	  NMR	  (188	  MHz,	  CDCl3)	  δ	  -­‐60.84	  (CF3);	  ESI/MS+	  m/z	  803.1	  







Trifluoroacetic	  acid	  (3	  mL)	  was	  added	  to	  a	  solution	  of	  {7-­‐tert-­‐butoxycarbonylmethyl-­‐
4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)-­‐methyl]-­‐1,4,7,10tetraaza-­‐cyclododec-­‐
1-­‐yl}-­‐acetic	   acid	   tert-­‐butyl	   ester	   (0.12	   g,	   0.15	  mmol)	   in	  CH2Cl2	   (5	  mL).	   The	   solution	  
was	   stirred	   at	   room	   temperature	   for	   2	   hours.	   The	   solvent	   was	   removed	   under	  




reduced	  pressure	  and	  the	  resulting	  solid	  repeatedly	  washed	  with	  CH2Cl2	  (5	  x	  5	  mL),	  
yielding	  the	  title	  compound	  as	  a	  trifluoroacetate	  salt	  (72.3	  mg,	  70	  %);	  1H	  NMR	  (400	  
MHz,	  CDCl3)	  δ	  2.23-­‐	  3.65	  (24H,	  br.	  m,	  CH2	  ring	  and	  CH2CO),	  	  7.28	  (2H,	  t,	  J=	  15	  Hz,	  Hd),	  
7.39	  (2H,	  t,	  J=	  15	  Hz,	  He),	  7.52	  (2H,	  d,	  J=	  8Hz,	  Hc),	  7.83	  (2H,	  d,	  J=8	  Hz,	  Hf),	  8.07	  (2H,	  s,	  






tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (16.1	   mg,	   23.3	   µmol)	   was	   dissolved	   in	   H2O	  
(3mL)	   and	   the	   pH	   adjusted	   to	   ~6.	   TbIIICl3	   (7.4	   mg,	   28.0	   µmol)	   was	   added	   to	   the	  
solution,	  which	  was	  subsequently	  left	  to	  boil	  under	  reflux	  for	  3	  h.	  Once	  cooled,	  the	  
solvent	  was	  removed	  under	  reduced	  pressure.	  The	  complex	  was	  re-­‐dissolved	  in	  H2O	  
(5	  mL)	  and	  stirred	  for	  2	  h	  with	  anion	  exchange	  resin	  (DOWEX	  1X8	  200-­‐400	  MESH	  Cl,	  
pre-­‐treated	  with	  1M	  HCl)	  to	  give	  the	  chloride	  salt.	  Following	  filtration,	  the	  water	  was	  
lyophilized	   to	   yield	   the	   title	   complex	   as	   a	  white	   powder	   (15.9	  mg,	   81	  %);	   1H	  NMR	  
(200	  MHz,	  D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐80.04	  to	  109.23.	  Selected	  peaks	  at:	  -­‐80.04,	  
-­‐64.06,	   -­‐60.89,	   -­‐50.42,	   -­‐30.26,	   -­‐20.78,	  30.14,	  32.56,	  51.46,	  64.69,	  82.96,	  109.23;	   19F	  
NMR	   (376	  MHz,	  D2O,	   pD	   5.4)	   δ	   -­‐61.9	   (CF3,	  major	   species,	   87	  %),	   -­‐73.2	   (CF3,	  minor	  
species);	  ESI/MS+	  m/z	  847.2	   [M]+;	  MS	  Calcd	   for	  C30H34O6N6F6159Tb	  847.1692.	   Found	  
847.1704;	  τ	  (H2O)	  1.80	  ms,	  τ	  (D2O)	  3.18	  ms;	  q=	  0.90;	  HPLC:	  tR	  =	  7.9	  min. 
	  
	  





An	  analogous	  procedure	   to	   that	  described	   for	   [Tb.L8(H2O)]+	  was	   followed	  using	   {7-­‐
carboxymethyl-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10	  
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (12.7	  mg,	   18.4	   µmol)	   and	  HoIII(OAc)3	   (7.6	  mg,	  
22.0	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (11.1	  mg,	  71	  %);	  1H	  NMR	  (200	  
MHz,	  D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐104.21	  to	  87.48.	  Selected	  peaks	  at:	  -­‐104.23,	  -­‐
73.56,	  -­‐62.59,	  -­‐59.63,	  -­‐40.78,	  -­‐27.80,	  21.47,	  30.80,	  48.97,	  63.00,	  70.07,	  79.63,	  87.48;	  
19F	  NMR	  (376	  MHz,	  D2O,	  pD	  5.4)	  δ	  -­‐57.71	  (CF3,	  major	  species,	  82	  %),	  -­‐60.63,	  -­‐61.80,	  -­‐
66.83,	   -­‐68.21,	   -­‐71.23	   (CF3,	   minor	   species);	   	   ESI/MS+	   m/z	   853.2	   [M]+;	  MS	   Calcd	   for	  
C30H34O6N6F6165Ho	  853.1747	  Found	  853.1740.  
	  
64.	  [Gd.L8(H2O)]+	  
An	  analogous	  procedure	   to	   that	  described	   for	   [Tb.L8(H2O)]+	  was	   followed	  using	   {7-­‐
carboxymethyl-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10	  
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (22.1	   g,	   32.0	   µmol)	   and	   GdIII(OAc)3	   (12.8	   mg,	  
38.4	  µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (21.1	  mg,	  78	  %);	  19F	  NMR	  (188	  
MHz,	   D2O,	   pD	   5.4)	   δ	   -­‐62.41	   (CF3);	   ESI/MS+	   m/z	   846.0	   [M]+;	   MS	   Calcd	   for	  
C30H34O6N6F6158Gd	  846.1685.	  Found	  846.1690;	  r1p	  =	  6.3	  mM-­‐1s-­‐1	  (20	  MHz,	  298	  K).	  
	  
65.	  [Er.L8(H2O)]+	  	  
An	  analogous	  procedure	   to	   that	  described	   for	   [Tb.L8(H2O)]+	  was	   followed	  using	   {7-­‐
carboxymethyl-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10	  
tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	  acid	   (10.4	  mg,	  15.1	  µmol)	  and	  ErIIICl3	   (4.9	  mg,	  18.1	  
µmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (9.4	  mg,	  73	  %);	  1H	  NMR	  (200	  MHz,	  
D2O,	   pD	   5.4)	   Peaks	   range	   from	   -­‐139.40	   to	   182.30.	   Selected	   peaks	   at:	   -­‐139.40,	   -­‐
100.53,	   -­‐82.07,	   -­‐62.89,	   -­‐60.48,	   -­‐59.81,	   21.03,	   37.61,	   41.89,	   120.13,	   170.00,	   179.02,	  
182.30;	  19F	  NMR	  (376	  MHz,	  D2O,	  pD	  5.4)	  δ	  -­‐58.45	  (CF3,	  major	  species,	  78	  %),	  -­‐59.80,	  -­‐
61.65	   (CF3,	  minor	  species);	  ESI/MS+	  m/z	  855.2	   [M]+;	  MS	  Calcd	   for	  C30H34O6N6F6166Er	  
854.1742.	  Found	  854.1747.	  
 
 
66.	  [Tm.L8(H2O)]+	  	  
An	  analogous	  procedure	   to	   that	  described	   for	   [Tb.L8(H2O)]+	  was	   followed	  using	   {7-­‐
carboxymethyl-­‐4,10-­‐bis-­‐[(2-­‐trifluoromethyl-­‐phenylcarbamoyl)methyl]-­‐1,4,7,10	  




tetraaza-­‐cyclododec-­‐1-­‐yl}-­‐acetic	   acid	   (11.3	  mg,	   16.4	   µmol)	   and	   TmIII(OAc)3	   (6.8	  mg,	  
19.6	  µmol)	   to	  yield	   the	  title	  complex	  as	  a	  white	  solid	   (8.9	  mg,	  64	  %);	   1H	  NMR	  (200	  
MHz,	  D2O,	  pD	  5.4)	  Peaks	  range	  from	  -­‐220.87	  to	  240.43.	  Selected	  peaks	  at:	  -­‐220.87,	  -­‐
180.69,	   -­‐160.45,	   -­‐89.01,	   -­‐60.23,	   -­‐40.56,	   38.94,	   48.96,	   70.51,	   92.22,	   109.53,	   180.78,	  
240.43;	  19F	  NMR	  (376	  MHz,	  D2O,	  pD	  5.4)	  δ	  -­‐77.2	  (CF3,	  major	  species,	  91	  %),	  -­‐62.19,	  -­‐
65.32	  (CF3,	  minor	  species);	  ESI/MS+	  m/z	  846.0	  [M]+;	  MS	  Calcd	  for	  C30H34O6N6F6169Tm	  
857.1786.	  Found	  857.1780. 
 
67.	  Ethyl	  4-­‐amino-­‐3-­‐(trifluoromethyl)benzoate 
 
4-­‐Amino-­‐3-­‐(trifluoromethyl)benzonitrile	   (1.0	   g,	   5.4	   mmol)	   was	   added	   to	   a	   stirred	  
solution	  of	  H2SO4	  (1	  mL),	  ethanol	  (5	  mL)	  and	  H2O	  (0.5	  mL).	  The	  mixture	  was	  stirred	  at	  
95oC	  for	  48	  h.	  Once	  cooled,	  CHCl3	  (20	  mL)	  and	  H2O	  (20	  mL)	  were	  added	  and	  the	  pH	  
was	  adjusted	  to	  7	  by	  the	  careful	  addition	  of	  K2CO3.	  The	  product	  was	  extracted	  into	  
CHCl3	   (3	   x	   30	   mL),	   dried	   over	   MgSO4,	   and	   the	   solvent	   removed	   under	   reduced	  
pressure.	  The	  resulting	  oil	  was	  purified	  by	  silica	  gel	  column	  chromatography,	  eluting	  
with	  a	  gradient	  starting	  from	  100	  %	  toluene	  to	  5	  %	  CH2Cl2	  /	  toluene	  to	  yield	  the	  title	  
compound	  as	  a	  white	  solid	  (0.84	  g,	  64	  %);	  m.p.	  82-­‐84oC;	  1H	  NMR	  (200	  MHz,	  CDCl3)	  δ	  
1.36	  (3H,	  t,	  J=	  7,	  CH3),	  4.33	  (2H,	  q,	  J=	  7,	  CH2CH3),	  4.61	  (2H,	  br.	  s,	  NH2),	  6.72	  (1H,	  d,	  J=	  
9	  Hz,	  He),	  7.94	  (1H,	  d,	  J	  =	  9	  Hz,	  Hf),	  8.13	  (1H,	  s,	  Hb),	  9.50	  (1H,	  s,	  NH);	  13C	  NMR	  (176	  
MHz,	   CDCl3)	   δ	   14.5	   (CH2CH3),	   60.7	   (CH2CH3),	   112.7	   (q,	   2JCF	   =	   31	  Hz,	   Cc),	   116.3	   (Ce),	  
119.0	  (Ca),	  125.1	  (q,	  1JCF	  =	  272	  Hz,	  CF3),	  129.1	  (q,	  3JCF	  =	  5	  Hz,	  Cb),	  134.1	  (Cf),	  148.6	  (Cd),	  
166.0	  (CO);	  19F	  NMR	  (188	  MHz,	  CDCl3)	  δ	  –	  63.49	  (CF3);	  ESI/MS+	  m/z	  234.1	  [M+H]+;	  MS	  


























Chloroacetylchloride	  (0.45	  g,	  4.0	  mmol)	  was	  added	  dropwise	  to	  a	  stirred	  solution	  of	  
ethyl	  4-­‐amino-­‐3-­‐(trifluoromethyl)benzoate	   (0.78	  g,	  3.3	  mmol)	  and	  Et3N	   (0.40	  g,	  4.0	  
mmol)	  in	  CH2Cl2	  (15	  mL)	  at	  0oC	  under	  argon.	  After	  4	  h,	  the	  crude	  mixture	  was	  washed	  
with	   HCl	   (20	   mL,	   0.1M),	   NaOH	   (20	   mL,	   0.1	   M)	   and	   H2O	   (20	   mL).	   The	   combined	  
organic	   extracts	   were	   dried	   over	  MgSO4	   and	   the	   solvent	   removed	   under	   reduced	  
pressue.	  The	  resulting	  residue	  was	  purified	  by	  recrystallisation	  from	  hexane/	  Et2O	  to	  
yield	  the	  title	  compound	  as	  white	  needles	  (0.84	  g,	  82	  %);	  mp	  98-­‐101oC;	  	  1H	  NMR	  (400	  
MHz,	  CDCl3)	  δ	  1.39	   (3H,	   t,	   J=	  7	  Hz,	  CH3),	  4.24	   (2H,	  s,	  CH2CO),	  4.39	   (2H,	  q,	   J	  =	  7	  Hz,	  
CH2CH3),	  8.21	  (1H,	  dd,	  J=	  8,	  1	  Hz,	  Hf),	  8.30	  (1H,	  d,	  J=	  1	  Hz,	  Hb),	  8.45	  (1H,	  d,	  J=	  8	  Hz,	  
He),	   8.96	   (1H,	   s,	   NH);	   13C	   NMR	   (126	  MHz,	   CDCl3)	   δ	   14.6	   (CH3),	   43.2	   (CH2CO),	   61.8	  
(CH2CH3),	  119.8	  (q,	  2JCF	  =	  30	  Hz,	  Cc),	  122.7	  (Ce),	  123.7	  (q,	  1JCF	  =	  274	  Hz,	  CF3),	  127.2	  (	  
Ca),	  128.1	   (q,	   3JCF	  =	  5	  Hz,	  Cb),	  134.6	   (Cf),	  138.3	   (Cd),	  164.3	   (CONH),	  165.1	   (COO);	   19F	  
NMR	   (376	  MHz,	   CDCl3)	   δ	   –	   61.32	   (CF3);	   ESI/MS+	   m/z	   310.0	   [M+H]+;	   MS	   Calcd	   for	  






2-­‐Chloro-­‐N-­‐(4-­‐(ethoxycarbonyl)-­‐2-­‐trifluoromethylphenyl)-­‐ethanamide	   (0.40	   g,	   1.29	  
mmol)	  was	  added	  to	  a	  stirred	  solution	  of	  1,4,7,10	  –	  tetraazacyclododecane	  (2.29	  g,	  
12.9	  mmol)	  in	  anhydrous	  CH3CN	  (10mL)	  at	  40oC	  under	  argon.	  After	  4	  h,	  the	  solvent	  
was	   removed	  under	   reduced	  pressure	  and	   the	   residue	  dissolved	   in	  CH2Cl2	   (20	  mL).	  




The	  solution	  was	  washed	   repeatedly	  with	  H2O	   (4	  x	  20	  mL),	  dried	  over	  MgSO4,	  and	  
the	  solvent	  removed	  under	  reduced	  pressure	  to	  yield	  the	  title	  compound	  as	  a	   light	  
yellow	  oil	  (0.24	  g,	  43	  %);	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.33	  (3H,	  t,	  J=	  7	  Hz,	  CH3),	  2.56	  
(4H,	  m,	   CH2	   ring),	   2.64	   (4H,	  m,	   CH2	   ring),	   2.69-­‐2.73	   (8H,	  m,	   CH2	   ring),	   3.28	   (2H,	   s,	  
CH2CO),	  4.32	  (2H,	  q,	  J=	  7	  Hz,	  CH2CH3),	  8.12	  (1H,	  dd,	  J=	  8,	  1	  Hz,	  1,	  Hf),	  8.22	  (1H,	  d,	  J=	  1	  
Hz,	  Hb),	  8.26	   (1H,	  d,	   J=	  8	  Hz,	  He),	  9.52	   (1H,	  br.	  s,	  NH);	   13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  
14.4	   (CH3),	   45.6,	   46.3,	   47.3	   (CH2	   ring),	   53.3	   (CH2CO),	   61.3	   (CH2CH3),	   19F	   NMR	   (188	  
MHz,	  CDCl3)	  δ	  –	  60.81	  (CF3);	   	  ESI/MS+	  m/z	  446.2	  [M+H]+;	  MS	  Calcd	  for	  C20H31O3N5F3	  









benzoate	  (1.01	  g,	  2.5	  mmol)	  was	  heated	  to	  80oC	  in	  anhydrous	  tetrahydrofuran	  under	  
argon.	  Paraformaldehyde	  (0.33	  g,	  11.1	  mmol)	  followed	  by	  diethoxymethyl	  
phosphine	   (1.51	  g,	  11.1	  mmol)	  were	  added.	  The	  solution	  was	  boiled	  at	   reflux	  over	  
molecular	  sieves.	  After	  15	  h,	  the	  excess	  paraformaldehyde	  was	  removed	  by	  filtration	  
and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	   resulting	   orange	   oil	   was	  
purified	   by	   alumina	   gel	   column	   chromatography,	   eluting	   with	   a	   gradient	   starting	  
from	   100%	   CH2Cl2	   to	   0.6	  %	   CH3OH	   /	   CH2Cl2	   to	   yield	   the	   title	   compound	   as	   a	   pale	  
yellow	  oil	  (1.14	  g,	  57	  %);	  1H	  NMR	  (200	  MHz,	  CDCl3)	  δ	  1.11-­‐1.21	  (9H,	  m,	  2JHP	  =	  14	  Hz,	  
PCH3),	  1.24-­‐1.30	  (9H,	  m,	  POCH2CH3),	  1.43	  (3H,	  t,	  J=7	  Hz,	  COCH2CH3),	  2.62-­‐3.04	  (22H,	  
br.	  m,	  CH2	  ring	  and	  CH2P),	  3.12	  (2H,	  s,	  CH2CO),	  3.98	  (6H,	  m,	  POCH2),	  4.31	  (2H,	  q,	  J=	  7	  
Hz,	  COCH2),	  8.14	  (2H,	  m,	  He	  and	  Hf),	  8.21	  (1H,	  d,	  J=	  1Hz,	  Hb),	  9.52	  (1H,	  br.	  s,	  NH);	  13C	  




NMR	  (126	  MHz,	  CDCl3)	  δ	  14.6	  (br.	  m,	  1JCP	  =	  89	  Hz,	  PCH3),	  15.0	  (OCH2CH3),	  16.9	  (t,	  3JCP	  
=	  4	  Hz,	  CH2CH3),	  50.4,	  51.5,	  52.6,	  53.9	  (br.,	  CH2	  ring),	  54.9	  (CH2N),	  60.7	  (br.,	  m,	  PCH2)	  
61.3	  (OCH2CH3),	  121.6	  (q,	  2JCF	  =	  30	  Hz,	  Cc),	  124.0	  (q,	  1JCF	  =	  274,	  CF3),	  125.7	  (Ce),	  126.1	  
(Ca),	  129.0	  (q,	  3JCF	  =	  5	  Hz,	  Cb),	  132.8	  (Cf),	  139.3	  (Cd),	  168.0	  (CONH),	  171.0	  (COO);	  31P	  
NMR	  (81	  MHz,	  CDCl3)	  δ	  -­‐51.84	  (2P,	  s,	  PCH3),	  -­‐52.82	  (1P,	  s,	  PCH3);	  19F	  NMR	  (188	  MHz,	  
CDCl3)	   δ	   -­‐61.28	   (CF3),	   -­‐61.26	   (CF3);	   	   ESI/MS+	   m/z	   806.2	   [M	   +	   H]+;	   MS	   Calcd	   for	  








Freshly	  prepared	  aqueous	  KOD	  solution	  (5	  mL,	  0.1	  M)	  was	  added	  to	  ethyl-­‐({4-­‐[2-­‐({4-­‐
[ethoxy(hydroxy)methyl]-­‐2-­‐(trifluoromethyl)cyclohexyl}amino)-­‐2-­‐hydroxyethyl]-­‐7,10-­‐
di{[ethoxy(methyl)phosphoryl]methyl}-­‐1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐
yl}methyl)(methyl)phosphinate	   (0.30	  g,	  0.37	  mmol).	  The	   solution	  was	   left	   to	   stir	  at	  
40oC	  under	  argon	  and	  the	  reaction	  monitored	  by	  1H	  and	  31P	  NMR.	  After	  72	  h,	  the	  pH	  
of	  the	  solution	  was	  lowered	  to	  ~6	  by	  the	  addition	  of	  HCl.	  The	  solvent	  was	  removed	  
under	  reduced	  pressure	  and	  the	  residue	  washed	  repeatedly	  with	  CH2Cl2	  (3	  x	  5	  mL).	  
The	   resulting	   oil	   was	   dissolved	   in	   ethanol.	   The	   white	   precipitate	   was	   removed	   by	  
filtration	   and	   the	   solvent	   removed	   under	   reduced	   pressure	   to	   yield	   the	   title	  
compound	  as	  a	  pale	  yellow	  oil	  (0.21	  g,	  83%);	  1H	  NMR	  (400	  MHz,	  D2O)	  δ1.03-­‐1.15	  (9H,	  
br.	  m,	  PCH3),	  2.48-­‐	  2.58	  (8H,	  br.	  m,	  CH2	  ring),	  2.63-­‐2.81	  (16H,	  br.	  m,	  CH2	  ring,	  CH2P	  
and	  CH2CO),	  7.42	  (1H,	  dd,	  J	  =	  8,	  1	  Hz,	  Hf),	  7.92	  (1H,	  d,	  J=	  8,	  He),	  8.05	  (1H,	  s,	  Hb);	  31P	  
NMR	  (162	  MHz,	  D2O)	  δ	  -­‐40.28	  (3P,	  s,	  PCH3);	  19F	  NMR	  (376	  MHz,	  D2O)	  δ	  –	  61.46	  (CF3).	  
	  

























An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  ({4-­‐
[2-­‐({4-­‐[ethoxy(hydroxy)methyl]-­‐2-­‐(trifluoromethyl)cyclohexyl}amino)-­‐2-­‐hydroxy	  
ethyl]-­‐7,10-­‐di{[hydroxy(methyl)phosphoryl]methyl}-­‐1,4,7,10-­‐tetraazacyclododecan-­‐
1-­‐yl}methyl)(methyl)phosphinic	  acid	  (0.20	  g,	  0.28	  mmol)	  and	  TbIII(OAc)3	  (0.11	  g,	  0.33	  
mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (0.17	  g,	  70	  %);	  19F	  NMR	  (376	  MHz,	  
D2O,	   pD	   5.4)	   δ	   –48.43	   (CF3,	   major	   species),	   -­‐52.06,	   -­‐53.80	   (CF3,	   minor	   species);	  
ESI/MS+	   m/z	   850.1	   [M+H]+;	   MS	   Calcd	   for	   C24H39O9N5P3F3159Tb	   850.1161.	   Found	  
850.1180;	  τ	  (H2O)	  2.56	  ms,	  τ	  (D2O)	  3.70	  ms;	  q=	  0.30;	  HPLC:	  tR	  =	  5.8	  min. 
 
73.	  [Gd.L9]	  	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  ({4-­‐
[2-­‐({4-­‐[ethoxy(hydroxy)methyl]-­‐2-­‐(trifluoromethyl)cyclohexyl}amino)-­‐2-­‐hydroxy	  
ethyl]-­‐7,10-­‐di{[hydroxy(methyl)phosphoryl]methyl}-­‐1,4,7,10-­‐tetraazacyclododecan-­‐
1-­‐yl}methyl)(methyl)phosphinic	  acid	  (0.18	  g,	  0.26	  mmol)	  and	  GdIII(OAc)3	  (0.10	  g,	  0.31	  
mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (0.14	  g,	  66	  %);ESI/MS-­‐	  m/z	  860.1	  [M-­‐
H]-­‐;	  MS	  Calcd	   for	   C24H37O9N5P3F3154Gd	   843.0995.	   Found	   843.0965;	   r1p=	   3.3	  mM-­‐1s-­‐1	  
(60	  MHz,	  298	  K).	  
	  
74.	  [Tm.L9]	  	  
An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  ({4-­‐
[2-­‐({4-­‐[ethoxy(hydroxy)methyl]-­‐2-­‐(trifluoromethyl)cyclohexyl}amino)-­‐2-­‐hydroxy	  
ethyl]-­‐7,10-­‐di{[hydroxy(methyl)phosphoryl]methyl}-­‐1,4,7,10-­‐tetraazacyclododecan-­‐
1-­‐yl}methyl)(methyl)phosphinic	   acid	   (0.20	   g,	   0.28	   mmol)	   and	   TmIII(OAc)3	   (0.12	   	   g,	  
0.33	  mmol)	  to	  yield	  the	  title	  complex	  as	  a	  white	  solid	  (0.13	  g,	  54	  %);	  19F	  NMR	  (376	  
MHz,	  D2O,	  pD	  5.4)	  δ	  –88.90	  (CF3,	  major	  species),	  -­‐90.12,	  -­‐91.69	  (CF3,	  minor	  species);	  

















Triethyleneglycol	   monomethyl	   ether	   (3.28	   g,	   20	   mmol)	   was	   added	   to	   a	   stirred	  
solution	   of	   phthalimide	   (3.53	   g,	   24.0	  mmol)	   and	   triphenylphosphine	   (6.30	   g,	   24.0	  
mmol)	   in	   anhydrous	   THF	   (100	   mL)	   under	   argon.	   After	   15	   min,	   diisopropyl	  
azodicarboxylate	   (4.85	   g,	   24	   mmol)	   was	   added.	   After	   24	   h,	   the	   reaction	   was	  
quenched	   by	   the	   addition	   of	   ethanol	   (20	   mL).	   The	   solvent	   was	   removed	   under	  
reduced	  pressure	  and	  the	  resulting	  viscous	  oil	  dissolved	  in	  a	  petroleum	  ether:	  ethyl	  
acetate	  mixture	  (1:1,	  20	  mL).	  The	  mixture	  was	  stirred	  at	  40oC	  for	  1	  h,	  yielding	  a	  white	  
precipitate.	  The	  precipitate	  was	  removed	  by	  filtration	  and	  the	  filtrate	  evaporated	  to	  
dryness.	  The	  crude	  material	  was	  purified	  on	  silica	  gel	  colum	  chromatography,	  eluting	  
with	   a	   gradient	   starting	   from	   Petroleum	   Ether/	   25	  %	   Ethyl	   Acetate	   to	   	   Petroleum	  
Ether/	  40	  %	  Ethyl	  Acetate	  	  to	  yield	  the	  title	  compound	  as	  a	  viscous	  yellow	  oil	  (4.98	  g,	  
85	  %);	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  3.31	  (3H,	  s,	  CH3),	  3.45	  (2H,	  t,	  J=	  7	  Hz,	  CH2),	  3.55-­‐
3.99	   (6H,	  m,	  CH2),	  3.63	   (2H,	   t,	   J=	  7	  Hz,	  CH2CH2N),	  3.88	   (2H,	   t,	   J	  =	  7	  Hz,	  CH2N),	  7.69	  
(2H,	  m,	  Ar),	  7.82	   (2H,	  m,	  Ar);	   13C	  NMR	  (126	  MHz,	  CDCl3)	  δ	  37.5	   (CH2N),	  59.2	   (CH3),	  
68.11	   (CH2CH2CN),	   70.3,	   70.7,	   70.8	   (CH2),	   72.1	   (CH2COCH3),	   123.4	   (Cc),	   132.3	   (Cb),	  
134.1	  (Cd),	  168.4	  (Ca);	  ESI/MS+	  m/z	  294.3	  [M+H]+;	  MS	  Calcd	  for	  C15H20O5N	  294.1336.	  









Hydrazine	   (0.39	   g,	   12.1	   mmol)	   was	   added	   to	   a	   stirred	   solution	   of	   2-­‐(2-­‐(2-­‐(2-­‐
methoxyethoxy)ethoxy)ethyl)isoindoline-­‐1,3-­‐dione	   (3.24	   g,	   11.0	   mmol)	   in	   ethanol	  




(35	  mL)	  at	  100oC.	  After	  3	  h,	  the	  resulting	  slurry	  was	  allowed	  to	  cool	  and	  the	  pH	  was	  
lowered	   to	   ~2	   by	   the	   addition	   of	   HCl.	   The	   mixture	   was	   heated	   to	   100oC	   for	   1h,	  
yielding	  a	  colourless	  solution	  and	  white	  precipitate.	  The	  precipitate	  was	  removed	  by	  
filtration	  and	  the	  solvent	  removed	  under	  reduced	  pressure.	  H2O	  (30	  mL)	  was	  added	  
to	  the	  resulting	  oil	  and	  the	  pH	  increased	  to	  11	  by	  the	  addition	  of	  NaOH.	  The	  crude	  
material	  was	   extracted	   into	  CH2Cl2	   (3	   x	   30	  mL),	   dried	  over	  MgSO4	   and	   the	   solvent	  
removed	  under	  reduced	  pressure	  to	  give	  the	  title	  compound	  as	  a	  colourless	  oil	  (1.12	  
g,	  62	  %);	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  2.84	  (2H,	  br.	  s,	  NH2),	  3.01	  (2H,	  t,	  J	  =	  7	  Hz,	  CH2N),	  
3.34	  (3H,	  s,	  CH3),	  3.52	  (2H,	  t,	  J=	  7	  Hz,	  CH2),	  3.58	  (2H,	  t,	  J=	  7	  Hz,	  CH2),	  	  3.59-­‐3.62	  (6H,	  
m,	  CH2),	  3.80	   (2H,	   t,	   J	  =	  7	  Hz,	  CH2CH2N);	   13C	  NMR	  (100	  MHz,	  CDCl3)	  δ	  41.7	   (CH2N),	  
53.6	  (CH3),	  67.9	  (CH2CH2CN),	  69.1,	  70.5,	  71.9,	  73.4	  (CH2);	  ESI/MS+	  m/z	  164.3	  [M+H]+;	  
MS	  Calcd	  for	  C7H18O3N	  164.1281.	  Found	  164.12823.	  
	  













Freshly	  prepared	  aqueous	  KOD	  solution	  (5	  mL,	  0.1	  M)	  was	  added	  to	  ethyl	  4-­‐amino-­‐3-­‐
(trifluoromethyl)benzoate (2.01	   g,	   8.6	  mmol).	   The	   solution	  was	   left	   to	   stir	   at	   40oC	  
under	   argon	   and	   the	   reaction	   monitored	   by	   1H	   NMR.	   After	   72	   h,	   the	   pH	   of	   the	  
solution	  was	   lowered	   to	  ~5	  by	  addition	  of	  HCl.	  The	   resulting	  white	  precipitate	  was	  
filtered	  and	  dried	  under	  reduced	  pressure	  to	  give	  the	  title	  compound	  as	  a	  white	  solid	  
(1.51	  g,	  86	  %);	  m.p.	  =	  80–	  82oC;	  1H	  NMR	  (500	  MHz,	  CD3OD)	  δ	  4.90	  (2H,	  s,	  NH),	  6.84	  
(1H,	  d,	   J	  =	  9	  Hz,	  He),	  7.93	  (1H,	  d,	   J=	  9	  Hz,	  Hf),	  8.05	  (1H,	  s,	  Hb);	   	   13C	  NMR	  (126	  MHz,	  
CD3OD)	  δ	  111.2	  (q,	  2JCF	  =	  31	  Hz,	  Cc),	  115.9	  (Ce),	  117.4	  (Ca),	  125.0	  (q,	  1JCF	  =	  270	  Hz,	  CF3),	  
128.9	   (q,	   3JCF	   =	   5	   Hz,	   Cb),	   134.2	   (Cf),	   150.3	   (Cd),	   168.1	   (CO);	   19F	   NMR	   (376	   MHz,	  























4-­‐Amino-­‐3-­‐(trifluoromethyl)benzoic	   acid	   (0.76	   g,	   3.71	   mmol)	   was	   dissolved	   in	  
anhydrous	  DMF	  (4	  mL)	  to	  which	  N-­‐methylmorphiline	  (0.45	  g,	  4.46	  mmol)	  and	  TBTU	  
(1.43	  g,	  4.46	  mmol)	  were	  added.	  The	  mixture	  was	   left	   to	  stir	  at	   room	  temperature	  
for	  30	  mins	  after	  which	  the	  solvent	  was	  removed	  under	  reduced	  pressure.	  The	  crude	  
material	   was	   purified	   by	   alumina	   gel	   column	   chromatography,	   eluting	   with	   a	  
gradient	   starting	   from	   100%	   CH2Cl2	   to	   5.4	   %	   CH3OH	   /	   CH2Cl2	   to	   yield	   the	   title	  
compound	  as	  a	  white	  solid	  (0.75	  g,	  63	  %);	  m.p.	  104	  -­‐106;	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  
6.88	  (1H,	  d,	  J	  =	  9	  Hz,	  He),	  7.46	  (2H,	  m,	  Ar),	  7.57	  (1H,	  t,	  J	  =	  8	  Hz,	  Ar),	  8.11	  (1H,	  d,	  J=8	  
Hz,	  Ar),	  8.18	  (1H,	  dd,	  J	  =	  8,	  1	  Hz,	  Hf),	  8.40	  (1H,	  d,	  J	  =	  1	  Hz,	  Hb);	  13C	  NMR	  (100	  MHz,	  
CDCl3)	   δ	   113.0	   (q,	   2JCF	   =	   31	  Hz,	   Cc),	   113.0	   (Ce),	   117.2	   (Ca),	   121.9,	   123.0,	   124.9	   (Ar),	  
125.7	  (q,	  1JCF	  =	  270	  Hz,	  CF3),	  129.0	  (Ar),	  129.2	  (q,	  3JCF	  =	  5	  Hz,	  Cb),	   	  131.3	  (Cf),	  135.7,	  
143.7	   (Ar(q)),	   151.3	   (Cd),	   162.1	   (CO);	   19F	   NMR	   (376	   MHz,	   CDCl3)	   δ	   –	   63.76	   (CF3);	  



















1H-­‐1,2,3-­‐Benzotriazol-­‐1-­‐yl	  4-­‐amino-­‐3-­‐(trifluoromethyl)benzoate	   (0.44	  g,	  1.37	  mmol)	  
was	  added	  to	  a	  stirred	  solution	  of	  2-­‐(2-­‐(2-­‐methoxyethoxy)ethoxy)ethanamine	  (0.29	  
g,	  1.78	  mmol)	  and	  N-­‐methylmorphiline	  (0.18	  g,	  1.78	  mmol)	  in	  anhydrous	  DMF	  (5	  mL)	  
under	  argon	  at	  40oC.	  After	  4	  h,	   the	   solvent	  was	   removed	  under	   reduced	  pressure.	  
The	  crude	  material	  was	  purified	  by	  alumina	  gel	  column	  chromatography,	  eluting	  with	  
a	   gradient	   starting	   from	   100%	   CH2Cl2	   to	   4.3	   %	   CH3OH	   /	   CH2Cl2	   to	   yield	   the	   title	  




compound	  as	  a	  white	  solid	  (0.44	  g,	  91	  %);	  m.p.	  124-­‐125oC;	  1H	  NMR	  (400	  MHz,	  CDCl3)	  
δ	  3.30	  (3H,	  s,	  CH3),	  3.52	  (2H,	  m,	  CH2),	  3.65	  (10H,	  m,	  CH2),	  6.41	  (1H,	  d,	   J=	  9	  Hz,	  He),	  
6.84	  (2H,	  NH2),	  7.76	  (1H,	  dd,	  J	  =	  8,	  1	  Hz,	  Hf),	  7.92	  (1H,	  s,	  Hb),	  7.99	  (1H,	  br.	  s,	  NH);	  13C	  
NMR	  (100	  MHz,	  CDCl3)	  δ	  40.9	  (CH2N),	  57.8	  (CH3),	  69.3,	  70.1,	  70.4,	  72.1,	  73.0	  (CH2),	  
113.5	  (q,	  2JCF	  =	  31	  Hz,	  Cc),	  114.5	  (Ce),	  119.6	  (Ca),	  124.7	  (q,	  1JCF	  =	  270	  Hz,	  CF3),	  128.0	  (q,	  
3JCF	  =	  5	  Hz,	  Cb),	  133.4	  (Cf),	  147.0	  (Cd),	  170.4	  (CO);	  19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	  –	  63.48	  
(CF3);	   ESI/MS+	   m/z	   351.3	   [M+H]+;	   MS	   Calcd	   for	   C15H22O4N2F3	   351.1526.	   Found	  
351.1530.	  
	  




















Chloroacetyl	   chloride	   (0.17	   g,	   1.55	  mmol)	  was	   added	   dropwise	   to	   a	   solution	   of	   4-­‐
amino-­‐N-­‐{2-­‐[2-­‐(2-­‐methoxyethoxy)ethoxy]ethyl}-­‐3-­‐(trifluoromethyl)benzamide	   (0.42	  
g,	  1.18	  mmol)	  and	  Et3N	  (0.15	  g,	  1.53	  mmol)	  in	  anhydrous	  CH2Cl2	  (10	  mL)	  at	  -­‐4oC	  (H2O	  
/	  ice)	  under	  argon.	  After	  4	  h,	  the	  solvent	  was	  removed	  under	  reduced	  pressure.	  The	  
crude	  material	  was	  purified	  by	  alumina	  gel	  column	  chromatography,	  eluting	  with	  a	  
gradient	   starting	   from	   100%	   CH2Cl2	   to	   1.8	   %	   CH3OH	   /	   CH2Cl2	   to	   yield	   the	   title	  
compound	  as	  a	  viscous	  colourless	  oil	  (0.36	  g,	  72	  %);	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  3.32	  
(3H,	  s,	  CH3),	  3.54	  (2H,	  m,	  CH2),	  3.67	  (10H,	  m,	  CH2),	  4.26	  (2H,	  s,	  CH2Cl),	  7.16	  (1H,	  br.	  s,	  
NH),	  8.03	  (1H,	  dd,	  J	  =	  8,	  1	  Hz,	  Hf),	  8.20	  (1H,	  dd,	  J	  =	  1	  Hz,	  Hb),	  8.43	  (1H,	  d,	  J=	  9	  Hz,	  He),	  
8.91	   (1H,	   br.	   s,	   NH);	   13C	   NMR	   (126	  MHz,	   CDCl3)	   δ	   40.2	   (CH2N),	   43.1	   (CH2Cl),	   59.1	  
(CH3),	  69.9,	  70.5,	  70.7,	  70.8,	  72.1	  (CH2),	  119.9	  (q,	  2JCF	  =	  30	  Hz,	  Cc),	  123.0	  (Ce),	  123.8	  (q,	  
1JCF	  =	  270	  Hz,	  CF3),	  126.1	  (q,	  3JCF	  =	  5	  Hz,	  Cb),	  131.3	  (Ca),	  131.8	  (Cf),	  137.0	  (Cd),	  164.5	  
(CO),	   165.6	   (CO);	   19F	   NMR	   (376	   MHz,	   CDCl3)	   δ	   –	   61.21	   (CF3);	   ESI/MS+	   m/z	   449.3	  














A	  solution	  of	  sodium	  nitrite	  (5.51	  g,	  80.1	  mmol)	  dissolved	  in	  H2O	  (50mL)	  was	  added	  
dropwise	   to	   a	   stirred	   solution	   of	   sodium	  bromide	   (16.03	   g,	   116	  mmol)	   in	   1M	  HBr	  
(250	  mL),	  cooled	  at	  -­‐5oC.	  After	  18	  h,	  conc.	  H2SO4	  (1	  mL)	  was	  added	  dropwise	  to	  the	  
reaction	  mixture,	  which	  was	  subsequently	  extracted	  with	  diethyl	  ether	  (2	  x	  250	  mL).	  
The	   combined	   organic	   extracts	   were	   washed	   with	   brine	   (2	   x	   200	   mL),	   dried	   over	  
MgSO4,	   filtered	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	   crude	  
material	  was	  purified	  by	   silica	  gel	   column	  chromatography,	  eluting	  with	  a	  gradient	  
starting	  from	  100%	  hexane	  to	  20%	  ethyl	  acetate	  /	  hexane	  to	  yield	  the	  title	  compound	  
as	  a	  pale	  yellow	  oil	  (6.82	  g,	  53	  %);	  1H	  NMR	  (400	  MHz,	  CDCl3)	  2.34	  (1H,	  m,	  CH2CHBr),	  
2.45	   (1H,	   m,	   CH2CHBr),	   2.61	   (2H,	   m,	   CH2CH2CHBr)	   4.41	   (1H,	   m,	   CH),	   5.15	   (2H,	   s,	  
CH2Ar),	   7.34-­‐7.38	   (5H,	  m,	   Ph);	   13C	  NMR	   (126	  MHz,	   CDCl3)	   29.7	   (CH2CH2CHBr),	   31.8	  
(CH2CHBr),	  44.5	  (CH),	  67.1	  (CH2Ar),	  128.6,	  128.7,	  128.8,	  129.1	  (Ar(o/m)),	  129.6	  (Ar(p)),	  
135.8	  (Ar(q)),	  172.5	  (COOCH2),	  174.9	  (COOH);	  ESI/MS+	  m/z	  323.1	  [M+Na]+;	  MS	  Calcd	  
for	  C12H13O4BrNa	  322.9889.	  Found	  322.9892.	  
 





A	   solution	   of	   (S)-­‐2-­‐bromo-­‐pentanedioic	   acid	   -­‐5-­‐benzyl	   ester	   (1.02g,	   3.43	  mmol)	   in	  
tert-­‐butyl	  acetate	  (15	  mL)	  and	  HClO4	  in	  H2O	  (70	  %,	  0.20	  mmol)	  was	  stirred	  at	  room	  
temperature.	   After	   16	   h,	  H2O	  was	   added	   to	   the	   reaction	  mixture,	   and	   the	   organic	  
phase	  separated.	  The	  organic	  phase	  was	  washed	  firstly	  with	  H2O	  (2x	  25mL),	  and	  then	  
5%	  Na2CO3	  (2	  x	  25mL).	  The	  solvent	  was	  removed	  under	  reduced	  pressure	  to	  yield	  the	  
title	  compound	  as	  a	  pale	  yellow	  oil	   (0.923	  g,	  81%);	   1H	  NMR	  (400	  MHz,	  CDCl3)	  1.47	  
(9H,	   s,	   CH3),	   2.30	   (1H,	   m,	   CH2CHBr),	   2.37	   (1H,	   m,	   CH2CHBr),	   2.60	   (2H,	   m,	  
CH2CH2CHBr),	  4.30	  (1H,	  d,	  J	  =	  8,	  6	  Hz,	  CH),	  5.11	  (2H,	  s,	  CH2Ar),	  7.30-­‐7.41	  (5H,	  m,	  Ar);	  




13C	  NMR	  (CDCl3,	  126	  MHz)	  δ	  27.8	  (CH3),	  30.0	  (CH2CH),	  31.8	  (CH2CH2),	  47.1	  (CH),	  66.9	  
(CH2Ar),	  82.8	  (CCH3),	  128.3,	  129.5,	  128.7	  (Ar(o/m)),	  128.8	  (Ar(o/m)),	  128.9	  (Ar(p)),	  136.2	  
(Ar(q)),	   169.5	   (CO),	   173.1	   (CO).	   ESI/MS+	   m/z	   379.2	   [M+Na]+;	   MS	   Calcd	   for	  
C16H21O4BrNa	  379.0521.	  Found	  379.0529.	  
	  
83.	   5-­‐Benzyl-­‐1-­‐tert-­‐butyl	   (2R)-­‐2-­‐{4,10-­‐bis[2-­‐(tert-­‐butoxy)-­‐2-­‐oxoethyl]-­‐1,4,7,10-­‐
tetraazacyclododecan-­‐1-­‐yl}pentanedioate	  
	  
(7-­‐tert-­‐Butoxycarbonylmethyl-­‐1,4,7,10-­‐tetraazacyclododec-­‐1-­‐yl)-­‐acetic	   acid	   tert-­‐
butyl	   ester	   (1.21	   g,	   3.03	  mmol)	   and	  NaHCO3	   (0.23	   g,	   2.7	  mmol)	  were	   dissolved	   in	  
anhydrous	   CH3CN	   (40	  mL).	   After	   stirring	   at	   room	   temperature	   under	   argon	   for	   15	  
mins,	   (S)-­‐2-­‐Bromo-­‐pentanedioic	   acid	   5-­‐benzyl	   ester	   1-­‐tert-­‐butyl	   ester	   (0.96	   g,	   2.7	  
mmol)	  dissolved	   in	  anhydrous	  CH3CN	  (10	  mL)	  was	  added	  dropwise.	  After	  18	  h,	   the	  
resulting	  mixture	  was	   filtered	  and	   the	  solvent	   removed	  under	   reduced	  pressure	   to	  
give	   a	   dark	   orange	   oil.	   The	   crude	   material	   was	   purified	   by	   silica	   gel	   column	  
chromatography,	  eluting	  with	  a	  gradient	  starting	  from	  100	  %	  CH2Cl2	  to	  5	  %	  CH3OH/	  
CH2Cl2	  to	  give	  the	  title	  compound	  as	  a	  pale	  yellow	  viscous	  oil	  (1.00	  g,	  55	  %);	  1H	  NMR	  
(500	  MHz,	  CDCl3)	  δ	  1.21	  (27H,	  s,	  CH3),	  1.83	  (2H,	  m,	  CHCH2),	  2.24	  (2H,	  m,	  CHCH2CH2),	  
2.45-­‐2.98	   (16H,	   br.	   m,	   CH2	   ring),	   3.04	   (2H,	   CH2COtBu),	   3.15	   (1H,	   s,	   CH),	   4.98	   (2H,	  
CH2Ar),	  7.08	   (5H,	  br.	   s,	  Ar),	  9.02	   (1H,	  br.	   s.,	  NH);	   13C	  NMR	  (126	  MHz,	  CDCl3)	  δ	  24.9	  
(CHCH2CH2),	  28.2	  (CH3),	  30.8	  (CHCH2CH2),	  46.2,	  49.3,	  50.2,	  51.0	  (CH2	  ring),	  60.6	  (CH),	  
66.4	  (CH2Ar),	  81.3	  (CH2CO2CCH3),	  81.9	  (CHCO2CCH3),	  128.2,	  128.3,	  128.6	  (Ar),	  135.9	  
(Ar(q)),	   170.3	   (CHCO2tBu),	   171.3	   (CH2CO2tBu),	   172.7	   (CO2CBz);	   ESI/MS+	   m/z	   677.1	  
[M+H]+;	  MS	  Calcd	  for	  C36H61O8N4	  677.4487.	  Found	  677.4491.	  





























4-­‐(2-­‐Chloroacetamido)-­‐N-­‐{2-­‐[2-­‐(2-­‐methoxyethoxy)ethoxy]ethyl}-­‐3-­‐	  	  	  
(trifluoromethyl)benzamide	  (0.36	  g,	  0.84	  mmol)	  was	  added	  to	  a	  stirred	  solution	  of	  5-­‐
benzyl-­‐1-­‐tert-­‐butyl(2R)-­‐2-­‐{4,10-­‐bis[2-­‐(tert-­‐butoxy)-­‐2-­‐oxoethyl]-­‐1,4,7,10-­‐
tetraazacyclododecan-­‐1-­‐yl}pentanedioate	   (0.48	   g,	   0.70	   mmol)	   and	   K2CO3	   (1.16	   g,	  
0.84	  mmol)	   in	  anhydrous	  CH3CN	   (30	  mL)	  at	  80oC.	  After	  15	  h,	   the	   resulting	  mixture	  
was	   filtered	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	   crude	   product	  
was	   purified	   by	   silica	   gel	   column	   chromatography,	   eluting	  with	   a	   gradient	   starting	  
from	  100	  %	  CH2Cl2	  to	  2.5	  %	  CH3OH/	  CH2Cl2	  to	  give	  the	  title	  compound	  as	  an	  orange	  
oil	  (0.48	  g,	  	  65	  %);	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.20	  (9H,	  s,	  CCH3),	  1.40	  (18H,	  s,	  CCH3),	  
1.98	   (2H,	   m,	   CHCH2),	   2.20	   (2H,	   m,	   CHCH2CH2),	   2.28-­‐2.84	   (20H,	   m,	   CH2	   ring	   and	  
CH2CO),	  3.28	  (3H,	  s,	  CH3),	  3.24	  (1H,	  s,	  CH),	  3.62	  (12H,	  CH2),	  5.04	  (2H,	  s,	  CH2Ph),	  7.21	  
(5H,	  m,	  Ph),	  7.70	  (1H,	  br.,	  Ar),	  7.98	  (1H,	  d,	  J=	  8	  Hz,	  Ar),	  8.11	  (1H,	  s,	  Ar),	  9.23	  (1H,	  br.	  
s.,	   NH);	   13C	  NMR	   (100	  MHz,	   CDCl3)	   δ	   22.4	   (CHCH2CH2),	   27.8,	   28.1,	   28.2	   (tBu),	   32.2	  
(CHCH2CH2),	  40.0	   (CH2NHCO),	  44.0,	  45.8,	  46.2,	  47.4,	  51.0	   (br.,	  CH2	   ring),	  54.3,	  58.2	  
(CH2),	  59.0	   (OCH3),	  60.6	   (CH),	  66.6	   (CH2Ph),	  70.0,	  70.3,	  70.5,	  70.6,	  72.0	   (CH2),	  82.1,	  
82.3,	  82.7	  (CCH3),	  121.0	  (q,	  2JCF	  =	  30	  Hz,	  Ar),	  123.2	  (Ar),	  124.9	  (q,	  1JCF	  =	  270	  Hz,	  CF3),	  
127.0	   (Ar),	   128.4,	   128.6,	   128.8	   (Ph),	   	   131.8,	   132.2,	   135.7	   (Ar),	   137.9	   (Ph),	   166.1,	  
172.3,	  172.8,	  173.1,	  175.0	  (CO);	  19F	  NMR	  (376	  MHz,	  CDCl3)	  δ	  –	  63.19	  (CF3);	  ESI/MS+	  


































1,4,7,10-­‐tetraazacyclododecan-­‐1-­‐yl}pentanedioate	   (240	   mg,	   0.23	   mmol)	   was	  
dissolved	  in	  HBr	  (48	  %	  in	  acetic	  acid,	  5	  mL).	  The	  reaction	  was	  monitored	  by	  1H	  NMR.	  
After	  1	  h,	  the	  solution	  was	  diluted	  with	  H2O	  (30	  mL)	  and	  then	  dialysed	  (MWCO	  500D)	  
against	   purite	   water	   until	   the	   pH	   of	   the	   tube	   contents	   reached	   neutral	   (48	   h).	  
Lyphilisation	   yielded	   a	  white	   solid	   (129	  mg,	   71	  %);	  m.p.	   229-­‐230oC	   (dec);	   1H	  NMR	  
(400	  MHz,	  D2O)	  δ	  1.20	  (9H,	  s,	  CCH3),	  1.40	  (18H,	  s,	  CCH3),	  1.98	  (2H,	  m,	  CHCH2),	  2.20	  
(2H,	  m,	  CHCH2CH2),	  2.28-­‐2.84	  (20H,	  m,	  CH2	  ring	  and	  CH2CO),	  3.28	  (3H,	  s,	  CH3),	  3.24	  
(1H,	  s,	  CH),	  3.62	  (12H,	  CH2),	  5.04	  (2H,	  s,	  CH2Ph),	  7.21	  (5H,	  m,	  Ph),	  7.70	  (1H,	  br.,	  Ar),	  
7.98	   (1H,	  d,	   J=	  8	  Hz,	  Ar),	  8.11	   (1H,	   s,	  Ar),	  9.23	   (1H,	  br.	   s.,	  NH);	   19F	  NMR	  (376	  MHz,	  
























An	  analogous	  procedure	  to	  that	  described	  for	  [Tb.L4(H2O)]3-­‐	  was	  followed	  using	  (2R)-­‐
2-­‐[4,10-­‐bis(carboxymethyl)-­‐7-­‐{3-­‐[4-­‐({2-­‐[2-­‐(2-­‐methoxyethoxy)ethoxy]ethyl}	  





dodecan-­‐1-­‐yl]pentanedioic	  acid	   (129	  mg,	  0.16	  mmol)	  and	  TbIII(OAc)3	   (65.2	  mg,	  0.19	  
mmol)	   to	   yield	   the	   title	   complex	   as	   a	  white	   solid	   (124.6	  mg,	   82	  %);	   19F	  NMR	   (376	  
MHz,	   D2O,	   pD	   5.4)	   δ	   –45.12	   (CF3,	   major	   species),	   -­‐42.06,	   -­‐43.98,	   -­‐49.78.	   -­‐50.10,	   -­‐
50.14,	   56.98	   (CF3,	  minor	   species);	   ESI/MS+	  m/z	  1003.6	   [M+Na]+;	   τ	   (H2O)	  1.68	  ms,	   τ	  



































[Tm.L9]	  (109.1	  mg,	  127.1	  µmol),	  was	  dissolved	  in	  anhydrous	  DMF	  (2	  mL)	  to	  which	  N-­‐
methylmorpholine	   (13.0	   mg,	   128.5	   µmol)	   and	   TBTU	   (41.5	   mg,	   128.5	   µmol)	   were	  
added.	  The	  mixture	  was	   left	   to	   stir	   for	  30	  min,	  under	  argon,	  at	   room	   temperature	  
then	   β-­‐cyclodextrin	   (16.4	  mg,	   12.8	   µmol),	   dissolved	   in	   1	   mL	   H2O	   was	   added.	   The	  
mixture	  was	  left	  stirring	  overnight	  at	  40oC.	  The	  crude	  product	  was	  diluted	  with	  H2O	  
(10	  mL)	  and	  dialysed	  against	  Purite	  water	  over	  48	  h	   (MWCO	  1000	  D).	  The	  solution	  
was	  lyophilised	  to	  yield	  the	  title	  compound	  as	  a	  white	  solid	  (82.0	  mg,	  	  89	  %);	  19F	  NMR	  
(376	  MHz,	  D2O,	  pD	  5.4)	  δ	  –89.23	  (CF3);	  MALDI+	  7242	  [M+Na]+;	  Anal	  Found	  Tm,	  2.1	  %;	  
HPLC:	  tR	  =	  9.6	  min. 
Procedure	  B	  
An	   analogous	   procedure	   to	   that	   described	   for	   [(Tm.L9).Cyclodextrin]	   Procedure	   A	  
was	  followed,	  using	  [Tm.L9]	  (130.6	  mg,	  152.0	  µmol),	  N-­‐methylmorpholine	  (19.4	  mg,	  




193.2	  µmol),	  TBTU	  (63.0	  mg,	  196.3	  µmol)	  and	  β-­‐cyclodextrin	  (16.2	  mg,	  12.3	  µmol)	  to	  
yield	  the	  title	  compound	  as	  a	  white	  solid	  (62.9	  mg,	  71	  %);	  19F	  NMR	  (376	  MHz,	  D2O,	  
pD	  5.4)	  δ	  –90.04	  (CF3);	  MALDI+	  7219	  [M+H]+;	  Anal	  Found	  Tm,	  2.6	  %;	  HPLC:	  tR	  =	  9.6	  
min.	  
Procedure	  C	  
Cumene	   (6.9	  mg,	   58.2	   µmol)	  was	   dissolved	   in	   anhydrous	  DMF	   (2	  mL)	   to	  which	  N-­‐
methylmorpholine	  (5.9	  mg,	  58.4	  µmol)	  and	  TBTU	  (18.9	  mg,	  59.0	  µmol)	  were	  added.	  
The	  mixture	  was	  left	  to	  stir	  for	  30	  mins,	  under	  argon,	  at	  room	  temperature	  then	  β-­‐
cyclodextrin	  (7.4	  mg,	  5.6	  µmol)	  and	  [Tm.L9]	  (49.7	  mg,	  57.9	  µmol)	  dissolved	  in	  1	  mL	  
H2O	  were	  added.	  The	  mixture	  was	  left	  stirring	  overnight	  at	  40oC.	  The	  crude	  product	  
was	  diluted	  with	  H2O	   (10	  mL)	  and	  dialysed	  against	  Purite	  water	  over	  48	  h	   (MWCO	  
1000	  D).	   The	   solution	  was	   lyophilised	   to	   yield	   the	   title	   compound	   as	   a	  white	   solid	  
(62.9	   mg,	   71	   %);	   19F	   NMR	   (376	   MHz,	   D2O,	   pD	   5.4)	   δ	   –89.05	   (CF3);	   MALDI+	   7219	  














































[Tm.L9]	   (108	  mg,	   125.7	   µmol),	  was	   dissolved	   in	   anhydrous	  DMSO	   (2	  mL)	   to	  which	  
N,N-­‐diisopropylethylamine	   (16.2	  mg,	  125.8	  µmol)	   and	  TBTU	   (40.9	  mg,	  127.4	  µmol)	  
were	   added.	   The	  mixture	  was	   left	   to	   stir	   for	   20	  mins	   at	   room	   temperature,	   under	  
argon,	   and	   then	   T8-­‐silsesquioxane	   (10.7	  mg,	   12.0	   µmol)	   was	   added.	   After	   3	   h	   the	  
reaction	  mixture	  was	  dropped	  slowly	  into	  diethyl	  ether.	  The	  resulting	  precipitate	  was	  
filtered,	  dissolved	  in	  H2O	  (10	  mL)	  and	  dialysed	  against	  Purite	  water	  over	  48	  h	  (MWCO	  
1000	  D).	   The	   solution	  was	   lyophilised	   to	   yield	   the	   title	   compound	   as	   a	  white	   solid	  
(62.9	  mg,	  71	  %);	  19F	  NMR	  (376	  MHz,	  CD3OD:D2O	  (50:	  50),	  pD	  5.4)	  δ	  –89.23	  (CF3);	  19F	  




NMR	  (139	  MHz,	  CD3OD:D2O	  (50:	  50),	  pD	  5.4)	  δ	  –65.8	  (SiO);	  Anal	  Found	  Tm,	  17.4	  %;	  














































An	  analogous	  procedure	  to	  that	  described	  for	  [(Tm.L9).Silsesquioxane]	  was	  followed,	  
using	   [Tb.L12(H2O)]-­‐	   (124.6	   mg,	   127.5	   µmol),	   N,N-­‐diisopropylethylamine	   (16.5	   mg,	  
128.0	  µmol),	  TBTU	  (41.1	  mg,	  127.9	  µmol)	  and	  T8-­‐silsesquioxane	  (11.4	  mg,	  12.8	  µmol)	  
to	   yield	   the	   title	   compound	   as	   a	   light	   brown	   solid	   (51	   mg);	   19F	   NMR	   (376	   MHz,	  
CD3OD:D2O	  (20:	  80),	  pD	  5.4)	  δ	  –45.39	  (CF3);	  29S	  NMR	  (139	  MHz,	  CD3OD:D2O	  (20:	  80),	  





































An	  analogous	  procedure	  to	  that	  described	  for	  [(Tm.L9).Silsesquioxane]	  was	  followed,	  
using	   [Tb.L6]	   (220.1	  mg,	   258.9	   µmol),	   N-­‐methylmorpholine	   (26.3	  mg,	   260.1	   µmol),	  




TBTU	   (83.6	   mg,	   260.5	   µM)	   and	   chitosan	   (40	   mg,	   MW	   ~	   6500)	   to	   yield	   the	   title	  
compound	  as	  a	  white	  solid	  (83	  mg);	  19F	  NMR	  (376	  MHz,	  D2O,	  pD	  5.4)	  δ	  -­‐58.46	  (CF3);	  
For	  GCP	  analysis	  refer	  to	  Table	  5.2.	  
	  
91.	  [(Gd.L9).Chitosan]	  
An	  analogous	  procedure	  to	  that	  described	  for	  [(Gd.L9).Silsesquioxane]	  was	  followed,	  
using	   [Gd.L6]	   (223.9	  mg,	   260.3	  µmol),	  N-­‐methylmorpholine	   (26.1	  mg,	   258.0	  µmol),	  
TBTU	   (82.9	   mg,	   26.6	   µM)	   and	   chitosan	   (40	   mg,	   MW	   ~	   6500)	   to	   yield	   the	   title	  
compound	   as	   a	   white	   solid	   (91	   mg);	   r1p=	   12.4	   mM-­‐1s-­‐1	   (60	   MHz,	   298	   K);	   For	   GCP	  
analysis	  refer	  to	  Table	  5.2.	  
	  
Sample	   Mw	  a	   Mn	  b	   PDI	  c	  
Chitosan	   6,590	   2,250	   2.9	  
[(Gd.L9).Chitosan]	   16,500	   8,565	   1.9	  
[(Tb.L9).Chitosan]	   16,300	   8,615	   1.9	  
Table	  5.2:	  Gel	  permeation	  chromatography	  (GPC)	  data	  for	  the	  starting	  glycol	  chitosan	  sample	  and	  the	  
corresponding	  Tb	  and	  Gd	  conjugates.	  Mean	  values	  obtained	  from	  two	  successive	  scans.	  a	  calculated	  
molecular	  weight	  averages	  expressed	  as	   the	  pullulan	  polysaccaride	  equivalent	  molecular	  weights;	   b	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